#version: 0.2
t h
t i
th e</w>
i n
a n
r e
o n</w>
e n
o f</w>
e r
o n
e d</w>
a r
o r
r o
an d</w>
t o</w>
a ti
e s</w>
i n</w>
i t
i s
e r</w>
a l
a t
in g</w>
o r</w>
o u
a l</w>
i c
e c
o m
a c
s t
ati on</w>
i s</w>
a p
o s
m en
p ro
s u
s i
l e</w>
a t</w>
t s</w>
a n</w>
f or</w>
e s
e l
c on
a s</w>
a s
u l
T h
p l
v e</w>
u r
i l
t r
s h
q u
u n
o l
@ -
@- @</w>
e m
b e</w>
a b
ti on</w>
2 0
on s</w>
ti c
men t</w>
a d
w h
e n</w>
d i
c e</w>
th at</w>
i m
c om
u s
it h</w>
al l</w>
a g
w ith</w>
n o
e x
e g
Th e</w>
d u
ap os
& apos
o p
l y</w>
a m
e t
e v
b y</w>
o t
it y</w>
c i
f or
at e</w>
C om
re s
n g</w>
v i
l o
r i
l i
Com m
p or
ou n
p ar
e re
p e
ar e</w>
c h
b er</w>
m e
t a
A r
si on</w>
20 0
f i
c l
sh all</w>
Ar tic
t ed</w>
er s</w>
no t</w>
a y</w>
i t</w>
f f
&apos ;
re c
Artic le</w>
n e
du c
l d</w>
th er</w>
en t</w>
ti ng</w>
i on</w>
p er
h a
t er
u ro
e t</w>
E uro
ou ld</w>
S t
th is</w>
er e</w>
em ber</w>
an ce</w>
qu ot
ul ation</w>
d ing</w>
quot ;</w>
& quot;</w>
a r</w>
R eg
g h
d e
ro m</w>
is sion</w>
th e
f rom</w>
d s</w>
at ed</w>
p os
o v
ac c
a i
d ed</w>
o u</w>
ic h</w>
re g
on al</w>
Reg ulation</w>
wh ich</w>
b e
Euro pe
p ec
ab le</w>
Europe an</w>
d er</w>
o w
ti es</w>
ti ve</w>
Comm ission</w>
ati ons</w>
ti ons</w>
at es</w>
men ts</w>
st r
20 1
t er</w>
ar y</w>
i es</w>
ur e</w>
c h</w>
pro duc
E C</w>
ou t</w>
d e</w>
M ember</w>
for m
it s</w>
b u
ha ve</w>
an t</w>
a u
&apos; s</w>
re d</w>
y ou</w>
l e
& #
&# 9
s e
es s</w>
w or
m a
N o</w>
c o
e st
f in
es s
d is
re s</w>
ap pl
p r
sh ould</w>
a v
u m
por t</w>
cl u
o ther</w>
g r
su b
ou r
&apos ;</w>
e ment</w>
U n
a f
o d</w>
w e
ou r</w>
on e</w>
c er
m e</w>
in g
m ar
qu i
r e</w>
lo w
in e</w>
k e</w>
an y</w>
E U</w>
l is
i c</w>
t u
o c
St ates</w>
t e
s o</w>
re f
com p
il l</w>
as e</w>
e p
A n
j ec
os e</w>
I n</w>
en ti
s ec
h as</w>
ar d</w>
s er
re l
i th
. .
i d
us e</w>
ic ation</w>
o b
w as</w>
w ill</w>
h i
m in
th or
s pec
gh t</w>
o g
or d
a y
an g
al ly</w>
u b
c re
ag e</w>
i r</w>
t h</w>
pro vi
k ing</w>
m ay</w>
v is
ati onal</w>
ic e</w>
as s
v er
an s
C oun
pro c
ci al</w>
d er
or e</w>
p re
e l</w>
p res
f ol
t en
op er
a su
s y
ci l</w>
us t</w>
Coun cil</w>
i r
e ar
au thor
D i
re n
p ri
u m</w>
the ir</w>
mar k
com m
ap pro
I n
Un ion</w>
i ties</w>
u p</w>
en ts</w>
me asu
w ith
W h
ic al</w>
Th is</w>
c oun
p o
in clu
f ac
ec is
be en</w>
t ec
ati ng</w>
r a
par tic
k s</w>
re at
e ff
pl e
i a</w>
ev el
u s</w>
fol low
P ar
form ation</w>
e d
ser v
tr ans
ic i
a in
ai d</w>
Di rec
m ore</w>
in ter
m an
ere d</w>
al so</w>
h e
g en
c es</w>
i v
t o
m on
el y</w>
a il
n ational</w>
t y</w>
Comm un
in v
1 9
es t</w>
spec i
al s</w>
ag r
es e</w>
re qui
su l
in to</w>
b le</w>
su p
c an</w>
g n
s t</w>
ow n</w>
g h</w>
con t
ti v
p h
s ti
3 ;</w>
&#9 3;</w>
ecis ion</w>
in formation</w>
1 ;</w>
&#9 1;</w>
b et
en ce</w>
th an</w>
p en
su ch</w>
un der</w>
for e</w>
u t
il ity</w>
si d
st e
str u
I t</w>
or y</w>
0 0</w>
ad e</w>
ati ve</w>
p ol
b o
or s</w>
ere n
en t
acc ord
d ic
s e</w>
men t
st an
ov er
u e</w>
Direc tive</w>
coun tr
T H
per i
ou s</w>
ul ar</w>
s o
T I
g o
m o
ne x</w>
Commun ity</w>
ic es</w>
pl ac
b as
ac h</w>
lis h
c ar
c y</w>
follow ing</w>
as t</w>
wor k</w>
v al
An nex</w>
measu res</w>
ti n
th ere
si gn
p ub
accord ance</w>
St ate</w>
g ro
w e</w>
am e</w>
r is
con cer
tr i
i f</w>
est ab
us ed</w>
i ons</w>
eff ec
produc ts</w>
i f
the y</w>
l a
fin an
agr ap
ta in
a d</w>
mark et</w>
p ur
in t</w>
fi ed</w>
r u
al l
e ar</w>
l es</w>
y our</w>
er red</w>
evel op
ti me</w>
n ec
we en</w>
i g
t ur
par agrap
p e</w>
d o
li c</w>
bet ween</w>
concer n
an s</w>
in t
t or</w>
l eg
m ust</w>
el l</w>
or der</w>
fi r
wh ere</w>
is t
ing s</w>
ar g
1 0</w>
w ere</w>
p on
a re
er al</w>
O N</w>
P ro
te e</w>
o w</w>
a men
estab lish
s el
en tr
su re</w>
w ould</w>
por t
ref erred</w>
f un
ta in</w>
C O
om e</w>
oun t</w>
C on
ac t</w>
bu t</w>
n o</w>
f o
os t</w>
com pl
th ese</w>
d et
s et</w>
1 .
th ose</w>
ne w</w>
d at
on ly</w>
O J</w>
u p
d evelop
paragrap h</w>
i ti
sti tu
u d
partic ular</w>
pro vis
with in</w>
1 0
an is
D ecision</w>
ste m</w>
d ec
ch ang
stru c
c or
m at
re e</w>
ev er</w>
p ati
res pon
C h
provi ded</w>
gr am
s ol
appl ic
per s
h n
ec on
e y</w>
t ly</w>
d own</w>
si ble</w>
reg ard</w>
am p
ta k
2 .
E U
con di
su r
in cre
fi c</w>
k no
m il
li a
g u
v en
f r
inclu ding</w>
i p
e w</w>
ar ds</w>
it tee</w>
u st
re ement</w>
is tr
c ap
ov er</w>
F or</w>
p a
un der
af ter</w>
ta ke</w>
im ple
r it
finan cial</w>
I I</w>
lo c
d ay</w>
l ev
dat a</w>
er g
om ic</w>
or g
t w
ro u
e f
o ff
ul es</w>
i tion</w>
jec t</w>
2 0</w>
di rec
d oc
in es</w>
sy stem</w>
wh en</w>
di ff
TH E</w>
f l
n um
ad op
c ur
d o</w>
on g</w>
is e</w>
pro pos
nec ess
peri od</w>
A N
ti c</w>
it ed</w>
Par lia
is ed</w>
4 .
il l
19 9
pol ic
t ure</w>
v e
th ere</w>
R E
Parlia ment</w>
for m</w>
i d</w>
s it
ti f
m ade</w>
countr ies</w>
su m
ex c
pro tec
ay s</w>
is su
Comm ittee</w>
I N
el l
n al</w>
pati ents</w>
tri bu
vi r
re qu
necess ary</w>
ar i
ti onal</w>
lev el</w>
tec hn
t y
requi re
ti on
c ol
h y
appro pri
lo w</w>
T E
d ur
et y</w>
author ities</w>
en g
ab ility</w>
.. .</w>
l l</w>
cont ro
re sul
em s</w>
I S
an n
200 6</w>
th er
en sure</w>
fir st</w>
condi tions</w>
y ing</w>
at eg
st s</w>
i ght</w>
w ay</w>
al ity</w>
serv ices</w>
f e
po int</w>
r ules</w>
I f</w>
ac h
h ol
pro gram
c ase</w>
ol og
v ing</w>
por ts</w>
res pec
pub lic</w>
ad min
pl o
f u
Y ou</w>
d el
u t</w>
d g
e ther</w>
l im
oper ation</w>
R O
wh o</w>
1 2</w>
ad di
i de</w>
b en
e ments</w>
av ing</w>
e ach</w>
c a
v es</w>
th rou
a m</w>
&apos; t</w>
m g</w>
in ation</w>
ear s</w>
v ed</w>
tr ac
re sid
200 7</w>
y ear</w>
o ds</w>
em b
is h
E C
T reat
ne ed</w>
m s</w>
ab out</w>
ai r
num ber</w>
produc t</w>
appl ication</w>
require ments</w>
E E
the m</w>
b ec
.. ..
f ul
A c
as es</w>
man ag
tic al</w>
appropri ate</w>
provis ions</w>
ir d</w>
y ears</w>
oun d</w>
rel ev
se e</w>
gh ts</w>
A g
d ate</w>
O F</w>
t reat
E EC</w>
tw o</w>
con tain
5 0</w>
3 0</w>
l ess</w>
cer tain</w>
3 .
eren ce</w>
av ail
200 4</w>
im port
A R
ma in
dur ing</w>
par t</w>
a st
h e</w>
ment ation</w>
tak en</w>
c ri
sup port</w>
Treat y</w>
w ell</w>
p tion</w>
vi ew</w>
rec e
H aving</w>
el ec
im um</w>
erg y</w>
org anis
develop ment</w>
200 5</w>
ac tion</w>
econ omic</w>
ic ul
1 5</w>
1 1</w>
t e</w>
de fin
ow ever</w>
ris k</w>
treat ment</w>
e e
200 9</w>
ac k</w>
er i
u ation</w>
plo y
n on</w>
bas is</w>
g iv
e qui
speci fic</w>
200 8</w>
M E
comm on</w>
ti m
me ans</w>
p er</w>
th ird</w>
stan d
there fore</w>
over n
W e</w>
s af
y s
s ame</w>
c al
con tin
polic y</w>
di es</w>
d es</w>
ver y</w>
me th
be fore</w>
appl y</w>
h el
ha d</w>
re port</w>
ed ure</w>
concern ed</w>
an d
ex t</w>
for ce</w>
throu gh</w>
is ation</w>
u tion</w>
comp et
b el
si ons</w>
Ag reement</w>
e ts</w>
D ec
applic able</w>
avail able</w>
relev ant</w>
ta king</w>
ff ici
ass ess
an ts</w>
pur pos
m y</w>
li ke</w>
ur ity</w>
as ed</w>
bas ed</w>
admin istr
plac e</w>
d ose</w>
vir on
l ec
in stitu
in ci
in dic
en d</w>
it ted</w>
cur ren
e qu
with out</w>
acc ount</w>
m ost</w>
ma ke</w>
con sid
it al</w>
in al</w>
p ow
c r
0 0
chang e</w>
enti al</w>
P resid
in iti
an im
ac ti
wh at</w>
s ch
me di
ob jec
op le</w>
f ur
doc u
p ay
o l</w>
provi de</w>
d es
ri ght</w>
ar m
M ar
sub m
res s</w>
Euro pe</w>
ac tions</w>
im p
A TI
c ould</w>
produc tion</w>
s ome</w>
1 4</w>
do es</w>
d em
l ine</w>
1 3</w>
ac k
in du
er y</w>
inv est
h ic
2 5</w>
countr y</w>
b ot
at er</w>
proc edure</w>
201 3</w>
i ed</w>
vi ties</w>
protec tion</w>
s ed</w>
or ig
E n
en cy</w>
pe ti
al th</w>
u al</w>
i z
an ti
d y</w>
t ors</w>
diff eren
re duc
h is</w>
amen ded</w>
5 .
d r
A s</w>
c our
on g
con tribu
pos sible</w>
ou t
b i
si de</w>
m p
por ted</w>
ai r</w>
acti vities</w>
l ed</w>
am e
ment al</w>
i ve</w>
A S</w>
s al
c ul
proc e
c an
me dic
op in
tur al</w>
in f
reg ul
a k
con sum
6 .
en ergy</w>
imple mentation</w>
b ility</w>
is l
R e
Dec ember</w>
em ploy
contro l</w>
s p
200 3</w>
b r
leg al</w>
re pres
are a</w>
li g
com e</w>
men ting</w>
en viron
a use</w>
1 2
h um
c entr
ve hic
sh i
om s</w>
res t</w>
so cial</w>
det er
ot al</w>
pen d
l in
M r</w>
d ecision</w>
r ang
201 1</w>
im pro
pe ople</w>
manag ement</w>
A u
id enti
E x
re ad
th ing</w>
it e</w>
a in</w>
sub ject</w>
la w</w>
us in
m i
val ue</w>
as s</w>
1 6</w>
S ec
at ure</w>
Wh at</w>
giv en</w>
sy st
there of</w>
ere as</w>
ro s
i l</w>
be ing</w>
if ic
shi p</w>
EU R</w>
com men
Presid ent</w>
un d</w>
1 8</w>
sup pl
tiv es</w>
ame work</w>
t re
compet ent</w>
respec t</w>
on d</w>
ty pe</w>
A L</w>
o f
201 0</w>
si ve</w>
rel ated</w>
P E
at ory</w>
d ro
l ab
ex is
kno w
O R
st u
in ten
adop ted</w>
U N
am ount</w>
ain st</w>
m any</w>
author ity</w>
com peti
co sts</w>
T r
an k</w>
establish ed</w>
leg isl
car ri
j o
d ra
e ting</w>
A l
un e</w>
wh ether</w>
k ed</w>
S I
ne e
at ely</w>
mat eri
o m</w>
u fac
comp an
concern ing</w>
ag ainst</w>
le ast</w>
comm un
ATI ON</w>
3 1</w>
H owever</w>
di vi
pr inci
b l
ati c</w>
re as
por ting</w>
com b
fur ther</w>
ri ghts</w>
a ff
tic e</w>
s k
ou s
consid ered</w>
opin ion</w>
A d
an t
o k</w>
ad ing</w>
l aid</w>
in ce</w>
plac ed</w>
g l
B A
bot h</w>
201 2</w>
o ve</w>
hi gh</w>
0 .
re commen
inter national</w>
con clu
c ed</w>
requi red</w>
kno w</w>
l ic
pr ice</w>
s ev
eg r
ag es</w>
th s</w>
CO M
b usin
n ing</w>
our ces</w>
hi gh
i onal</w>
ati s
I C
201 4</w>
str y</w>
o x
pur su
p ot
m ul
pos ition</w>
gen eral</w>
y l
1 7</w>
us ing</w>
a z
i an</w>
elec tr
con s
tr ade</w>
ad d
g overn
import ant</w>
b re
ac hi
co operation</w>
ul y</w>
a si
A D
sec tor</w>
li on</w>
saf ety</w>
techn ical</w>
gr an
ch il
tic s</w>
he alth</w>
2 1</w>
fun c
bo dy</w>
partic ip
sec urity</w>
c op
qu es
mon it
o d
ur al</w>
th ree</w>
o ci
e b
de sign
v al</w>
rece iv
I m
par t
program me</w>
establish ing</w>
or m
o t</w>
1 3
serv ice</w>
st ar
an al
In ter
at or</w>
An d</w>
j ust</w>
li f
inv ol
differen t</w>
i le</w>
r ate</w>
2 4</w>
in stru
R ep
po in
ep t
1 7
Wh ereas</w>
el s</w>
di t</w>
f ish
t ab
ad v
en s</w>
qu ality</w>
effec ts</w>
J une</w>
sign ific
acc ess</w>
m u
ob lig
1 8
at ors</w>
l ast</w>
syst ems</w>
ven tion</w>
incre ase</w>
u es</w>
assess ment</w>
proc ess
C o
m an</w>
t otal</w>
ab ove</w>
hum an</w>
ing le</w>
c ases</w>
h ow</w>
bec ause</w>
h al
trans port</w>
man ufac
d ers</w>
an u
v ari
t al
are as</w>
v ol
ma in</w>
du e</w>
propos al</w>
stan ces</w>
no w</w>
du res</w>
2 2</w>
tiv ity</w>
ref erence</w>
B r
A C
g o</w>
li ght</w>
per form
pr ac
F in
l and</w>
so ci
read y</w>
st at
emb ers</w>
ex clu
m is
divi du
200 2</w>
we e
m ov
a vi
ter m</w>
ac tive</w>
ag re
ear ch</w>
m et
fr amework</w>
con si
O n</w>
is h</w>
bu dg
c ust
c ing</w>
deter min
go ods</w>
no v
is t</w>
ub lic</w>
1 9</w>
COM M
p ut</w>
th en</w>
ros s</w>
ep t</w>
g et</w>
ti g
c ov
Wh ere</w>
f ication</w>
proce dures</w>
r y</w>
inclu de</w>
J anu
gro up</w>
y l</w>
mon ths</w>
u r</w>
A N</w>
sec tion</w>
o od</w>
t em
l ong</w>
I II</w>
ent ly</w>
h ere</w>
E S</w>
d re
indu stry</w>
Janu ary</w>
f il
equi p
O c
1 00</w>
in dividu
rit er
gen cy</w>
in te
l arg
h ar
j ud
amp ;</w>
& amp;</w>
proc ess</w>
&apos; re</w>
b ro
ar an
gro w
se qu
o p</w>
S C</w>
eff ici
&apos; m</w>
tr ain
str ateg
effec t</w>
cer tif
jec ts</w>
p i
cl os
0 00</w>
1 4
sec ond</w>
Th at</w>
a w
I S</w>
F r
ben ef
P ol
c riter
om e
t est</w>
n eg
lo od</w>
amp le</w>
a im
Un ited</w>
ou gh</w>
G en
l ing</w>
J uly</w>
7 .
ot e</w>
2 3</w>
s en
N E
direc tly</w>
ati on
addi tional</w>
fi t</w>
ev en</w>
or ing</w>
m es</w>
o le</w>
A p
pl es</w>
ag reement</w>
al low
cl ear</w>
s es</w>
n et
fi x
Th ere</w>
w ater</w>
l evel
resul ts</w>
p le</w>
ci r
inv es
d ays</w>
x imum</w>
t en</w>
n ess</w>
pursu ant</w>
aff ec
con trac
EE A</w>
P TE
in k</w>
1 5
Th ey</w>
Artic les</w>
carri ed</w>
en ter</w>
inte rest</w>
go od</w>
fo od</w>
pec i
in jec
lo b
2 8</w>
sel f</w>
re placed</w>
ass oci
busin ess</w>
effec tive</w>
ar ly</w>
cap ac
hi m</w>
level s</w>
200 1</w>
ati ves</w>
int egr
gen er
sit uation</w>
.... ....
C our
l et</w>
en d
N ov
comp any</w>
or ding</w>
Oc to
t ers</w>
Octo ber</w>
b lood</w>
ev al
il y</w>
requ est</w>
pr ices</w>
ac e</w>
ic ations</w>
inves tig
g s</w>
con sul
trans f
201 5</w>
de b
ol d</w>
st ri
i ther</w>
BA R</w>
l at
e ve</w>
1 6
bu il
m l</w>
legisl ation</w>
du ce</w>
M in
str ic
ti fied</w>
il ities</w>
pro f
ec h
b an
compan ies</w>
invest ment</w>
lis t</w>
ch arg
ha ving</w>
im port</w>
olog y</w>
incre ased</w>
pa ren
ti l</w>
des cri
ex peri
d ri
Th ese</w>
imp act</w>
al ready</w>
Cour t</w>
st ud
pers on</w>
e w
sch em
tu al</w>
T o</w>
f ree</w>
fi el
su g
og n
institu tions</w>
ay ing</w>
ma j
AN D</w>
t ;</w>
is ing</w>
st ance</w>
compl et
purpos es</w>
qu anti
gr ap
gran ted</w>
si bility</w>
rel ating</w>
Rep ublic</w>
2 9</w>
criter ia</w>
agr icul
oun ts</w>
est ed</w>
n er
di d</w>
dis e
O n
200 0</w>
s ingle</w>
gu aran
im ports</w>
ex am
Br us
M ay</w>
wor king</w>
curren t</w>
equip ment</w>
det ail
s m
sel s</w>
EU RO
defin ed</w>
af t</w>
subm itted</w>
ex ten
Brus sels</w>
cov ered</w>
ma ximum</w>
e a
ist ered</w>
int ro
ut e</w>
B o
struc ture</w>
lif e</w>
c all
mil lion</w>
4 0</w>
fl u
ta x</w>
par ties</w>
pers ons</w>
. e
de f
ad j
O ffici
anal ys
d on</w>
n orm
speci fied</w>
st ain
k in
dra w
col lec
rec ogn
cir c
con tr
ter rit
dre n</w>
or ies</w>
O N
d om
ici al</w>
S u
2 6</w>
res ources</w>
capac ity</w>
E S
ist ance</w>
ch ec
appro val</w>
n er</w>
ob serv
on ic</w>
k ey</w>
our nal</w>
2 7</w>
ut ure</w>
reg ards</w>
ic ally</w>
en ces</w>
reg ar
acc ording</w>
Mar ch</w>
U L
201 6</w>
e th
n ame</w>
i um</w>
ch ar
EURO PE
m embers</w>
stand ards</w>
Offici al</w>
J o
P l
EUROPE AN</w>
repres ent
en ing</w>
A ll</w>
ann ual</w>
res earch</w>
pres ent</w>
b ed</w>
J ournal</w>
est s</w>
ter ms</w>
se ts</w>
pre par
can not</w>
exis ting</w>
vehic le</w>
tion ing</w>
hi b
ther ap
resul t</w>
b al
u an
ai l</w>
t le</w>
issu e</w>
un til</w>
t es</w>
b in
objec tives</w>
g re
pay ment</w>
stu dies</w>
program mes</w>
pri v
our s</w>
i ble</w>
l os
no tif
on n
con stitu
wh ile</w>
cl in
r an
f uture</w>
ex pos
v er</w>
E R
hel p</w>
sur ance</w>
d ev
we ight</w>
entr y</w>
199 9</w>
ful l</w>
ti z
L ith
1 2.
6 0</w>
contain ing</w>
S T
s ing</w>
c y
EE SC</w>
A T
hal f</w>
A s
hy dro
an other</w>
addi tion</w>
tiv ely</w>
purpos e</w>
as si
signific ant</w>
h er</w>
nee ds</w>
ne t</w>
Nov ember</w>
Lith uan
cr im
wor k
pow er</w>
appl ied</w>
doc tor</w>
O ther</w>
S ept
S e
contro l
o re
c ateg
in ary</w>
su ffici
inten ded</w>
Sept ember</w>
ex port</w>
arm ac
b ack</w>
lis ted</w>
lis h</w>
tain ed</w>
s ince</w>
de pend
poin ts</w>
ren g
t or
go ing</w>
train ing</w>
Gen eral</w>
fin al</w>
P RO
chil dren</w>
ci tiz
employ ment</w>
con nec
G er
su stain
M an
p ass
s et
u c
b ur
i ance</w>
p ack
cre dit</w>
k g</w>
administr ation</w>
8 .
wor ld</w>
st ate</w>
t ation</w>
inter nal</w>
i gh
respon sible</w>
asi c</w>
pri l</w>
Au thor
9 .
loc al</w>
ques tion</w>
or ity</w>
t arg
pro m
anim als</w>
anim al</w>
amen d
w ant</w>
9 0</w>
pot ential</w>
sit e</w>
wor ks</w>
si mil
A pril</w>
er ing</w>
ap pe
G re
chang es</w>
s aid</w>
ic ate</w>
w ays</w>
E con
monit oring</w>
c ost</w>
H e</w>
econ om
an ds</w>
achi ev
og ether</w>
individu al</w>
ex pl
ac y</w>
budg et</w>
int ere
es sion</w>
re ported</w>
Wh en</w>
un i
con centr
t ro
e ither</w>
ex pec
H e
a red</w>
fu l</w>
bet ter</w>
S o
T S</w>
imple menting</w>
g ive</w>
cap ital</w>
appro ved</w>
i ous</w>
administr ative</w>
l or
s pe
pl an</w>
partic ul
sti ll</w>
ad ded</w>
F un
ear ly</w>
grow th</w>
H AS</w>
injec tion</w>
per vis
instru ments</w>
8 0</w>
stand ard</w>
m er
z e</w>
agricul tural</w>
intro duc
reg ional</w>
n at
pol i
it ure</w>
en ess</w>
measu re</w>
r ap
t ogether</w>
pro jects</w>
contin u
ev ery</w>
sol ution</w>
h ere
inclu ded</w>
val ues</w>
min imum</w>
environ mental</w>
up s</w>
u re
Im ple
re view</w>
adj ust
receiv ed</w>
simil ar</w>
pro g
ev er
ar rang
co ord
l ong
olog ical</w>
a ve</w>
fiel d</w>
d os
manufac tu
speci al</w>
s ome
b asic</w>
C I
G ro
tr an
ous ly</w>
ac tivity</w>
follow s</w>
en s
compl iance</w>
docu ments</w>
speci f
AD O
th ink</w>
ma king</w>
bo dies</w>
g reat
ad i
ord ers</w>
v ent</w>
su c
ac ter
e duc
TH IS</w>
PTE D</w>
m ission</w>
s w
Econ omic</w>
co de</w>
produc ers</w>
ADO PTED</w>
re stric
direc t</w>
stud y</w>
ur o</w>
ou se</w>
- -
pro ject</w>
w om
fac t</w>
f re
ver s
mul ti
ap ter</w>
l ar
ic ity</w>
en ted</w>
mark ets</w>
st reng
consi der
author isation</w>
provi des</w>
er c
in d
O R</w>
le ts</w>
port un
G u
form s</w>
ac ts</w>
in nov
grap h
polic ies</w>
ex ample</w>
id el
know n</w>
t able</w>
propos ed</w>
bel ow</w>
al i
dise ase</w>
therap y</w>
competi tion</w>
fix ed</w>
dis c
tre ated</w>
R es
r ing</w>
sel ec
clin ical</w>
1 ,
ben e
fun ds</w>
L i
al low</w>
ne w
ou th</w>
bel i
fish ing</w>
A gency</w>
cal cul
sub paragraph</w>
op portun
S tr
ill ed</w>
g n</w>
de si
pos i
lim ited</w>
contin ue</w>
suppl y</w>
ex pres
7 5</w>
n am
cor rec
amen ding</w>
er age</w>
do m</w>
7 0</w>
sh or
I V</w>
l ication</w>
d en</w>
x im
vi l</w>
l it
ic a</w>
environ ment</w>
is es</w>
f ound</w>
ai m</w>
m ech
orig in</w>
si on
ver se</w>
materi al</w>
cop e</w>
is ter</w>
o s</w>
citiz ens</w>
F eb
appro ach</w>
E R</w>
is m</w>
ro le</w>
t ow
en h
il it
Feb ru
SI ON</w>
cont ent</w>
ful ly</w>
y s</w>
Febru ary</w>
o ti
ass istance</w>
C H
at s</w>
fac e</w>
re pe
cor por
sm all</w>
p op
high er</w>
m ember</w>
O r
N or
s c
pro per
se e
oper ations</w>
pub lication</w>
Imple menting</w>
in s</w>
issu ed</w>
organis ation</w>
organis ations</w>
mu ch</w>
st oc
comm it
ci es</w>
tiv eness</w>
tim es</w>
m un
mar k</w>
ecis ions</w>
pa in</w>
ag ed</w>
us es</w>
al loc
U S
vehic les</w>
investig ation</w>
bin ding</w>
analys is</w>
docu ment</w>
u res</w>
c o</w>
ch em
3 4</w>
g e
AN NE
b est</w>
f ail
UN I
g as</w>
m ach
s or
ch o
im pl
pend iture</w>
sub stances</w>
A L
se par
poli tical</w>
sh ip
author ised</w>
b on</w>
b order</w>
im medi
issu es</w>
perform ance</w>
inf ec
pos ed</w>
9 5</w>
B el
materi als</w>
nat ural</w>
of f</w>
B ut</w>
rec or
ANNE X</w>
finan cing</w>
su pervis
pre vi
priv ate</w>
0 ,
gro ups</w>
9 6</w>
E N
con duc
c ris
Par t</w>
w ard</w>
bene fit</w>
le dg
exc ee
ter nal</w>
e .
le ase</w>
associ ated</w>
ee p</w>
ev id
m m</w>
men ted</w>
tur n</w>
oper ating</w>
provis ion</w>
p es</w>
9 8</w>
recommen ded</w>
ing ly</w>
in surance</w>
f am
p s</w>
Sec tion</w>
cust oms</w>
a k</w>
t om
g .</w>
j us
Tr ans
IN G</w>
th ough</w>
as h</w>
sub stance</w>
pub lish
A t</w>
co l</w>
w ast
w ar
c over</w>
ph armac
me eting</w>
D one</w>
IS SION</w>
er v
contain s</w>
s pen
av erage</w>
suc c
b le
D o</w>
av o
com par
C entr
diff icul
ol ution</w>
d ings</w>
dis tribu
oblig ations</w>
I tal
en ter
p aid</w>
ic k
if ication</w>
add res
c are</w>
Ch in
S y
du ty</w>
on ce</w>
COMM ISSION</w>
c ell
du mp
li k
c ent
tion ed</w>
j ur
ex change</w>
o graph
disc us
la w
Author ity</w>
pro bl
ig n</w>
ess ential</w>
reduc tion</w>
ter n
fo re
Th ere
ut es</w>
ex penditure</w>
tu res</w>
comp on
p at
princi ple</w>
in sul
ar ies</w>
medic inal</w>
adop t</w>
ang u
regar ding</w>
RE G
norm al</w>
g e</w>
particul arly</w>
tur ing</w>
h ear
ol s</w>
w at
soci ety</w>
op en</w>
in ed</w>
an ces</w>
objec tive</w>
add ress</w>
g lob
idel ines</w>
vol um
Jo int</w>
agre ements</w>
ar s</w>
strateg y</w>
to o</w>
tr y</w>
contribu tion</w>
know ledg
contr act</w>
b er
great er</w>
A f
manufactu re
Ch apter</w>
schem e</w>
ef for
c ross</w>
tr av
f ar</w>
et er
f av
ing dom</w>
rel ation</w>
b il
et ary</w>
st atis
A U
territ ory</w>
ab les</w>
mark eting</w>
A S
There fore</w>
si a</w>
suffici ent</w>
tran si
inf ra
detail ed</w>
cor respon
as sets</w>
wh ole</w>
H ow</w>
P h
probl ems</w>
e uro</w>
n u
re main
h ap
cont ext</w>
s ci
respon se</w>
cris is</w>
par ts</w>
3 2</w>
sh ow
is sions</w>
tr ad
h ours</w>
9 1</w>
net work</w>
me et</w>
rang e</w>
neg oti
hel d</w>
vi a</w>
me an</w>
in st
at t
experi ence</w>
3 5</w>
to col</w>
consum ption</w>
educ ation</w>
impro ve</w>
n ers</w>
lim it</w>
larg e</w>
on str
ad equ
com ple
pr im
&apos; ll</w>
comm er
princi ples</w>
sug ar</w>
in spec
R I
n ature</w>
3 3</w>
publish ed</w>
evid ence</w>
determin ed</w>
wom en</w>
maj or</w>
low er</w>
at ten
m ob
process ing</w>
invol ved</w>
si m
s cope</w>
tab lets</w>
s ay</w>
4 3</w>
wast e</w>
ail y</w>
up on</w>
dem onstr
design ed</w>
regul atory</w>
it ation</w>
G overn
So cial</w>
9 2</w>
ci vil</w>
et ed</w>
sh are</w>
in ated</w>
h and</w>
f requ
M a
in ating</w>
th em
arrang ements</w>
equi val
p an
d ecisions</w>
sustain able</w>
cour se</w>
3 6</w>
i al</w>
en e</w>
l ines</w>
d a
econom y</w>
bec ome</w>
ev ent</w>
K ingdom</w>
prog ress</w>
pro por
as ing</w>
8 7</w>
N e
ea h</w>
stan ding</w>
l aying</w>
in depend
ell ing</w>
ta x
wee ks</w>
compl y</w>
ant i</w>
indic ated</w>
mech anis
al e</w>
par ty</w>
char acter
h owever</w>
ME N
D U
cons is
pres sure</w>
men tioned</w>
0 1</w>
R ec
struc tion</w>
enti re
an ing</w>
vari ous</w>
E D</w>
mat ter</w>
l angu
under tak
d aily</w>
all eng
m ine</w>
re duce</w>
ex erc
go t</w>
1 1.
c e
over all</w>
our ce</w>
D e
w el
EC B</w>
ac id</w>
fac ilit
ser ious</w>
eval uation</w>
Ger many</w>
p ed</w>
ti al</w>
Comm on</w>
af f</w>
t as
es tim
vi ew
reg ulation</w>
pl as
sign ed</w>
reduc ed</w>
st aff</w>
sev eral</w>
ar ound</w>
hol ders</w>
f ru
provi ding</w>
expec ted</w>
el ig
S h
applic ations</w>
f y</w>
B y</w>
produc ed</w>
comb ination</w>
A n</w>
st or
ex ternal</w>
T O</w>
cl assi
ris ks</w>
spec ies</w>
requi re</w>
nee ded</w>
ch lor
sal es</w>
func tion</w>
meth od</w>
M on
e. g.</w>
pr e</w>
9 3</w>
circ um
P r
a x
pl ant</w>
th ro
W or
ch alleng
dec lar
pri or</w>
A T</w>
4 8</w>
indu stri
con fir
O L
S P
t ent</w>
du ties</w>
I T
call ed</w>
am ong</w>
p ing</w>
S o</w>
ex per
W ith</w>
f oc
M ed
es ting</w>
dec re
Gro up</w>
u l</w>
f our</w>
ON S</w>
expos ure</w>
10 .
n ed</w>
2 5
no tified</w>
er ies</w>
E F
s atis
commun ication</w>
i ded</w>
c at
Pro duc
st ed</w>
undertak ings</w>
UL ATION</w>
g t;</w>
& gt;</w>
a w</w>
A I
estab lish</w>
recommen d
F ur
ner ship</w>
4 5</w>
mo di
star t</w>
comp ared</w>
under taking</w>
Pro tocol</w>
trans paren
m ic
fun ding</w>
reg ions</w>
sh e</w>
l y
requ ested</w>
ar ity</w>
transf er</w>
tow ards</w>
h s</w>
l et
it ors</w>
S peci
ess els</w>
reas ons</w>
benef its</w>
me d
ar tic
cl aim
b eg
REG ULATION</w>
m a</w>
em issions</w>
pro mo
amend ments</w>
un ds</w>
sim pl
prof es
insul in</w>
oper ators</w>
mi gr
applic ant</w>
oc c
enti fic</w>
S ub
reg n
s am
em ia</w>
o th
institu tion</w>
v ely</w>
o il</w>
ach ed</w>
201 7</w>
ar if
v essels</w>
Lithuan ia</w>
F und</w>
ob tained</w>
r s</w>
D evelop
pre vent</w>
is tics</w>
re t
identi fied</w>
bo ard</w>
f er
s em
work ers</w>
Fin an
r adi
B ank</w>
meth ods</w>
6 5</w>
cl im
og ue</w>
3 0
ag ing</w>
re ports</w>
ty pes</w>
ou l
p ir
on es</w>
th us</w>
Inter national</w>
fi ve</w>
ap er</w>
Pro gram
O p
equ al</w>
infra structure</w>
establish ment</w>
an e
observ ed</w>
r ati
v o
de l</w>
electr onic</w>
p rec
o di
fin d</w>
off icial</w>
le ad</w>
e ed</w>
c ement</w>
t ext</w>
ex em
es peci
6 8</w>
ti s</w>
th y</w>
an tly</w>
Con vention</w>
I s
adop tion</w>
long er</w>
der iv
re porting</w>
commer cial</w>
prac tic
su spen
glob al</w>
equival ent</w>
f t</w>
M e
en cour
especi ally</w>
sy mp
ref lec
istr ation</w>
re al</w>
in form</w>
appro xim
Y eah</w>
r ates</w>
t on</w>
dump ing</w>
vis ion</w>
ad ap
B e
conclu ded</w>
effici ency</w>
sh own</w>
sur ing</w>
b or
bal ance</w>
reg ion</w>
d en
cont act</w>
20 20</w>
effici ent</w>
Fun c
volum e</w>
exc ep
Fr ance</w>
certif icate</w>
ch es</w>
comp ati
contrac ts</w>
an e</w>
har mon
n ext</w>
p ul
d ou
3 7</w>
per m
guaran tee</w>
mil k</w>
be half</w>
ro ad</w>
am ounts</w>
m ight</w>
pay ments</w>
los s</w>
us ers</w>
4 9</w>
A M
paragrap hs</w>
d am
achi eve</w>
pers onal</w>
m ed</w>
mon th</w>
tin gs</w>
in form
CO N
oc r
A G
re actions</w>
v acc
con f
G od</w>
ic s</w>
propos als</w>
con c
consum ers</w>
k ay</w>
evel op</w>
por te
e m</w>
ti n</w>
el ements</w>
pl ay</w>
e y
con fi
A mer
eg et
R om
D is
descri bed</w>
car ry</w>
entire ty</w>
P or
lab our</w>
represent ative</w>
e ding</w>
exclu ding</w>
E ach</w>
al ised</w>
immedi ately</w>
sec tors</w>
he ad
C l
innov ation</w>
medic ine</w>
lik ely</w>
f illed</w>
charg e</w>
T able</w>
f a
for ward</w>
con form
at h</w>
inst all
9 9</w>
sub si
b ers</w>
n i
Q u
in c
me at</w>
ca use</w>
knowledg e</w>
m or
prom ote</w>
Develop ment</w>
un g
D I
reg istered</w>
mi x
excee ding</w>
com es</w>
en cies</w>
ab ol
stor age</w>
consum er</w>
d evelop</w>
out side</w>
3 9</w>
en suring</w>
t oms</w>
comp ens
Finan cial</w>
d one</w>
tu ally</w>
TI ES</w>
oper ational</w>
medic ines</w>
re new
pres ented</w>
I M
c le</w>
org an
ec hn
ag ain</w>
admin istered</w>
del eg
k es</w>
ten ance</w>
previ ous</w>
adv ant
pl ann
l ater</w>
intere sts</w>
categ ory</w>
jo int</w>
gro und</w>
T R
to day</w>
prac tice</w>
manufacture r</w>
sol id
pur ch
3 5
al tern
complet e</w>
........ ........
9 7</w>
ab ly</w>
9 4</w>
si onal</w>
der og
al isation</w>
acc ounts</w>
stat us</w>
A P
e an</w>
as pec
initi ative</w>
dom es
pass eng
import ance</w>
wh ose</w>
posi tive</w>
co h
ten ce</w>
quanti ties</w>
clim ate</w>
lim its</w>
cl ose</w>
ul ations</w>
w ise</w>
ar ri
R us
F OR</w>
r o</w>
con sequ
me aning</w>
pre jud
develop ed</w>
ev ents</w>
circum stances</w>
ever y
an ced</w>
4 2</w>
con ver
Func tioning</w>
respon sibility</w>
agre ed</w>
lo o
centr al</w>
subm it</w>
Au g
curren tly</w>
notif ication</w>
v ement</w>
On e</w>
particip ation</w>
2 ,
sec ur
in corpor
O ff
8 5</w>
ag ement</w>
S U
th re
Af ter</w>
8 9</w>
&apos; ve</w>
exc ept</w>
N ot</w>
enter pr
ess es</w>
sk in</w>
t onn
re li
enti ty</w>
air s</w>
v eget
t ests</w>
ou ng</w>
ph ys
lo ok</w>
An n
cust om
7 1</w>
Mar k
Par ties</w>
c ut
imple mented</w>
instru ment</w>
4 4</w>
si ze</w>
S lo
wh y</w>
mon ey</w>
symp toms</w>
Aug ust</w>
beli eve</w>
he ading</w>
n ation
ed ings</w>
govern ment</w>
mo der
ac ross</w>
Program me</w>
un it</w>
contribu te</w>
4 6</w>
eval u
4 7</w>
i de
acc oun
ex tent</w>
an y
wee k</w>
adequ ate</w>
l t;</w>
& lt;</w>
prejud ice</w>
achiev ed</w>
buil ding</w>
is sion
guaran te
c all</w>
fru it</w>
pop ulation</w>
calcul ated</w>
t a</w>
dr aft</w>
med ical</w>
an c
pack age</w>
reas on
benef ici
w ide</w>
qu e</w>
sub stan
h en
t ell</w>
Bo ard</w>
pati ent</w>
ou ght</w>
oper ator</w>
ar ing</w>
elig ible</w>
di al
hol d</w>
qu al
draw n</w>
pl ay
sy n
ar t
IS I
del i
tem por
develop ing</w>
E N</w>
proce edings</w>
enti ties</w>
di um</w>
en z
8 8</w>
gre at</w>
orig inating</w>
fam ily</w>
f arm
ad verse</w>
l ack</w>
f ish</w>
al ways</w>
addres sed</w>
L E</w>
effor ts</w>
affec t</w>
shor t</w>
set ting</w>
porte ur</w>
del iv
E X
am p</w>
techn ology</w>
o red</w>
conform ity</w>
re si
p ay</w>
a ke</w>
in flu
li gh
N o
he ad</w>
en for
sev ere</w>
repe al
dec ided</w>
g ar
practic es</w>
O h</w>
fi le</w>
am es</w>
b ra
P er
li qui
distribu tion</w>
off ice</w>
ac compan
main tenance</w>
domes tic</w>
T el</w>
h and
S up
b ir
ill s</w>
mo ve</w>
me t</w>
7 2</w>
exc eed</w>
Ac cor
m en</w>
to x
Su ch</w>
Bel g
8 2</w>
ble m</w>
ari an</w>
u su
avo id</w>
ic k</w>
character istics</w>
h ist
olog ies</w>
6 2</w>
Centr al</w>
.e .</w>
sci entific</w>
en ed</w>
d ated</w>
p regn
8 4</w>
y et</w>
im e</w>
C F
oblig ation</w>
re main</w>
produc er</w>
re ven
le ar
over y</w>
si x</w>
desi gn</w>
i .e.</w>
20 0</w>
y oung</w>
pro blem</w>
v ot
ha em
sh ow</w>
h ome</w>
m b
com ing</w>
struc turing</w>
er ation</w>
e a</w>
w in
or al</w>
re mov
fu el</w>
f ri
os is</w>
lab or
arif f</w>
tr a</w>
st and</w>
pres cri
6 6</w>
coord ination</w>
fe ed</w>
fac tors</w>
da mental</w>
kin d</w>
con tain</w>
0 6</w>
consid ers</w>
si b
h o
v eter
7 7</w>
ul t</w>
Se e</w>
gu idelines</w>
b an</w>
5 5</w>
t le
ph en
il s</w>
P R
W ith
w rit
3 8</w>
fu sion</w>
control led</w>
Comm ission
V E</w>
di g
re ally</w>
TI C
un its</w>
e x</w>
sal e</w>
declar ation</w>
of ten</w>
k eep</w>
un less</w>
e u
F ir
d ence</w>
targ et</w>
N ational</w>
L I
pos t</w>
resul ting</w>
b ri
regul ations</w>
ve ill
D EC
l ands</w>
veill ance</w>
ch ing</w>
s on</w>
res olution</w>
DU C
cl early</w>
correspon ding</w>
ther wise</w>
N G</w>
Ac c
mo del</w>
lit tle</w>
e f</w>
we b
pers on
os ph
throu gh
onn a</w>
ne l</w>
0 5</w>
law s</w>
il i
br ing</w>
B al
P e
off er</w>
an cy</w>
vers ity</w>
expres sed</w>
sel ves</w>
ther more</w>
consi der</w>
as k</w>
trans actions</w>
avi r</w>
su s</w>
in hib
e tic</w>
cre ate</w>
r ing
it able</w>
h er
P o
P AR
fail ure</w>
it ary</w>
independ ent</w>
Ital y</w>
N ew</w>
f all
integr ation</w>
industri al</w>
In formation</w>
wor ds</w>
C N</w>
part ners</w>
cr aft</w>
id es</w>
deter mine</w>
dis orders</w>
ab ilities</w>
P re
ren al</w>
g en</w>
ment ary</w>
h or
cur red</w>
condi tion</w>
COMM UNI
au tom
S erv
un d
iz ed</w>
pol y
hol ding</w>
approxim ately</w>
sub sequ
receiv ing</w>
ex porting</w>
g onna</w>
jud g
v es
re turn</w>
ti s
t al</w>
ar ily</w>
bro ad
se en</w>
rece ive</w>
u tions</w>
6 1</w>
atten tion</w>
st age</w>
legisl ative</w>
pos sibility</w>
s ent</w>
I R
some thing</w>
l ate</w>
An y</w>
he al
L u
T echn
d ru
h ep
Accor ding</w>
O f</w>
ist ent</w>
ro w</w>
li ve</w>
p t</w>
opportun ities</w>
co ated</w>
M al
hol der</w>
6 7</w>
ec e</w>
ship s</w>
s ources</w>
I N</w>
coun ter
compon ents</w>
through out</w>
ti l
tas ks</w>
T ur
S ince</w>
in jur
gr ant</w>
dra w</w>
rel and</w>
Man agement</w>
to ok</w>
incre asing</w>
ri ting</w>
it self</w>
inclu des</w>
tem per
ob s</w>
7 8</w>
I reland</w>
chil d</w>
orig inal</w>
C E</w>
w w
allow ed</w>
oper ate</w>
s cal
hear t</w>
deb ate</w>
is on</w>
Sec urity</w>
pri ority</w>
requi res</w>
ak e
8 3</w>
I I
k e
i ds</w>
m ot
7 3</w>
quanti ty</w>
negoti ations</w>
chec ks</w>
men d
ri g
dec ide</w>
categ ories</w>
exerc ise</w>
se l</w>
pos al</w>
Par ty</w>
impl ement</w>
reg ular</w>
pro hib
w riting</w>
initi al</w>
de pen
dis crim
Govern ment</w>
S we
S P</w>
sum m
rec ent</w>
0 2</w>
connec tion</w>
pa red</w>
f ew</w>
4 1</w>
t ory</w>
fil m</w>
consul tation</w>
L E
v en</w>
t el
b ank</w>
dem and</w>
S w
mar g
L is
stoc k</w>
concern s</w>
separ ate</w>
Co de</w>
A fr
t ex
adjust ment</w>
L et</w>
J us
en able</w>
affec ted</w>
profes sional</w>
recommend ations</w>
P O
Y our</w>
aspec ts</w>
continu ed</w>
require ment</w>
facilit ate</w>
accord ingly</w>
M o
8 6</w>
reg istration</w>
am et
F or
on line</w>
acc ep
h ouse</w>
l an
fre ed
inform ed</w>
PRO DUC
c over
o therwise</w>
num bers</w>
dem ocr
8 1</w>
in come</w>
fol low</w>
E I
ple ase</w>
st ake
mov ement</w>
sp ace</w>
invest ments</w>
Commun ication</w>
L e
m y
om en
th ings</w>
ref eren
des tin
b a
appl ying</w>
mat ters</w>
A gr
d n</w>
det ec
protec t</w>
dur ation</w>
5 1</w>
Direc tor</w>
re structuring</w>
c ro
f air</w>
ec u
Chin a</w>
reas on</w>
g ame</w>
identi fication</w>
ter min
n ever</w>
so on</w>
R o
acc ept
w id
Off ice</w>
ro l
L o
c ru
or ities</w>
CO UN
Fur thermore</w>
sit u
rec overy</w>
ic an</w>
he sion</w>
intere sted</w>
A B
A R</w>
d y
trans mission</w>
integr ated</w>
st re
ag g
schem es</w>
appl ies</w>
ren ch</w>
li ghts</w>
A b
re d
Por tu
T A</w>
Ac tion</w>
as h
fore ign</w>
c el
st er</w>
ent ered</w>
defin i
dos es</w>
deb t</w>
neg ative</w>
ban ks</w>
sch o
AT E</w>
Amer ica</w>
tak es</w>
re ach</w>
c ar</w>
s ource</w>
COMMUNI TIES</w>
con struction</w>
l u
if y</w>
H um
vi ol
do ing</w>
i bility</w>
pow ers</w>
res er
maj ority</w>
com ments</w>
per cent
recogn ised</w>
n s</w>
at a</w>
F ol
E P
6 4</w>
7 9</w>
F rench</w>
em ic</w>
Jus tice</w>
5 8</w>
j obs</w>
t led</w>
mic ro
provis ional</w>
mach ines</w>
medi um</w>
ste p</w>
proper ty</w>
lo g
er n</w>
al ia</w>
bu t
ad s</w>
h op
CO M</w>
7 4</w>
5 2</w>
U R
En ergy</w>
perform ed</w>
stat ement</w>
langu age</w>
st ates</w>
Speci al</w>
ten der</w>
sug g
7 6</w>
tain ing</w>
pl ants</w>
og en
0 3</w>
defin ition</w>
5 4</w>
sy ring
let ter</w>
pl ans</w>
Pro c
S ch
ad vis
rap porteur</w>
spe ed</w>
bil lion</w>
Commission er</w>
Agr icul
Pol ic
ac qu
um in
ch ed</w>
st ep
no te</w>
electr icity</w>
t ariff</w>
compl ain
here by</w>
dev ice</w>
b loc
str ong</w>
As s
respec tive</w>
opportun ity</w>
sec on
O per
follow ed</w>
MEN T</w>
ge ograph
S ME
direc tive</w>
n it
5 6</w>
lic ence</w>
I P</w>
wh e
enterpr ises</w>
challeng es</w>
b on
C ol
cer tain
er o
initi atives</w>
ri c</w>
chang ed</w>
no tice</w>
ac ting</w>
contain ed</w>
chec k</w>
m ass</w>
fav our</w>
A re
H y
L O
a res</w>
i m</w>
cell s</w>
exam ination</w>
eb o</w>
fr on
W ell</w>
detail s</w>
i ting</w>
U S</w>
main tain</w>
frequ ency</w>
cl e
t i</w>
ec h</w>
t esting</w>
em er
lin ked</w>
v est
succ ess
Lithuan ian</w>
prim ary</w>
i i</w>
et c</w>
a way</w>
C y
M ore
ar m</w>
func tioning</w>
s l
dial ogue</w>
He alth</w>
ff s</w>
hy per
techn ologies</w>
SME s</w>
M ad
descri ption</w>
Lis bon</w>
S pain</w>
S p
re ci
Or g
I s</w>
pro te
R i
in ate</w>
re ment</w>
wh ite</w>
B ul
N C
C ar
net works</w>
d eg
Reg ulations</w>
T otal</w>
Fr amework</w>
transparen cy</w>
v ote</w>
c tion</w>
0 8</w>
c ulation</w>
respec tively</w>
M AR
a p</w>
enfor cement</w>
3 00</w>
i gn
s po
ste el</w>
op h
More over</w>
man ner</w>
Com e</w>
D es
an ks</w>
fi b
pre pared</w>
min utes</w>
we igh
F OR
e di
la un
ex es</w>
tempor ary</w>
complet ed</w>
met abol
temper ature</w>
i gh</w>
b ase</w>
0 7</w>
S af
compati ble</w>
n e</w>
5 3</w>
oth ers</w>
st ated</w>
4. 4</w>
ane ous</w>
0 4</w>
pro p
6 3</w>
signific antly</w>
inter vention</w>
le ft</w>
l ac
inspec tion</w>
l s</w>
e es</w>
al ities</w>
pos e</w>
val id
conclu sion</w>
jo b</w>
in ning</w>
air port</w>
vi al</w>
E m
wat ers</w>
indic ate</w>
m us
is ts</w>
compens ation</w>
gl ass</w>
st op</w>
w i
on ia</w>
d a</w>
stake holders</w>
pl at
tle ment</w>
D ur
dev ices</w>
P lease</w>
ac tual</w>
concentr ation</w>
derog ation</w>
effec tiveness</w>
streng th
air craft</w>
m ag
consider ation</w>
ac tually</w>
percent age</w>
y ond</w>
low ing</w>
recogn ition</w>
peri ods</w>
scal e</w>
op ening</w>
fun damental</w>
t ations</w>
Polic y</w>
sup porting</w>
TI ON</w>
veget ables</w>
AU TH
Fir st</w>
fac tor</w>
ro om</w>
arg u
p aper</w>
l ation</w>
collec tion</w>
propor tion
a u</w>
prepar ation</w>
au d
t op
lo t</w>
af fic</w>
s ence</w>
them selves</w>
rou ght</w>
AUTH OR
plac ebo</w>
Str ateg
veter inary</w>
E M
poin ted</w>
artic les</w>
ref und</w>
ass ess</w>
car bon</w>
I T</w>
F ood</w>
h t
commit ment</w>
ag ue</w>
lat est</w>
201 8</w>
A t
D el
s ample</w>
au gh
op tion</w>
af let</w>
-- --
c ere
Y es</w>
TI ONS</w>
occ ur</w>
sam pl
ca used</w>
5 9</w>
determin ing</w>
lic ences</w>
control s</w>
mechanis m</w>
ISI ON</w>
cul tural</w>
ma kes</w>
C or
L at
C ap
fish eries</w>
ques tions</w>
di a</w>
e p</w>
cl aim</w>
sup ported</w>
ph ase</w>
p u
assess ed</w>
in struc
Wh y</w>
el im
lat eral</w>
in ser
I U</w>
C C
re pl
phys ical</w>
P ati
to ols</w>
sup ple
ri a</w>
foc us</w>
clos ed</w>
ci d
Rom an
5 7</w>
in ter</w>
tr ading</w>
cre ation</w>
P L
quot a</w>
busin esses</w>
E ur
ta il</w>
fu c
eng ine</w>
re lease</w>
N ow</w>
tonn es</w>
g al</w>
ic ates</w>
z er
cons istent</w>
sur veillance</w>
sur face</w>
represent atives</w>
ab sence</w>
Sy stem</w>
amend ment</w>
p en</w>
chem ical</w>
impro ving</w>
fi l</w>
accep ted</w>
em ed</w>
c ent</w>
6 9</w>
R u
CI L</w>
D ate</w>
ser ies</w>
5 00</w>
um n</w>
E st
it er
injur y</w>
Ap pl
migr ation</w>
be yond</w>
ure ment</w>
contribu tions</w>
i on
ain ed</w>
r ying</w>
H ey</w>
li ver</w>
al one</w>
call s</w>
S he</w>
fl ex
re ad</w>
T y
COUN CIL</w>
accompan ied</w>
f f</w>
ves sel</w>
re p
ag ree</w>
ru le</w>
it ems</w>
design ated</w>
suppl i
rec ital</w>
secur ities</w>
pow der</w>
S A</w>
competi tiveness</w>
h ard</w>
ic t</w>
3 ,
n ight</w>
ra w</w>
C ha
comm ittee</w>
st ability</w>
Commun ities</w>
difficul t</w>
so dium</w>
E L
B ar
introduc tion</w>
fr ing
protec ted</w>
Min ister</w>
iz ation</w>
gen ce</w>
el ess</w>
T it
pri orities</w>
A F
D E</w>
clos ure</w>
imp air
conduc ted</w>
sit es</w>
uro pa
s ound</w>
IS ATION</w>
rel ations</w>
im posed</w>
ne ed
statis tics</w>
g ation</w>
istr y</w>
comp re
introduc ed</w>
competi tive</w>
subsi di
ish ed</w>
confir med</w>
ar t</w>
plas ma</w>
su ff
process es</w>
inter pre
claim s</w>
Th ose</w>
ver ification</w>
ra ther</w>
O kay</w>
cl ear
no tes</w>
V I</w>
sol utions</w>
er ous</w>
l eng
at ures</w>
ach es</w>
f all</w>
TI NG</w>
develop ments</w>
web site</w>
relev ance</w>
nu clear</w>
fac ilities</w>
freed om</w>
w ine</w>
CH A
sh ares</w>
reven ue</w>
infec tion</w>
t ol
Pol and</w>
a ther</w>
H ung
alloc ation</w>
ain s</w>
a .
C R
3 0.
ag encies</w>
de pos
val id</w>
res h</w>
in after</w>
accoun ting</w>
- -</w>
k ers</w>
at om</w>
compre hen
gl y
cal culation</w>
199 8</w>
alloc ated</w>
b ack
As soci
impair ment</w>
R ef
step s</w>
tr affic</w>
t un
H ol
se a</w>
diff erence</w>
IN AL</w>
G E
re form</w>
PTE R</w>
Chin ese</w>
measu red</w>
CHA PTER</w>
Pati ents</w>
am b
Ap pro
n or</w>
a x</w>
en ding</w>
Ap pen
conclu sions</w>
it em</w>
di men
geograph ical</w>
si an</w>
lo ans</w>
M i
in fring
altern ative</w>
stoc ks</w>
pro fit</w>
coun t</w>
estim ated</w>
D P</w>
jec ted</w>
vol un
con v
promo ting</w>
A B</w>
exten ded</w>
M y</w>
gr ad
a th
per man
D IC
d ates</w>
f la
sib ilities</w>
saf e</w>
a qu
struc tures</w>
here inafter</w>
AUTHOR ISATION</w>
reduc ing</w>
St and
Eur atom</w>
concer n</w>
S ol
CF SP</w>
Ch ar
bi o
Are a</w>
s mo
oun d
lo ad</w>
ans w
mo d
Sec ret
M embers</w>
1 50</w>
supervis ion</w>
gro unds</w>
commit ments</w>
le aflet</w>
writ ten</w>
star ting</w>
budg etary</w>
A ff
in de
rel ation
D en
con solid
eg u
m ing</w>
suspen sion</w>
T O
b rought</w>
ag ents</w>
us er</w>
iti onal</w>
tic ally</w>
e asi
constitu te</w>
e e</w>
statis tical</w>
c ou
p et
ex pen
syring e</w>
no ted</w>
pres ence</w>
ac cid
sk ills</w>
in fl
identi fy</w>
Med ic
notif y</w>
cl ass</w>
re ached</w>
Ne ther
f light</w>
z one</w>
process ed</w>
di x</w>
Y P
d ly</w>
en ough</w>
f low</w>
ol es
loc ated</w>
gener ally</w>
ot h</w>
advant age</w>
A TE
tin e</w>
i fied</w>
tr act</w>
et h</w>
in fusion</w>
B i
ox ide</w>
el ine</w>
am in
min d</w>
pre vention</w>
DEC ISION</w>
au dit</w>
V i
F rom</w>
le ave</w>
strateg ic</w>
exper ts</w>
cour t</w>
2 4
si z
Nether lands</w>
S ome</w>
ati c
tri als</w>
can c
dec la
id ance</w>
qu ar
co des</w>
K E
H ome</w>
M B
wh ereas</w>
Gre ece</w>
m ess
r un
view s</w>
in ing</w>
charg es</w>
de emed</w>
in ess</w>
I r
incorpor ated</w>
Ac t</w>
p ast</w>
hi le</w>
M s</w>
ph osph
I F
le ading</w>
k ra
SP EC
Fol lowing</w>
Re port</w>
plac ing</w>
ill ing</w>
Saf ety</w>
effec tively</w>
ef ul</w>
On ly</w>
hap pen
c ame</w>
pro duce</w>
P os
C an
b it
ow n
is c
Aff airs</w>
our g</w>
ic it</w>
compon ent</w>
sub jects</w>
it or</w>
govern ance</w>
Ann exes</w>
mechanis ms</w>
selec ted</w>
certif icates</w>
ra z
U se</w>
proc urement</w>
del ay</w>
manufac ture</w>
s ession</w>
In stitu
tab let</w>
adv ice</w>
o kin
modi fied</w>
lo dg
d ang
ach ing</w>
indic ators</w>
c ash</w>
gran ting</w>
pr in
su itable</w>
c lo
l ays</w>
T S
im al</w>
reason able</w>
Rus sia</w>
differen ces</w>
decre ase</w>
dam age</w>
main ly</w>
comb ined</w>
F e
l ad
G r
monit or</w>
c ell</w>
Lu x
jus tified</w>
A ust
ay er</w>
emer gency</w>
e tings</w>
particip ating</w>
R ev
por ter</w>
f lo
func tions</w>
ic h
E lec
c ut</w>
fin ance</w>
S ingle</w>
r .</w>
sh e
loc ation</w>
re vis
U kra
H igh</w>
car rying</w>
dis tor
op tions</w>
quot as</w>
mob ility</w>
pen sion</w>
C ust
dou b
si vely</w>
hy dr
Belg ium</w>
acc es
k ings</w>
pl an
dis t
trans m
C ro
ME DIC
al though</w>
su b</w>
ris e</w>
acc ession</w>
s cre
invol ving</w>
pre sid
ex pir
m al
n a
medi a</w>
conduc t</w>
M S</w>
con fl
N um
U N</w>
deli very</w>
ploy ment</w>
anis h</w>
c as
stu ffs</w>
ru n</w>
ver sion</w>
Mark et</w>
a king</w>
custom ers</w>
a ren
me etings</w>
em ission</w>
show s</w>
bir th</w>
R ules</w>
ent ation</w>
i e</w>
employ ed</w>
fi ght</w>
beg inning</w>
y e</w>
off ici
ac qui
l er</w>
r ating</w>
d on
comprehen sive</w>
en su
a emia</w>
te am</w>
certif ication</w>
to p</w>
usu ally</w>
ph ot
pre ven
it es</w>
T o
guarante es</w>
omen cl
remain s</w>
leng th</w>
d enti
saf egu
I C</w>
p tions</w>
ne y</w>
bo ok</w>
ist an</w>
enti tled</w>
MEDIC INAL</w>
m in</w>
Appen dix</w>
correc t</w>
0 9</w>
concentr ations</w>
aim ed</w>
V AT</w>
v it
targ ets</w>
trad itional</w>
Dur ing</w>
ex ports</w>
omencl ature</w>
ter r
bo o
chlor ide</w>
Tit le</w>
ag n
f a</w>
impro vement</w>
g t</w>
au th
Ad di
supervis ory</w>
St at
decla red</w>
cre ated</w>
subsequ ent</w>
re di
dis tin
S ta
Associ ation</w>
li ving</w>
t our
coh ol</w>
re in
plann ing</w>
curren cy</w>
a h</w>
streng then</w>
de al</w>
ic acy</w>
struc tural</w>
in a</w>
encour age</w>
am ine</w>
inclu sion</w>
ar r
cho ice</w>
Portu gal</w>
C AS</w>
lo ve</w>
restric tions</w>
Ad min
sign s</w>
4. 2</w>
se ed</w>
O b
fall ing</w>
reg ister</w>
fin dings</w>
C z
f resh</w>
impro ved</w>
ex plo
com pr
classi fication</w>
z z
ar dis
S al
under stand</w>
ti le</w>
ag end
classi fied</w>
h on
an ding</w>
l ying</w>
Par t
de al
w ood</w>
dic tion</w>
h ous
ast er</w>
pre ci
F ish
Un der</w>
A m
Strateg y</w>
C E
Roman ia</w>
wor d</w>
ass es</w>
&apos; d</w>
L aw</w>
c li
i o</w>
r onic</w>
Res earch</w>
pol l
igh b
pl us</w>
k ept</w>
In vest
Tr ade</w>
ha z
f low
r ural</w>
form er</w>
t ren
sol d</w>
ar d
En g
ri t</w>
mu tual</w>
im ported</w>
ag ency</w>
C o</w>
2 9
trav el</w>
ou se
ati vely</w>
ov ine</w>
pen al
los ses</w>
ph as
fe el</w>
hop e</w>
Hum an</w>
Den mark</w>
A C</w>
ing redi
ecu tive</w>
ur g
hydro x
S outh</w>
trans action</w>
de ath</w>
P ri
N U
posi tions</w>
du le</w>
3 1.
scho ol</w>
un to</w>
beli ev
hist ory</w>
thre sh
meth od
decre ased</w>
pro per</w>
P A</w>
exten sion</w>
it ting</w>
giv ing</w>
U K</w>
tic k
G e
ob tain</w>
cy cle</w>
D ata</w>
fun d</w>
ac ks</w>
res ol
I D
N O
g ir
as ked</w>
situ ations</w>
v ic
L eg
Inter net</w>
exem ption</w>
col umn</w>
passeng er</w>
u ally</w>
met al</w>
discrim ination</w>
199 6</w>
D on</w>
10 7</w>
mot or</w>
fi es</w>
prac tical</w>
L t
h in
y cl
V al
dru g</w>
di ed</w>
Slo ven
enti re</w>
ab sor
al cohol</w>
high ly</w>
purch ase</w>
art an</w>
Ger man</w>
W hile</w>
paren t</w>
star ted</w>
aim s</w>
st ore</w>
person nel</w>
is tic</w>
recor ded</w>
trac ting</w>
benefici ary</w>
ul ts</w>
out come</w>
in ery</w>
l em
ca ref
Gu idelines</w>
Lux emb
sen si
c ity</w>
th reat
Q U
es sive</w>
organ ic</w>
clos ely</w>
dig ital</w>
az ole</w>
ht t
specif ications</w>
centr e</w>
lat ter</w>
si ght</w>
v oc
recor ds</w>
reg ime</w>
a it</w>
u g
n a</w>
k en</w>
sul ph
a h
Cz ech</w>
jur is
p ic
T er
f ying</w>
ul ture</w>
se ar
langu ages</w>
exis tence</w>
em phas
destin ation</w>
crim inal</w>
mil itary</w>
bec om
appe ar</w>
2 8
acc ur
instruc tions</w>
gar ia</w>
s pre
T F
dr y</w>
agend a</w>
a i</w>
dise ases</w>
co hesion</w>
pub lic
G O
sp i
dri ve</w>
Bul garia</w>
cre d
199 5</w>
perman ent</w>
ati tis</w>
h ab
Ch ris
ar ms</w>
pharmac ist</w>
canc er</w>
si l
tw ice</w>
expir y</w>
b and</w>
r y
ref er</w>
eth yl
c ot
I L
S ur
st ly</w>
20 .
MAR KE
wh ere
k m</w>
amp s</w>
po st
J e
au di
t on
marg in</w>
UNI ON</w>
1. 1</w>
su m</w>
deliv ered</w>
ys is</w>
tis su
excep tion</w>
s we
re action</w>
ex tre
bur den</w>
rati o</w>
deg ree</w>
organis ed</w>
particip ate</w>
passeng ers</w>
en ced</w>
o es</w>
With out</w>
199 7</w>
En viron
C H</w>
hy p
comple x</w>
k a</w>
prepar ations</w>
terr or
adv ance</w>
Lt d</w>
c au
dis posal</w>
with draw
de ad
. .</w>
C YP
B u
ste ad</w>
Pro tec
employ ees</w>
s av
st ay</w>
ac tiv
ag o</w>
r are</w>
b at
ac et
collec ted</w>
ro w
b ul
he at</w>
Swe den</w>
she et</w>
di dn</w>
Wor ld</w>
bo x</w>
form al</w>
difficul ties</w>
lin k</w>
mi um</w>
compar ison</w>
gl uc
al most</w>
judg ment</w>
199 4</w>
tr ue</w>
og lob
plac ement</w>
y an
Presid ency</w>
renew able</w>
Centr e</w>
qu ali
part nership</w>
am s</w>
demonstr ated</w>
Ru le</w>
suppl ied</w>
lab el</w>
p age</w>
eff icacy</w>
Pl an</w>
Se a</w>
ran kings</w>
t ary</w>
tre at</w>
allow s</w>
en ting</w>
di ab
be ha
I AL</w>
al fa</w>
st ro
institu tional</w>
recor d</w>
govern ing</w>
at ur
ific ations</w>
part ment</w>
fix ing</w>
can di
R el
oc k</w>
success ful</w>
ist ers</w>
ther n</w>
avail ability</w>
V er
Num ber</w>
promo tion</w>
lear ning</w>
over ty</w>
p oul
need le</w>
ti lis
al ong</w>
lo an</w>
tal k</w>
ic ated</w>
2 3
erg ic</w>
uni form</w>
dou ble</w>
1 6.
fir m</w>
str ong
st op
exam ined</w>
p ite</w>
relation ship</w>
f ab
perm it</w>
oun ds</w>
p ack</w>
h ood</w>
f erence</w>
CO 2</w>
d own
repeal ing</w>
individu als</w>
ref unds</w>
incre ases</w>
m ac
2 7
f at</w>
R em
In du
H er
in curred</w>
Is ra
Fin ally</w>
S E
Org anis
htt p</w>
clear ance</w>
le ad
ti ally</w>
s pr
deleg ated</w>
il ing</w>
P ur
fin e</w>
farm ers</w>
consequ ences</w>
le ague</w>
C er
4 00</w>
Direc tives</w>
do or</w>
resid ence</w>
as y</w>
requ ests</w>
tic ip
grow ing</w>
off ic
beha vi
p y
comp u
plann ed</w>
amen d</w>
tox icity</w>
2. 1</w>
ab il
inser ted</w>
bre ast</w>
h ouse
k er</w>
b arri
Al though</w>
Th ank</w>
main tained</w>
provi ders</w>
PRODUC T</w>
N ame</w>
li ability</w>
inter medi
selec tion</w>
c ular</w>
specif ically</w>
off ered</w>
ass emb
if e</w>
finan ced</w>
g er</w>
hand ling</w>
as sum
et ting</w>
specif y</w>
Man ufac
ar ising</w>
connec ted</w>
Be fore</w>
norm ally</w>
re tail</w>
an cing</w>
ca emia</w>
harmon ised</w>
consis ten
adjust ed</w>
c u
he av
innov ative</w>
am m
enti ally</w>
M IN
A P</w>
Cust oms</w>
or i
summ ary</w>
S C
techn i
en ds</w>
ch e
ap s</w>
PR C</w>
Luxemb ourg</w>
car b
fo res
Un der
I cel
transi tional</w>
gram s</w>
G o
F ac
Ri ghts</w>
ex ported</w>
direc tion</w>
w ish</w>
ox y
manag ed</w>
gener ation</w>
Co operation</w>
Agricul ture</w>
jud icial</w>
docu mentation</w>
hep atic</w>
trav en
ul ly</w>
substan tial</w>
T w
Ukra ine</w>
J ust</w>
remain ing</w>
allow ing</w>
Rep res
meth yl</w>
S econ
b ab
subm ission</w>
occ up
repeal ed</w>
previ ously</w>
lab elling</w>
cl .</w>
S ci
Afr ica</w>
pharmac okin
vir us</w>
in e
ind ication</w>
atic ally</w>
TE R
ref er
Me asu
Pe ople</w>
up dated</w>
T ext</w>
fla g</w>
p il
exclu ded</w>
v ul
transparen t</w>
deriv ed</w>
h u
uropa .e
con sign
ap pointed</w>
V il
op ened</w>
ke ep
Ital ian</w>
at eral</w>
D S</w>
man date</w>
quali fied</w>
G H
ful fil</w>
iz e</w>
ur ren
m 2</w>
comm itted</w>
par amet
ex ha
Rec om
strength ening</w>
Slo v
Mad am</w>
or ial</w>
del eted</w>
particip ants</w>
h os
determin ation</w>
og s</w>
P P
ass et</w>
TI VE</w>
pres er
cover ing</w>
il d</w>
loo king</w>
Ar e</w>
part ner</w>
F ore
immedi ate</w>
mar i
pregn ancy</w>
accept able</w>
p overty</w>
00 00</w>
satis fac
D E
vot es</w>
S er
MARKE TING</w>
J ud
install ation</w>
vacc ine</w>
fiel ds</w>
cut aneous</w>
L ab
prec au
off ers</w>
Produc ts</w>
j u
G DP</w>
benefici aries</w>
se as
plac es</w>
m om
ent al</w>
inv itation</w>
cap able</w>
Aust ria</w>
1 4.
k id
no thing</w>
10 00</w>
fron t</w>
min im
sec tions</w>
prote in</w>
oc cur
4 ,
ser ve</w>
view ed</w>
resi du
un g</w>
fu els</w>
M ore</w>
wh om</w>
at us</w>
com it
prescri bed</w>
show ed</w>
li abilities</w>
monit ored</w>
mari time</w>
Produc t</w>
D oc
oglob in</w>
1 5.
is ion</w>
nam ely</w>
aren ess</w>
issu ing</w>
fi re</w>
iter ran
f ec
fir ms</w>
P ublic</w>
el low</w>
as signed</w>
o therapy</w>
Tur key</w>
N on</w>
dis p
Ty pe</w>
Cro ati
l ay</w>
ear li
Nor way</w>
v in
Lat via</w>
B ec
M E</w>
effor t</w>
rece ip
Con tracting</w>
c amp
s end</w>
G iv
Un i
Min imum</w>
C L
MB ER</w>
sec ure</w>
certain ty</w>
ten ts</w>
compet ence</w>
multi ple</w>
fo od
Serv ice</w>
p al</w>
sw it
Med iterran
set tlement</w>
sam ples</w>
cy cl
ben z
influ ence</w>
N et
compar able</w>
measu rement</w>
H IV</w>
re ments</w>
ra il
pregn ant</w>
Fin land</w>
ab sol
AM E</w>
b orders</w>
si gn</w>
RE C
gr am</w>
12 34</w>
B ure
Con tro
Mediterran ean</w>
cre ating</w>
bor n</w>
ter y</w>
form ul
In t
o kay</w>
S i
Stand ard</w>
isc al</w>
commun ity</w>
6 00</w>
fo ot
e tin</w>
SPEC IAL</w>
nation als</w>
Th en</w>
commun ications</w>
S k
f ro
er t</w>
A .
w an
fav our
stat ements</w>
mach inery</w>
transf erred</w>
F i
juris diction</w>
cri ption</w>
mark ed</w>
RE S
ad ults</w>
referen ces</w>
propor tion</w>
strateg ies</w>
so f
exis t</w>
ell ed</w>
M P</w>
s le
labor atory</w>
commun icate</w>
m ail</w>
anal y
Elec tr
secon d
im mun
dom in
dri ving</w>
A mend
ha ir</w>
ind ent</w>
1. 2</w>
B usin
et al</w>
th ank</w>
n om
ir on</w>
re al
ro r</w>
W H
y a</w>
V ery</w>
Isra el</w>
b ar
sev en</w>
r a</w>
r ail</w>
n ia</w>
sampl ing</w>
cop y</w>
br an
2 8.
Proc edure</w>
V II</w>
mark s</w>
EF TA</w>
th ought</w>
N ations</w>
n or
achiev ing</w>
opin ions</w>
at ric</w>
5. 1</w>
c in
p ig
manufac turing</w>
m ut
Je sus</w>
e ing</w>
ide a</w>
liqui d
aw areness</w>
ma x</w>
uropa.e u</w>
st ac
vot ed</w>
ver ti
fe atures</w>
claim ed</w>
aw are</w>
t old</w>
umin ium</w>
P H
out put</w>
w ent</w>
R T
nam es</w>
sh ap
high est</w>
z en</w>
OR D</w>
equ ity</w>
associ ation</w>
j un
ingredi ents</w>
electr ic</w>
O U
in king</w>
he ard</w>
2 6
en jo
G et</w>
st able</w>
jus tif
tw are</w>
de duc
Part nership</w>
pro b
form at</w>
r able</w>
el ement</w>
Sup pl
under taken</w>
2. 2</w>
techn ological</w>
prog res
reflec t</w>
inv o
TF EU</w>
tor al</w>
Bal tic</w>
A ir
re mun
en si
under lying</w>
air lines</w>
a b</w>
Giv en</w>
IS O</w>
C re
An imal</w>
sti mul
expos ures</w>
R ap
Fe der
it als</w>
St anding</w>
giv es</w>
en ab
pack aging</w>
str ain
oc ca
Techn ical</w>
ra ised</w>
V III</w>
sh are
par atus</w>
P S</w>
see k</w>
n ine</w>
gen t
r ul
in traven
T ri
oper ated</w>
buil d</w>
eren t</w>
repres ent</w>
si c</w>
og ly
i or</w>
di agn
b ound</w>
proper ly</w>
au d</w>
ri es</w>
ne ighb
................ ................
ww w
cere als</w>
fib res</w>
F l
Hung ary</w>
l a</w>
ch ain</w>
re tur
op tim
liqui d</w>
p ass</w>
ap ine</w>
in stance</w>
buil dings</w>
avi gation</w>
there to</w>
r ub
bas eline</w>
ever th
.e uropa.eu</w>
ar ch
indic ations</w>
o st
C S
pl en
fi gu
everth eless</w>
ati n</w>
tax ation</w>
gu idance</w>
enh ance</w>
att ached</w>
Invest ment</w>
artic le</w>
Protec tion</w>
deriv atives</w>
ang e</w>
Sw it
C i
agg reg
Repres ent
an a</w>
heal thy</w>
e k</w>
every thing</w>
rec ep
vi de
Bure au</w>
regul ated</w>
re m
er ship</w>
sur vi
lem en</w>
ne ur
N AME</w>
l t</w>
infec tions</w>
fil es</w>
cul ture</w>
199 2</w>
v ac
sear ch</w>
3. 1</w>
m outh</w>
contrac ting</w>
i b</w>
Reg ional</w>
s anc
mob ile</w>
e ous</w>
per form</w>
t ack
iti s</w>
ish ing</w>
adjust ments</w>
bi g</w>
am ide</w>
2 2
t ered</w>
haem oglobin</w>
ast ern</w>
Trans port</w>
L ORD</w>
Busin ess</w>
ch os
any thing</w>
Vil ni
suffici ently</w>
pi ents</w>
lodg ed</w>
ap paratus</w>
Bec ause</w>
4. 3</w>
Cy pr
enz y
evalu ated</w>
P C
ari at</w>
B E</w>
dis charge</w>
t ative</w>
pl ate</w>
O ver
A ir</w>
199 3</w>
Ph armac
B ri
qu ick
se at</w>
rec ently</w>
discus sion</w>
invol vement</w>
consis ting</w>
b one</w>
a c</w>
w r
eng en</w>
acc ept</w>
re ly</w>
Cypr us</w>
in duc
vi r</w>
Sch engen</w>
Com p
end ar</w>
f lights</w>
transi t</w>
trans lation</w>
S im
N ot
b all</w>
mix ed</w>
wel come</w>
gluc ose</w>
c ard</w>
dat ab
mo del
ver si
sel ling</w>
under standing</w>
invest ors</w>
1. 5</w>
re forms</w>
P al
con struc
qu es</w>
Op in
gre en</w>
e z
M ic
regul arly</w>
sur g
Addi tional</w>
democr atic</w>
regar ded</w>
g y
remov ed</w>
par tial</w>
acces sible</w>
fe eding</w>
withdraw al</w>
I X</w>
ey e</w>
th i
produc ing</w>
conc ept</w>
agricul ture</w>
D ep
f iscal</w>
5. 2</w>
we ak
pres sion</w>
In dia</w>
h ost</w>
discus sed</w>
sup ports</w>
sh aring</w>
el ing</w>
pro of</w>
tab ly</w>
dro me</w>
it ability</w>
B s</w>
aw ard</w>
appropri ations</w>
dist ance</w>
H ere</w>
all eg
excep tional</w>
fe es</w>
US E</w>
moder ate</w>
es tin
b ovine</w>
bel ong
Ex c
li p
r ac
exc essive</w>
cov ers</w>
gen der</w>
recommend ation</w>
a e</w>
re le
sol vent</w>
sti pul
receip t</w>
tr ust</w>
ad a</w>
augh ter</w>
gent lemen</w>
Wh o</w>
ad ult</w>
sen tence</w>
circ ulation</w>
um ul
A ud
m oun
T e
G ood</w>
cri tical</w>
deliv er</w>
be ar</w>
g ames</w>
exten d</w>
nam ic</w>
K eep</w>
Croati a</w>
food stuffs</w>
cru cial</w>
paramet ers</w>
Ex ecutive</w>
to ol</w>
l ess
st ored</w>
respon sibilities</w>
pro spec
proper ties</w>
il legal</w>
cre te</w>
Organis ation</w>
d ogs</w>
oc y
R ural</w>
sequ ently</w>
perm itted</w>
is s</w>
dis sem
ann oun
V E
us eful</w>
d il
depend ent</w>
Del eg
h our</w>
oc curred</w>
rap id</w>
proportion ate</w>
Rus sian</w>
govern ments</w>
f ast</w>
2 1.
p ted</w>
end or
earli er</w>
c ore</w>
model s</w>
h om
ord inary</w>
bre a
ful filled</w>
e ight</w>
0. 5</w>
cal endar</w>
figu res</w>
demonstr ate</w>
ne ither</w>
vic ti
avi ation</w>
j a</w>
4. 5</w>
ag ent</w>
FOR M
2. 5</w>
jus tice</w>
appe ars</w>
el d</w>
in stead</w>
electr ical</w>
pres s</w>
exam ine</w>
aw ar
mp le</w>
w ai
comple tion</w>
sen se</w>
2 50</w>
is ations</w>
wor ked</w>
our th</w>
our ing</w>
bre ak
revis ed</w>
lin ed</w>
TH ER</w>
sub stitu
S ev
P AC
mom ent</w>
D et
19 .
crim e</w>
expen ses</w>
initi ated</w>
si mple</w>
am ing</w>
M A</w>
on going</w>
am ber</w>
restric ted</w>
ust ed</w>
streng th</w>
tick ets</w>
ex ec
mon etary</w>
c m</w>
contin uation</w>
complet ely</w>
ali gn
appe al</w>
1 20</w>
if ying</w>
m ol
serv ation</w>
s aying</w>
m id
2 9.
provi der</w>
manufacture rs</w>
second ary</w>
Vilni us</w>
ru ption</w>
cap sul
shor t
bu d
simpl y</w>
2 4.
an k
poul try</w>
dat ory</w>
en vis
L im
ver ify</w>
d ar
E D
rel im
bil ateral</w>
l am
f em
J ap
ma p</w>
Opin ion</w>
sustain ability</w>
ser um</w>
inhib itors</w>
et es</w>
challeng e</w>
lic en
Nor th</w>
pro file</w>
vari ety</w>
dimen sion</w>
M O
B ud
char ac
dang erous</w>
repres ented</w>
reser ve</w>
er y
volun tary</w>
y our
succ ess</w>
l ost</w>
Serv ices</w>
cent res</w>
2 7.
ur ban</w>
flu or
all ergic</w>
N A</w>
er a</w>
ad d</w>
O ur</w>
he ar</w>
M R
addi tives</w>
sor ry</w>
in tra</w>
tol er
p um
eth yl</w>
re move</w>
collec tive</w>
at trac
Reg ions</w>
ex ac
W est
eu tic</w>
S m
Eng lish</w>
at tribu
ex trac
there by</w>
prohib ited</w>
consis ts</w>
conver sion</w>
remun eration</w>
p rece
4 14</w>
P ow
confi dence</w>
meth yl
in side</w>
tas k</w>
Fish eries</w>
M rs</w>
initi ation</w>
m iti
expl ained</w>
import ers</w>
plas tic</w>
C ateg
acqu is
fac ility</w>
tri al</w>
e asy</w>
v il
pre neur
loc k</w>
relim inary</w>
r im
prim arily</w>
E ff
der ing</w>
Th us</w>
Recom mend
4. 1</w>
no tably</w>
e .</w>
re jected</w>
dri ver</w>
C an</w>
C amp
method ology</w>
as ting</w>
quick ly</w>
mag ne
ex cl.</w>
in direct</w>
In f
mar ine</w>
democr acy</w>
em a</w>
Trans late</w>
M ul
hol dings</w>
th care</w>
w al
identi ty</w>
pos ing</w>
in put</w>
sec u
p ain
w ards</w>
b es</w>
3. 2</w>
l amps</w>
y st
chos en</w>
transi tion</w>
ro ute</w>
S E</w>
Fore ign</w>
S O
vers al</w>
tex tile</w>
dis closure</w>
R equi
mul ti</w>
defini tive</w>
t ested</w>
im bur
spre ad</w>
stu died</w>
fur n
Min istry</w>
ch i
b ing</w>
, 000</w>
Sp anish</w>
Af gh
dic ated</w>
tr a
fi g
is ol
ch ronic</w>
us h</w>
con tents</w>
re ve
all s</w>
constitu tes</w>
depen ding</w>
cho ose</w>
co m</w>
F ig
ban king</w>
T ake</w>
AN CE</w>
s s</w>
pa th
Lo ok</w>
desi rable</w>
P s</w>
def ence</w>
is o
custom er</w>
as yl
flow s</w>
nu tri
Est onia</w>
so il</w>
D ER</w>
v ers</w>
usu al</w>
ref ers</w>
hyp ogly
V ir
experi enced</w>
A G</w>
vul ner
al ed</w>
PRO V
equip ped</w>
ra ise</w>
es day</w>
tr u
si mul
Tw o</w>
G ames</w>
O m
capsul es</w>
Swit zer
z apine</w>
R S</w>
mis es</w>
vis a</w>
comm od
E u</w>
val uation</w>
M ari
offici als</w>
interpre tation</w>
ac tors</w>
asyl um</w>
p sy
valid ity</w>
prom ise</w>
g es</w>
ick ness</w>
radi o</w>
hor iz
ow s</w>
F il
bo x
v ail
s ation</w>
prepar e</w>
Switzer land</w>
e ties</w>
y ar
f ever</w>
trac k</w>
draw ing</w>
bre ak</w>
acc ess
inci dence</w>
tissu e</w>
ep h
cut ting</w>
or ation</w>
C ase</w>
l amp</w>
m al</w>
mo l</w>
gr ants</w>
Sub ject</w>
e en</w>
enz a</w>
vir al</w>
r on
reli able</w>
em erg
b es
B ased</w>
s aw</w>
design ation</w>
inter oper
spo t</w>
t ot
s pon
car di
Treat ment</w>
av es</w>
Th e
respon d</w>
spi rit</w>
dis h</w>
pres entation</w>
v als</w>
C al
Des cription</w>
ven cy</w>
inspec tions</w>
ass ist</w>
he ating</w>
AR S</w>
inv ited</w>
ad verti
Con sequently</w>
se ment</w>
harmon isation</w>
pl ane</w>
b s</w>
solid arity</w>
r ice</w>
sof tware</w>
wan ted</w>
Net work</w>
Afr ican</w>
eng ines</w>
M A
D em
stud ents</w>
thresh old</w>
fr aud</w>
co operate</w>
ev a</w>
territ ories</w>
4. 8</w>
wid th</w>
c os
Fun ds</w>
tax es</w>
inter net</w>
stand ardis
invol ve</w>
ob stac
barri ers</w>
G o</w>
st en
a ult</w>
qu ite</w>
mess age</w>
Aud itors</w>
re imbur
lo ading</w>
con ven
ent re
com position</w>
speci ally</w>
g etting</w>
st res
C ES
ph one</w>
pers ensi
ast ro
behavi our</w>
18 .
P aper</w>
AU C</w>
pe ace</w>
TE R</w>
suppli ers</w>
intro duce</w>
addi tive</w>
m emb
op s</w>
chang ing</w>
Euro system</w>
NU MBER</w>
defini tions</w>
um s</w>
ST R
Con di
sid es</w>
consul t</w>
sol id</w>
ex pan
S R</w>
lis ts</w>
PE R
easi ly</w>
Secret ary</w>
territ orial</w>
coord inated</w>
Fur ther</w>
Po int</w>
k et
if t</w>
hear ing</w>
l and
V I
val u
caref ully</w>
un employment</w>
H ouse</w>
V ol
S .
th ous
w o
continu ous</w>
In iti
pat ch</w>
fa ther</w>
siz ed</w>
sm all
f are</w>
par lia
defin e</w>
suppl ies</w>
B Y</w>
run ning</w>
g i
H or
ass is
con crete</w>
exc ell
syst em
b ia</w>
C op
buil t</w>
presid ent</w>
in ations</w>
hum an
rein for
sol ely</w>
multi lateral</w>
In de
z ones</w>
affec ting</w>
M at
corpor ate</w>
Pur su
precau tions</w>
wom an</w>
diab etes</w>
sh ared</w>
confl ict</w>
U p
intraven ous</w>
E r
en larg
answ er</w>
equ ality</w>
adv anced</w>
favour able</w>
def ici
play ers</w>
M r.</w>
sav ings</w>
re lig
ro und</w>
With in</w>
believ es</w>
con comit
M ac
f le
cer tified</w>
ic ing</w>
Contro l</w>
k il
H el
ten ders</w>
allow ances</w>
S pec
author isations</w>
B as
Or al</w>
some times</w>
mar king</w>
on avir</w>
flo or</w>
t um
tu red</w>
ey es</w>
consul tations</w>
4 0
il st</w>
poll ution</w>
repres ents</w>
s qu
o ts</w>
uc k</w>
Speci fic</w>
w on</w>
13 6</w>
up date</w>
sc en
mor t
man datory</w>
F R</w>
fro zen</w>
Ass ess
ble eding</w>
ba vir
M il
leg ally</w>
th ers</w>
om a</w>
rel ative</w>
ow ned</w>
f itted</w>
p y</w>
exper t</w>
fab r
h arm
vacc ination</w>
M ost</w>
g ave</w>
ap h
rail way</w>
hin d</w>
manag ing</w>
---- ----
ol der</w>
li ves</w>
8 00</w>
D ATE</w>
bavir in</w>
Represent ative</w>
p ip
fe e</w>
larg est</w>
infring ement</w>
go als</w>
le y</w>
where by</w>
Mal ta</w>
autom atic</w>
j our
techni ques</w>
b ad</w>
u n</w>
camp ai
at tem
ca uses</w>
pl aying</w>
m erg
fe ed
bro ad</w>
n ai
contrac tual</w>
1. 3</w>
h ot</w>
S um
h ands</w>
B et
g one</w>
extre m
hol ds</w>
e tics</w>
rub ber</w>
tour ism</w>
ov a</w>
awar ded</w>
sp ir
contr ary</w>
Pursu ant</w>
CR R</w>
compati bility</w>
l in</w>
bi odi
sal ary</w>
p .
tal king</w>
leg iti
al lo
heal thcare</w>
mo de</w>
repres enting</w>
jun ction</w>
be aring</w>
et e</w>
N ote</w>
B er
S .</w>
He ad</w>
s eg
s par
O D</w>
restric tive</w>
dos age</w>
or d</w>
lin ks</w>
Admin istr
your self</w>
hous ing</w>
fuc king</w>
ref rig
d uly</w>
H ar
flex ibility</w>
eng aged</w>
assess ing</w>
measu ring</w>
T E</w>
PAR TIC
Em ployment</w>
on tal</w>
PARTIC UL
inc enti
imp acts</w>
enh ouse</w>
Y ear</w>
Con ference</w>
re placement</w>
ic als</w>
st abil
keep ing</w>
inter action</w>
exclu sively</w>
viol ence</w>
man age</w>
ane ously</w>
ad oles
Cl ass</w>
gro ss</w>
acc el
T i
se ems</w>
pol ice</w>
d ys
t ob
mob il
PH AR
vis it</w>
st er
di c</w>
TI T
2. 3</w>
m em
Sloven ia</w>
v ey</w>
a .</w>
E l
liquid ity</w>
vide o</w>
f at
it arian</w>
charg ed</w>
Doc u
RE S</w>
der ly</w>
199 0</w>
protec tive</w>
T re
1 3.
M or
pet ro
L IS
weigh ted</w>
o ils</w>
sensi tive</w>
s an
mb H</w>
p ap
f ourth</w>
ri d</w>
m ate</w>
Par agrap
al uminium</w>
co operating</w>
suppli er</w>
pro long
m other</w>
fac ts</w>
g ets</w>
uni que</w>
pil ot</w>
L ev
D O
ai red</w>
there in</w>
Ge org
assi um</w>
st ood</w>
be hind</w>
PAC K
y m
a un
a ero
re place</w>
dis tur
17 .
A id</w>
Sup port</w>
ci um</w>
car s</w>
I A</w>
plen ary</w>
est er</w>
transf ers</w>
it ations</w>
M O</w>
i ding</w>
st ages</w>
fig ure</w>
Th ird</w>
laun ched</w>
in o</w>
dead line</w>
targ eted</w>
compu ter</w>
Ref erence</w>
mech an
har m</w>
lad ies</w>
c ents</w>
penal ties</w>
offic er</w>
plat form</w>
per fec
ca p</w>
tr ain</w>
L T
carri ers</w>
def icit</w>
c ros
read ing</w>
re insurance</w>
2 6.
ne ar</w>
entre preneur
propos e</w>
www .
but ter</w>
applic ants</w>
2 3.
po int
manufactu red</w>
stri al</w>
mach ine</w>
T ra
pre mium</w>
eg gs</w>
B R
Ann ual</w>
subsequ ently</w>
sch ed
ve ments</w>
Leg al</w>
Str uc
PARTICUL ARS</w>
ell ec
b lis
Pl ace</w>
6 ,
ben ch
amet er</w>
ac knowledg
inter fer
g g
bl ack</w>
B os
Char ter</w>
us al</w>
Comp any</w>
th ly</w>
assess ments</w>
re constitu
pow ered</w>
li ber
In nov
satis fy</w>
dump ed</w>
k n
G mbH</w>
spe ak</w>
incre as
dos ing</w>
ing ing</w>
Pro posal</w>
prepar ing</w>
sh it</w>
acc o</w>
edi atric</w>
ques tion
p reliminary</w>
enh anced</w>
bes artan</w>
confi d
et er</w>
Environ ment</w>
wel comes</w>
ti se</w>
gre enhouse</w>
Ad d
im age</w>
H OL
for ces</w>
s man</w>
ar ding</w>
L ot
war ning</w>
guarante ed</w>
W in
de ad</w>
consisten cy</w>
O THER</w>
L ist</w>
d in
ex port
up per</w>
sub s
cat ch</w>
des pite</w>
ex ed</w>
hep atitis</w>
Assess ment</w>
v is</w>
deleg ation</w>
remov al</w>
scen ari
every one</w>
Nor w
sid y</w>
exc ess</w>
b it</w>
fo rec
ag s</w>
Gre en</w>
NE R
E uro</w>
stre am</w>
enti c</w>
per spec
F RO
K ore
I D</w>
ak ia</w>
S hi
expl an
ac ute</w>
prece ding</w>
acquis ition</w>
re tro
rit onavir</w>
Sum m
te es</w>
2 2.
tr id
US A</w>
g ot
c am
d le</w>
associ ations</w>
accept ance</w>
go es</w>
fail ed</w>
B en
TE N
ex pi
v a</w>
li es</w>
hos p
consider able</w>
bu ty
Inter nal</w>
inde x</w>
as cular</w>
Suppl ement</w>
PACK AG
Bel ar
re member</w>
I F</w>
we ar</w>
di vision</w>
AC E</w>
T AR
inde ed</w>
S oci
oul dn</w>
tr ying</w>
ow ner</w>
iv es</w>
b un
EI B</w>
v ital</w>
m bo
Norw eg
industri es</w>
program ming</w>
s ory</w>
rec itals</w>
play ed</w>
pub lish</w>
wr ong</w>
IN FORM
CO D</w>
ere ly</w>
Recommend ation</w>
s ays</w>
Norweg ian</w>
ma b</w>
lan tic</w>
res istance</w>
complain t</w>
mus cle</w>
st ress</w>
i k
tain s</w>
cot ton</w>
difficul ty</w>
AC P</w>
influ enza</w>
s ex
m .</w>
rec ycl
co o
gr ade</w>
Condi tions</w>
199 1</w>
t ac
3 2
y outh</w>
fabr ics</w>
Gre ek</w>
c ab
re vision</w>
main taining</w>
INFORM ATION</w>
C I</w>
ten sion</w>
i az
con servation</w>
happen ed</w>
E duc
go al</w>
D o
M u
A .</w>
ellec tual</w>
dis ci
E ven</w>
install ations</w>
Afgh an
fol d</w>
conf erence</w>
V ice</w>
t ou
sub cutaneous</w>
5. 3</w>
v ar
therap eutic</w>
wee k
ci ties</w>
el ev
ad y</w>
victi ms</w>
du m</w>
ai ze</w>
g er
R yan
al le
Afghan istan</w>
exper tise</w>
MEN TS</w>
be au
ter ing</w>
exclu sion</w>
envis aged</w>
carri er</w>
po or</w>
n on
es el</w>
8 5
comb at</w>
ser i
hist or
3 A
incenti ves</w>
we b</w>
fin ding</w>
interoper ability</w>
fish ery</w>
en ia</w>
1 1
profes sion
col d</w>
Ryan air</w>
gener ated</w>
bot tle</w>
con junction</w>
adap t</w>
R en
bab y</w>
ow nership</w>
extrem ely</w>
ta il
contain er</w>
auth entic</w>
mis sible</w>
Medic inal</w>
A gen
ac ulture</w>
observ ations</w>
dru gs</w>
rele ased</w>
om iting</w>
Ch em
Slov akia</w>
10 4</w>
fri end
c k
sanc tions</w>
G lob
infec ted</w>
requi ring</w>
invest or</w>
the tic</w>
T A
ic king</w>
ten d
produc tive</w>
Agricul tural</w>
independ ence</w>
Fig ure</w>
enab ling</w>
res ource</w>
ec es</w>
th ou</w>
impro vements</w>
Un common</w>
10 3</w>
wor l
u ge
h n</w>
volum es</w>
increas ingly</w>
M et
acqui red</w>
appropri ation</w>
ogen ic</w>
datab ase</w>
separ ately</w>
mov ing</w>
es n</w>
transm itted</w>
air ports</w>
in sufficient</w>
Per s
ou red</w>
l en
conclu de</w>
qual ifications</w>
refrig er
C le
F o
we ap
m mol</w>
bet a</w>
P i
d l</w>
T AI
im pose</w>
injec tions</w>
hypogly caemia</w>
rel ate</w>
ut ro
6. 1</w>
e dule</w>
vis ions</w>
mil d</w>
su spec
he ight</w>
enti onal</w>
cre ati
Op en</w>
organis ms</w>
Re ad</w>
ograph ic</w>
det ail</w>
v ary</w>
inci d
M eth
vo ting</w>
IS TR
vulner able</w>
notif ications</w>
r ad
fi er</w>
v el
fl ying</w>
investig ations</w>
col labor
On ce</w>
fe eling</w>
u mab</w>
In tr
consequ ence</w>
hydr ate</w>
cl ean</w>
el se</w>
SI S</w>
reduc tions</w>
N omenclature</w>
exec ution</w>
acqu is</w>
bro ken</w>
ov ere
y es</w>
nov er</w>
hab it
es tion</w>
ol d
mic ro</w>
Deleg ated</w>
10 6</w>
dg e</w>
fl at</w>
di ameter</w>
princi pal</w>
em p
cons ent</w>
ri bavirin</w>
Con sum
conf erred</w>
5 ,
1 12</w>
re viewed</w>
re r</w>
Sta ff</w>
mar t</w>
m une</w>
d al</w>
H a
R E</w>
stan ds</w>
proc ee
elec tro
speci fication</w>
S H
kid ney</w>
sec toral</w>
expos ed</w>
min or</w>
residu es</w>
ti tle</w>
s ou
st at</w>
est er
reg im
A V
ell a</w>
ro un
migr ants</w>
sol vency</w>
c ep
N ING</w>
form ed</w>
inter ven
g ear</w>
W e
see king</w>
n ings</w>
satis fied</w>
u tr
whe at</w>
de par
bu y</w>
adoles cents</w>
autom atically</w>
mor ning</w>
int estin
an g</w>
syst emic</w>
inter im</w>
al y
Eff ec
Om bud
Techn ology</w>
t age</w>
with drawn</w>
H C
IC T</w>
i ances</w>
larg er</w>
str ai
tion ally</w>
an der</w>
harm ful</w>
C at
er r
Ci vil</w>
ligh ting</w>
gu ys</w>
ob ject</w>
back ground</w>
moder n
discus sions</w>
t ose</w>
bal anced</w>
IN T</w>
cover age</w>
divi ded</w>
sub sidy</w>
Str ong
vo ice</w>
fe der
pre mises</w>
ov ered</w>
rep air</w>
u k
id ly</w>
ish es</w>
M AN
no ise</w>
occur s</w>
nit ro
criter ion</w>
ac i
Oper ator</w>
detec tion</w>
resi due</w>
dr ink</w>
house hold</w>
ex tra</w>
E G
speci al
tu de</w>
ang i
com for
Categ ory</w>
for th
sc ru
ful fil
SU B
r h
di e</w>
E ast</w>
pre domin
u tilis
s ave</w>
econom ies</w>
fun ded</w>
1. 4</w>
safegu ard</w>
eren ces</w>
rel atively</w>
C T
2 5.
M ex
E astern</w>
ste in</w>
Det ail
establish ments</w>
00 1</w>
tr ic</w>
es tic
elim ination</w>
adap ted</w>
z o
mun ici
S EC
w n</w>
wel fare</w>
en th</w>
ov en</w>
dis cre
y er</w>
th al
ver ified</w>
y ed</w>
pu ts</w>
tex ts</w>
port fol
gr at
ethyl ene</w>
thre at</w>
Icel and</w>
oc k
adop ting</w>
terror ism</w>
car trid
Pol ish</w>
b acter
n avigation</w>
comp ounds</w>
vari able</w>
co al</w>
ous ness</w>
preven ting</w>
mis sions</w>
E L</w>
bir ds</w>
contin ues</w>
B an
St e
vis ible</w>
AD MIN
fri end</w>
di an</w>
B raz
assemb ly</w>
To day</w>
ot ed</w>
PRODUC TS</w>
tin y</w>
ist ant</w>
d i</w>
F re
f arm</w>
wat er
re ti
ner ships</w>
accompan ying</w>
st ers</w>
mix tures</w>
transf er
Under taking</w>
interfer on</w>
ann exed</w>
bi ological</w>
P L</w>
Bo x</w>
1 25</w>
commun icated</w>
becom es</w>
HOL DER</w>
at ell
ag on
continu ing</w>
En try</w>
D ef
r ash</w>
fac ing</w>
ADMIN ISTR
Ir an</w>
Acc ession</w>
ad es</w>
n omenclature</w>
small er</w>
M y
repl y</w>
al k
0 2
sib ly</w>
c k</w>
repe ated</w>
propos es</w>
Su pervis
horiz ontal</w>
bloc k</w>
ab sten
00 00
NC Bs</w>
do esn</w>
consolid ated</w>
vit ro</w>
trans l
loo ks</w>
prof itability</w>
w ait</w>
Camp ing</w>
ligh tly</w>
il ies</w>
appro aches</w>
te ach
calcul ating</w>
S ign
in ks</w>
ou ter</w>
p un
fl av
resid ent</w>
gr av
E T
n ur
def ault</w>
di versity</w>
12. 2006</w>
wh at
question nai
estim ates</w>
indic ator</w>
M ay
to m</w>
M us
hum ans</w>
v omiting</w>
f oun
cre w</w>
ut ting</w>
ph y
V is
ed ural</w>
Ad vis
tob acco</w>
P an
s .</w>
om atic</w>
B O
alle l</w>
advant ages</w>
ac king</w>
adap tation</w>
Strong est</w>
Res olution</w>
ensu red</w>
ON AL</w>
M F
w ar</w>
Medic ines</w>
bec ame</w>
r ats</w>
c ast</w>
us tion</w>
fr ag
arrang ement</w>
R O</w>
Al so</w>
u ty</w>
ty p
ub le</w>
coun ts</w>
N B</w>
ed ema</w>
M any</w>
C max</w>
o id</w>
tr aff
S T</w>
til ity</w>
tr ail
rap idly</w>
cour ts</w>
l ot
elec tions</w>
rec overed</w>
do g</w>
frequ ently</w>
dis til
consul ting</w>
acc red
TIC AL</w>
er ror</w>
om mun
tur nover</w>
declar ations</w>
3. 3</w>
off ering</w>
flex ible</w>
arm a</w>
Euro stat</w>
b ig
2. 4</w>
es h</w>
tion ary</w>
ic it
sign al</w>
Par ticip
z a</w>
gu y</w>
comb ating</w>
R ound</w>
resul ted</w>
play er</w>
k .
install ed</w>
fac es</w>
evalu ate</w>
charac ter</w>
Govern ing</w>
1 10</w>
disp ute</w>
K y
adverti sing</w>
Li ke</w>
18 0</w>
diagn os
M AC
indic ating</w>
indic ates</w>
form ing</w>
Dem ocr
pay ing</w>
si r</w>
ch ers</w>
human itarian</w>
absol ute</w>
tren d</w>
educ ational</w>
I denti
Ombud sman</w>
16 0</w>
expres s</w>
m el
3 8
lo x
M ission</w>
R is
substan tially</w>
ery thro
ound ation</w>
enter ing</w>
contribu ting</w>
discus s</w>
In sul
In stru
obstac les</w>
Pos ition</w>
urg ent</w>
de p
ar ti
B l
7 ,
laun ch</w>
bor ne</w>
I V
su per
CON DI
ex porter</w>
E gy
su me</w>
show ing</w>
v ince</w>
fores een</w>
R N</w>
ud ine</w>
cl ause</w>
fem ale</w>
pot assium</w>
consider ing</w>
us ea</w>
p al
dri ed</w>
ic ts</w>
inten tion</w>
ch ro
F orm
wh ilst</w>
W ater</w>
ex ci
el derly</w>
manag er</w>
C urren
bre eding</w>
nation ally</w>
adequ ately</w>
under take</w>
accid ent</w>
D C</w>
ur ine</w>
di oxide</w>
D A</w>
L ED</w>
eng ine
C ity</w>
pay able</w>
L oc
with standing</w>
O P
simul t
k i
o to</w>
g ain</w>
prescri ption</w>
jec tion</w>
establish es</w>
supple mentary</w>
sec re
comp ul
sched ul
pot entially</w>
persensi tivity</w>
u um</w>
func tional</w>
and om
absor ption</w>
do w</w>
det eri
h ot
RE P
B ur
ang le</w>
le um</w>
modi fication</w>
de stro
Sci entific</w>
ul l</w>
cons ist</w>
F IC
phosph ate</w>
s ought</w>
res erv
col lateral</w>
elec ommun
appl iances</w>
thro mb
g ate</w>
BA T
Cha ir
rol ling</w>
ra ising</w>
aqu aculture</w>
fi x</w>
consider ations</w>
tr um</w>
cli ents</w>
h ex
B re
le aving</w>
prob ably</w>
mu sic</w>
li able</w>
Com peti
clin ically</w>
let ters</w>
oth iaz
oper ative</w>
moder n</w>
exis ts</w>
bu s</w>
iti ous</w>
ati es</w>
st ation</w>
W S</w>
3 9
deal ing</w>
ac tively</w>
se x</w>
CONDI TIONS</w>
sampl ed</w>
f el
F OL
par allel</w>
exclu sive</w>
depen ds</w>
H ell
tren ds</w>
mark eted</w>
Manufac ture</w>
bit r
micro grams</w>
fri ends</w>
easi er</w>
s ell</w>
fi f
ob vi
W TO</w>
sur vey</w>
heav y</w>
mechan ical</w>
depos its</w>
Amer ican</w>
m 3</w>
ap point
pro ve</w>
har v
erg ies</w>
candi date</w>
intestin al</w>
excee ds</w>
addres sing</w>
res ear
tim ely</w>
in s
pr o</w>
Amend ment</w>
NC B</w>
achiev ement</w>
author ising</w>
R ight</w>
quanti tative</w>
es sions</w>
T V</w>
Pre par
surg ery</w>
so le</w>
O ut
A l</w>
hap pen</w>
dr af
c are
U B
Innov ation</w>
Can ada</w>
de ep</w>
t ap
contain ers</w>
st y
el i
sh o
cont am
b lin
amm ation</w>
amb itious</w>
fam ilies</w>
w all</w>
mix ture</w>
me ets</w>
re ality</w>
some one</w>
ol ing</w>
Acc ord
exac tly</w>
ac es</w>
syn drome</w>
br inging</w>
d ens
ter ies</w>
I ts</w>
sal ts</w>
mon o
at ories</w>
ne utr
M ag
a head</w>
explo itation</w>
ex cre
h un
enjo y</w>
farm ing</w>
veget able</w>
P C</w>
ot y
TO P</w>
disci pl
an aemia</w>
Mon it
carb ons</w>
pharmacokin etics</w>
R et
Wh ite</w>
estim ate</w>
P ack
gen u
allow ance</w>
C AR
satisfac tory</w>
n y</w>
Accord ingly</w>
TS I</w>
ch ance</w>
P en
with draw</w>
s lightly</w>
op a
ed ge</w>
cl arif
suspen ded</w>
sh ee
sex ual</w>
perspec tive</w>
e at</w>
assis ted</w>
tonn e</w>
N evertheless</w>
part ments</w>
ban kno
S il
renew al</w>
me al</w>
r andom
situ ated</w>
for tun
10 1</w>
mo tion</w>
Jap an</w>
ear th</w>
ho ea</w>
ran king</w>
Struc tural</w>
Ro ad</w>
DI REC
BAT CH</w>
I .
yar n</w>
confid ential</w>
cau tion</w>
a. k.
comm only</w>
C B</w>
fre ight</w>
bra ke</w>
10 9</w>
pre dic
seas on</w>
V e
hi bi
Educ ation</w>
Res pon
ro utes</w>
mat urity</w>
t an
friend ly</w>
IN I
off ices</w>
T ell</w>
multi pl
hydro gen</w>
s overe
mov ements</w>
re me
tor ate</w>
im porter</w>
Par ts</w>
subsi dies</w>
IC ES</w>
enterpr ise</w>
Int egr
CH MP</w>
it ec
D ecisions</w>
AR Y</w>
min ute</w>
T un
af for
remain ed</w>
p ine</w>
au ton
dis continued</w>
ach e</w>
chec ked</w>
Sw iss</w>
G N
cal cium</w>
b ar</w>
introduc ing</w>
h im
10 0
th anks</w>
protec ting</w>
direc tives</w>
Paragrap h</w>
cont ested</w>
De fin
P T</w>
D R
accel er
Secret ariat</w>
5 43</w>
profession als</w>
govern mental</w>
produc tivity</w>
ren t</w>
10 8</w>
y i
sci ence</w>
Con stitu
legiti mate</w>
Co hesion</w>
paren ts</w>
EU SR</w>
ch apter</w>
certain ly</w>
sp ent</w>
col our</w>
re l</w>
proportion ality</w>
identi fying</w>
expl ain</w>
W ed
d less</w>
West ern</w>
Ma ximum</w>
Monit oring</w>
tif ication</w>
rol led</w>
k ill</w>
dos si
si lic
bre ach</w>
author ise</w>
y n
EP AR</w>
fo rest</w>
s ors</w>
hap s</w>
E very</w>
reser ves</w>
ar ance</w>
fo ods</w>
af er
tel ev
sch edule</w>
a ur
cat ches</w>
recogn ise</w>
coh erent</w>
Kore a</w>
Administr ative</w>
A ut
proc edural</w>
EF SA</w>
ar th
rec ru
pig s</w>
discrim in
id en
U M</w>
At lantic</w>
secur iti
prof its</w>
k y</w>
circ u
id ity</w>
er n
f ications</w>
im migration</w>
enh ancing</w>
part nerships</w>
Author isation</w>
No .</w>
B oth</w>
re st
w ild</w>
pa ediatric</w>
K os
perform ing</w>
mon thly</w>
concomit ant</w>
com promise</w>
Belar us</w>
w ants</w>
Ch ec
consign ment</w>
9 0
ro oms</w>
argu ed</w>
Gre at</w>
dissem ination</w>
simpl ification</w>
po l</w>
S S</w>
stipul ated</w>
quar ter</w>
amin o</w>
es is</w>
ar ise</w>
E ver
C AP</w>
RE D</w>
so ft</w>
shee ts</w>
bra in</w>
cou pl
W AR
D r
de dicated</w>
head ings</w>
ri gh
TE D</w>
Bu il
import ation</w>
affec ts</w>
ch e</w>
s ity</w>
becom ing</w>
3A 4</w>
integr ity</w>
ad m
jo int
coun ter</w>
Reg ul
ol an
advis ed</w>
her it
prin ted</w>
5 0
orig in
ru p
Gro w
l ap
govern ed</w>
a er
strong ly</w>
im position</w>
H A</w>
ay ed</w>
ri d
GE NER
E qui
Dec lar
et able</w>
ES S
survi val</w>
mac ro
prohib ition</w>
cl asses</w>
3. 5</w>
or t</w>
y ro
ov o</w>
or row</w>
as surance</w>
tif ul</w>
MAC EU
N ew
2 -</w>
all ing</w>
C A</w>
subsidi ary</w>
infl ammation</w>
correc tion</w>
sec ret
un able</w>
In cre
F ree</w>
X X
1, 000</w>
fin ally</w>
re aching</w>
traff icking</w>
share holders</w>
distin gu
activ ated</w>
pe ak</w>
PHAR MACEU
chem otherapy</w>
EX P
an nex</w>
vi g
e able</w>
Appro pri
ide as</w>
par tly</w>
pass ed</w>
ir regul
ex ecu
schedul ed</w>
form in</w>
Inde ed</w>
w on
S am
emb ry
H R</w>
t .</w>
hel ping</w>
ap art
P u
public ly</w>
er ad
an o</w>
fi gh
th ickness</w>
joint ly</w>
correc ted</w>
ma ster</w>
fin ished</w>
concentr ate</w>
FOL LO
it ch
uni versal</w>
elig ibility</w>
H z</w>
Institu te</w>
FRO M</w>
sem i</w>
absten tions</w>
n ar
ar ities</w>
Portu gu
W om
ow ners</w>
de ployment</w>
ti ble</w>
IC AL</w>
re fin
int ellectual</w>
h am
multi annual</w>
access ories</w>
wi der</w>
i br
Gu aran
denti ality</w>
car ds</w>
b ic
fib re</w>
cycl es</w>
T em
win d</w>
re x
consul ted</w>
ad ed</w>
arr hoea</w>
zer o</w>
sw ine</w>
c ue</w>
predomin antly</w>
for get</w>
T C</w>
spec trum</w>
ref uge
In surance</w>
st e</w>
pr ud
ren z</w>
ch ol
oc ar
PHARMACEU TICAL</w>
facilit ating</w>
ri tis</w>
oles ale</w>
v o</w>
G al
conv entional</w>
10 5</w>
k i</w>
Mari time</w>
commun ities</w>
announ ced</w>
s aving</w>
o edema</w>
compl ied</w>
n one</w>
Dep uty</w>
him self</w>
13 8</w>
Ex ternal</w>
pan el</w>
m id</w>
iden tical</w>
ensu res</w>
see ds</w>
regar dless</w>
A no
ta r</w>
th ir
sugg est</w>
un known</w>
na usea</w>
m ph
auton om
Com pl
nom inal</w>
th inking</w>
pi ece</w>
IT Y</w>
la x
31. 12.
memb ership</w>
exerc ised</w>
the e</w>
pos sibly</w>
exam ples</w>
S I</w>
lo g</w>
im mune</w>
inten ds</w>
encour aged</w>
C ER
ri an</w>
formul a</w>
beg in</w>
ur ch</w>
pat h</w>
olan zapine</w>
j e
ex changes</w>
compul sory</w>
compl ies</w>
pi ent</w>
ann a</w>
week ly</w>
Y ah
fuc k</w>
Wed n
scre en</w>
Portugu ese</w>
ab dom
st ant</w>
excell ent</w>
clos er</w>
CES E</w>
idel ine</w>
C a
hydro chlor
hel ps</w>
bon ds</w>
we h</w>
dri ven</w>
2 99</w>
poin ting</w>
3 6
r ine</w>
D ut
Secon d</w>
hydro carbons</w>
den om
discrimin atory</w>
sh ar
al ysis</w>
wor th</w>
sw elling</w>
Com bin
pic ture</w>
enlarg ement</w>
ar bitr
analys ed</w>
Insul in</w>
belong ing</w>
here to</w>
St ud
GENER AL</w>
T Y</w>
m aize</w>
6. 2</w>
ten stein</w>
expres sion</w>
B .</w>
gir l</w>
ti er</w>
scru tiny</w>
restric tion</w>
Yah weh</w>
TE E</w>
un ion</w>
inten sity</w>
accur ate</w>
ac ted</w>
rel ates</w>
Ever y
in directly</w>
ro se</w>
p referen
fr ame</w>
weap ons</w>
ren tal</w>
PO S
telev ision</w>
l ending</w>
ten tion</w>
P ay
ch ann
appoint ment</w>
Sec ur
reflec ted</w>
G R
Mark eting</w>
at oes</w>
cl ar
Measu res</w>
tr ans</w>
fall s</w>
ar tif
ne um
bra king</w>
Reg ion</w>
RO U
biodi versity</w>
bran ch</w>
m ale</w>
as ti
Wedn esday</w>
A vi
com posed</w>
d wide</w>
J er
A O</w>
Rom a</w>
avi renz</w>
8 4
shap e</w>
I AS</w>
me an
E qu
ent ure</w>
ra in</w>
est ate</w>
Sim il
Stat ute</w>
chem icals</w>
s mart</w>
g ing</w>
lear n</w>
d ol
D G</w>
wh ol
suff ered</w>
p utting</w>
ATI ONS</w>
J O
IN G
2 1
Requi rements</w>
Grow th</w>
i ii</w>
concentr ated</w>
tack le</w>
ver tical</w>
oblig ed</w>
atell ite</w>
y ellow</w>
ti ll</w>
sign ature</w>
le aves</w>
co hol
bal ances</w>
othiaz ide</w>
19 87</w>
d ating</w>
H O
COMM IT
vol tage</w>
cro ps</w>
confir m</w>
ur y</w>
Cha in</w>
encour aging</w>
ed ly</w>
Braz il</w>
4 68</w>
D s</w>
f al
dep th</w>
Di d</w>
Coun try</w>
st om
boo ks</w>
S ME</w>
7. 5</w>
preser ved</w>
Jo hn</w>
Swe dish</w>
ox y</w>
pos sibilities</w>
inc en
for war
f it
pen ding</w>
e ast</w>
D ue</w>
em powered</w>
Lim ited</w>
Uni versity</w>
all ed</w>
prec ise</w>
en ever</w>
ID ED</w>
ER S</w>
A F</w>
ol ic</w>
vis ual</w>
rou gh</w>
Rev i
g ases</w>
pl ates</w>
ma y
cop ies</w>
.e .
al g
Li ech
Agen da</w>
tu s</w>
Li b
Hy dro
t les</w>
pop ular</w>
P a
4. 6</w>
i tions</w>
EX P</w>
sc ep
po i
siz es</w>
ap preci
under stood</w>
objec ts</w>
E ME
Liech tenstein</w>
Th ree</w>
hy po
T ime</w>
ment ally</w>
D u
Bos nia</w>
direc ted</w>
k illed</w>
f en
l ers</w>
P res
ex hib
dy namic</w>
gir ls</w>
prolong ed</w>
g ap</w>
po ol</w>
strai ght</w>
pir atory</w>
Wom en</w>
P V
pi eces</w>
h it</w>
w as
exten ding</w>
Advis ory</w>
pursu e</w>
S an
In stance</w>
volun te
lan ding</w>
n esses</w>
in compatible</w>
ri ed</w>
ag en</w>
ADMINISTR ATION</w>
recommen ds</w>
Ch amber</w>
subsidi arity</w>
ol ds</w>
scho ols</w>
cli ent</w>
ban k
sal t</w>
f on
T aking</w>
radi o
hu ge</w>
L ord</w>
ne utro
Dut ch</w>
ST ATE
al ph
portfol io</w>
ard ous</w>
z eg
s or</w>
met formin</w>
appe arance</w>
ATI VE</w>
doub t</w>
t ang
f illing</w>
requ esting</w>
hydrox y
win dow</w>
L on
T u
beau tiful</w>
w ing</w>
T est</w>
employ ers</w>
mov ed</w>
h ur
cle an
U AB</w>
0 4
w are</w>
avi an</w>
anti bodies</w>
Mi x
AP PE
n .e.
low est</w>
Wor king</w>
Kos ovo</w>
r ab
cl arity</w>
ex tract</w>
St reng
h orm
1 15
strong er</w>
P ress</w>
dis order</w>
a ment</w>
St atis
sl augh
ke ys</w>
DIREC TIVE</w>
hap py</w>
argu ment</w>
Ch il
W ee
Par is</w>
N u
s pl
ov ina</w>
S ome
P ak
sh op</w>
H A
pharmacokin etic</w>
TAI L</w>
0 9.
un anim
see m</w>
depos it</w>
Ser bia</w>
Egy pt</w>
di pl
n gs</w>
men tion</w>
ab use</w>
im possible</w>
Declar ation</w>
res ting</w>
op e</w>
detec ted</w>
lip tin</w>
N R
ref use</w>
rec ording</w>
vac uum</w>
p ality</w>
T ali
inter vals</w>
oc curren
D ay</w>
re ver
derog ations</w>
accur acy</w>
P E</w>
deli ver
compr ising</w>
Sur veillance</w>
az one</w>
op position</w>
exci pients</w>
Mul ti
petro leum</w>
M ain</w>
distribu ted</w>
4. 2004</w>
B ro
dro p</w>
Hung arian</w>
Cap ital</w>
alleg ed</w>
invol ves</w>
id al</w>
ap parent</w>
ce iling</w>
radi ation</w>
ill u
Tali ban</w>
10 2</w>
s per
Add ress</w>
m ir
di zz
um ulation</w>
in land</w>
ac ids</w>
oci dal</w>
analys es</w>
U F
w ife</w>
Ph arma</w>
18 2</w>
questionnai re</w>
o z
ac in</w>
Combin ed</w>
Au str
F er
I P
correc tive</w>
tax able</w>
F R
ME TH
CYP 3A4</w>
worl dwide</w>
ut ory</w>
f ill</w>
s y</w>
reven ues</w>
confi dentiality</w>
zeg ovina</w>
al cohol
ab road</w>
i b
e ds</w>
lot tery</w>
expec t</w>
gl u
nu ts</w>
can cell
ir a</w>
differen ti
Her zegovina</w>
indic ative</w>
aspec t</w>
break down</w>
l ayer</w>
li e</w>
ut ely</w>
an ticip
inhib itor</w>
whe el</w>
correc tly</w>
tom orrow</w>
Ve hic
Ch ange</w>
analy tical</w>
ac commod
S or
simpl ified</w>
dis play</w>
particul ars</w>
argu ments</w>
accid ents</w>
s outh</w>
mis sing</w>
commit tees</w>
lin ing</w>
j ust
an ese</w>
al ogue</w>
par tially</w>
depar ture</w>
administr ations</w>
Fun damental</w>
sk i</w>
c it
S cho
Nor thern</w>
competi tors</w>
export ers</w>
ol ive</w>
comb ustion</w>
Produc tion</w>
pro mp
D anish</w>
or atory</w>
W est</w>
p in</w>
consolid ation</w>
at ch</w>
COMMIT TEE</w>
re strain
standardis ation</w>
cons ci
For um</w>
termin ation</w>
pow er
co ast
pack ages</w>
collec t</w>
Vir afer
wat ch</w>
li ons</w>
ch an
mat ch</w>
im posing</w>
refer ring</w>
O ver</w>
ell s</w>
us ting</w>
necess arily</w>
out standing</w>
S elec
G en</w>
war ran
n ice</w>
entire ly</w>
ail and</w>
ES MA</w>
int el
con stant</w>
avo ided</w>
respec ted</w>
preferen tial</w>
F u
am mon
ab normal</w>
elecommun ications</w>
depen d</w>
WAR NING</w>
r ated</w>
ar ia</w>
ili ation</w>
initi ate</w>
Feder al</w>
Appl ication</w>
equ ally</w>
selec tive</w>
magne tic</w>
yl ene</w>
stu ff</w>
fortun ately</w>
spr ing</w>
fi able</w>
S ust
M I</w>
medi an</w>
sur ve
201 9</w>
inclu sive</w>
V eter
rul ing</w>
g old</w>
dis tr
recycl ing</w>
incen tive</w>
EC R</w>
respon ses</w>
eph one</w>
Georg ia</w>
t own</w>
ax is</w>
lim itations</w>
aud its</w>
re tain</w>
be am</w>
inv est</w>
an ol</w>
Th ailand</w>
ad ding</w>
op tional</w>
entr ies</w>
Lat vi
emerg ing</w>
cour ses</w>
H is</w>
Ano ther</w>
s .
D avi
exem pt</w>
termin al</w>
veter in
p ill
fo ot</w>
conver gence</w>
Th anks</w>
P ub
trans position</w>
trans port
bot tom</w>
air y</w>
wor ding</w>
a to</w>
am oun
sh ops</w>
C hi
cre am</w>
S TE
ISI ONS</w>
C S</w>
I mp
re ar</w>
gro up
star ch</w>
consequ ently</w>
P ass
St ore</w>
ad er</w>
eng age</w>
al ert</w>
struc tured</w>
Com pet
p estic
FOLLO WS</w>
Un it</w>
GH T</w>
syn thetic</w>
AL S</w>
chec king</w>
Con tin
c in</w>
EC D</w>
ici an</w>
Admin istration</w>
col or</w>
cap e</w>
capac ities</w>
St u
1. 6</w>
doub ts</w>
Belg ian</w>
t ability</w>
selec t</w>
a sts</w>
D IS
st one</w>
resear chers</w>
ti les</w>
design ate</w>
U r
astro intestinal</w>
T eva</w>
Direc torate</w>
foc used</w>
reli ef</w>
ic o</w>
su le</w>
on a</w>
exten sive</w>
gen e
fore stry</w>
our hood</w>
i re</w>
se where</w>
grad ually</w>
on azole</w>
le ads</w>
Revi ew</w>
s k</w>
enzy me</w>
do ors</w>
3 7
jo in</w>
dimen sions</w>
K ar
weigh ing</w>
ly mph
L s</w>
od y
U ru
LT 0000
En ter
w ind
represent ation</w>
reci pient</w>
os la
strength ened</w>
car ton</w>
20 1</w>
impl ications</w>
expl os
ch air
Acc ess</w>
mi x</w>
pos ite</w>
D F</w>
m it
cre di
cr yst
conclu des</w>
vir tu
tox ic</w>
r ich</w>
Org an
F ri
renew ed</w>
on ing</w>
F an</w>
writ e</w>
cor ruption</w>
confl icts</w>
Sy st
Re porting</w>
exem ptions</w>
en sus</w>
bun al</w>
C PA</w>
3. 4</w>
w ash
prin ting</w>
inter val</w>
Hor iz
DEC IDED</w>
individu ally</w>
4 4
cro ch
su n
haz ardous</w>
ex it</w>
cas ting</w>
calcul ate</w>
di arrhoea</w>
cau ght</w>
Y ug
comp res
what ever</w>
smo oth</w>
Sh ould</w>
sp p</w>
retur ned</w>
h a</w>
S D</w>
FOR M</w>
ir respective</w>
d ex
V ER
se ats</w>
any one</w>
Guaran tee</w>
9 ,
vi ability</w>
W IT
Pro f
D NA</w>
flu id</w>
tempor arily</w>
v ents</w>
quar ters</w>
id ay</w>
a fil</w>
hous es</w>
candi dates</w>
O ECD</w>
pr icing</w>
ov is
w it
R D</w>
P RI
kn itted</w>
ref usal</w>
fle et</w>
cle aning</w>
success fully</w>
IF RS</w>
reimbur sement</w>
on ian</w>
clarif y</w>
s port</w>
The ir</w>
4 50</w>
ti a</w>
coord inate</w>
sit ting</w>
particip ant</w>
S atur
clos ing</w>
T AB
ci vil
ab ine</w>
Yug osla
erythro poi
compet ences</w>
e sia</w>
measu rements</w>
emphas is</w>
mod ules</w>
Europe ans</w>
M ob
Con t
Wor k</w>
P eg
tend ere
l ose</w>
W A
voc ational</w>
justif y</w>
el sewhere</w>
ri ver</w>
µ g</w>
ea p</w>
Indu strial</w>
Ass emb
imp aired</w>
bl ue</w>
19 89</w>
N at
Lon don</w>
spen ding</w>
perfec t</w>
ovis ual</w>
odi c</w>
s in
org an</w>
a.k. a.</w>
ev ol
A sia</w>
RE N
Euro pol</w>
Buil ding</w>
haz ard</w>
b ru
manag ers</w>
ag liptin</w>
ur gency</w>
occa sion</w>
co efficient</w>
Is lands</w>
m L</w>
con g
EME A</w>
leg e</w>
Imple mentation</w>
on ed</w>
excee ded</w>
AR TIC
eu tical</w>
stat utory</w>
law ful</w>
M old
issu er</w>
pass ing</w>
new s</w>
intermedi ate</w>
al bu
fir m
scenari o</w>
Tra ining</w>
Gu ideline</w>
14 0</w>
w age</w>
whol ly</w>
h ell</w>
w anna</w>
bu ying</w>
infra structures</w>
in ts</w>
ul ate</w>
ma xim
4. 2.
pro gram</w>
Ris k</w>
I ris
AL L</w>
sum mar
men s</w>
car go</w>
F ather</w>
Davi d</w>
6 0
tr ies</w>
enti eth</w>
croch eted</w>
as tic</w>
ro b
bo y</w>
an i</w>
an dic</w>
se as</w>
B lack</w>
en ship</w>
Icel andic</w>
l ing
Detail ed</w>
squ are</w>
ed onia</w>
O B
su d
res istant</w>
offici ally</w>
d ered</w>
counter party</w>
broad band</w>
lo ts</w>
correspon d</w>
bankno tes</w>
over dose</w>
Rap porteur</w>
tw entieth</w>
larg ely</w>
genu ine</w>
cu ts</w>
acet ate</w>
10 ,000</w>
id ine</w>
car cin
op ol
St ability</w>
C D</w>
st ations</w>
Iris h</w>
head s</w>
C ulture</w>
stop ped</w>
s ick</w>
coh erence</w>
bo ost</w>
approxim ation</w>
p ers</w>
got ta</w>
com ment</w>
Min isters</w>
seri ously</w>
phen yl</w>
al ism</w>
se iz
tun a</w>
gener ate</w>
B .
sle ep</w>
sem en</w>
arch itec
creati nine</w>
bl ing</w>
acc umul
Uru gu
bur g</w>
ver sus</w>
Y outh</w>
Glob al</w>
E s
ob taining</w>
mess ages</w>
Con sul
fo ster</w>
lim itation</w>
histor ical</w>
illu str
subsidi aries</w>
my self</w>
cy lin
cont acts</w>
tem plate</w>
n r</w>
li gence</w>
fer tilis
Comm er
pro jec
conc ep
w ines</w>
veterin arian</w>
am a</w>
Urugu ay</w>
Docu ment</w>
gu ide</w>
STR U
ter n</w>
ep id
ch eap</w>
thous and</w>
subs cri
Not withstanding</w>
1 107</w>
8 0
prohib it</w>
organ ization</w>
cul tiv
en ded</w>
fel t</w>
A D</w>
ow ing</w>
0, 5</w>
call ing</w>
ax el</w>
t oc
campai gn</w>
Hell o</w>
ov e
hy bri
Feder ation</w>
res cue</w>
exha ust</w>
. com</w>
dev i
APPE AR</w>
Ph il
miti gation</w>
frequ ent</w>
L T</w>
vi als</w>
serv ed</w>
m erely</w>
M id
secu red</w>
pot en
penal ty</w>
le ather</w>
Avi ation</w>
dens ity</w>
ca using</w>
o k
att ack</w>
Secon dly</w>
H ave</w>
Di g
fre ez
be an</w>
Appro val</w>
wh olesale</w>
terror ist</w>
be ef</w>
speci alised</w>
pe p
marg ins</w>
lit er
ev olution</w>
d ness</w>
min eral</w>
d ecis
ain ing</w>
pop ulations</w>
metabol ism</w>
expec tations</w>
stric t</w>
anal ogue</w>
employ ee</w>
ar k</w>
Secur ities</w>
secon ds</w>
blin d</w>
o g</w>
ple ased</w>
tru th</w>
Assemb ly</w>
um b
pl ays</w>
ev en
man ual</w>
furn iture</w>
P ot
off ences</w>
su scep
-- -</w>
s li
v an</w>
e ase</w>
un likely</w>
in hal
dri vers</w>
x th</w>
enzy mes</w>
Con clu
an te</w>
C au
ri x</w>
employ er</w>
00 000</w>
feder ation</w>
Over all</w>
D ER
is ely</w>
great est</w>
S chem
g ed</w>
dis posed</w>
pres erv
carri age</w>
F ound</w>
vail ing</w>
II I
nutri tion</w>
1 14</w>
pum p</w>
ti an</w>
summ er</w>
la z
PAR T</w>
Tre aties</w>
Sy n
h ec
US ED</w>
rec urren
procee ding</w>
inv ent
separ ation</w>
M P
wor th
fac ed</w>
Ex port</w>
tu bes</w>
tr im
suff ering</w>
Sal es</w>
G l
constitu tional</w>
comp ound</w>
valu able</w>
de pression</w>
WIT H</w>
nor th</w>
di versi
blis ter</w>
hosp ital</w>
comm and</w>
repl ies</w>
S ha
s n
initi ally</w>
chil d
al es</w>
infring ements</w>
St op</w>
Veter inary</w>
ord ination</w>
in tr
tr ation</w>
L and</w>
but ton</w>
att acks</w>
sur roun
feed ing
there after</w>
PROV ISIONS</w>
Bal k
pursu ed</w>
17 8</w>
ST O
Pro ject</w>
W ait</w>
am in</w>
s en</w>
con grat
car bon
D G
IR Y</w>
2 b</w>
Environ mental</w>
defin ing</w>
over sight</w>
ligh ted</w>
con strain
V A</w>
s tic
R are</w>
phen omen
per cent</w>
Sm all</w>
integr al</w>
B or
contribu ted</w>
as sive</w>
elim inate</w>
T el
W el
addres ses</w>
ab led</w>
in su
system atic</w>
sh eep</w>
i ans</w>
appro ve</w>
So dium</w>
dis patch</w>
AC H</w>
refriger ator</w>
c c
Ad just
suspec ted</w>
p neum
6. 3</w>
for th</w>
8 ,
s atellite</w>
r ace</w>
ad just</w>
re tention</w>
o ting</w>
f os
nitro gen</w>
Tr an
Ex change</w>
EC E</w>
R adi
IM O</w>
chann els</w>
Chec k</w>
dis pen
them e</w>
fe et</w>
distin c
C .</w>
ep iso
Indu stry</w>
wid ely</w>
r ic
ph eral</w>
ty res</w>
figh ting</w>
M os
ste ady</w>
mat ely</w>
g ur
ship ping</w>
un certainty</w>
in ject</w>
tab led</w>
num erous</w>
bi ocidal</w>
organ iz
Hol der</w>
occup ational</w>
11. 2007</w>
dec line</w>
1, 5</w>
C O</w>
tain ment</w>
utilis ation</w>
swit ch</w>
appe ared</w>
mat ure</w>
s ports</w>
T ai
Y Y
complain ant</w>
Im pro
spar e</w>
si um</w>
Chil dren</w>
L .</w>
sal aries</w>
gen tly</w>
EXP IRY</w>
g am
S S
connec tions</w>
1 30</w>
arth ritis</w>
u de</w>
Des pite</w>
complain ts</w>
z i
k new</w>
ess entially</w>
an ded</w>
spe ak
Pri v
ot ox
I B
bor row
tur ned</w>
ship ment</w>
ast ers</w>
mat ory</w>
i tical</w>
artif icial</w>
Tun is
p o</w>
icit ly</w>
s ac
a j
st o
ri f
C ir
it us</w>
inten sive</w>
egr ad
threat s</w>
collabor ation</w>
beg an</w>
gro w</w>
g est</w>
Mac edonia</w>
G ar
b y
vari eties</w>
METH OD</w>
Austr alia</w>
mis sed</w>
em ail</w>
plat el
Pack age</w>
def ec
author ized</w>
an ch
Sust ain
dizz iness</w>
benef icial</w>
am bi
contrac ep
pr is
g ained</w>
forwar ded</w>
Ap pe
brea thing</w>
In don
correspon ds</w>
s er</w>
Pr inci
H i</w>
T ru
lig ible</w>
C D
PL Y</w>
lead ers</w>
coast al</w>
CYP 2
thro p</w>
3 4
Lev el</w>
high lighted</w>
aff airs</w>
engine ering</w>
dossi er</w>
2, 5</w>
bl u
virtu e</w>
exclu de</w>
PACKAG ING</w>
Bo ok</w>
12 3</w>
attrac tive</w>
caref ul</w>
inte resting</w>
Win throp</w>
ec os
accommod ation</w>
an o
sev er
pr int</w>
fix es</w>
de struction</w>
asti m</w>
2 10</w>
cartrid ge</w>
as king</w>
M ach
ong ue</w>
citiz en</w>
fr ac
compl ying</w>
met ers</w>
met als</w>
coord in
May be</w>
relig ious</w>
Satur day</w>
col our
TE N</w>
Pro vi
.. ..</w>
CON TEN
TIT LE</w>
13 9</w>
v or
oph il
on y</w>
a us
prepar atory</w>
mo dule</w>
tab les</w>
occurren ce</w>
AG E</w>
sh ing</w>
of i</w>
charg ing</w>
Mold ova</w>
Con cer
re iter
B on
ME T</w>
17 2</w>
tle ments</w>
ann ually</w>
AS E</w>
reve aled</w>
simult aneously</w>
T 2</w>
provis ion
d u</w>
tern s</w>
am ong
MR Ls</w>
Ag re
modi fications</w>
h us
J os
entr usted</w>
e uro
bloc ks</w>
per haps</w>
buty l</w>
AC T
om er
g el
C as
7 0
ag eing</w>
Fin ance</w>
C s</w>
gene tically</w>
M un
ro ll</w>
resid ents</w>
ep o
il e
cons ensus</w>
al t</w>
JO INT</w>
pres ents</w>
err ors</w>
en ty</w>
en tic
s low
loo ked</w>
di et</w>
al ist</w>
PRO CE
F ax</w>
I G
on to</w>
log ical</w>
Mon ten
E th
PROCE DU
vis its</w>
deal t</w>
O F
sugg ests</w>
Mon etary</w>
eri al</w>
construc ted</w>
Ar t</w>
du pl
no tic
desi red</w>
um p</w>
erad ication</w>
cell ul
ot echn
s ph
bu re
observ ation</w>
Im port</w>
Monten egr
Inf ra
v ill
phen yl
compr ise</w>
Amend ments</w>
stres sed</w>
Stud y</w>
sustain ed</w>
Con federation</w>
thresh olds</w>
em i
S et</w>
defici ency</w>
S en
L iv
3 -</w>
Al ban
exem pted</w>
aqu atic</w>
. 1</w>
s low</w>
S on</w>
C ar</w>
ti li
invo ice</w>
f ear</w>
we ak</w>
suff er</w>
w ishes</w>
f ail</w>
ad mission</w>
tis h</w>
w in</w>
st ory</w>
out comes</w>
RI P</w>
labor atories</w>
hydro chloride</w>
ens in</w>
no t
H u
Pak istan</w>
P A
Identi fication</w>
destin ations</w>
M el
herit age</w>
poll ut
o dy</w>
fil ter</w>
among st</w>
M ech
plat forms</w>
ch ick
fif th</w>
incorpor ating</w>
sign ing</w>
man if
du al</w>
acces sibility</w>
OR T</w>
In dian</w>
bo at</w>
subsi dis
mon ary</w>
for ced</w>
bro ther</w>
Ob jec
3 50</w>
econom ically</w>
wh enever</w>
res piratory</w>
absol utely</w>
en cing</w>
compl ex
experi ences</w>
S pr
Ac count</w>
tu be</w>
In dic
re verse</w>
occur ring</w>
ur s</w>
every body</w>
F oundation</w>
y eah</w>
l ay
exc ise</w>
CI P
tr y
bench mark</w>
T ax</w>
poten sion</w>
inten si
comple mentary</w>
Chris t</w>
expan sion</w>
cl ari
ti ous</w>
om ide</w>
lox acin</w>
bran ches</w>
Ma ke</w>
LI C</w>
reflec ts</w>
en tion</w>
it ment</w>
an cies</w>
valid ation</w>
perm its</w>
ST OR
qual ification</w>
new ly</w>
irregul arities</w>
sh ore</w>
ir besartan</w>
H ep
De partment</w>
Con tent</w>
p el
l un
contribu tes</w>
12 2</w>
comb in
Th ur
hyper tension</w>
ev ening</w>
trans ported</w>
c umul
Th er
und red</w>
af ter
accred itation</w>
work er</w>
m osph
el ong</w>
web sites</w>
horm one</w>
ec .europa.eu</w>
T im
wai ting</w>
6. 6</w>
coun ting</w>
D ose</w>
cro p</w>
rein force</w>
extrac tion</w>
ab ove
b id
transm it</w>
op id
b ound
Pr ice</w>
wi re</w>
og rel</w>
C iti
d ens</w>
sh ed</w>
reti rement</w>
stimul ate</w>
distor tions</w>
S un
in c</w>
house holds</w>
mo des</w>
eg g</w>
F O
disp utes</w>
O K</w>
reci proc
ra rely</w>
Pow er</w>
Con si
serv ants</w>
mort ality</w>
re rs</w>
organis ational</w>
abdom inal</w>
1 .</w>
12 6</w>
co ins</w>
Ch ang
freed oms</w>
P regn
f ellow</w>
15 7</w>
N S</w>
regim en</w>
ain t</w>
Pro vince</w>
reason ably</w>
UR E</w>
opid ogrel</w>
lis ten</w>
duc tion</w>
p H</w>
J HA</w>
L et
g ue</w>
v enture</w>
Instru ment</w>
Bud get</w>
Institu tions</w>
B S</w>
ic in</w>
foot note</w>
de partments</w>
D om
resol ve</w>
ure ly</w>
C lin
resol ved</w>
Montenegr o</w>
ther mal</w>
Compet ent</w>
l asting</w>
tax pay
B A</w>
A IN
pre t
ec o</w>
diff er</w>
Scho ol</w>
3 18</w>
as is</w>
sol ar</w>
ap hy
ho c</w>
dis continuation</w>
Dig ital</w>
n evertheless</w>
injec ted</w>
ros is</w>
consider ably</w>
OU T</w>
CONTEN TS</w>
above mentioned</w>
r an</w>
Manufac tu
versi ties</w>
R ed</w>
co ff
in solvency</w>
ef avirenz</w>
1 11</w>
requ is
Fil m</w>
pat tern</w>
dis aster</w>
pat terns</w>
k W</w>
foun ded</w>
safegu ards</w>
gr astim</w>
est ers</w>
H am
ma kers</w>
k ids</w>
h undred</w>
bo ys</w>
p. m.</w>
il ed</w>
vig il
om as</w>
ograph y</w>
is n</w>
al ise</w>
ox e
sh ift</w>
may be</w>
ty re</w>
forth with</w>
enti s</w>
cl es</w>
si t</w>
calcul ations</w>
surve ys</w>
distr ict</w>
O r</w>
K aun
35 4</w>
U CI
g ains</w>
Or der</w>
L ast</w>
suppl ement</w>
prec isely</w>
St re
Mor oc
wor se</w>
conduc ting</w>
L in
sub str
UB LIC</w>
A M</w>
haem at
gly cer
dis abled</w>
justif ication</w>
v as
om et
o dic
lev y</w>
b ol
F IN
iz z
ra p</w>
Chem ical</w>
bri dge</w>
T é
p ts</w>
ill ary</w>
cap sule</w>
tri p</w>
over come</w>
s co
S ou
No tice</w>
ref used</w>
reas ing</w>
p it
ac ad
1. 7</w>
im ages</w>
Pol y
sugg ested</w>
residu al</w>
gl and</w>
OU TER</w>
advis ory</w>
happen s</w>
ter ly</w>
A A</w>
contr ast</w>
N S
C MO</w>
pr ise</w>
cap it
bu ff
agre es</w>
audi ovisual</w>
ti mately</w>
cor tic
F E</w>
5 9
br and</w>
Cor por
C lim
ap pointing</w>
lis ting</w>
UCI TS</w>
fin ds</w>
at mosph
pen sions</w>
con form</w>
wo ol</w>
l as
activ ation</w>
ARTIC LE</w>
organis m</w>
S ource</w>
N ACE</w>
g ress</w>
neighb ouring</w>
assum ed</w>
sti c</w>
compl ement</w>
1 15</w>
priv acy</w>
un used</w>
nation ality</w>
D S
purch ased</w>
peri odic</w>
ex act</w>
vacc ines</w>
M er
y r
partic les</w>
inv al
expl icitly</w>
S em
re combin
At omic</w>
oxe tine</w>
Cer tif
w est</w>
preven tive</w>
ba g</w>
Cont act</w>
oper ates</w>
fe ature</w>
4 -</w>
stom ach</w>
big gest</w>
RES S</w>
uni verse</w>
ot ensin</w>
fu n</w>
recombin ant</w>
p acks</w>
reconstitu ted</w>
alcohol ic</w>
ag on</w>
infl ation</w>
reinfor ced</w>
investig ated</w>
1 18</w>
p ure</w>
know s</w>
soci eties</w>
u v
ou gh
s ail
qual ify</w>
suspen d</w>
it ory</w>
SUB ST
rang ing</w>
minim ise</w>
ROU TE</w>
A ver
Pregn ancy</w>
SEC TION</w>
Cre dit</w>
f air
cl ass
che ese</w>
C F</w>
consign ments</w>
N ext</w>
mo stly</w>
s om
4. 7</w>
organis e</w>
18 5</w>
tou ch</w>
or rh
aggreg ate</w>
Form er</w>
Mic ro
p ped</w>
hy persensitivity</w>
as c
Appl ic
metabol ites</w>
simpl ify</w>
20 th</w>
rec over</w>
m ation</w>
head ache</w>
mbo l</w>
emp ty</w>
G A</w>
pap er
cardi ac</w>
M aster</w>
plas tics</w>
care er</w>
am ic</w>
sub jected</w>
spe aking</w>
deriv ative</w>
bat ch</w>
specif ying</w>
pre mi
alph a</w>
counter parties</w>
t ar
ap point</w>
adj usting</w>
2. 6</w>
forec ast</w>
ev i
ol ate</w>
di ver
chan nel</w>
arri val</w>
re tained</w>
ti tude</w>
reason ed</w>
ter ial</w>
random ised</w>
peri pheral</w>
ri de</w>
confi gur
t elecommunications</w>
it ai
Sustain able</w>
Min utes</w>
e ze</w>
eli hood</w>
ag ues</w>
pret ty</w>
di esel</w>
C he
tri ed</w>
restric t</w>
cent ury</w>
S an</w>
altern ate</w>
O rig
ann ing</w>
min ing</w>
T ariff</w>
dec reasing</w>
TR AN
En ti
rem ote</w>
threat ening</w>
og le</w>
N L</w>
Su b</w>
Pol itical</w>
merg er</w>
reflec ting</w>
cat aly
i us</w>
Horiz on</w>
en ables</w>
condi tional</w>
excre ted</w>
12 1</w>
cred itors</w>
sem in
et te</w>
deteri oration</w>
ati gue</w>
a sive</w>
treat ments</w>
p ages</w>
bi om
auth entic
d or
W il
ol er
dem ands</w>
cur y</w>
syn ergies</w>
M ee
t s
2 70</w>
sup posed</w>
purch asing</w>
C am
S om
Lab our</w>
LIS T</w>
Al tern
un changed</w>
on ate</w>
Nat ural</w>
discre tion</w>
au l</w>
wal k</w>
fa ith</w>
le uk
pro lif
post al</w>
au t
M em
An ti</w>
30. 4.2004</w>
3, 5</w>
parlia mentary</w>
O ption</w>
reci pients</w>
conv in
a es
i ant</w>
electr on
dec ides</w>
condi tioning</w>
t m
sl aughter</w>
ant agon
W ar
D O</w>
AC TIVE</w>
spe ech</w>
pro ven</w>
op tical</w>
Slov ak</w>
cop per</w>
Tri bunal</w>
re views</w>
qu in
oxy gen</w>
clear ing</w>
Citi z
toler ance</w>
th yro
i di
box es</w>
Stu dies</w>
stan tly</w>
demonstr ation</w>
sen ding</w>
elec ted</w>
e br
cir cul
D ar
LI A
restrain t</w>
Schem e</w>
refuge es</w>
reli ability</w>
mot or
as m
inter face</w>
de partment</w>
recep tion</w>
mac ro</w>
dam aged</w>
dang er</w>
am ed</w>
hot el</w>
secret ariat</w>
ir rit
y ers</w>
l uc
clu b</w>
d am</w>
spl it</w>
r i</w>
prote ins</w>
ac tor</w>
Belg i
descri be</w>
RE F
constrain ts</w>
a side</w>
ten ing</w>
Meth od</w>
7 00</w>
Soci ety</w>
h at
un necessary</w>
anti bio
securiti sation</w>
fail s</w>
B ayer</w>
te aching</w>
negoti ated</w>
b is</w>
Agre ements</w>
se es</w>
P M</w>
te m</w>
pro tocol</w>
pre n
am az
nur se</w>
w a
tissu es</w>
TAR GE
vi able</w>
set tled</w>
un desirable</w>
Wee k</w>
Li ber
-------- --------
supple menting</w>
il eg
I .</w>
teach ers</w>
le agues</w>
contam ination</w>
C r
S us
ste ering</w>
complex ity</w>
ex p
yi eld</w>
rati ngs</w>
pass port</w>
Yugosla v</w>
worth iness</w>
see ks</w>
endor sed</w>
4 8
broad er</w>
Chair man</w>
ten sive</w>
hydrochlor othiazide</w>
om y
Z one</w>
e u</w>
S pi
Am ount</w>
Constitu tion</w>
in qui
co oling</w>
B e</w>
es c
az ine</w>
d airy</w>
ro lim
sol ve</w>
inser t</w>
re payment</w>
P at
ung er</w>
acknowledg ed</w>
0, 1</w>
psy ch
design ations</w>
ber ries</w>
gr ading</w>
In te
D an
lim iting</w>
de ep
asu re</w>
priv ileg
ci ally</w>
5 5
1 17</w>
Clim ate</w>
dis per
C R</w>
rolim us</w>
Appropri ations</w>
tel ephone</w>
arm ed</w>
Ad d</w>
fer tility</w>
reconstitu tion</w>
pen ia</w>
re store</w>
inter actions</w>
dis ability</w>
PAR LIA
recep tor</w>
finan ces</w>
swe et
Go ogle</w>
aim ing</w>
ul ated</w>
b id</w>
M ain
G ive</w>
Alban ia</w>
and a</w>
10. 2003</w>
po sts</w>
out lined</w>
E ar
thous ands</w>
im ag
Reg arding</w>
uni versities</w>
st a</w>
lik elihood</w>
Est ab
16. 11.2007</w>
satisfac tion</w>
hy potension</w>
hydrox ide</w>
tom atic</w>
reme dy</w>
offic ers</w>
jour ney</w>
dead lines</w>
un acceptable</w>
P V</w>
vol ati
ea red</w>
ap p
U E</w>
vis ibility</w>
pos s
gen etic</w>
dis abilities</w>
cor relation</w>
Bo dy</w>
mon otherapy</w>
et axel</w>
V en
ure a</w>
stric tly</w>
ch air</w>
fat al</w>
deli ber
mid dle</w>
1 16</w>
org ans</w>
og ues</w>
S ud
N GO
entrepreneur ship</w>
diab etic</w>
budg ets</w>
B LE</w>
p ment</w>
f er</w>
S ar
sy mbol</w>
st atic</w>
M erc
es tiv
ann ul
k itch
th r
Mil k</w>
v ice</w>
a f</w>
ME DI
ES A</w>
T P</w>
Consum er</w>
sen ior</w>
L ong</w>
T ab
iv udine</w>
U sing</w>
n ic
1, 3</w>
S a
H S</w>
b ever
S F</w>
dis asters</w>
av a</w>
k er
phys ician</w>
p referred</w>
exha usted</w>
I ra
trav elling</w>
al tered</w>
P RE
RE ACH</w>
f arms</w>
PARLIA MENT</w>
n ish</w>
c enter</w>
G I</w>
ome tric</w>
T al
20 6</w>
spir it
ody namic</w>
collec ting</w>
Competi tion</w>
p refer
com ed</w>
trac tor</w>
top ic</w>
12. 2013</w>
was n</w>
comfor t</w>
syring es</w>
ero ids</w>
pos es</w>
Electr onic</w>
li vest
n d</w>
S har
NGO s</w>
n aph
livest ock</w>
transport ation</w>
on set</w>
ic ks</w>
Latvi an</w>
evalu ations</w>
vers ely</w>
lac tic</w>
ag u
un due</w>
ro aming</w>
trans national</w>
dil ution</w>
coff ee</w>
peri odic
tim ate</w>
O pen
ign ition</w>
apart ment</w>
1. 8</w>
as ks</w>
B ut
9 9
p an</w>
ex ecutive</w>
clo thing</w>
3. 6</w>
sensi tivity</w>
suc rose</w>
kil o
SU P
15 6</w>
provision ally</w>
Fac ility</w>
glob alisation</w>
P act</w>
s our
1 13</w>
pe ac
TH AT</w>
sign als</w>
radio active</w>
un fair</w>
at er
F I
oty pe</w>
macro economic</w>
ist ure</w>
Jer us
attem pt</w>
me tic</w>
Z e
US T</w>
ne uro
deleg ations</w>
te en</w>
ten dering</w>
K al
pr a
SUP PLY</w>
P op
lead ership</w>
hy gi
ne arly</w>
sh ot</w>
Ma x</w>
war nings</w>
i j
Y or
In clu
red ness</w>
A E
pati al</w>
un lawful</w>
t ant</w>
g a
sp aces</w>
s a</w>
d res
OP INI
Cl assi
preci ous</w>
plan es</w>
environ mentally</w>
Di ff
fulfil ment</w>
di al</w>
sy mb
induc ed</w>
loc ations</w>
5 6
u ted</w>
t ree</w>
del ays</w>
itai .
e um</w>
docu mented</w>
Gre itai.
tr e</w>
angi otensin</w>
allo y</w>
tum our</w>
str ain</w>
Sor ry</w>
campai gn
sever ity</w>
ph r
3 47</w>
pum ps</w>
character ised</w>
tr uly</w>
initi ating</w>
gener ating</w>
da e</w>
Not es</w>
pres sed</w>
kin ds</w>
continu ously</w>
Val ue</w>
Un less</w>
Ir besartan</w>
ro ot</w>
dis closed</w>
brea ks</w>
en ic</w>
separ ated</w>
Infra structure</w>
ut sch
S G</w>
M L</w>
FIC ATION</w>
receiv es</w>
f ell</w>
trad ers</w>
inf ants</w>
D ING</w>
i tive</w>
1 19</w>
pur ity</w>
our selves</w>
h ath</w>
no w
ch urch</w>
tion ality</w>
ap art</w>
Jud g
BA T</w>
S Y
re es</w>
ou d</w>
n ic</w>
liber alisation</w>
ill ness</w>
hand le</w>
pe t</w>
confir mation</w>
pul monary</w>
yl ate</w>
cellul ose</w>
D ub
diagn osis</w>
V ari
dec l
Gen er
grow n</w>
des er
tribu tion</w>
p ush</w>
Com ments</w>
op a</w>
ammon ium</w>
Comm ander</w>
reser ved</w>
ap ters</w>
ch illed</w>
6. 5</w>
tot ally</w>
reduc es</w>
ma d</w>
recommen d</w>
Thur s
D er
prospec ts</w>
signific ance</w>
see ing</w>
Fir stly</w>
qu e
par ti
vigil ance</w>
b ate</w>
op en
isol ated</w>
soci o</w>
qual it
or an
excep tions</w>
me ant</w>
fr ame
Imp act</w>
col leagues</w>
B P</w>
progres sion</w>
lac tose</w>
ju ice</w>
ov ascular</w>
feeding stuffs</w>
T our
har d
Syst ems</w>
public ations</w>
ch est</w>
Mo ham
pro ved</w>
Par k</w>
gu ests</w>
ris ing</w>
pro sper
AS S
pl y</w>
as sume</w>
ren e</w>
por tion</w>
5 4
5 000</w>
Summ ary</w>
cou ple</w>
distin ction</w>
H o
diagnos tic</w>
C e
sulph on
cre ative</w>
ak es</w>
IN STRU
K l
loc ks</w>
2 a</w>
V .</w>
ner v
P OL
in adequate</w>
seg ment</w>
fil ament</w>
defici encies</w>
dec om
Bri tish</w>
control ler</w>
c ited</w>
ax le</w>
it ely</w>
en de
1 a</w>
sci enti
H igh
Aver age</w>
n al
epo etin</w>
Direc t</w>
lo aded</w>
hy th
w illing</w>
re productive</w>
pr acti
em y</w>
Sev eral</w>
pl ant
attribu ted</w>
seas onal</w>
m on</w>
effici ently</w>
6. 4</w>
analy se</w>
12 8</w>
f aster</w>
Loc al</w>
Effec ts</w>
17 84</w>
am i
t os
remov ing</w>
on ally</w>
Qu ality</w>
D ru
O il</w>
w er</w>
Bar ro
low ering</w>
broad casting</w>
Pol ice</w>
d ust</w>
N et</w>
be ings</w>
Lib ya</w>
inten d</w>
t ons</w>
Thurs day</w>
St abil
p ping</w>
br ings</w>
te ams</w>
poly m
je op
an ia</w>
L ac
trans formation</w>
par king</w>
inv ite</w>
Equi pment</w>
s ake</w>
rec alled</w>
moun ted</w>
inter ference</w>
B U
presid ency</w>
sel ler</w>
progres sive</w>
Nov o
form ulation</w>
fit tings</w>
ED F</w>
substan ti
rel ess</w>
p in
ori ented</w>
m align
L L
K O
ren der</w>
prom ised</w>
g al
os ing</w>
12 7</w>
coord inating</w>
sh el
sti m
st ones</w>
Le ader</w>
AS A</w>
con azole</w>
w an</w>
T RI
avo iding</w>
summ it</w>
L atin</w>
ce iv
OPINI ON</w>
wel comed</w>
17 1</w>
k in</w>
grap es</w>
F requ
Mex ico</w>
continu ity</w>
be d
F uck</w>
licen sing</w>
Lot to</w>
E V
foc using</w>
fi re
power ful</w>
h ence</w>
p a</w>
hibi tions</w>
C ur
prom ot
pro sec
Indon esia</w>
w are
exam ining</w>
W ill</w>
sur plus</w>
N ature</w>
sol ved</w>
R A</w>
dr inking</w>
S he
sh r
elec tion</w>
r aid</w>
hel ped</w>
S W
ick el</w>
as th
met res</w>
hon ey</w>
en tail</w>
al em</w>
jo ined</w>
PV C</w>
L AB
sk a</w>
S cot
sty le</w>
c s</w>
bul k</w>
S how</w>
re vo
phot os</w>
sc ore</w>
isl and</w>
propos ing</w>
ang er</w>
c us
b its</w>
Pro ce
H E
real istic</w>
sub heading</w>
12 4</w>
re n</w>
14 7</w>
volunte ers</w>
AD D
18 31</w>
o fo
pos session</w>
co ast</w>
P ost</w>
whe els</w>
n am</w>
l es
M ATE
K ey</w>
un related</w>
f um
ess ed</w>
Jerus alem</w>
decl are</w>
qu ick</w>
acc umulation</w>
5 75</w>
ul i
2 30</w>
o tic</w>
cri tic
Moroc co</w>
wh ich
subm itting</w>
ende av
conc iliation</w>
P eri
po etin</w>
co di
T AL</w>
pip es</w>
lead er</w>
ro t
deduc tion</w>
Mex ican</w>
Comm it
1, 4</w>
SI BLE</w>
N avigation</w>
D ri
termin ated</w>
STATE MENT</w>
L ow</w>
F lu
t ank</w>
J EC
trac tors</w>
fre ely</w>
cam era</w>
H ot
Air port</w>
obvi ous</w>
n ations</w>
com ings</w>
appro ving</w>
ul timately</w>
smo king</w>
Tur k
S ER
M ot
prop ylene</w>
Ti er</w>
independ ently</w>
es tions</w>
ec ological</w>
chair man</w>
stres ses</w>
ly mp
anis m</w>
et tlement</w>
fru its</w>
2 18</w>
suffici ency</w>
ne e</w>
elim inated</w>
Simil arly</w>
we ather</w>
H on
C rim
stri p</w>
er ly</w>
2 .</w>
relig ion</w>
di ox
ra m</w>
ca emic</w>
explan ation</w>
ati s</w>
techni que</w>
num b
g au
D oes</w>
13 5</w>
oran dum</w>
mort g
introduc tory</w>
b a</w>
star ts</w>
is tering</w>
fre eze</w>
bio fuels</w>
ne ys</w>
nat ur
R ot
optim al</w>
con fusion</w>
bre l</w>
M C</w>
view ing</w>
prom oted</w>
adv oc
W izz
pat ent</w>
ari ffs</w>
P D</w>
A mon
premi ums</w>
deg rees</w>
cap ability</w>
tap e</w>
sle ep
answ ers</w>
anc illary</w>
prof loxacin</w>
ch er</w>
PROCEDU RE</w>
En brel</w>
tw el
r ation
ro ots</w>
Bet ter</w>
mis s</w>
f atigue</w>
lin ear</w>
ni b</w>
belong s</w>
g ol
cal ibr
Bl ue</w>
r ich
Tu esday</w>
be st
min ority</w>
Pr ime</w>
00 2</w>
fo reg
con secu
Ex per
De utsch
e ti
ur inary</w>
o ate</w>
biom ass</w>
citiz enship</w>
M M</w>
ter most</w>
ten d</w>
tri g
recru itment</w>
St ar
Mal ay
3. 2.
enh agen</w>
bel ong</w>
HA VE</w>
z er</w>
retur ns</w>
con stantly</w>
14 5</w>
scre ening</w>
Fr on
Ass istance</w>
prop yl</w>
de als</w>
unanim ously</w>
distor t</w>
S F
lit azone</w>
happen ing</w>
g rid</w>
No thing</w>
stain less</w>
af raid</w>
S K</w>
20 7</w>
Tunis ia</w>
B V</w>
Sci ence</w>
AR D</w>
supervis ed</w>
ess ing</w>
civil ian</w>
x i
erythropoi etin</w>
preven ted</w>
o grap
Yor k</w>
preser ve</w>
bel t</w>
IC AO</w>
Clin ical</w>
g ent</w>
X III</w>
P lat
mer cury</w>
pi g</w>
cap abilities</w>
fulfil s</w>
t ancy</w>
D am
2 20</w>
Cha ir</w>
Stabil isation</w>
cre ates</w>
campaign s</w>
ME AS
dem ographic</w>
Spec ies</w>
sor t</w>
depend ence</w>
deb tor</w>
am matory</w>
Def ence</w>
rec over
num er
conc essions</w>
ati nib</w>
Cop enhagen</w>
ca st
bur dens</w>
adm itted</w>
prop ag
appropri ately</w>
14 2</w>
them atic</w>
fac tory</w>
distil lation</w>
Mark ets</w>
C C</w>
short comings</w>
clari fied</w>
PO L</w>
pre sum
P hy
5 10</w>
ir regular</w>
H old</w>
AP PRO
sol uble</w>
X I</w>
mo isture</w>
mil lions</w>
in take</w>
X II</w>
k id</w>
desi re</w>
at e
Kaun as</w>
g ri
Fr ank
CL AS
qual ifying</w>
grad u
au c
R ob
per missible</w>
16 9</w>
re production</w>
inform al</w>
ast e</w>
an tic
Up on</w>
M is
tre ating</w>
R iv
li fe
de tri
Econ om
ro ads</w>
L ife</w>
interven tions</w>
acqui re</w>
SUBST ANCE</w>
Com ple
B asic</w>
14 9</w>
haem orrh
S pe
im pe
az ol
typ ically</w>
pi pe</w>
constitu ents</w>
S el
Par tic
retro viral</w>
W OR
Tran si
In struc
ome th
ic ed</w>
w oven</w>
Pre vi
ro ad
s in</w>
pre me</w>
invent ory</w>
ili ary</w>
distor tion</w>
Summ it</w>
Ad verse</w>
princi p
9 00</w>
7 50</w>
MAN UF
rou gh
Ber lin</w>
neutro penia</w>
for um</w>
b ance</w>
Re sul
or a</w>
dial ysis</w>
Euro just</w>
s cr
modern isation</w>
ex tra
An y
v ity</w>
serv ing</w>
ch ron
O PER
MANUF ACT
B ab
long it
op posed</w>
b ars</w>
al ising</w>
................................ ................................
mono hydrate</w>
control ling</w>
Rem ove</w>
ton ight</w>
it y
my el
h ed
z e
s a
decis ive</w>
recogn ises</w>
ab or
y lic</w>
tin ib</w>
requis ite</w>
N EC
C ases</w>
0, 000</w>
17 0</w>
pre ad</w>
st eri
p eg
dr inks</w>
D EN
pres sive</w>
lif elong</w>
Re pe
paper board</w>
l ung</w>
in h
constitu ted</w>
16 8</w>
N a
1 st</w>
ogen icity</w>
extre me</w>
deduc ted</w>
enti tlements</w>
com partment</w>
Estab lish
ru it</w>
mem ory</w>
g as
Tai wan</w>
M an</w>
so far</w>
e ability</w>
bo ards</w>
secre t</w>
over view</w>
conven i
S OL
Nu clear</w>
IN TER
administr ator</w>
R os
13 08</w>
cred its</w>
ce ase</w>
compl iant</w>
assum ptions</w>
barri er</w>
intermedi aries</w>
y early</w>
judg ments</w>
coun ted</w>
relation ships</w>
compar ative</w>
1 -</w>
Supervis ory</w>
ó n</w>
2 16</w>
prof itable</w>
o .
metabol ite</w>
cop y
ag er</w>
In spec
proce ed</w>
lab els</w>
dis count</w>
consisten tly</w>
atis ation</w>
ocy top
f in</w>
conver ted</w>
19 88</w>
repe at</w>
n ation</w>
gro und
Pl ayer</w>
high light</w>
3 96</w>
counter fe
up dating</w>
toc ols</w>
D V
trail ers</w>
broad ca
aud itors</w>
L am
Con nec
y oun
t anks</w>
im migrants</w>
Char acter
dar k</w>
S H</w>
pres enting</w>
di pine</w>
sovere ign
interpre ted</w>
atten d</w>
N AT
migr ant</w>
int oler
conc ession</w>
substitu tion</w>
st ering</w>
inter nationally</w>
Fri day</w>
se al</w>
D ad</w>
pre clu
c ats</w>
Fin nish</w>
su n</w>
MATE RI
il ings</w>
fe wer</w>
sulph ur</w>
respec ting</w>
circu it</w>
PACKAG E</w>
m ur
c .</w>
hygi ene</w>
al ing</w>
An ti
compet e</w>
O s</w>
phosph or
L ic
freez ing</w>
Institu tion</w>
v ine</w>
tox ic
propor tional</w>
F P
spen d</w>
respec ts</w>
person ality</w>
asm us</w>
st ating</w>
s ons</w>
olog ically</w>
f ar
w ouldn</w>
C V
conven tions</w>
6 8
frame works</w>
B rit
ev il</w>
ati n
f ats</w>
be at</w>
Is su
T RE
cortic ost
p m</w>
H U</w>
try meat</w>
si l</w>
typ ical</w>
infl ammatory</w>
RE QU
Im port
wor ry</w>
Est onian</w>
Gre en
d aughter</w>
b ought</w>
N atur
ti um</w>
raz y</w>
b ags</w>
Fish ing</w>
Chang es</w>
9 99</w>
S EC</w>
ES F</w>
grap e</w>
Re al</w>
prec ed
it alisation</w>
ME S</w>
den afil</w>
al ter</w>
T RO
4. 9</w>
sub system</w>
cros sing</w>
z y
W o
3 43</w>
u d</w>
consecu tive</w>
at or
ac ity</w>
C all</w>
l us
tr ap
r al</w>
la h</w>
dys function</w>
reg isters</w>
re vol
Democr atic</w>
cel ebr
EP A</w>
valid ated</w>
car ded</w>
train ed</w>
m es
av entis</w>
T ax
P il
odi ties</w>
Ad v
e astern</w>
d .
eth anol</w>
eng agement</w>
in ity</w>
C RI
tre es</w>
sy m
pharmac eutical</w>
los ing</w>
am us
Tr av
pr ison</w>
k o</w>
14 8</w>
ti gh
less ons</w>
h em
L Y</w>
Inf o</w>
ic tion</w>
Er asmus</w>
ilit ary</w>
wor sen
san ofi</w>
id osis</w>
d ine</w>
S O</w>
Off ic
cho ices</w>
ab norm
u ph
ne ts</w>
enti tlement</w>
del ayed</w>
g astrointestinal</w>
direc tor</w>
autonom ous</w>
nec k</w>
sev enth</w>
el ed</w>
ath ered</w>
aci fic</w>
T om
Pr ac
need les</w>
ent an
F inal</w>
adap ting</w>
T 1</w>
P re</w>
CI AL</w>
12 60</w>
mo tiv
cep hal
un common</w>
cumul ative</w>
au ction</w>
POS AL</w>
techn ically</w>
row s</w>
cultiv ation</w>
par k</w>
lig ent</w>
Strateg ic</w>
off set</w>
r he
Ne ighb
L a</w>
Coun c
suscep tible</w>
reg re
an th
Cer tain</w>
tu ber
Li et
AI F
L ist
w et</w>
p urely</w>
5 28</w>
m ar</w>
hyper tensive</w>
M ov
Pro visions</w>
Aust rian</w>
S cope</w>
Hel p</w>
g aps</w>
I ES</w>
Al ways</w>
Defin itions</w>
inhib ition</w>
farm er</w>
r d</w>
ori entation</w>
ou termost</w>
co ating</w>
al in</w>
quar terly</w>
expen sive</w>
di visions</w>
Un til</w>
P acific</w>
pri or
ann ed</w>
nam ed</w>
under going</w>
seiz ures</w>
p ical</w>
defin itely</w>
Balk ans</w>
exhib ition</w>
R equ
C U
congrat ulate</w>
L ast
Ban king</w>
vari ation</w>
sh ock</w>
princip ally</w>
de ploy
con train
F IR
statis tically</w>
x y
silic on</w>
se af
episo des</w>
1, 2</w>
tm as</w>
s z
expl ains</w>
ta ste</w>
sk illed</w>
ce ilings</w>
ban ces</w>
Mo del</w>
Ma j
negoti ating</w>
inter ru
in ner</w>
bo ats</w>
u red</w>
off ence</w>
grad ual</w>
HC V</w>
17 6</w>
Ex am
Amon g</w>
18 7</w>
reg istry</w>
p up
distur bance</w>
R ome</w>
L angu
Ky oto</w>
J ord
ox id
detec t</w>
a rest</w>
ici ans</w>
s patial</w>
port able</w>
o pro
necess ity</w>
parlia ments</w>
log ic</w>
inter f
K E</w>
convin ced</w>
32 23</w>
pot atoes</w>
op i
r ay</w>
ill a</w>
dam n</w>
altern atives</w>
On line</w>
chol ester
pres su
is tence</w>
Sy ria</w>
og litazone</w>
en n
M Hz</w>
bro m
and is</w>
k al
in puts</w>
anti body</w>
pro files</w>
mar row</w>
configur ation</w>
b ourg</w>
L ot</w>
z ed</w>
Inte rest</w>
B at
stro ke</w>
stre et</w>
is ting</w>
ast atin</w>
19 75</w>
tack ling</w>
great ly</w>
eth nic</w>
Coun tries</w>
thro mbo
kitch en</w>
en vel
di gn
4 5
str ing
8 7
re dem
are r</w>
Ac tions</w>
o ing</w>
exerc ising</w>
concep ts</w>
I O
I EN
ha ven</w>
M ove</w>
z inc</w>
swe et</w>
et us</w>
Con struction</w>
distur bances</w>
Jap anese</w>
to ys</w>
integr ate</w>
effec ted</w>
Chris tmas</w>
0. 1</w>
mean ing
S M
sum s</w>
gu ess</w>
expi re</w>
y ard</w>
fal se</w>
T ex
15 2</w>
ful filling</w>
17 5</w>
objec tion</w>
evalu ating</w>
min isters</w>
Ther ap
Sk in</w>
warran ty</w>
Sub cutaneous</w>
run s</w>
crim es</w>
US D</w>
Wizz air</w>
tim etable</w>
modi fy</w>
Judg ment</w>
5. 4</w>
sovere ign</w>
op hen
cardi ovascular</w>
W i
D I</w>
poly ethylene</w>
c able</w>
ver i
ven ue</w>
in ea</w>
anti retroviral</w>
W ind
Po st
Di vision</w>
d ul
author ization</w>
accoun ted</w>
B G</w>
N 1</w>
Hy per
E P</w>
rob ust</w>
por ary</w>
hybri d</w>
frequ encies</w>
ad missible</w>
Stre et</w>
14 3</w>
hor se</w>
a ks</w>
ES CB</w>
prud ential</w>
Mid dle</w>
REP UBLIC</w>
bever ages</w>
air space</w>
N one</w>
Ren al</w>
form alities</w>
Roman ian</w>
Al l
w arm
ot a</w>
N orm
L B</w>
rati fication</w>
p ick</w>
nov el</w>
Ch ild</w>
th es</w>
fr action</w>
conf erences</w>
us age</w>
o v</w>
on e
lo dipine</w>
en .
w il
ut ers</w>
Vi et
w ill
fi ers</w>
List en</w>
y ours</w>
L ad
v ap
colour less</w>
A 00
reat h</w>
deliver ing</w>
acc ru
re strial</w>
natur ally</w>
Curren t</w>
surroun ding</w>
supple ments</w>
sul f
sh ad
Reg ister</w>
G as</w>
ch amber</w>
I M</w>
im balances</w>
connec t</w>
I E</w>
sud den</w>
red und
ab and
f ly</w>
em o
Har mon
m ell
al and</w>
fi ting</w>
curren cies</w>
26 58</w>
it ching</w>
car box
bal ancing</w>
at ers</w>
ar ks</w>
Integr ated</w>
negoti ation</w>
induc tion</w>
gl ing</w>
aes the
L and
I U
t ness</w>
Intr on
3 a</w>
lab elled</w>
gr ain</w>
Wh ich</w>
pos iti
odi um</w>
ap peti
al ive</w>
Str as
Concer ning</w>
Ar ch
5 40</w>
19 80</w>
lev erage</w>
Author ities</w>
MATERI ALS</w>
pill ar</w>
el etal</w>
demonstr ating</w>
ST E</w>
enab led</w>
weak ness</w>
12 55</w>
tro uble</w>
c tu
denom inated</w>
co w</w>
co ol</w>
An im
trail er</w>
pers istent</w>
jeop ardis
Intron A</w>
16 5</w>
share holder</w>
M ilitary</w>
P I</w>
ve in</w>
compr ises</w>
v enti
organiz ations</w>
B C</w>
vacc inated</w>
particul ate</w>
in correct</w>
commod ity</w>
advant aged</w>
14 1</w>
Ter ms</w>
In dividu
D A
0. 3</w>
lac t
es pread</w>
X X</w>
co a</w>
fe els</w>
dis proportionate</w>
Stras bourg</w>
P REC
Ira q</w>
iz ing</w>
nerv ous</w>
destro yed</w>
cere al</w>
tim ing</w>
stimul ating</w>
platel et</w>
bri ef
regim es</w>
se aled</w>
phenomen on</w>
dis close</w>
equival ence</w>
en ta
L ear
G U
magne sium</w>
ack ed</w>
Ex peri
vail able</w>
standardis ed</w>
reve al</w>
op ping</w>
li br
Oper ational</w>
M en</w>
mut atis</w>
exam inations</w>
ut ation</w>
mut andis</w>
ali as</w>
Com b</w>
supple mented</w>
Appe al</w>
er as</w>
draf ting</w>
6 4
of the</w>
K in
sy l
re tail
sk y</w>
ha m</w>
Streng th</w>
vi vo</w>
neg ligible</w>
Com par
13 2</w>
sulph ate</w>
domin ant</w>
M T</w>
Reg istration</w>
I tem</w>
Com b
slow ly</w>
periodic ally</w>
T H</w>
Chi ef</w>
2 34</w>
sh oul
issu ance</w>
Mech anism</w>
p hi
os s</w>
spirit ual</w>
l t.</w>
fore sts</w>
dre w</w>
bu yer</w>
Pe g</w>
expi red</w>
vin yl</w>
twel ve</w>
viol ations</w>
L igh
opa thy</w>
Initi ative</w>
o vigilance</w>
f ast
top ics</w>
d ance</w>
sub cut
impl ies</w>
intermedi ary</w>
LE T</w>
fat ty</w>
1 19
s and
produc es</w>
adv ances</w>
C ere
sum an</w>
re min
B lood</w>
te l</w>
os up
in sofar</w>
Ar g
i er</w>
reci pes</w>
purch ases</w>
In suman</w>
viol ation</w>
me als</w>
ti de</w>
subcut aneously</w>
pen s</w>
fam ili
answ ered</w>
tu m</w>
Pro gress</w>
G az
EG F</w>
Ph ot
si le</w>
s car
la d</w>
Co ordination</w>
For ce</w>
op ath
b reath</w>
IL D
C AT</w>
s ly</w>
ill icit</w>
fin alised</w>
AI D</w>
25 1</w>
ten ed</w>
Fin d</w>
saf ely</w>
i ghts</w>
cred itor</w>
ag ic</w>
wid espread</w>
der mal</w>
u x</w>
pl ug
b and
isl ands</w>
F EC
edi ble</w>
det ention</w>
R C</w>
ph y</w>
min us</w>
WA STE</w>
En gland</w>
ame th
surg ical</w>
smo ke</w>
T or
B est</w>
lap se</w>
Ph ase</w>
treat y</w>
ish ment</w>
dra ul
achiev ements</w>
trad ed</w>
I RE
PREC AU
G S</w>
inf o</w>
bene fiting</w>
L eb
fos sil</w>
Greitai. lt.</w>
th esis</w>
con dem
NO T</w>
recurren ce</w>
13 3</w>
cru de</w>
P en</w>
Chris tian</w>
1 31</w>
om er</w>
lit res</w>
g ar</w>
ew ise</w>
au x
30 4</w>
16 2</w>
invest ed</w>
2, 4</w>
2 80</w>
P ut</w>
in sufficiency</w>
anticip ated</w>
origin ally</w>
cl a
STOR AGE</w>
L U
5 a</w>
6 6
thor ough</w>
re act</w>
gener ations</w>
M UST</w>
Malay sia</w>
ADD RESS</w>
transi ent</w>
sovereign ty</w>
en a</w>
Gal ile
d ents</w>
ord ered</w>
Rap id</w>
17 82</w>
B ir
qualit ative</w>
lac tation</w>
NEC ESS
C ot
ann i
pro pri
estiv al</w>
corpor ations</w>
G lax
ong side</w>
NECESS ARY</w>
Ab out</w>
12 9</w>
there for</w>
confir ms</w>
in k
For m</w>
rest aur
clar ification</w>
al er
Jord an</w>
n.e. c</w>
ar rest</w>
absor bed</w>
20 2</w>
prolif eration</w>
pris on
hydro us</w>
ha ir
16 4</w>
redem ption</w>
poul trymeat</w>
ip s</w>
Neighb ourhood</w>
3 3
perman ently</w>
ef in</w>
bro w
Sol id
foot wear</w>
PRECAU TIONS</w>
E AG
Appl ications</w>
t ling</w>
W h</w>
RE N</w>
cul osis</w>
EU R
. 2</w>
dis c</w>
sou l</w>
j i</w>
execu ted</w>
dom ain</w>
ang a</w>
P et
Barro so</w>
pestic ides</w>
an aphy
up dates</w>
obvi ously</w>
Nov ar
30 2</w>
qu an
met al
ai ds</w>
scenari os</w>
lo ves</w>
im porting</w>
Sud an</w>
no ti
guarante eing</w>
Virafer on
t es
C ard</w>
t ariffs</w>
preserv ation</w>
coupl ing</w>
vari ations</w>
bur ning</w>
Open ing</w>
land s
commer ce</w>
com pe
we alth</w>
ograph ical</w>
Fu el</w>
fron tier</w>
firm ly</w>
T ow
Statis tical</w>
Exc ept</w>
A 2</w>
p ace</w>
embry os</w>
ph ases</w>
Mee ting</w>
18 4</w>
20 30</w>
w ave</w>
tendere r</w>
es tive</w>
at ro
S of
comm odities</w>
b al</w>
audi o</w>
as one</w>
Th rough</w>
R T</w>
fab ric</w>
under mine</w>
re alised</w>
port al</w>
un ions</w>
gener ic</w>
est ation</w>
stre am
flow ers</w>
Viraferon Peg</w>
E f
C enter</w>
Oper ation</w>
DIS POSAL</w>
A O
prosper ity</w>
par c
an ium</w>
pe o
h an
Un fortunately</w>
R ail
SC R</w>
advis e</w>
L an
bot tles</w>
Col lec
em atic</w>
E valuation</w>
un employed</w>
s atur
fail ing</w>
are t
He ad
wi reless</w>
Pay ment</w>
Pl us</w>
Classi fication</w>
C ould</w>
15 80</w>
Ukra in
Col lege</w>
sk im
re medi
E TS</w>
il ly</w>
Last ly</w>
C TIONS</w>
20. 12.2013</w>
fores ee
em plo
deploy ed</w>
ATE D</w>
N O</w>
D im
ycl es</w>
mov able</w>
di ure
de preci
bo iling</w>
dis advantaged</w>
c razy</w>
Qu anti
charac ters</w>
be ans</w>
es hi
ling u
dy nam
SU CH</w>
i v</w>
fe asi
Novar tis</w>
um e</w>
, 5</w>
vis as</w>
cla uses</w>
Galile o</w>
U p</w>
ER DF</w>
res sive</w>
T ON</w>
Im ports</w>
pursu it</w>
discipl ine</w>
gam bling</w>
align ment</w>
coo ked</w>
identi fier</w>
em ea
circu its</w>
arg e</w>
B B</w>
Ad voc
PO SI
1. 0</w>
C ross</w>
AP PROV
2 11</w>
um ns</w>
bacter ial</w>
D eb
1. 9</w>
tim ber</w>
gl omer
forec asts</w>
cris es</w>
Ste el</w>
hol iday</w>
ber g</w>
Dec ree</w>
B ot
trad em
under gone</w>
pollut ants</w>
got ten</w>
egrad ation</w>
u ous</w>
ew s</w>
Intr on</w>
CO R
cap rine</w>
Indu stri
pic tures</w>
form ally</w>
fa x</w>
bure au
s is</w>
P ap
worsen ing</w>
string ent</w>
om eter</w>
f ound
0 8
S aint</w>
IM I</w>
3 70</w>
prof ession</w>
compens ate</w>
E AF
war r
pre mature</w>
p references</w>
W ord
Lot teries</w>
le g</w>
al i</w>
incid ents</w>
Program mes</w>
an es
16 1</w>
mar ried</w>
forth coming</w>
D istr
defin es</w>
war m</w>
emphas ise</w>
F I</w>
fin es</w>
demonstr ates</w>
bo il
09. 4
thre ad</w>
p ar</w>
down stream</w>
chem ically</w>
decre ases</w>
rang es</w>
in complete</w>
K i
14 4</w>
od en</w>
Solid arity</w>
s ickness</w>
rever sible</w>
circ le</w>
Vehic le</w>
Trans fer</w>
Th ir
7. 1</w>
tw enty</w>
comm it</w>
F am
CLAS SI
6 7
reserv ation</w>
nar row</w>
al ter
affor d
Gr ade</w>
E d
Ac ting</w>
serv er</w>
R ol
si xth</w>
co cc
UN USED</w>
S OR
objec tions</w>
EAF RD</w>
Con ver
clean er</w>
set tings</w>
ingredi ent</w>
2. 7</w>
y al</w>
uni versity</w>
ox ides</w>
atten ing</w>
Previ ous</w>
IM UM</w>
compl icated</w>
EN TR
fe a
experi encing</w>
e k
Tour ism</w>
te dly</w>
method ologies</w>
gly caemia</w>
dec ades</w>
T T</w>
re ject</w>
19 86</w>
dec entr
Com pan
wind ows</w>
tur ning</w>
Al uminium</w>
d ental</w>
AS T</w>
5. 5</w>
em et
F ull</w>
ceiv ed</w>
bas es</w>
Per man
Cau tion</w>
Ac tive</w>
sil ver</w>
li ved</w>
K u
3 37</w>
on om
log istics</w>
fo il</w>
Pos sible</w>
sen ten
feasi bility</w>
ep il
con vention</w>
30. 6.
pul sion</w>
N ation
entrepreneur s</w>
pre val
fea sible</w>
Sou thern</w>
Ex penditure</w>
te x</w>
aggreg ated</w>
Re form</w>
Commun ications</w>
peac eful</w>
albu min</w>
N es
Leg isl
expres sly</w>
c a</w>
architec ture</w>
P F
psy cho
al ized</w>
remain der</w>
an hydrous</w>
As k</w>
m esh</w>
don ors</w>
st ake</w>
a ths</w>
mar ri
3. 7</w>
blis ters</w>
b les</w>
B anks</w>
incorpor ation</w>
P G</w>
C NS</w>
promp tly</w>
mo re
in habit
di verse</w>
L y
fo stering</w>
the ore
F eed</w>
2 nd</w>
inves ting</w>
entan yl</w>
ash ion</w>
HO W</w>
APPRO PRI
c en
16 7</w>
steri le</w>
read ily</w>
hydr o</w>
gr ation</w>
de pri
appro vals</w>
tang ible</w>
inter connection</w>
extra ordinary</w>
Priv ate</w>
Peg Intron</w>
encour ages</w>
Spr ing</w>
r us</w>
ord inated</w>
excell ence</w>
epil ep
bloc king</w>
Stand ards</w>
IS A</w>
w ages</w>
v ast</w>
reg istr
mol lus
metabol ised</w>
In stead</w>
w est
urg es</w>
deb ts</w>
cos metic</w>
ox ib</w>
autom ated</w>
TE X
sor i
ma z
bat tery</w>
substan tive</w>
col oured</w>
jud ge</w>
ici de</w>
g athered</w>
consum ed</w>
17 7</w>
work force</w>
up take</w>
e tr
be et</w>
W aste</w>
shor ter</w>
pl unger</w>
lear ned</w>
bo dy
16 6</w>
rup t
re voc
min orities</w>
li th
co operative</w>
T arg
Re ally</w>
20 4</w>
19 5</w>
C ON</w>
sh ell</w>
TO TAL</w>
CH ILD
tri gg
U l
trig ger</w>
hydrox y</w>
trad er</w>
distinc t</w>
TAB LE</w>
P a</w>
ti tu
li ance</w>
compl ications</w>
win ter</w>
rec ap
occa sions</w>
carri es</w>
b und
porte urs</w>
is terial</w>
geograph ic</w>
CHILD REN</w>
respon ding</w>
pro pan
all ine</w>
cr y
vit amin</w>
e ans</w>
In tro
Fre ed
p d
R F
μ m</w>
my cin</w>
l um
P O</w>
allo ys</w>
rim p</w>
WH AT</w>
Sta r</w>
AI L
ci g
b ond</w>
C Y
dis played</w>
7. 2</w>
is ure</w>
flu ctu
er o</w>
comfor table</w>
Pan el</w>
ex changed</w>
Ref erences</w>
Inde x</w>
115 1</w>
INSTRU CTIONS</w>
19 85</w>
ver te
T I</w>
Proce dures</w>
I l
D on
am lodipine</w>
Objec tive</w>
MEAS U
reg en
our se</w>
hu h</w>
distribu tors</w>
R A
wash ing</w>
ul in</w>
dil uted</w>
RE V
17 4</w>
th a</w>
hor ses</w>
copy right</w>
N ice</w>
Appl ause</w>
n m</w>
Pri or</w>
A men
ph thal
k as</w>
isol ation</w>
exac er
ere s</w>
at tract</w>
Rel ations</w>
L ight</w>
IM P
Dub lin</w>
Distr ict</w>
0. 9</w>
min ation</w>
elev ated</w>
Go ods</w>
trac eability</w>
direc tors</w>
ar a</w>
accoun tability</w>
M G</w>
o ste
leg s</w>
high lights</w>
deteri or
under cutting</w>
epid emi
Ar ab</w>
fa ult</w>
correc tions</w>
E ffici
ofo vir</w>
expen se</w>
cat tle</w>
al tar</w>
X VI</w>
S hel
C la
C ari
prior iti
oc ks</w>
equi dae</w>
cor rid
auth or</w>
Brit ain</w>
stud ent</w>
Ze aland</w>
ograph s</w>
abnorm alities</w>
pan cre
ol ence</w>
foresee able</w>
bio availability</w>
an as</w>
a. m.</w>
New s</w>
execu ting</w>
a g</w>
ear ing</w>
coo king</w>
contr ad
SI GHT</w>
ul timate</w>
sho ot</w>
RE LE
slaugh ter
SER V
PL IC
multipl ied</w>
P .
Ear th</w>
P ath</w>
stic k</w>
cylin der</w>
O thers</w>
observ er</w>
inh erent</w>
bri ef</w>
appeti te</w>
al arm</w>
20 3</w>
arbitr ation</w>
particip ated</w>
diversi fication</w>
wast es</w>
le th
j ack
In st
oun ded</w>
os es</w>
sc rap</w>
hur t</w>
rou tine</w>
In ves
o tive</w>
dam ages</w>
cholester ol</w>
13 7</w>
draul ic</w>
cor n</w>
A k
per id
miti gate</w>
in struction</w>
fil grastim</w>
emphas ised</w>
Lab oratory</w>
H al
sh ut</w>
p acking</w>
net working</w>
er ated</w>
wor st</w>
val ve</w>
dis pat
Sm ith
L og
swit ching</w>
investig ate</w>
in avir</w>
fish er
f itting</w>
bacter ia</w>
Op ti
F ar
under lined</w>
under ing</w>
lam ivudine</w>
dipl omatic</w>
comb inations</w>
Commer cial</w>
Adjust ment</w>
Cl u
pe er</w>
metabol ic</w>
K az
Fol low</w>
expl icit</w>
ell ers</w>
ac idosis</w>
AL T</w>
tuber culosis</w>
rol ls</w>
cancell ation</w>
Offic er</w>
C .
umin ous</w>
thyro id</w>
he sive</w>
foc uses</w>
weak nesses</w>
ent ers</w>
ap ping</w>
which ever</w>
incid ent</w>
don or</w>
Ma ur
LE AF
or o
n an
adequ acy</w>
yst ems</w>
leg ality</w>
cl ick</w>
PE N
l ity</w>
H ence</w>
EF FEC
Arg enti
d op
air line</w>
P age</w>
A v
ver sions</w>
op t</w>
back ed</w>
W I
where ver</w>
mol ec
fur t</w>
d ad</w>
co d</w>
al og</w>
Turk ish</w>
Hy persensitivity</w>
ous es</w>
n ickel</w>
expl ore</w>
Nes po</w>
atmosph ere</w>
ach ment</w>
Em ploy
Perman ent</w>
grav ity</w>
au tical</w>
LEAF LET</w>
col umns</w>
bench marks</w>
datab ases</w>
E .
D ou
gly col</w>
exp and</w>
cy clo
Ukrain ian</w>
d in</w>
meaning ful</w>
c ouldn</w>
acad emic</w>
ti e</w>
system atically</w>
mat ching</w>
c tic</w>
ad o</w>
O lymp
DER IV
Selec t</w>
disper sible</w>
sou thern</w>
v ascular</w>
or ous</w>
fam ous</w>
d .</w>
ol ine</w>
Pl ant</w>
Manufactu rer</w>
harv est</w>
ti vities</w>
skim med</w>
ic ular</w>
di methyl
PE T</w>
Pre vention</w>
Bul g
med ication</w>
special ist</w>
ak h
Ha em
Gu idance</w>
ple asure</w>
gu n</w>
resol utions</w>
compens atory</w>
MIN IMUM</w>
thor ough
out break</w>
as sign
Me dia</w>
CLASSI FICATION</w>
connec ting</w>
youn ger</w>
ran dom</w>
counter vailing</w>
compe ting</w>
chi atric</w>
ant a</w>
poli tic
ow ns</w>
Pal estin
H and
vari ables</w>
CYP2 C
A sh
3 000</w>
st an</w>
gu ard</w>
cartrid ges</w>
Té l</w>
vill age</w>
prefer ably</w>
ot rex
mix ing</w>
liquid ation</w>
f attening</w>
M om</w>
13 4</w>
0. 2</w>
0. 0
spo ke</w>
r up</w>
comm ission</w>
ac r
Man ual</w>
A z
bur n</w>
N on
ro g
L ea
Gr and</w>
2 25</w>
pan els</w>
l o</w>
vis itors</w>
b ow
P eter</w>
pd f</w>
hom ogen
APPROPRI ATE</w>
deb ates</w>
temper atures</w>
on wards</w>
ax es</w>
aud itor</w>
suppl ying</w>
re placing</w>
Su preme</w>
E .</w>
hus band</w>
dis par
19 70</w>
19 2</w>
cam eras</w>
main tains</w>
contrac tors</w>
Pro per
K line</w>
Inter action</w>
pul p</w>
pro jected</w>
n t</w>
M L
G all
p ist
f ai
train s</w>
ren dered</w>
RE SP
F our</w>
or ally</w>
intel ligence</w>
II .
A x
ne arest</w>
form ity</w>
believ ed</w>
B E
F ive</w>
Bi o
2 90</w>
peo ples</w>
otrex ate</w>
lia ison</w>
Mon day</w>
Measu re</w>
inst al
Con go</w>
Compan ies</w>
trad ition</w>
class ical</w>
Ch o
CC P</w>
destro y</w>
T 2
sav ed</w>
res sion</w>
Pers ons</w>
incorpor ate</w>
W rit
и я</w>
in i</w>
Bet ween</w>
t ongue</w>
heav en</w>
soci etal</w>
munici pality</w>
le ak
c up</w>
ad versely</w>
sub paragraphs</w>
minim is</w>
injur ious</w>
cour age</w>
Vehic les</w>
TS O</w>
J ack</w>
15 3</w>
29 13</w>
Word Press</w>
B en</w>
0 7
ocytop enia</w>
c ann
G ICAL</w>
8. 1</w>
lax is</w>
in cl.</w>
discipl inary</w>
reinfor cing</w>
ic onazole</w>
W ould</w>
fin ish</w>
ket o
biodi esel</w>
bank rupt
ban ds</w>
Pharmac okin
35 8</w>
0. 4</w>
cryst alline</w>
L D
FIN AN
secur ing</w>
gar den</w>
Smith Kline</w>
Mun ici
F lo
them es</w>
ti me
br on
ac etic</w>
tex tiles</w>
te tr
g all
St ock</w>
IN TE
jo ints</w>
c ks</w>
pack ed</w>
inter n
pap ers</w>
low s</w>
Anim als</w>
a. m</w>
S olution</w>
Mar ine</w>
C Y</w>
under go</w>
neutr al</w>
l ar</w>
de hy
cont em
Ac ad
24. 12.
def end</w>
16 3</w>
pul l</w>
fir stly</w>
es cape</w>
Y et</w>
lif t</w>
g in</w>
spo ken</w>
plant ation</w>
cul tures</w>
O M
mu tually</w>
ig a</w>
dis h
antibio tics</w>
E RE
sy rup</w>
sup por
see kers</w>
od opa</w>
bat teries</w>
an on</w>
rec ast</w>
du m
C PC</w>
pres sing</w>
infec tious</w>
D eter
Con taining</w>
trans plant</w>
buff er</w>
Re as
evid ent</w>
EI T</w>
Character istics</w>
per mission</w>
Pro mo
Conclu sion</w>
CL U
cros s
contrain dicated</w>
carbon ate</w>
T s</w>
rap porteurs</w>
precau tionary</w>
n ose</w>
ambi ent</w>
Radi o</w>
4 7
targ eting</w>
p ation</w>
dec or
y cle</w>
de aths</w>
ther ing</w>
st em
reme dies</w>
regul ate</w>
organis ing</w>
m ic</w>
ht m</w>
dispen s
character istic</w>
ag e
Spi rit</w>
Resul ts</w>
OL AF</w>
0. 6</w>
observ ance</w>
ap le</w>
subsidis ed</w>
Ac counting</w>
work shops</w>
Kl ai
20 9</w>
kilo grams</w>
RESP ON
attribu table</w>
shad ow</w>
loc ally</w>
dec iding</w>
clo thes</w>
Ter rit
19 0</w>
taxpay ers</w>
mobil isation</w>
impl y</w>
resi li
con stru
c ine</w>
PP E</w>
2 40</w>
m atic</w>
en rich
Sh it</w>
F lights</w>
18 3</w>
17 3</w>
12 49</w>
15 1</w>
symp tomatic</w>
EC SC</w>
Certif icate</w>
w s</w>
re pos
construc tive</w>
10 000</w>
Wh ether</w>
p ays</w>
eu tic
beg ins</w>
G i
O lan
alloc ations</w>
20 8</w>
projec tions</w>
Inves tig
prospec tus</w>
path ogenic</w>
an cement</w>
transl ated</w>
Re structuring</w>
te a</w>
in ding</w>
Olan zapine</w>
12. 5</w>
ecos ystems</w>
T V
P aul</w>
C P</w>
per for
cig aret
certif ying</w>
E T</w>
vis ited</w>
pursu ing</w>
exerc ises</w>
STO RED</w>
p alities</w>
S R
IC CAT</w>
tor que</w>
EL L
stop per</w>
it ri
found ations</w>
concomit antly</w>
as ser
any where</w>
Merc k</w>
Initi al</w>
identi fies</w>
duc t</w>
alg ia</w>
u tili
ol i
ell er</w>
Gu inea</w>
at titude</w>
M ON
. int</w>
C el
B order</w>
ex tin
ar c
MO s</w>
dec k</w>
bre ad</w>
0. 00
vers ary</w>
ti ght</w>
or age</w>
ne uropa
memb ran
en orm
ac compl
St art</w>
sp ac
cast le</w>
Hol y</w>
0 1.
xi ety</w>
po t</w>
consci ousness</w>
CAR TON</w>
B T</w>
G ross</w>
rec ourse</w>
fil ed</w>
amoun ted</w>
Is lam
Cari b
X IV</w>
Au di
z ing</w>
v astatin</w>
h lor
endeav our</w>
c ad
cong estion</w>
Sun day</w>
22. 12.
eth eless</w>
enfor ce
Glax o
3 20</w>
c and
T ro
com a</w>
St ock
Proc ess</w>
He ads</w>
thorough ly</w>
t elling</w>
pro vince</w>
al ongside</w>
K ing</w>
sur faces</w>
lodg ing</w>
accid ental</w>
min ent</w>
me tric</w>
ER A</w>
5 7
Green land</w>
hand led</w>
GO C</w>
D r.</w>
feed back</w>
NAT O</w>
constru ed</w>
re jection</w>
no on</w>
cap ture</w>
cap tain</w>
ad ine</w>
Glaxo SmithKline</w>
st amp</w>
2, 2</w>
15 8</w>
ob serve</w>
2. 8</w>
Carib bean</w>
insu red</w>
inhabit ants</w>
h ole</w>
er ic</w>
al is
fu r</w>
dis pose</w>
credi bility</w>
cap tive</w>
TEX T</w>
Man ager</w>
2 200</w>
5 8
refin ed</w>
min imal</w>
integr ating</w>
contrac ted</w>
aero plane</w>
accred ited</w>
doc etaxel</w>
I L</w>
ro ck</w>
sph ere</w>
seri ousness</w>
fair ly</w>
experi mental</w>
amoun ting</w>
s artan</w>
in di
group ing</w>
admin istering</w>
notif ying</w>
en coun
Su gar</w>
D .</w>
y stem</w>
recep tors</w>
ester day</w>
chi ef</w>
teach er</w>
immun ity</w>
A syl
inc in
be er</w>
ad dy</w>
a a</w>
C A
ph il
dign ity</w>
S ir</w>
ter ri
Ne o
CS D</w>
Ar ab
Hot el</w>
k ingdom</w>
20 5</w>
mis artan</w>
k illing</w>
ch ains</w>
Leb anon</w>
w alls</w>
stake holder</w>
CF P</w>
stabil isation</w>
ol ed</w>
anes p</w>
Ex pos
Ar anesp</w>
f oundation</w>
LI FE</w>
DERIV ED</w>
CIP IEN
as pir
Citiz ens</w>
Frank furt</w>
Bulg arian</w>
shap ed</w>
negoti ate</w>
expan ded</w>
c ess
f ashion</w>
s cri
or th
Integr ation</w>
ol e
Ir on</w>
safegu arding</w>
St ep</w>
ill us</w>
discus sing</w>
car cases</w>
any more</w>
an avir</w>
Mi gration</w>
even tually</w>
Electr ic</w>
subm issions</w>
Ar men
0 10</w>
m ouse</w>
Viet nam</w>
Statis tics</w>
Sec tor</w>
off al</w>
slaugh tered</w>
jo ining</w>
aud ited</w>
or ph
ess or</w>
U h</w>
Pr im
tig mine</w>
amus cular</w>
H ist
Asyl um</w>
s light</w>
mon ella</w>
Virafer on</w>
25 8</w>
ter restrial</w>
t aneous</w>
car c
L it
work place</w>
h r</w>
Re ports</w>
h ate</w>
expl oratory</w>
emea .</w>
AP PLIC
b ad
nit ude</w>
flav ouring</w>
0, 2</w>
la undering</w>
explan ations</w>
bu b
X V</w>
im per
Sp ace</w>
Ex em
substanti ated</w>
V .
ã o</w>
v aries</w>
ur ia</w>
pressu res</w>
QU AL
Pow der</w>
14 6</w>
s al</w>
dec ent</w>
Ob serv
Mic ha
K r
ATI ONAL</w>
sh alt</w>
amin o
CIPIEN TS</w>
AIN EN</w>
substr ate</w>
law yer</w>
Pl ay</w>
seg ments</w>
satis fies</w>
meth otrexate</w>
Pl ants</w>
O U</w>
R ou
w ishing</w>
observ ers</w>
judg es</w>
ic ating</w>
Main tenance</w>
0 3
spr ay</w>
compar e</w>
Rail way</w>
M .</w>
min ors</w>
verte br
MF Is</w>
Organ ization</w>
Instruc tions</w>
19 77</w>
b ones</w>
N r.</w>
mo vi
Mo der
Man aging</w>
hom es</w>
electron ically</w>
assemb led</w>
U .
suppor tive</w>
2, 3</w>
er als</w>
R IS
Exc use</w>
plan et</w>
o ids</w>
haz ards</w>
conform ing</w>
ad al
Regul atory</w>
18 8</w>
ver ifying</w>
tur b
en cephal
cer amic</w>
Incre ased</w>
aero drome</w>
Par kin
H IC
Curren tly</w>
1 C
reci pe</w>
petro l</w>
car dia</w>
adap tations</w>
comp uters</w>
anc er</w>
alloc ate</w>
EX CIPIENTS</w>
m os
graph ic</w>
C ES</w>
tow ard</w>
bankrupt cy</w>
f ed</w>
Per form
P P</w>
G ul
F F
en comp
al ty</w>
K S</w>
im en</w>
tic aria</w>
id ae</w>
au s</w>
W AL</w>
Mad rid</w>
s ister</w>
ass ay</w>
SOR AINEN</w>
sub period</w>
Appro xim
E F</w>
constitu ting</w>
ac tu
ac company</w>
Sloven ian</w>
Rec overy</w>
ph oto</w>
cur ve</w>
ab el</w>
u h</w>
lar s</w>
ad or</w>
tak e
r at</w>
pain ting</w>
mortg age</w>
fac tual</w>
Oper ations</w>
compar ing</w>
west ern</w>
practic able</w>
mil es</w>
hol m</w>
aesthe sia</w>
N ob
J u
C arri
nu cle
M c
eth ical</w>
dis pos
al ine</w>
II a</w>
2 24</w>
stop ping</w>
or g</w>
fail ures</w>
R NA</w>
w ound</w>
ic op
go od
frag mentation</w>
exis ted</w>
D EF
tif y</w>
m ice</w>
dre ds</w>
per cep
benef ited</w>
mell itus</w>
la g</w>
marri age</w>
j an</w>
con ve
circum vention</w>
Z im
ti p</w>
re mind</w>
PL N</w>
instruc ted</w>
h id
transfer ring</w>
tr aw
depreci ation</w>
Sev enth</w>
AD R</w>
A h
4 9
rec re
promot es</w>
est ations</w>
R econ
M IR
un ity</w>
ti tan
ocar dial</w>
d egradation</w>
circ ular</w>
thro at</w>
pl ing</w>
com posite</w>
ip p
Advoc ate</w>
re conciliation</w>
du ci
compu ter
broad ly</w>
Qu al
POSI TION</w>
18 6</w>
sign alling</w>
phen ol</w>
av er
IM F</w>
Ar t.</w>
Sev ere</w>
ci a</w>
Tr ading</w>
Hum ira</w>
Democr ats</w>
ro of</w>
ock et</w>
devi ation</w>
compar ability</w>
Experi ence</w>
theore tical</w>
repe at
r in
p sori
n olence</w>
eri als</w>
di min
MEASU RES</w>
p iv
a sion</w>
sur pr
af ts</w>
win ding</w>
uc ks</w>
T en
EU RES</w>
v an
pi oglitazone</w>
P R</w>
B ra
L ES</w>
3. 8</w>
yi el
der ful</w>
Z Z</w>
Bri g</w>
ru pt</w>
respon ded</w>
fr actions</w>
A th
25 6</w>
odi alysis</w>
ass is</w>
rab bits</w>
munici palities</w>
speci fies</w>
G B</w>
ro les</w>
COMMUNI TY</w>
p .</w>
if ts</w>
dre am</w>
t est
re stor
os ting</w>
fisher men</w>
e uropa
dec e
stipul ates</w>
laun ching</w>
en se</w>
autonom y</w>
2 47</w>
19 76</w>
hel p
excre tion</w>
B ack</w>
ur gently</w>
preval ence</w>
direc tions</w>
Particip ation</w>
symb ols</w>
semin ars</w>
invo ked</w>
conf er</w>
ad ise</w>
regul ating</w>
WH O</w>
ern ity</w>
grad es</w>
g lad</w>
c is
4 6
ici ous</w>
Natur a</w>
M e</w>
p are
gau ge</w>
cle ans
Lad ies</w>
C ul
resid ential</w>
le isure</w>
sul fon
sac rif
process or</w>
po sted</w>
contam inated</w>
Pil ot</w>
L V</w>
IN E</w>
tick et</w>
pro ud</w>
ar my</w>
Oc ean</w>
AIL LE</w>
V it
ot ro
BR AILLE</w>
c asu
serv es</w>
en ue</w>
14 93</w>
col ours</w>
A sian</w>
ro ds</w>
repres sion</w>
24 54</w>
gen e</w>
ger ia</w>
Enter prise</w>
19 72</w>
y ach
op posite</w>
moun tain</w>
mon y</w>
il le</w>
ic on
end ant</w>
dr am
Re duc
ide al</w>
fur thermore</w>
fr ames</w>
satis fying</w>
pres s
ol ym
bureau cr
preser ving</w>
epidemi ological</w>
C ru
Al geria</w>
met ast
En d</w>
aut umn</w>
Ste ering</w>
AD E</w>
introduc es</w>
b et</w>
scienti sts</w>
ery them
ass e</w>
are n</w>
TAR IC</w>
resi ding</w>
p reference</w>
m ere</w>
ES S</w>
lic k</w>
differenti ated</w>
head quarters</w>
In jection</w>
7 7
righ tly</w>
St .</w>
wai ver</w>
pestic ide</w>
fin ed</w>
dehy de</w>
az ep
jus ti
Pub lic
K en
I TS</w>
sal ic
rhe um
life time</w>
he im</w>
ast ed</w>
Glob alisation</w>
am bers</w>
mus cles</w>
acceler ate</w>
pe l</w>
end point</w>
head lamp</w>
recogn ized</w>
pro tocols</w>
do x
ann exes</w>
Pal anga</w>
intoler ance</w>
Stat ement</w>
o ks</w>
europa .</w>
om ers</w>
F ro
tum ours</w>
more over</w>
fl our</w>
ar re
So vi
victi m</w>
s and</w>
i .</w>
eutic als</w>
titan ium</w>
fertilis ers</w>
P y
AT A</w>
ur ge</w>
Maj or</w>
Au dit</w>
afford able</w>
Hol iday</w>
Ac tivities</w>
3 rd</w>
MEDI ATE</w>
2 68</w>
un usual</w>
aqu eous</w>
tre m
st ear
clos ures</w>
IL O</w>
Rec ogn
Hydro chlor
E col
Compl iance</w>
hyper glycaemia</w>
M ill
15 5</w>
t ants</w>
succ essive</w>
p as
longit ud
ket ball</w>
hibi ting</w>
Med ical</w>
2 26</w>
subm its</w>
su sp
for gotten</w>
IC H</w>
EN TI
ser ial</w>
polic y
electro magnetic</w>
procee ds</w>
dec ade</w>
cess ation</w>
B ru
recogn ising</w>
prescri be</w>
og en</w>
neighb ourhood</w>
mark etable</w>
P ack</w>
termin ate</w>
ow ed</w>
Pers onal</w>
E l</w>
Competi tiveness</w>
ö r
ME MBER</w>
trans plantation</w>
d ili
Ar rang
st ain</w>
off shore</w>
car bo
arg ues</w>
D ex
A Z</w>
TARGE T2</w>
F ruit</w>
y y
L ive</w>
Phy s
ation ary</w>
ail s</w>
L e</w>
Individu al</w>
some body</w>
pr on
e ating</w>
V ic
RE STR
un loading</w>
otox icity</w>
hy persensi
dic es</w>
coupl ed</w>
liter ature</w>
chick ens</w>
K ING</w>
fil ms</w>
extrac ts</w>
equ ine</w>
sequ ence</w>
pre vents</w>
lith ium</w>
constitu ent</w>
Trav el</w>
N G
tac rolimus</w>
purch as
aux iliary</w>
Presid ents</w>
W al
Instru ments</w>
Bud g
famili ar</w>
ear nings</w>
cy to
Wind ows</w>
O S</w>
Air lines</w>
ou ghts</w>
Uni versal</w>
Every thing</w>
un fortunately</w>
Pass port</w>
indu ce</w>
appe aring</w>
annul ment</w>
Perform ance</w>
APPROV AL</w>
mod al</w>
gr and
Sy rian</w>
o res
Fi re</w>
3 86</w>
ro tation</w>
sit agliptin</w>
regul ators</w>
Y Y</w>
Ch lor
xim ab</w>
a ul
S anc
Pay ments</w>
A I</w>
De pos
3 .</w>
o a</w>
lev odopa</w>
Transi tional</w>
fi br
Micha el</w>
thir ds</w>
privileg es</w>
in appropriate</w>
00 3</w>
speak ers</w>
Reg istr
N -</w>
Int ere
AI DS</w>
Sec tions</w>
sh opping</w>
hypersensi tive</w>
cor ro
Pr in
EE AS</w>
inform ing</w>
Cor rec
envel ope</w>
comb ine</w>
c ables</w>
FIR ST</w>
th es
olog ic</w>
co ag
accumul ated</w>
reg ab
9 51</w>
con signed</w>
Con tract</w>
tour ist</w>
regab alin</w>
o ic</w>
descri bes</w>
Simil ar</w>
re aches</w>
ab sent</w>
D .
Bar cel
ta u
real ise</w>
n as
N .
B ER
influ enced</w>
gr y</w>
T AC
ME Ps</w>
thro w</w>
nov ads</w>
S ave</w>
Jud ah</w>
D own
Cl opidogrel</w>
tal ks</w>
farm ed</w>
determin es</w>
Prof es
An alysis</w>
retail ers</w>
c lic</w>
w ake</w>
imp regn
W atch</w>
ten ofovir</w>
par a</w>
est ro
Prepar ation</w>
P SC</w>
Pharmacokin etic</w>
preclu de</w>
GH z</w>
vir uses</w>
on ym
occup ation</w>
ni e</w>
enorm ous</w>
c m3</w>
bloc kers</w>
2 97</w>
bi og
anni versary</w>
Vol ume</w>
red ress</w>
m assive</w>
Ch urch</w>
swit ched</w>
ul c
sal mon</w>
Sub total</w>
Fi x
ASS ESS
ven ess</w>
tran shipment</w>
inter active</w>
ero id</w>
en force</w>
d ap
REQU IRE
munici pal</w>
Dr aft</w>
A le
align ed</w>
N ig
simult aneous</w>
pub lik
obstac le</w>
inter ruption</w>
explo it</w>
R est
s ounds</w>
out breaks</w>
leak age</w>
dr ying</w>
credi ble</w>
cl eared</w>
Under standing</w>
Proc urement</w>
4 32</w>
prote ase</w>
down load</w>
D ev
af fixed</w>
W ife</w>
Ret ur
AT T</w>
ve al</w>
Barcel ona</w>
W eb
W N</w>
Categ ories</w>
B I
lif ting</w>
2 48</w>
nit rate</w>
vi br
compres sion</w>
LE G
B AN
2 60</w>
pa thy</w>
in os</w>
17 0
а р
sugg estions</w>
restor ation</w>
mor al</w>
air worthiness</w>
C riter
it ro
S ul
Elec tro
we ights</w>
r .
net ting</w>
lo go</w>
Gro ups</w>
new sp
th in</w>
y an</w>
tic ul
oper atives</w>
fl esh</w>
W eight</w>
Freed om</w>
val ent</w>
Invest ments</w>
30 9</w>
th oughts</w>
pol lu
ol a</w>
F F</w>
19 82</w>
rul ed</w>
F ail
mis leading</w>
eng th</w>
apart ments</w>
admin ister</w>
Detail s</w>
Un its</w>
Pl ay
17 9</w>
Res ources</w>
tin g
s ca
ha r</w>
decentr alised</w>
E le
val ves</w>
man ip
harv ested</w>
exacer b
Budg etary</w>
30 5</w>
repe al</w>
hi re</w>
A qu
00 4</w>
RE L
P DO</w>
Ital ia</w>
Inter institutional</w>
He ight</w>
ta p</w>
inst all</w>
emer gence</w>
bound ary</w>
e str
diagnos ed</w>
bre aking</w>
ad ds</w>
19 6</w>
ing ness</w>
fav or
S eri
8 8
1. 1.
sti pation</w>
plug in</w>
M etal</w>
Frequ ency</w>
COM P
b lo
S V</w>
ee ds</w>
Cl ose</w>
person ally</w>
asth ma</w>
ki ren</w>
V eget
M T
s essions</w>
nutri tional</w>
ent ations</w>
ar di
st aple</w>
lo ads</w>
big ger</w>
o x</w>
fun ny</w>
Palestin ian</w>
N E</w>
sev erely</w>
pl atin</w>
Clu b</w>
Ar ti
Add res
comple ting</w>
Wor kers</w>
harmon ise</w>
8 53</w>
amp ou
At t
tendere rs</w>
simpl ifying</w>
b om
trac ts</w>
N ic
8 81</w>
3 01</w>
rati fied</w>
prec ision</w>
defec ts</w>
K ong</w>
H ong</w>
G BP</w>
yl an</w>
it ter</w>
In tel
tr adi
inter view</w>
cab in</w>
F ine</w>
F ile</w>
B SE</w>
0 5
water way</w>
repl ied</w>
k ey
T EC</w>
H az
some what</w>
inspec tors</w>
encoun tered</w>
distingu ish</w>
emphas ises</w>
are rs</w>
loc ked</w>
interf ere</w>
enta ils</w>
bel ts</w>
35 7</w>
corticost eroids</w>
c up
Pro vision</w>
Inter im</w>
6. 2011</w>
e h
bar ley</w>
N ever</w>
25 3</w>
to s</w>
ord in
g nee</w>
III a</w>
Exam ples</w>
Ex clu
hun dreds</w>
K h
revis e</w>
is s
intel ligent</w>
calibr ation</w>
ap pen
dis solved</w>
6 9
speak er</w>
re marks</w>
pro mis
ph ones</w>
Accor d</w>
re af
d B</w>
b i</w>
Sovi et</w>
P erc
Finan cing</w>
Ag ainst</w>
19 78</w>
we igh</w>
haemorrh age</w>
d an
ar ction</w>
analys ing</w>
B a
neighb ours</w>
el les</w>
best os</w>
3 49</w>
x in</w>
radi us</w>
my ocardial</w>
assis ting</w>
Pet ro
rec y</w>
le sions</w>
fo etal</w>
dis su
d ress</w>
v ec
tr uck</w>
su itability</w>
star s</w>
py ro
interru pted</w>
c ub
b us
L AN
cou p
Vi ew</w>
chlor o
avo idance</w>
F uture</w>
4 20</w>
mag nitude</w>
a emic</w>
vi c</w>
stri ke</w>
se p
man ure</w>
to il
loc king</w>
L ine</w>
volati lity</w>
it a</w>
conver t</w>
Shel f</w>
Ch apters</w>
6 48</w>
innov ations</w>
bi o</w>
serv ant</w>
Sk y</w>
Respon se</w>
law fully</w>
am i</w>
WI TH
process ors</w>
il ateral</w>
borrow ing</w>
UN ECE</w>
Sus pension</w>
an xiety</w>
M D</w>
Impro ving</w>
ul tr
iz umab</w>
dis carded</w>
bre aches</w>
ak ed</w>
YY YY</w>
licen sed</w>
f lower</w>
N i
stim ulation</w>
i os</w>
d as</w>
contrac tor</w>
O l
μ g</w>
at tained</w>
ast a</w>
REQUIRE MENTS</w>
8. 2</w>
b ill</w>
Jud ge</w>
Addi tionally</w>
under lines</w>
inter ior</w>
im s</w>
es cal
ur ticaria</w>
priv atisation</w>
mat ches</w>
W oven</w>
S AL
will ingness</w>
mon opol
maxim ise</w>
F ish</w>
Al liance</w>
reimbur sed</w>
QU AN
19 9</w>
comm ission
Sh ort</w>
Fo ot
v s</w>
sto res</w>
m m
in stances</w>
Olymp ic</w>
Appro ach</w>
7 5
19 67</w>
18 1</w>
wal king</w>
stem ming</w>
mod alities</w>
li p</w>
inspec ted</w>
col lege</w>
P GI</w>
OR E</w>
20 50</w>
wor thy</w>
inf arction</w>
fol lic
draf ted</w>
bit ch</w>
RESTR IC
un a</w>
pip eline</w>
longitud inal</w>
al ign</w>
V ide
vo id</w>
sec recy</w>
o de</w>
lo s</w>
19 3</w>
yl ated</w>
won derful</w>
sol di
ry lic</w>
F resh</w>
1. 7.
Commer ce</w>
pren avir</w>
id a</w>
gen ital</w>
fin ger
En h
19 07</w>
spec imen</w>
plan ting</w>
Jo hn
G AR
tr ucks</w>
tr o</w>
is er</w>
Stock holm</w>
Dis tribution</w>
14. 12.2006</w>
practi tion
inqui ry</w>
Tal k</w>
sk ins</w>
conclu ding</w>
F UN
ong s</w>
edi tion</w>
cro w
brom ide</w>
an itary</w>
Fam ily</w>
un authorised</w>
ov arian</w>
W ood</w>
G ra
et tes</w>
righ te
immun osup
under ground</w>
sw ap</w>
broadca sters</w>
V o
M yan
Langu age</w>
3 60</w>
mis sion
V acc
E BA</w>
is ch
export ation</w>
Fl ex
C ash</w>
s ing
func tionality</w>
enter tainment</w>
tos anitary</w>
cl opidogrel</w>
Equ ity</w>
C ub
C it
ut a</w>
marg inal</w>
it ably</w>
intraven ously</w>
g ift</w>
T ables</w>
GN I</w>
6 5
4 a</w>
bro wn</w>
U RI
O ff</w>
z h
mollus cs</w>
Zim bab
ici ary</w>
foreg oing</w>
arg ue</w>
J ean</w>
D e</w>
v ol</w>
appreci ate</w>
irrit ation</w>
arti sts</w>
al ization</w>
audi ting</w>
ti red</w>
pro pulsion</w>
phr ase</w>
in dispens
gas eous</w>
Gen der</w>
ATI NG</w>
bound aries</w>
af ore
toler ated</w>
G F</w>
18 33</w>
lev ied</w>
excep tionally</w>
su it</w>
speci mens</w>
se ments</w>
De sign</w>
enlarg ed</w>
J .</w>
som nolence</w>
refer ral</w>
fil ters</w>
Appropri ate</w>
ol y
at oid</w>
Be sides</w>
0. 8</w>
w ash</w>
pill ars</w>
Corpor ation</w>
A RE
tradi tions</w>
trad es</w>
ilit ation</w>
L ef
warr ant</w>
sco res</w>
aler ts</w>
Un desirable</w>
program s</w>
pot ent</w>
fall en</w>
Gul f</w>
G EN
ch er
4, 5</w>
defini tively</w>
assum ption</w>
acqui ring</w>
RESPON SIBLE</w>
3 27</w>
in spi
dili gence</w>
abol ition</w>
3 28</w>
ti bility</w>
dupl ication</w>
Armen ia</w>
work shop</w>
tau ght</w>
il ian</w>
attem pts</w>
Sta y</w>
Sanc tions</w>
roun ded</w>
dev oted</w>
Y oung</w>
De sign
5. 6</w>
notic es</w>
beli ef</w>
affor d</w>
accel eration</w>
S AF
lay ers</w>
bi e</w>
post pon
form ats</w>
dic hlor
te eth</w>
las er</w>
inhib it</w>
19 68</w>
T AC</w>
blu efin</w>
afore mentioned</w>
W ash
RELE ASE</w>
Por t</w>
rep utation</w>
id ov
fem ales</w>
el ines</w>
cataly tic</w>
ad hesive</w>
L aughter</w>
z umab</w>
str a</w>
Me an</w>
re viewing</w>
C L</w>
ASSESS MENT</w>
col league</w>
chro me</w>
IC E</w>
transfer able</w>
pa st
ill um
develop s</w>
25 5</w>
re publik
audi ence</w>
ac ent</w>
30 8</w>
perfec tly</w>
g ather</w>
at tain</w>
In fec
haem odialysis</w>
explan atory</w>
euro s</w>
SI DE</w>
H D
refuge e</w>
rati os</w>
mis take</w>
bic ycles</w>
15 9</w>
indispens able</w>
ac knowledge</w>
Mach inery</w>
3 75</w>
reserv ations</w>
rem it</w>
autom otive</w>
id omide</w>
arrang e</w>
acceler ated</w>
Som alia</w>
C T</w>
lin king</w>
M I
out door</w>
G E</w>
pist on</w>
al a</w>
D K</w>
Approxim ately</w>
ol ed
lands cape</w>
ar ises</w>
SPEC IF
Econom y</w>
sp ite</w>
os k
observ es</w>
cancell ed</w>
ap est</w>
rec all</w>
pharmac ovigilance</w>
op harm</w>
in ev
ec an</w>
st on</w>
Parkin son</w>
AB LE</w>
19 1</w>
ta res</w>
al dehyde</w>
2 28</w>
ut or</w>
ing ton</w>
dispat ched</w>
contin ent</w>
REG ARD</w>
L S</w>
sh es</w>
L ow
re nov
ere l</w>
S earch</w>
15 00</w>
centr alised</w>
Vol un
J on
Li qui
i dis
histor ic</w>
comple mented</w>
certif y</w>
SH ALL</w>
O H
az ol</w>
FINAN CIAL</w>
recycl ed</w>
Constitu tional</w>
19 4</w>
tur ns</w>
t ere
sail ing</w>
publish ing</w>
M R</w>
AN T</w>
ecos ystem</w>
ash es</w>
ar omatic</w>
var ying</w>
spre ading</w>
docu mentary</w>
ER IC</w>
Cle ar</w>
2 23</w>
ys or
reflec tion</w>
Ex pl
Enti ty</w>
sion ally</w>
dis continue</w>
2 14</w>
met er</w>
as bestos</w>
Mob ile</w>
s owing</w>
l ub
Si xth</w>
rel ap
ati tude</w>
V O</w>
Plat form</w>
progres sively</w>
dic ations</w>
Ag e</w>
succ eed</w>
gener alised</w>
di am
adj acent</w>
ut most</w>
trans dermal</w>
ce ased</w>
Tr ad
M en
35 1</w>
kid neys</w>
cons or
b ird</w>
Po ints</w>
Del ete</w>
ven ted</w>
it i</w>
M .
N F
H ague</w>
A ung</w>
o res</w>
bo osting</w>
all evi
aff ili
doc tors</w>
cas ino</w>
be poetin</w>
M ess
clu bs</w>
al an
st aying</w>
prud ent</w>
in equ
as su
G astrointestinal</w>
st up
assemb lies</w>
vari ability</w>
hib ition</w>
fl u</w>
aero planes</w>
re financing</w>
mobil ise</w>
b is
Import ant</w>
hol id
fa thers</w>
Par adise</w>
CH AR
rap e</w>
Can ary</w>
en ers</w>
de plo
M ary</w>
foot ball</w>
explos ive</w>
ag ram</w>
ad h
A ri
r am
hy draulic</w>
g ast
explos ives</w>
R h
sh ir
phen y
idov udine</w>
O therwise</w>
Ex plan
agu e.
C lick</w>
Bel ow</w>
ob struc
ex ole</w>
00 5</w>
per taining</w>
nor thern</w>
ci ent</w>
C are</w>
2 62</w>
sa ith</w>
or na
o h</w>
hel icop
facilit ated</w>
destin ed</w>
b .</w>
am ip
Le ague.
I PA</w>
Conclu sions</w>
f an</w>
Proper ty</w>
soci ally</w>
d ent</w>
correspon dence</w>
Car di
W C</w>
IM MEDIATE</w>
35 2</w>
y esterday</w>
r ors</w>
help ful</w>
E E</w>
sp ouse</w>
aran tine</w>
Every one</w>
advis able</w>
Sof tware</w>
G h
substitu te</w>
se am
poss ess</w>
hon our</w>
d der</w>
En sure</w>
ysor bate</w>
summar ised</w>
c lock</w>
V OL
L A</w>
str ains</w>
00 6</w>
ste am</w>
fun gal</w>
amb ition</w>
acknowledg es</w>
u si
b ath</w>
assign ment</w>
O S
pop ul
im pression</w>
im er</w>
den ly</w>
c ough</w>
a o</w>
Inst all
In v
warran ted</w>
otechn ical</w>
g el</w>
for d</w>
OR Y</w>
D y
Pl astic</w>
t ese</w>
ag ons</w>
IN N</w>
meth oxy
ic its</w>
ef ully</w>
concentr ates</w>
a .europa.eu</w>
QUAN TIT
Argenti na</w>
phosphor us</w>
inf ant</w>
far in</w>
T ob
profes sions</w>
prob ability</w>
den ds</w>
announ cement</w>
amip exole</w>
shar p</w>
g li
Le aflet</w>
Hum alog</w>
D ra
su peri
s i</w>
co gn
N either</w>
3. 2004</w>
we d
is ted</w>
em ul
au x</w>
Sel f</w>
Mem orandum</w>
16 05</w>
til l
s pa
res ort</w>
m oul
l é
Wh ilst</w>
G ran
special ists</w>
d ere
adop ts</w>
19 79</w>
ra ises</w>
kil omet
k o
2 98</w>
18 9</w>
te ach</w>
set tle</w>
mo m</w>
inv ites</w>
S K
paren tal</w>
hid den</w>
A 1</w>
water ways</w>
comb ining</w>
E u
thromb osis</w>
lingu istic</w>
ir ub
dispar ities</w>
dig it</w>
UN SCR</w>
S ing
D D</w>
trac tion</w>
crim in
H en
Establish ment</w>
w ell
ic ked</w>
en qui
S mo
Defin ition</w>
am pl
Zimbab we</w>
Te am</w>
Pos ology</w>
Paragrap hs</w>
Crim inal</w>
t our</w>
st ar</w>
prim e</w>
over seas</w>
g ers</w>
lit re</w>
def endant</w>
co coa</w>
or ange</w>
gener ators</w>
eg a</w>
ag as
Rem arks</w>
oc olate</w>
issu ers</w>
ack erel</w>
7. 2005</w>
2 201</w>
ten s</w>
promis ing</w>
bank as</w>
N R</w>
D os
Al ex
rex ed</w>
os oph
o king</w>
min es</w>
dro pped</w>
M ab
E ASA</w>
lat er
g un
L R</w>
vir tual</w>
val sartan</w>
regre t</w>
h edge</w>
gr ains</w>
T am
R ate</w>
M W</w>
impregn ated</w>
Recom men
Chem icals</w>
C M</w>
4 25</w>
2 B
man n</w>
bre ed</w>
N eg
28. 11.
ch aired</w>
arri ve</w>
V IS</w>
dispos able</w>
att ach</w>
antagon ists</w>
up grading</w>
sweet ening</w>
pri ests</w>
libr ary</w>
0. 7</w>
ou ts</w>
Min sk</w>
st ret
og luc
Registr ar</w>
pl a
pare dness</w>
draw s</w>
7 th</w>
t one</w>
del ete</w>
Let ter</w>
C AP
authentic ity</w>
Cere als</w>
z ation</w>
pre vailing</w>
moun ting</w>
less er</w>
emet rexed</w>
Mal tese</w>
Mag ne
19 74</w>
viol ent</w>
boo k
Princi ples</w>
H os
6 42</w>
aw n</w>
ST RI
G MOs</w>
3 63</w>
Partic ular</w>
12 90</w>
w ro
reg on</w>
Com pon
Col om
t ells</w>
recap italisation</w>
L ink</w>
selec ting</w>
ro d</w>
rati opharm</w>
a ments</w>
T U
Cap tain</w>
ur itus</w>
thromb ocytopenia</w>
phot ographs</w>
lo ved</w>
asu ry</w>
K o
poly propylene</w>
mi le</w>
enfor ced</w>
bat tle</w>
2 31</w>
10 49</w>
tradem ark</w>
politic ians</w>
descri ptions</w>
atic s</w>
ak er</w>
Fix ed</w>
prolong ation</w>
m o</w>
j e</w>
inequ alities</w>
am prenavir</w>
Profes sional</w>
B ase</w>
vi ro
Qu ota</w>
ens is</w>
Tow ards</w>
n .
estim ation</w>
c at</w>
RESTRIC TIONS</w>
G A
Con comit
rec alls</w>
neuropa thy</w>
al ties</w>
Over dose</w>
OB D</w>
Kaz akh
Commit tees</w>
shor tly</w>
ju ven
extrac ted</w>
et a</w>
diure tics</w>
POL IC
E mer
un limited</w>
repeat edly</w>
ir s</w>
go ats</w>
en shr
arr hyth
WH ICH</w>
M Y
Dis cus
head ed</w>
R a
pack aged</w>
jo y</w>
di methyl</w>
def icits</w>
d end</w>
EC U</w>
u tionary</w>
Reg istry</w>
B 1</w>
th an
oled ronic</w>
min erals</w>
O x
Kazakh stan</w>
19 58</w>
reciproc al</w>
lam inated</w>
dg es</w>
cell aneous</w>
Mus eum</w>
Islam ic</w>
3 38</w>
substitu tes</w>
pro ph
por in</w>
af en
Therap eutic</w>
R ati
sen sor</w>
li que
Concomit ant</w>
C ab
1 200</w>
u ter
ocy tes</w>
lev ies</w>
formul ated</w>
atten ded</w>
t ase</w>
satur ated</w>
k ling</w>
ju red</w>
cor ner</w>
Retur n</w>
rel ax
re sum
medi ated</w>
hydro gen
g a</w>
ai re</w>
C ENTR
og y</w>
fore ver</w>
char ter</w>
V EN
I ran
18 29</w>
www .</w>
ar i</w>
comple ment
amaz ing</w>
He al
Dep ending</w>
2 35</w>
bed ded</w>
y le</w>
respon dents</w>
p assive</w>
d n
concer t</w>
b in</w>
W ar</w>
STATE S</w>
us able</w>
syn chron
Tab let</w>
inten se</w>
glob ally</w>
T ox
6 59</w>
so ever</w>
opin avir</w>
imag ine</w>
pro mises</w>
ac le</w>
S impl
ogluc ose</w>
ligh t
arri ved</w>
Ab sol
AN D
7, 5</w>
dis comfort</w>
consolid ate</w>
computer ised</w>
W ine</w>
Con c
f entanyl</w>
acet am</w>
C G</w>
O CT
ar ate</w>
Ar ctic</w>
oun ced</w>
osk eletal</w>
hear t
R iga</w>
NO x</w>
Gen eva</w>
A K
19 73</w>
san itary</w>
op es</w>
hon est</w>
han dic
ad en
UR ING</w>
G Y</w>
Public ations</w>
E CO
Comple tion</w>
Al t
ground water</w>
G ame</w>
i ja</w>
co stly</w>
AIF M</w>
trac king</w>
ot ecan</w>
Vi en
Electr ical</w>
r is</w>
G 20</w>
E di
26. 6.
secon ded</w>
mun ition</w>
miti g
ent ally</w>
electro ly
ch amp
ocy te</w>
et ongue</w>
esc .europa.eu</w>
broad cast</w>
Ma king</w>
H U
C min</w>
15 4</w>
Mad agas
L AG</w>
polym ers</w>
per ceived</w>
col i</w>
We b</w>
Li k
Appen dices</w>
A maz
interven e</w>
Met abol
Comm and</w>
arti st</w>
acet yl
S it
la p</w>
hec tares</w>
din ner</w>
Sh ut</w>
Pri ority</w>
Particip ants</w>
H 5
Docu ments</w>
inter governmental</w>
C los
н а</w>
trans late</w>
op hy
in jured</w>
ber ry</w>
tonn age</w>
th inks</w>
rheum atoid</w>
Gl ass</w>
3 40</w>
19 84</w>
diff ers</w>
a ine</w>
S ure</w>
Aut om
o C</w>
de x</w>
contracep tion</w>
US E
whe el
licen se</w>
f its</w>
ag grav
vari ed</w>
incin eration</w>
g gling</w>
dic t
boo king</w>
b ai
alleg edly</w>
e v</w>
P sy
3. 9</w>
z om
c t</w>
arrang ed</w>
3 91</w>
l i</w>
enh ancement</w>
b o</w>
Promo ting</w>
AI F</w>
ti ed</w>
stre aming</w>
no body</w>
Pro jects</w>
Con duct</w>
z in</w>
incre mental</w>
R s</w>
P ic
Oper ating</w>
N erv
K on
enjo yed</w>
dis covered</w>
design s</w>
Orig in</w>
6 50</w>
3 25</w>
identi fiable</w>
h all
L ess</w>
Be au
pe di
e i</w>
Madagas car</w>
A li
fin ite</w>
deriv ing</w>
any way</w>
Ch an
B un
un expected</w>
referen dum</w>
cul oskeletal</w>
b ilities</w>
Some times</w>
A vailable</w>
20 21</w>
ref rain</w>
Me at</w>
L illy</w>
C hile</w>
C V</w>
w av
perid one</w>
mal es</w>
m ass
divi dends</w>
He ading</w>
im movable</w>
gly caemic</w>
tre aties</w>
coup on</w>
- 2</w>
P fi
M ir
sh oes</w>
es tic</w>
comm ander</w>
T l
H BV</w>
Equi valent</w>
AF O</w>
3, 4</w>
in sec
EM AS</w>
liqui ds</w>
l uck</w>
b alls</w>
ag eous</w>
M aize</w>
Cle an</w>
tin al</w>
c amp</w>
C ED</w>
7. 3</w>
in i
he aters</w>
dol lars</w>
A E</w>
21. 10.2003</w>
y ards</w>
ee ding</w>
compens ated</w>
Com pu
reg ion
pe ts</w>
es .
U s</w>
S M</w>
Pa ediatric</w>
ρ ο
tri glycer
cust ody</w>
S t</w>
7 9
hat ching</w>
gu il
any body</w>
M ass</w>
J ur
E G</w>
3 11</w>
sen sors</w>
NU TS</w>
2 21</w>
lin er</w>
gr ass</w>
ci profloxacin</w>
Y OU</w>
Gu ide</w>
mb ass
compati bilities</w>
ME D</w>
2 96</w>
threat ened</w>
tal ked</w>
A h</w>
wro te</w>
dis bur
attem pted</w>
Re stric
RE NE
L if
B lu
paramet er</w>
olym er</w>
counterfe iting</w>
Mos es</w>
ti ps</w>
pup ils</w>
detri mental</w>
F IS
8 83</w>
zo otechnical</w>
p air</w>
d. o.
Vide o</w>
Direc tors</w>
2. 0</w>
sour ced</w>
k a
ich lor
dissu asive</w>
Pharmac odynamic</w>
Pfi zer</w>
K ING
streng ths</w>
revo ked</w>
eng er</w>
amb ig
O ld</w>
B atch</w>
p and
occup ied</w>
heav ily</w>
ap pra
H ex
valu ed</w>
subscri bed</w>
res ettlement</w>
p ic</w>
le asing</w>
dis appear</w>
at tainment</w>
asi a</w>
Cap acity</w>
lun gs</w>
stri ps</w>
qu arantine</w>
percent ages</w>
creati vity</w>
accep ting</w>
G L
republik a</w>
fl ag
en. htm</w>
aggreg ation</w>
Let ters</w>
3. 1.
prin ts</w>
depri ved</w>
acc e
n is</w>
h amp
co operatives</w>
as sure</w>
H ur
1 H</w>
F INAL</w>
l en</w>
TE S</w>
Riv er</w>
Hydrochlor othiazide</w>
E missions</w>
3 21</w>
spir its</w>
reg i
out look</w>
meth oxy</w>
G M</w>
ur ic</w>
e igh
dis ruption</w>
C ell
el a</w>
dis man
ac rylic</w>
Su per
MA H</w>
AT C</w>
3 88</w>
imper ative</w>
el abor
Pu regon</w>
M F</w>
C Z</w>
und uly</w>
V an</w>
Per haps</w>
fun g
Mu sic</w>
Di men
mov es</w>
ic idal</w>
ed y</w>
conver ting</w>
S tri
L arge</w>
B LIS
vap our</w>
e c</w>
toil et</w>
stric ter</w>
fu sions</w>
chang e
Tem porary</w>
se emed</w>
retur ning</w>
la ke</w>
chick en</w>
b ly</w>
- I</w>
exha us
Pre clinical</w>
CO LO
re location</w>
pri est</w>
extin gu
T EU</w>
E p
Ch ic
C ASE</w>
revoc ation</w>
molec ular</w>
it ate</w>
el ap
ca usal</w>
ap p</w>
V O
im balance</w>
Wel come</w>
T ak
Pers on
pre v
ev ed</w>
Mos cow</w>
Li pro
D um
2 38</w>
tin ation</w>
ex changing</w>
contin gent</w>
T ogether</w>
Lipro log</w>
Lab or
pol y</w>
pass es</w>
Cal culation</w>
T ask</w>
Rem ember</w>
s son</w>
alis kiren</w>
Shar p</w>
R as
inhal ation</w>
Pl ac
Lear ning</w>
syn thesis</w>
pneum onia</w>
duc tor</w>
Munici pality</w>
endor ses</w>
be l</w>
as ant</w>
Targ et</w>
Ren ew
termin als</w>
cle arer</w>
categ or
W EI
No tification</w>
GE I</w>
19 71</w>
11. 2005</w>
pack ings</w>
op o
is oglucose</w>
Phil ipp
B MS</w>
8 82</w>
spe eds</w>
refin ing</w>
every where</w>
cur r
MANUFACT U
M odi
IR B</w>
I g
sc ene</w>
ograp h</w>
b red</w>
war farin</w>
tom atoes</w>
ship ments</w>
b acking</w>
Micro soft</w>
un k</w>
tr icit
fa eces</w>
un t</w>
Ne der
Nation ality</w>
H PV</w>
35 3</w>
metal lic</w>
cl ou
Recommen ded</w>
m ia</w>
holid ays</w>
R .</w>
8 50</w>
1, 1</w>
fin ger</w>
dam aging</w>
Wh at
M ON</w>
pos ting</w>
ith ro
corpor ation</w>
O u
M 1</w>
2 12</w>
ophil ia</w>
haemat ological</w>
c um
sud denly</w>
sk ill</w>
fo dder</w>
expan ding</w>
dro w
Nerv ous</w>
M ol
EN P</w>
7 6
re construction</w>
pro pi
Myan mar</w>
Dur ation</w>
2 22</w>
malign ant</w>
s ations</w>
institu tes</w>
confir ming</w>
cho osing</w>
ca th
COM POSITION</w>
sulphon yl
Tur n</w>
Intro duction</w>
won der</w>
ware house</w>
ro ck
gr ass
concer ted</w>
bi al</w>
al umin
Thir dly</w>
Co sts</w>
lu x</w>
dul oxetine</w>
SP C</w>
tr am
h i</w>
30 3</w>
wit ness</w>
substr ates</w>
n ch
at re</w>
S ide</w>
2 33</w>
el le</w>
coordin ator</w>
bu ck
2. 2.
sl ud
habit ats</w>
elec toral</w>
2 95</w>
V II
O ut</w>
E ye</w>
CS F</w>
AG R
2 15</w>
some where</w>
re hab
har dly</w>
applic ability</w>
Chair person</w>
tel misartan</w>
reiter ates</w>
lodg e</w>
invo ices</w>
ch ment</w>
all et</w>
un justified</w>
t am
n i</w>
facilit ation</w>
Streng th
r on</w>
mor ph
ev asion</w>
au to
DEF INI
1 10
wat ching</w>
og ens</w>
investig ating</w>
hi de</w>
U. S.</w>
I R</w>
Coun ter
reg ation</w>
pat ches</w>
finan cially</w>
evol ving</w>
T ATION</w>
ter at
rac ing</w>
organ ized</w>
ca us
aer on
te tra
ess ence</w>
em ies</w>
V. Part</w>
qui et</w>
Wor ks</w>
S even</w>
Loc ation</w>
Ecol abel</w>
recurren t</w>
Is land</w>
su its</w>
stup id</w>
se d
promp t</w>
pro v
on ium</w>
om al
no tion</w>
kal aemia</w>
e or
wo oden</w>
est ly</w>
QUANTIT ATIVE</w>
D 6</w>
é s</w>
w ere
ver ifications</w>
sw im
se wing</w>
mo thers</w>
er ative</w>
TER S</w>
F T</w>
shoul der</w>
c us</w>
Sol vency</w>
Re production</w>
Philipp ines</w>
Exper t</w>
8 9
under stand
the ory</w>
gl it
O TC</w>
Iran ian</w>
re paid</w>
ithro mycin</w>
ec tion</w>
comp il
col ouring</w>
bil irub
Si x</w>
Pro sec
G ibr
C u
7 68</w>
venti lation</w>
remedi al</w>
pre paredness</w>
enshr ined</w>
agg age</w>
Dru g</w>
Con train
Be hold</w>
partic le</w>
coag ulation</w>
r umin
ac illus</w>
Gaz a</w>
Fi eld</w>
Deutsch land</w>
T N
quot ed</w>
F on
D r</w>
A zer
lis tening</w>
expi res</w>
Rep air</w>
Cat alogue</w>
&apos; S</w>
Up dated</w>
L ou
Ac tivity</w>
3 13</w>
12 24</w>
u va</w>
REP ORT</w>
G ONAL</w>
EM U</w>
taxpay er</w>
su ited</w>
s now</w>
poli tics</w>
er nal</w>
em en</w>
du s</w>
1 c</w>
sol ving</w>
beau ty</w>
Consum ers</w>
no ea</w>
mon es</w>
TI V
lin en</w>
irregul arity</w>
suspec t</w>
saf er</w>
pe d
op raz
e esc.europa.eu</w>
cas inos</w>
Ph en
O wn</w>
CL IN
mis sibility</w>
gran ules</w>
cor d</w>
ar b
Scot land</w>
6 71</w>
30 7</w>
li ps</w>
est i</w>
assi gn</w>
D PR
sh rimp</w>
orig inate</w>
C ars</w>
Ma j</w>
Corpor ate</w>
pr azole</w>
Aut omatic</w>
pul se</w>
phil osoph
lad en</w>
impro ves</w>
con stipation</w>
Electr icity</w>
s mu
pain ful</w>
lin ide</w>
ban anas</w>
S GEI</w>
K e
Gibr altar</w>
ov ens</w>
conf isc
be it</w>
E arly</w>
at adine</w>
anti hypertensive</w>
Sal monella</w>
AI Ds</w>
2 61</w>
le af</w>
hos ting</w>
hear ts</w>
all ergy</w>
PP P</w>
Consum ption</w>
2. 9</w>
oro dispersible</w>
cigaret tes</w>
Mul ti</w>
vor iconazole</w>
t ories</w>
t are</w>
ri ding</w>
al ists</w>
O PS</w>
Altern atively</w>
trac e</w>
inv asive</w>
im a</w>
fil ing</w>
c on</w>
ang ible</w>
Ver ification</w>
Inter ior</w>
paren tly</w>
DPR K</w>
B ER</w>
ogen ous</w>
o date</w>
emb ol
conv ul
NS AIDs</w>
Contro l
3 A</w>
è re</w>
tricit abine</w>
psy chiatric</w>
gu ards</w>
gen ous</w>
c .
b arg
D IT
3 84</w>
po ds</w>
phthal ate</w>
or i</w>
met ro
ci f</w>
am ines</w>
Rec i
sal ted</w>
ob enz
beg un</w>
accep ts</w>
DO B</w>
p refer</w>
discre pan
cover ings</w>
P F</w>
Int ellectual</w>
Consi dering</w>
2 36</w>
bra kes</w>
Sy mp
Mob ility</w>
M AN</w>
vi d</w>
u .int</w>
enforce able</w>
agg ressive</w>
V AL
Di alogue</w>
m er</w>
fun da
V R</w>
Pow er
P 450</w>
L NG</w>
3. 2005</w>
worl ds</w>
res ale</w>
phys ically</w>
di hydrate</w>
coo k
EE E</w>
Con formity</w>
5 0000</w>
threat en</w>
es tine</w>
consul ar</w>
Tl f</w>
TR A</w>
f ans</w>
effici ents</w>
e ure</w>
be hold</w>
ad ian</w>
accoun table</w>
J ac
ti ers</w>
injur ies</w>
in th</w>
ap or
EI F</w>
AT M</w>
ea e</w>
Parlia mentary</w>
H g</w>
wor n</w>
pel lets</w>
h as
form ations</w>
ear th
sug ars</w>
ri gen
il legally</w>
resili ence</w>
otechn ology</w>
on i</w>
hal er</w>
gl ut
Prepar atory</w>
PRO PER
Azer bai
3 00
wa ste
ti redness</w>
gen otype</w>
ga thering</w>
ab is</w>
a e
S L
3 66</w>
phy tosanitary</w>
iv al
gre y</w>
Represent atives</w>
G ol
20 81</w>
inter faces</w>
RENE WAL</w>
Dri ving</w>
B ack
trav ellers</w>
poly ester</w>
cell ular</w>
bo w</w>
pi x
o ag
Vol vo</w>
Ob lig
H er</w>
5 -</w>
mat ernity</w>
lu gg
guaran tor</w>
gl ory</w>
carcin ogenic</w>
T2 S</w>
ST S</w>
re b
mus ical</w>
law yers</w>
k B</w>
am ins</w>
PROPER TIES</w>
Conver gence</w>
4 21</w>
prosec ution</w>
mobil ised</w>
st ories</w>
m acy</w>
l ens</w>
jec ting</w>
de hydr
m ad
e ira</w>
Writ ten</w>
L en
s ong</w>
mor tal</w>
h me</w>
elim inating</w>
don ation</w>
D anu
ur anium</w>
ear marked</w>
As sets</w>
x il</w>
S et
Emer gency</w>
Counc il
á n
z idovudine</w>
co ach</w>
C 1</w>
Altern ative</w>
21 st</w>
r in</w>
8. 3</w>
se di
rec tang
ot ting</w>
he y</w>
direc tory</w>
dig its</w>
w is
al is</w>
F AO</w>
DV D</w>
ur a</w>
tri fu
rig id</w>
hydro l
distingu ished</w>
Re si
DR C</w>
D R</w>
Cap e</w>
w ax</w>
mic ros
gu ided</w>
cad mium</w>
Th ro
Ch amp
x y</w>
deleg ate</w>
commer cially</w>
ad ver
H ER
Am ster
terri ble</w>
explo ited</w>
dis advantage</w>
Mo dule</w>
pur ities</w>
pri ze</w>
g ears</w>
every day</w>
5 46</w>
what soever</w>
sil k</w>
Organ ic</w>
4 70</w>
bon us</w>
arg o</w>
Rel ated</w>
H R
Danu be</w>
CLIN ICAL</w>
am munition</w>
tran che</w>
foc al</w>
cl er
blu etongue</w>
seaf arers</w>
fluctu ations</w>
Stand ardis
L AND</w>
Are as</w>
sil ent</w>
q q
men tia</w>
draw ings</w>
def erred</w>
ari al</w>
after noon</w>
3 17</w>
b os
Mat erial</w>
erythem a</w>
bir th
n ap
c ic
Com position</w>
CO L</w>
sub headings</w>
att achment</w>
Fl at</w>
2 29</w>
val d</w>
ord ering</w>
nom inated</w>
consi gnee</w>
Z o
Res er
G D</w>
Contrain dications</w>
Co al</w>
str o</w>
s word</w>
in herit
30. 12.2006</w>
10 ,
r ings</w>
hol y</w>
h ang
gal ac
ar row</w>
QUAL IT
re board</w>
micro gram</w>
differen tly</w>
clim atic</w>
ain ting</w>
FP 7</w>
3 72</w>
ac comm
35 9</w>
3 30</w>
circul ating</w>
P la
MEN D
Amster dam</w>
t an</w>
k Pa</w>
en ergies</w>
connec tivity</w>
Re duction</w>
Eng ine
po oled</w>
p. m</w>
maj eure</w>
Ro yal</w>
E A</w>
r ational</w>
plan ted</w>
Sub stances</w>
QUALIT ATIVE</w>
H as</w>
F UR
un clear</w>
person als</w>
gr ace</w>
coordin ates</w>
accomm odate</w>
T op</w>
S port</w>
O DS</w>
H S
slaughter house</w>
or ith
nal ists</w>
im aging</w>
dec lined</w>
at ured</w>
ar ts</w>
Vien na</w>
REF ER
M ylan</w>
In come</w>
G rap
on i
jun c
id ation</w>
cl oud</w>
N N</w>
LT0000 8
Deter mination</w>
CC S</w>
dem anding</w>
bub bles</w>
as y
T ags</w>
G AN
3 12</w>
2 17</w>
regi mens</w>
ophen yl</w>
intr amuscular</w>
19 7</w>
spon sors</w>
mot ors</w>
l ump</w>
en closed</w>
u sion</w>
specif ic
lor atadine</w>
Fur n
EE S</w>
7 4
3 14</w>
η λ</w>
reason ing</w>
b ye</w>
Car bon</w>
stat utes</w>
r hyth
pl ain</w>
assum ing</w>
3 71</w>
tiv e
swe ating</w>
pot ato</w>
not withstanding</w>
S ize</w>
Recommend ations</w>
Industri es</w>
Effec tive</w>
2 32</w>
pain t</w>
di r
TE CH
Ph one</w>
Alt mark</w>
Fron tex</w>
C ast
3 19</w>
b right</w>
alloc ating</w>
Jud ges</w>
E vi
predic table</w>
doub tedly</w>
TIC S</w>
C in
B I</w>
opath ic</w>
judg ement</w>
T T
REV ISION</w>
Mot or</w>
there on</w>
prec ur
can e</w>
Res .</w>
2 45</w>
org e</w>
inval idity</w>
hor mones</w>
Sign ature</w>
High er</w>
Ch er
A part</w>
3 65</w>
str ange</w>
st ad
challeng ing</w>
ba thro
accur ately</w>
ab s</w>
Sing ap
Ligh ting</w>
C ath
10 th</w>
rul ings</w>
road map</w>
pro xim
em bedded</w>
cleans ing</w>
attrac tions</w>
SY STE
IL ITY</w>
weigh ting</w>
paren cy</w>
fit ness</w>
di vor
Tr y</w>
TS Os</w>
For ces</w>
C ô
w agons</w>
dro ps</w>
Char les</w>
3 15</w>
st airs</w>
occa sionally</w>
bi ds</w>
1 A2</w>
otox ic</w>
co efficients</w>
Respon sible</w>
MANUFACTU RE
IC s</w>
vide os</w>
ren ce</w>
es oph
TR AC
s h</w>
pro ves</w>
p ting</w>
em a.europa.eu</w>
Pe ace</w>
Im mun
y alty</w>
tic a</w>
n avi
Trans mission</w>
P ul
G ATT</w>
public ity</w>
cocc us</w>
co in</w>
amp icin</w>
Compl ete</w>
3 31</w>
yl on</w>
trac ks</w>
entr icular</w>
depos ited</w>
DE M</w>
shi re</w>
pr uritus</w>
k ar
Y E
Azerbai jan</w>
AR E</w>
ten ded</w>
re mission</w>
i .
consolid ating</w>
Manufactu rers</w>
Dom estic</w>
D ays</w>
B enz
19 83</w>
sleep ing</w>
positi oning</w>
pig meat</w>
ev ac
deliver ies</w>
Con tribu
volati le</w>
on o</w>
anti gen</w>
I t
F SH</w>
D a
short age</w>
f asting</w>
codi fication</w>
adj uv
Exem ption</w>
pr ises</w>
m amm
keep s</w>
here after</w>
dis pu
Lea ve</w>
HC T</w>
H all</w>
Con tents</w>
to in</w>
sh if
ov al</w>
lad y</w>
bas ically</w>
AG RE
pre hen
he imer</w>
ar in
Trans parency</w>
MR L</w>
A U</w>
35 6</w>
ï ve</w>
o .</w>
den ied</w>
H C</w>
Deb t</w>
jeopardis e</w>
eg ra
Sup ple
Ro ad
Contin ue</w>
th at
sup pression</w>
feder al</w>
d egr
ac avir</w>
T ren
Effici ency</w>
tend ency</w>
os ide</w>
3 10</w>
imple ments</w>
et an
ap ers</w>
---------------- ----------------
lac king</w>
fla kes</w>
col ors</w>
abdom en</w>
Fo rest</w>
m ang
lay out</w>
k et</w>
el i</w>
br ack
ad ec
Norm al</w>
en emies</w>
cor on
Initi ation</w>
Er ror</w>
A Z
prospec tive</w>
prison ers</w>
open ness</w>
Colom bia</w>
B ang
9 66</w>
transfer ase</w>
our al</w>
b aggage</w>
TECH N
REN E</w>
Ad ap
str ap</w>
sour cing</w>
as certain</w>
su icide</w>
stop s</w>
spon sor</w>
presum ed</w>
ord erly</w>
hard ware</w>
tic es</w>
redund ant</w>
pay er</w>
in organic</w>
e ply</w>
wed ding</w>
w rap
di vine</w>
at eness</w>
percep tion</w>
me tr
k Wh</w>
P .</w>
grad ed</w>
Strength ening</w>
Qu estion</w>
OCT s</w>
Ci profloxacin</w>
k el</w>
h ast</w>
Recogn ition</w>
F C</w>
C ali
un ited</w>
g laz
bre ast
antic oag
an onym
TRE AT
GN SS</w>
E O
titu des</w>
res in</w>
r acetam</w>
m ackerel</w>
emerg ed</w>
AE A</w>
2, 6</w>
ter ior</w>
sor ption</w>
descri bing</w>
azol am</w>
anaphy lactic</w>
acc used</w>
POLIC Y</w>
N AT</w>
Mal i</w>
Do hme</w>
Commission ers</w>
ledg e</w>
hosp itals</w>
e in</w>
Per son</w>
deser ve</w>
E MENT</w>
1. 10</w>
а н
sw ift</w>
ov ol
n igh
k r
embry o</w>
Singap ore</w>
5. 7</w>
12 ,
we aring</w>
under p
reiter ated</w>
eti racetam</w>
ech es</w>
13 01</w>
re per
medic ations</w>
gly co
der ive</w>
de ems</w>
U ser</w>
Requi rement</w>
Acad emy</w>
23 77</w>
18 98</w>
sw if
pro vin
m ust
dis placement</w>
Oper ators</w>
N ATIONAL</w>
2 39</w>
19 81</w>
ship ped</w>
qual ities</w>
associ ate</w>
a is</w>
tail ored</w>
hop es</w>
F RE
Exc ep
lo op</w>
dist ress</w>
dish es</w>
app ell
S ard
S G
tic ated</w>
mat ernal</w>
go d
benz oate</w>
ap ple</w>
What ever</w>
S etting</w>
Q T</w>
stre ets</w>
op pose</w>
icon ductor</w>
fer ry</w>
clean ed</w>
P ig
Govern ments</w>
Ben ef
00 7</w>
ten ds</w>
re places</w>
lan ded</w>
fi bro
complement arity</w>
Sem ester</w>
OL O
sk á</w>
oty pes</w>
medi ation</w>
k s
PHAR MA
MF I</w>
An dor
win ning</w>
ut able</w>
decom mission
appe als</w>
5 48</w>
19 64</w>
author s</w>
Mo de</w>
4 01</w>
tol l</w>
gen s</w>
b ac
Shi pping</w>
M iss</w>
F ourth</w>
3. 2006</w>
19 66</w>
weigh ed</w>
s inc
off en
mi gh
hi p</w>
for cement</w>
N T1</w>
J ames</w>
Hep atic</w>
Dru gs</w>
fac to</w>
environ ments</w>
cis platin</w>
Kore an</w>
y cin</w>
v et</w>
id able</w>
endor se</w>
TI ONAL</w>
IB B</w>
Con centr
secon dly</w>
our able</w>
fre sh
det erg
Vis a</w>
TIT U
In compatibilities</w>
COLO GICAL</w>
Ar ts</w>
stear ate</w>
es sively</w>
el e
divi de</w>
tour na
mil li
int .</w>
gre w</w>
ax les</w>
at lantic</w>
Supervis or</w>
Out turn</w>
Georg e</w>
Ex isting</w>
E vent</w>
9. 1</w>
tot ox
sub ordinated</w>
renew ables</w>
l av
aud i</w>
Li ghts</w>
2 87</w>
ocar b
h all</w>
ath ers</w>
28. 2.
o des</w>
juris dic
bi od
Liet uva</w>
Ex ci
on el</w>
it ant</w>
ag en
S ES
Perc ent
En ter</w>
23 71</w>
en rolled</w>
ef s</w>
acc or
CON CER
supervis or</w>
PHARMA COLOGICAL</w>
Harmon ised</w>
C 00
25 9</w>
merg ers</w>
lo ose</w>
h ad
e book</w>
attrac tiveness</w>
ang les</w>
R am
Bur ma</w>
un paid</w>
tri ps</w>
b uses</w>
Install ation</w>
supervis ors</w>
oph osph
mo od</w>
angi oedema</w>
H om
F en
bure au</w>
V el
M r
pers ist</w>
loc ate</w>
is ers</w>
hybri ds</w>
down ward</w>
Th omas</w>
pl ated</w>
p pm</w>
oblig atory</w>
inherit ance</w>
eng aging</w>
conveni ent</w>
con fined</w>
stru gg
ind ents</w>
igh ted</w>
hydrochlor ic</w>
be ach</w>
bas ketball</w>
b .
My int</w>
weap on</w>
sub division</w>
se ating</w>
scal es</w>
s lots</w>
pat ri
im purities</w>
emplo y</w>
an cient</w>
abol ished</w>
B ye</w>
sulphonyl urea</w>
st en</w>
out puts</w>
he ated</w>
grap h</w>
fol der</w>
aw ards</w>
Prim ary</w>
F oc
p ag
o b</w>
low ers</w>
i es
hec tare</w>
glit azone</w>
S AN
bot t
Rec ent</w>
Mi x</w>
Ef avirenz</w>
4 24</w>
transm itting</w>
restaur ant</w>
quot ations</w>
polym er</w>
harv esting</w>
gast ric</w>
eri an</w>
con fron
access ing</w>
Dex ia</w>
CI A</w>
200 00</w>
b age</w>
az z</w>
G I
u ity</w>
Metabol ism</w>
G ly
B EF
movi e</w>
flag ship</w>
dis k</w>
2 19</w>
un c
survi ve</w>
s au
platel ets</w>
hum idity</w>
depos itary</w>
ple a</w>
our ings</w>
dr illing</w>
El derly</w>
r ue</w>
op ens</w>
flo ating</w>
co operated</w>
ch apters</w>
T ub
S ES</w>
L ar
senten ces</w>
f locks</w>
de ar</w>
Rou te</w>
zz le</w>
phy laxis</w>
le ep</w>
fav oured</w>
be ars</w>
SEC URI
Exper ts</w>
En tre
Effec t</w>
CC Ps</w>
Bi g</w>
Afgh an</w>
pneum atic</w>
out line</w>
mir rors</w>
fluor o
co ding</w>
ab und
Sen ior</w>
IN V
Gu ard</w>
Al i</w>
2 75</w>
ro si
re alisation</w>
hypogly caemic</w>
assu red</w>
Stat us</w>
S mart</w>
G ot</w>
13 03</w>
oti de</w>
mark et
M B</w>
19 8</w>
ur ing</w>
trigg ered</w>
psych ological</w>
in door</w>
ic ro
cap s</w>
re ward</w>
fore most</w>
exten ds</w>
de eply</w>
capit a</w>
R P</w>
design ing</w>
countr y
T a
Bab y</w>
s at</w>
bab ies</w>
Proc essing</w>
l or</w>
instal ments</w>
Seri ous</w>
Pl as
Intere sted</w>
C os
BEF ORE</w>
n as</w>
group ed</w>
b all
ar tery</w>
acquis itions</w>
N or</w>
Mar k</w>
G ab
Eng ine</w>
detri ment</w>
Tr affic</w>
Can adian</w>
z o</w>
salic ylic</w>
phenomen a</w>
inc umb
expres sing</w>
egra vir</w>
Fr an
tem plates</w>
al beit</w>
W ow</w>
Aut onom
restric ting</w>
rem emb
measu rable</w>
be dro
PC Bs</w>
4 04</w>
č ius</w>
rad ar</w>
iti sation</w>
flu ids</w>
S QU
E g
Der og
2 27</w>
mon keys</w>
earli est</w>
ag glomer
S audi</w>
S L</w>
OPER ATION</w>
M ur
J RC</w>
G SP</w>
pre requisite</w>
iti onally</w>
acti vis
Bro ad
2 43</w>
sp ouses</w>
pow ders</w>
mem orandum</w>
dupl icate</w>
c umulation</w>
V ia</w>
S TITU
Ref uge
New castle</w>
Al z
vin ey
j ew
arri ving</w>
REFER RED</w>
3 22</w>
2 83</w>
micro biological</w>
de mentia</w>
co inci
boil ers</w>
bloc ked</w>
C P
is ons</w>
av y</w>
Citiz enship</w>
hin der</w>
fum arate</w>
2 84</w>
13 33</w>
reli ed</w>
il ine</w>
ñ a</w>
sugg esting</w>
5 24</w>
rosi glitazone</w>
pen sation</w>
ameth asone</w>
Le ad</w>
L uc
E QU
Andor ra</w>
0, 3</w>
un doubtedly</w>
rough ly</w>
portfol ios</w>
oc ular</w>
at ri
ans opraz
SI RENE</w>
8 6
seiz ure</w>
promo tional</w>
JEC T</w>
Develop ing</w>
pro ving</w>
o therapeutic</w>
lik ewise</w>
consci ous</w>
c enti
auc tions</w>
S anta</w>
Rel ev
O s
N os</w>
L I</w>
2 81</w>
parc el</w>
i a
cal m</w>
an es</w>
ac o</w>
P TION</w>
Ad ult</w>
7. 1999</w>
10 37</w>
mean time</w>
frag ile</w>
en emy</w>
Des tination</w>
scre w</w>
ol ysis</w>
l opinavir</w>
bi an</w>
b ills</w>
appl es</w>
S ac
Pub lish
l as</w>
genu in
dar bepoetin</w>
ap one</w>
CC C</w>
Ac counts</w>
questionnai res</w>
im umab</w>
St orage</w>
F if
know ing</w>
dossi ers</w>
cri p
COM MENTS</w>
0. 001</w>
sz á
gen cies</w>
M it
Cô te</w>
y el
is ot
carc asses</w>
bro mo
4 .</w>
tro pical</w>
t as</w>
go xin</w>
es k
diff ering</w>
GO VER
9 22</w>
hep at
d al
collec tively</w>
Ac ute</w>
tow ns</w>
recre ational</w>
inten tions</w>
g eared</w>
c ups</w>
Kal e
IU U</w>
CC MI</w>
9 50</w>
trans posed</w>
suscep tibility</w>
noti fier</w>
i x</w>
fl at
Administr ator</w>
30 6</w>
warm ing</w>
tor ture</w>
ob sol
e tration</w>
dis missed</w>
h o</w>
fl ash</w>
deb it</w>
Té lé
I Z
Ash ton</w>
9. 2</w>
2 64</w>
electron ics</w>
dis counts</w>
Nob ody</w>
Neder land</w>
Ge ographical</w>
G MES</w>
Expos ure</w>
subs istence</w>
sm ell</w>
pol ar</w>
mis use</w>
metast atic</w>
elev ations</w>
ed ges</w>
approxim ate</w>
Prac tice</w>
N A
Gar den</w>
F estival</w>
Bas el</w>
practic ally</w>
oun ding</w>
mod elling</w>
exec ute</w>
at az
Me dium</w>
H an
Deutsch e</w>
DS M</w>
D ES
ul a</w>
mir ror</w>
deduc tions</w>
S co
P reliminary</w>
Mr s.</w>
E 172</w>
ship building</w>
phy si
it abine</w>
inhib its</w>
bas in</w>
W all</w>
TA KE</w>
legiti macy</w>
is al</w>
in no
in n</w>
Con solid
tro ops</w>
pro du
inv itations</w>
agg ing</w>
rele ases</w>
kilomet res</w>
in ia</w>
alg orith
VE LO
St al
č i
ev es</w>
di etary</w>
dec lining</w>
Vari ous</w>
Belgi que</w>
ъ л
é r
ataz anavir</w>
TO L</w>
15. 6.2011</w>
rehab ilitation</w>
lis pro</w>
habit at</w>
episo de</w>
dur able</w>
dop amine</w>
comp iled</w>
Rev enue</w>
Liet uv
26.6. 1999</w>
е н
oc ean</w>
i x
er to</w>
ch ips</w>
0 s</w>
st eroids</w>
opro xil</w>
dis oproxil</w>
BAN K</w>
rest oring</w>
ot er
expl aining</w>
el and</w>
S ri</w>
ter t</w>
constitu tion</w>
behavi oural</w>
tu b
prece ded</w>
perform ances</w>
o be
con vers
c ows</w>
Sur vey</w>
L aw
In c</w>
psori asis</w>
po ols</w>
nar row
exhaus tive</w>
anti psycho
ad missibility</w>
soldi ers</w>
pass age</w>
or ages</w>
com promised</w>
ca ine</w>
ation s
arti stic</w>
y n</w>
tor ily</w>
jo s</w>
dar k
cop ic</w>
fin ishing</w>
d ication</w>
contin gency</w>
cl ay</w>
Tr ans</w>
15. 12.
emo tional</w>
Tax ation</w>
J ews</w>
wis dom</w>
transl ator</w>
m aps</w>
favor ite</w>
aggreg ates</w>
S s</w>
sh ake</w>
complet eness</w>
R ad
EAG GF</w>
protec tion
piv otal</w>
head lamps</w>
grat eful</w>
ex trap
cont est</w>
bankno te</w>
acr ylate</w>
SO C</w>
Measu rement</w>
Mar tin</w>
pir acy</w>
g loves</w>
appropri ateness</w>
RT P</w>
Chic ago</w>
strai gh
str a
smo ked</w>
ner ve</w>
3 48</w>
0 6
show er</w>
genuin ely</w>
ell o</w>
bl ack
W ing</w>
tin a</w>
ti tration</w>
pl ur
optim ise</w>
mod est</w>
T YP
1. 2.
read s</w>
na ïve</w>
am or
Pharmac eutical</w>
Percent age</w>
Cul tural</w>
ti ans</w>
sur prise</w>
repos itory</w>
regul arity</w>
re tri
col lapse</w>
Kale tra</w>
5. 8</w>
ė s</w>
jour nalists</w>
he ts</w>
distribu te</w>
der ness</w>
ca b</w>
x ia</w>
vir tually</w>
re stored</w>
pot enti
indi genous</w>
ep ine</w>
confid ent</w>
up grade</w>
sub systems</w>
semin ar</w>
pe de
et c.</w>
chlor o</w>
appl iance</w>
I TER</w>
emb olic</w>
conf ers</w>
Rot ter
L a
Deleg ation</w>
rec ession</w>
ic able</w>
Dos age</w>
12 72</w>
v ag
st amp
p est</w>
ic urity</w>
endor sement</w>
buil ds</w>
an tim
V III
Tr ust</w>
O ri
DG s</w>
men u</w>
embol ism</w>
I AEA</w>
E li
Can di
Arab ia</w>
wr ong
propri et
hol es</w>
graph y</w>
adi ol</w>
Priv acy</w>
G RO
E poetin</w>
y me</w>
s oph
en ė</w>
anch orages</w>
S CH
&apos; I
p ile</w>
men to</w>
en th
e tion</w>
curr icul
ble ached</w>
Rotter dam</w>
FUR THER</w>
proxim ity</w>
jud iciary</w>
inter act</w>
ere c
MANUFACT URING</w>
29. 6.
2 73</w>
vit amins</w>
inter institutional</w>
hy cardia</w>
entrepreneur ial</w>
Sam pling</w>
AN IM
ear ned</w>
divi ding</w>
c ils</w>
Enter prises</w>
Con tribution</w>
1 b</w>
mark ings</w>
glycer ol</w>
ep tic</w>
ap pren
ELL ING</w>
C ost</w>
17 66</w>
V C</w>
R ed
Pr ices</w>
Del i
Ch ronic</w>
7 77</w>
2 63</w>
perspec tives</w>
min i</w>
interoper able</w>
ent an</w>
deliv ers</w>
bilirub in</w>
Ro che</w>
K now
BR IS
G reat
7. 4</w>
sw aps</w>
rang ed</w>
er os
N V</w>
Lef t</w>
En forcement</w>
with held</w>
se als</w>
mark er</w>
coron ary</w>
com partments</w>
bro thers</w>
am ate</w>
Ven ez
Mon ey</w>
Inter pre
E stim
tour ists</w>
tis ation</w>
tic us</w>
tax ed</w>
superi or</w>
shap es</w>
respon sive</w>
lugg age</w>
gun s</w>
ex tern
enti onally</w>
ST ATE</w>
Ch un</w>
judg ed</w>
ex er
ali ke</w>
W as</w>
3 44</w>
z es</w>
u sian</w>
min ister</w>
fib rosis</w>
change over</w>
T op
EF SI</w>
C ris
u el</w>
rel ax</w>
oc t
impe de</w>
control lers</w>
ME MO</w>
Legisl ative</w>
In gel
rac es</w>
ment s
in ward</w>
il li
ep ing</w>
consul tative</w>
L AR
4 71</w>
trans porting</w>
pen etration</w>
in oc
differenti ation</w>
d agliptin</w>
BRIS TOL</w>
12 91</w>
un treated</w>
revis ions</w>
con ce
Mad eira</w>
E Q
Con fi
B row
read mission</w>
mat ched</w>
inspec tor</w>
entr ance</w>
a z</w>
T M
SQU IBB</w>
MY ERS</w>
In vented</w>
B B
sca red</w>
pun ishment</w>
pr ay</w>
flav ourings</w>
f estival</w>
eshi ps</w>
child care</w>
as ys</w>
R ub
Coun ty</w>
- 3</w>
poli tically</w>
il a</w>
che aper</w>
ch ocolate</w>
br ine</w>
b low</w>
Sol o
Lik ewise</w>
t ough</w>
h anded</w>
frag mented</w>
fer mented</w>
draw back</w>
D ys
CO UR
v on</w>
jour n
fer ro
con serv
naph tha</w>
monit ors</w>
g on
epilep sy</w>
Un bound</w>
Oc cup
K A</w>
An gel
6 00
ur g</w>
survi v
stac eans</w>
manif est</w>
bl ank</w>
S av
S CO
OR S</w>
Mu tual</w>
tr ic
regen eration</w>
mu sh
W all
S am</w>
oun ce</w>
lif ted</w>
her d</w>
E quality</w>
Bas al</w>
Amaz on</w>
notic ed</w>
import antly</w>
emb ar
an tine</w>
Road map</w>
Multi ple</w>
Gener ally</w>
Ap ple</w>
2 69</w>
nas al</w>
k ill
ind ex
corrid ors</w>
A ar
4 th</w>
trans form</w>
Trans lation</w>
P har
L A
IS T
ES As</w>
8. 5</w>
sho oting</w>
p ac
gl asses</w>
fr aud
distingu ishing</w>
bro ke</w>
be ar
TYP E</w>
Ha qq
Every body</w>
y lox
ultr as
fla x</w>
dre ams</w>
d ay
aeron autical</w>
ab at
Suppl y</w>
C ent
rigen dum</w>
injec ting</w>
anti viral</w>
Provi de</w>
zom ib</w>
up coming</w>
re side</w>
gu iding</w>
ep h</w>
Swe et</w>
Inspec tion</w>
D ating</w>
time frame</w>
run way</w>
rab ies</w>
SU M
AI R</w>
A bra
14 08</w>
ur b
min al</w>
brow ser</w>
G ER
Dis ease</w>
10 0000</w>
pass word</w>
modern ise</w>
j ack</w>
int angible</w>
Some thing</w>
R ail</w>
H un
p ink</w>
orna mental</w>
om on</w>
e h</w>
be ds</w>
Pro motion</w>
P reven
Con tracts</w>
struc k</w>
spo ts</w>
satisfac torily</w>
ro l</w>
predic ted</w>
in activated</w>
detec table</w>
alan ine</w>
Pol ska</w>
practition ers</w>
V ac
Sign ific
Low er</w>
Balk an</w>
A ci
thi az
pand emic</w>
ic am</w>
her bal</w>
ap ost
Cal cium</w>
8 a</w>
comb ed</w>
arm ing</w>
U V</w>
EU POL</w>
1. 2004</w>
Τ ηλ</w>
por cine</w>
an i
Offici als</w>
6 th</w>
exten sively</w>
equ itable</w>
SI s</w>
In ser
5 39</w>
4, 4</w>
un certain</w>
tro ub
su rely</w>
o o</w>
j i
cat chment</w>
ab acavir</w>
TI s</w>
SERV ICES</w>
ON E</w>
Haqq ani</w>
tec h</w>
perm itting</w>
len ec
aph ane</w>
LE MEN
Fail ure</w>
E lev
nat al</w>
f i</w>
dec imal</w>
R ic
E esti</w>
press ants</w>
on in</w>
o on</w>
mil est
dissem inate</w>
aband oned</w>
Su n</w>
Nor dic</w>
LAB EL</w>
Fr ank</w>
Es pa
shi eld</w>
py rid
po oling</w>
peti tion</w>
if ene</w>
M IU</w>
K ur
AM S</w>
3, 3</w>
er arch
comm anded</w>
alter ation</w>
Q T
O M</w>
No .
L PG</w>
Im mune</w>
H ab
o otic</w>
en erg
contracep tive</w>
Ret ail</w>
M other</w>
Y ellow</w>
DO M</w>
Alz heimer</w>
specific ities</w>
ri m</w>
disc ard</w>
co caine</w>
Op tions</w>
Mat erials</w>
E ry
Belar usian</w>
2 67</w>
2 13</w>
birth day</w>
Pl ans</w>
EX PEN
B ah
mer its</w>
lub ric
lu x
ing er</w>
h ang</w>
expl oration</w>
ber t</w>
ab r
EAG F</w>
ri vas
ig e</w>
eter nal</w>
Pol l
Enti ties</w>
n ut</w>
R ental</w>
Im age</w>
H b
UL N</w>
T M</w>
Pre pared</w>
P OR
B N</w>
9. 5</w>
ä r
vis iting</w>
mus eum</w>
hy nch
heal ing</w>
fo g</w>
derog ating</w>
dece ased</w>
ari um</w>
rivas tigmine</w>
ref rac
neutr ality</w>
sched ules</w>
numb ering</w>
mat rix</w>
gh um</w>
cas el
c av
adal afil</w>
7 3
un controlled</w>
u tility</w>
opi oid</w>
j ug
em itted</w>
ang ina</w>
ai ting</w>
UNI TS</w>
H av
under line</w>
in active</w>
gr ave</w>
critic ism</w>
are ly</w>
VE T</w>
SM ALL</w>
Gro unds</w>
Eff icacy</w>
Ath ens</w>
0 20
reserv o
emerg e</w>
to l</w>
reti no
pro t
hed ging</w>
gen us</w>
end ang
claim ing</w>
ch ambers</w>
TARGE T</w>
S NC
Croati an</w>
.. ...</w>
prospec t</w>
dg ing</w>
UNI T</w>
P el
Ex tract</w>
EFFEC TS</w>
Counc ils</w>
Con ven
x yl
prop yl
incre di
hall uc
favour ing</w>
INTE RES
B ay</w>
2 93</w>
v i</w>
th ine</w>
soph is
inspi red</w>
cust om</w>
compil ation</w>
bru cell
Fr anc
25 4</w>
waste water</w>
s on
pl asia</w>
ot age</w>
eor ological</w>
c z
ass ica</w>
B lock</w>
AI N</w>
pro minent</w>
pharmac ological</w>
cyto chrome</w>
Reg ular</w>
Know ledge</w>
Fl av
10 6
undertak es</w>
rif ampicin</w>
hi ves</w>
de pu
avo idable</w>
3 78</w>
thir ty</w>
tack led</w>
antibio tic</w>
Spe ed</w>
Dec re
kid ding</w>
En suring</w>
Doc etaxel</w>
ti ary</w>
th ful</w>
pr iced</w>
ogen ated</w>
mis takes</w>
min ed</w>
fer mentation</w>
expec ts</w>
che stra</w>
T ar
jur y</w>
Pro te
F L
An aly
res ins</w>
posi tively</w>
Jos eph</w>
5 50</w>
trans posing</w>
sim ulation</w>
pollut ant</w>
m i</w>
keto conazole</w>
deep er</w>
RIS K</w>
LAB ELLING</w>
H ouse
F U
sil denafil</w>
rectang ular</w>
fe el
en e
d or</w>
S par
N .</w>
Moham mad</w>
CON CLU
C W</w>
Ad verti
4 93</w>
sup er</w>
migh ty</w>
I so
4. 1.
2 92</w>
2 91</w>
toxic ological</w>
swif tly</w>
clu sters</w>
Y emen</w>
Entre preneur
é e</w>
differen tial</w>
decommission ing</w>
aer os
2 41</w>
vo y
competi tions</w>
char t</w>
antagon ist</w>
Tex tile</w>
SI ONS</w>
REG AR
RE Y
MAR Y</w>
Fro zen</w>
uni ver
ma them
consis ted</w>
29 0
- What</w>
sur render</w>
subsidis ation</w>
p noea</w>
flu shing</w>
dis advantages</w>
der m
clarif ying</w>
agg ed</w>
Tru dex
R .
Prosec utor</w>
Ingel heim</w>
A 1c</w>
5 00
st y</w>
overn ight</w>
in ability</w>
distribu tor</w>
V ar
Observ atory</w>
O w
IC ATION</w>
CON TRO
8 000</w>
1, 0</w>
- You</w>
path ways</w>
frac tures</w>
facilit ates</w>
bin d</w>
Selec tion</w>
Govern or</w>
Go als</w>
F air</w>
Autonom ous</w>
pron ounced</w>
i ers</w>
ch ew
Opti Set</w>
MANUFACTURE R</w>
Incre ase</w>
stoc k
T om</w>
Relev ant</w>
Min isterial</w>
G C</w>
3 41</w>
0 -</w>
ne ph
lo com
it ex</w>
fru c
f ate</w>
cont acted</w>
Pres sure</w>
EUR .1</w>
un stable</w>
t rough</w>
stor m</w>
op or
luc ky</w>
ir rig
Cot on
subs cription</w>
o zone</w>
log ged</w>
os sed</w>
in ned</w>
h at</w>
fi red</w>
Lietuv os</w>
Jos é</w>
Ex cell
to y</w>
s avi
hun ting</w>
amaz epine</w>
Quanti ty</w>
5. 2005</w>
2 82</w>
re purchase</w>
rail ways</w>
protec ts</w>
m m3</w>
iz es</w>
enn ium</w>
U sed</w>
S ound</w>
N AFO</w>
Klai pe
EXPEN DIT
Coton ou</w>
4 000</w>
3 33</w>
vac ant</w>
consign or</w>
E CON
wor ried</w>
w af
tr ated</w>
se c</w>
fores ees</w>
benz ene</w>
ay a</w>
Consul tation</w>
vo ire</w>
un preced
re actor</w>
le an</w>
dol lar</w>
disc over</w>
al idomide</w>
F A</w>
Bre ez
serv icing</w>
sen i
s wee
o eu
conf used</w>
ca ke</w>
Sci ences</w>
Consul tative</w>
Br an
4. 1.1</w>
stabil ise</w>
j ump</w>
gu est</w>
en ant</w>
cylin ders</w>
canc el</w>
WEI GHT</w>
LE X</w>
ec itabine</w>
Sh o
C TION</w>
secre tion</w>
jurisdic tions</w>
hi erarch
commen cement</w>
CYP2 D6</w>
5. 9</w>
ev ing</w>
ee ded</w>
bott lenec
be es</w>
4, 6</w>
ä n
uni fied</w>
mal t</w>
leuk aemia</w>
equ ili
dum my</w>
ap parently</w>
WH ERE
EXPENDIT URE</w>
s ers</w>
parc els</w>
lo zin</w>
gr inding</w>
gluc agon</w>
des k</w>
attribu te</w>
ak a</w>
Pot assium</w>
John son</w>
G ir
te d
sem iconductor</w>
neg atively</w>
los porin</w>
lor d</w>
lif lozin</w>
jack ets</w>
it ories</w>
elec t</w>
aqu inavir</w>
ad ren
R e</w>
EF F</w>
Co R</w>
7 98</w>
multi national</w>
in comes</w>
g p</w>
dis plays</w>
authentic ation</w>
ad der</w>
REY AT
REYAT AZ</w>
Criter ia</w>
C as</w>
с т
win ner</w>
random ized</w>
ot ted</w>
3 16</w>
spon taneous</w>
amen to</w>
vil le</w>
unpreced ented</w>
under signed</w>
thrombo tic</w>
brucell osis</w>
benz yl</w>
ampou le</w>
Peri od</w>
J U
Gall us</w>
Engine ering</w>
Dou ble</w>
00 8</w>
substitu ted</w>
re sume</w>
lo be</w>
electr on</w>
de pl
ECON OM
&apos;I voire</w>
suspen ding</w>
simpl er</w>
ord inate</w>
m apping</w>
ad y
V inc
Trudex a</w>
G ard
Breez haler</w>
ADMINISTR ATIVE</w>
stre ams</w>
pro hibiting</w>
fire arms</w>
dy e</w>
ar ose</w>
UL ES</w>
Mov ement</w>
therap ies</w>
tail ed</w>
ish able</w>
ht ml</w>
deliber ations</w>
b anned</w>
agr i</w>
Mill ennium</w>
y o</w>
su icidal</w>
shap ing</w>
ple asant</w>
fi res</w>
ev o</w>
em tricitabine</w>
conveni ence</w>
consor tium</w>
anticoag ul
a.k. a</w>
Ben e
z ine</w>
tr au
te zomib</w>
restaur ants</w>
ost er
casel aw</w>
Pu gh</w>
Hb A1c</w>
C EL
eth ane</w>
dom ains</w>
bl ades</w>
activ ate</w>
S A
u als</w>
institu te</w>
ge o
com pos
bre vi
astro ph
ag liflozin</w>
H5 N1</w>
lif est
en er</w>
bus y</w>
b n</w>
G li
2 49</w>
pol ysorbate</w>
out set</w>
in consistent</w>
el on</w>
S ettlement</w>
M ethyl</w>
Ex ample</w>
top ical</w>
ob ic</w>
ig no
es es</w>
cat ching</w>
Pop ulation</w>
Au to</w>
0 2.
г ар
rad ical</w>
W in</w>
Th ink</w>
PAR TIES</w>
1 182</w>
less ness</w>
g os
am id
S qu
S ep
reg ret
prov el</w>
break fast</w>
Lo ans</w>
Kar ve
Consi der
A provel</w>
sur ances</w>
pl u
man dates</w>
juven ile</w>
illustr ated</w>
e g</w>
conv ic
alk aline</w>
Peg asys</w>
wav el
trad itionally</w>
tal ent</w>
resol ving</w>
re use</w>
eg ar</w>
dis odium</w>
awar ding</w>
Hy p
4 02</w>
tin es</w>
indic es</w>
he ater</w>
ch ose</w>
and ers</w>
accru ed</w>
Techn ologies</w>
J a
un ning</w>
ir relevant</w>
h eter
distor ted</w>
cit rate</w>
9 6
ring er</w>
main streaming</w>
dec itex</w>
N az
Belgi en</w>
erg er</w>
dram atic</w>
ad apter</w>
ach lor
LIS H
sti n
elecommun ication</w>
e -</w>
divi dend</w>
dimen sional</w>
cy totox
cataly st</w>
az o</w>
accid entally</w>
VOL U
Sk ills</w>
val dy
spar kling</w>
sol vents</w>
dex amethasone</w>
chem istry</w>
F E
ques tioned</w>
hynch us</w>
depend ency</w>
Objec tives</w>
DEN A</w>
C lar
un like</w>
s lic
optim um</w>
n ative</w>
mis sile</w>
imp etus</w>
conver ter</w>
V or
Ru n</w>
Dan i
Agen cies</w>
AN Y</w>
A ST
27. 6.
1. 25</w>
mag ic</w>
Re sid
Phys ical</w>
Great er</w>
st ationary</w>
occa sional</w>
ab uses</w>
Web site</w>
Bo dies</w>
tur keys</w>
pede stri
pa ths</w>
intensi fied</w>
her ring</w>
Wh enever</w>
ъл гар
ro m
revo ke</w>
objec tively</w>
bre eds</w>
um ps</w>
ul ty</w>
regul ator</w>
po o
compar ator</w>
challeng ed</w>
POS SIBLE</w>
N orge</w>
GAR DENA</w>
membran e</w>
kin s</w>
fl ora</w>
Hist ory</w>
H ot</w>
Cla ims</w>
Б ългар
ow ls</w>
k it</w>
di goxin</w>
defin ite</w>
agr ams</w>
adm it</w>
M arg
Govern ance</w>
Dis orders</w>
14. 12.
rol ler</w>
parlia ment</w>
conven ed</w>
au g
L t</w>
Col onel</w>
ha ul</w>
PRODUC TION</w>
IS CED</w>
ü r
p ell
li ked</w>
ent a</w>
def en
Sol omon</w>
Requ est</w>
AR T</w>
sk i
receip ts</w>
land ings</w>
incumb ent</w>
del etion</w>
de em</w>
codi fied</w>
attribu tes</w>
ab u
D ogs</w>
Be ing</w>
3 95</w>
oeu v
migr atory</w>
har b
denom ination</w>
ch icks</w>
W ol
Li abilities</w>
Lan ka</w>
Hol ding</w>
D ATA</w>
reve als</w>
re pay</w>
om at
cyclo hex
cop hen
bu yers</w>
E co
Cer tification</w>
ven ues</w>
S take
E NER
2 44</w>
t ful</w>
contracep tives</w>
affili ated</w>
St age</w>
On cor
Liv ing</w>
sh ut
or ly</w>
malign ancies</w>
go ds</w>
en cry
at um</w>
PRO TE
threat ens</w>
ref using</w>
mur der</w>
TAC s</w>
KING DOM</w>
25 7</w>
prescri bing</w>
itri le</w>
explo iting</w>
cred ited</w>
ci le</w>
ch assis</w>
V IR
Ty re</w>
Sol ar</w>
S eries</w>
S MS</w>
tem ple</w>
techn ic</w>
radio activity</w>
int entionally</w>
in spir
dres sing</w>
d ying</w>
chro mium</w>
certain ties</w>
T an
Oncor hynchus</w>
E lim
C RE
Bal ance</w>
199 0s</w>
v ou
ov ers</w>
om nia</w>
adjust able</w>
Ur ban</w>
PRO GR
Orig inal</w>
sp inal</w>
sh ouldn</w>
e j
Post al</w>
Fre ight</w>
Compar e</w>
Ab u</w>
19 69</w>
sph eres</w>
re new</w>
ic ion</w>
Soci alist</w>
E 171</w>
Amer ic
stri ve</w>
sci ences</w>
fl ags</w>
ammon ia</w>
Rec ital</w>
M anu
Liqui d</w>
I B</w>
succ eeded</w>
reinfor cement</w>
ou stic</w>
origin ator</w>
marg in
is ter
ass ing</w>
ap ped</w>
E vents</w>
CENTR AL</w>
AS I</w>
l atitude</w>
ep tion</w>
di o</w>
Re portable</w>
P UR
H erc
Cop per</w>
mer cy</w>
lim e</w>
em itting</w>
at al</w>
VOLU ME</w>
J obs</w>
Fron t</w>
tran ship</w>
att estation</w>
ash ing</w>
appreci ation</w>
alter ations</w>
Regul ators</w>
R B</w>
A zo
A ye</w>
t ung
gar lic</w>
bud dy</w>
b ė</w>
b acks</w>
C AL
vers a</w>
ur red</w>
mo ther
Télé com</w>
Liv er</w>
GH G</w>
Cho ose</w>
9. 2002</w>
6. 7</w>
mon u
SPECIF IC</w>
Pri ze</w>
Ad am</w>
t elec
res ses</w>
reli eve</w>
pro jection</w>
contem porary</w>
albu m</w>
ac eae</w>
Le ague</w>
DE VELO
AU C
3 35</w>
1 A</w>
step ping</w>
ren dering</w>
phi l</w>
c ure</w>
Se par
S till</w>
Equ al</w>
E ligible</w>
Bre ak
An g
30. 12.
sh an</w>
re plac
pep per</w>
pat ents</w>
ometh yl</w>
in os
C old</w>
vil dagliptin</w>
t une</w>
surpr ised</w>
obsol ete</w>
ind inavir</w>
dispu ted</w>
cop olymer</w>
anal ogues</w>
N ar
prop elled</w>
T ol
Res ource</w>
En larg
f lood</w>
ex pedi
at o
af lu
Sub section</w>
P ull</w>
Maur it
K no
J an</w>
7 65</w>
sp ices</w>
sign atures</w>
li b
feel ings</w>
G R</w>
D aily</w>
22.12. 2009</w>
res or
agon ist</w>
Com pati
BER EC</w>
3 76</w>
0 30</w>
h ose</w>
cy an
ag us</w>
V A
T esting</w>
Measu ring</w>
susp icion</w>
po ker</w>
hon ourable</w>
en do</w>
an ical</w>
administr ators</w>
Pharmac euticals</w>
Collec tion</w>
y t
ver t</w>
rh osis</w>
Sur name</w>
Cop y</w>
Adv anced</w>
í a</w>
utilis ed</w>
pro phylaxis</w>
pen sion
ici ally</w>
gar ments</w>
f .</w>
ea u</w>
dr um</w>
Sol vent</w>
PROGR AM
F s</w>
it ol</w>
hot els</w>
fil tration</w>
ch ances</w>
brief ly</w>
T elecommunications</w>
CYP 1A2</w>
C li
step ped</w>
rumin ants</w>
par in</w>
off s</w>
as a</w>
SUM MARY</w>
3 b</w>
sw allowed</w>
des c
Non etheless</w>
H T
Bl ack
peg interferon</w>
ox o</w>
orm on</w>
her ds</w>
gr aft</w>
dis placed</w>
ad e
Particip ating</w>
CO DE</w>
yiel ds</w>
vulner ability</w>
vis ually</w>
poo rest</w>
pharmac odynamic</w>
M SC
In dependent</w>
8 52</w>
up stream</w>
ro bo
rel la</w>
purchas er</w>
lif ts</w>
gu t</w>
enrich ment</w>
ar ded</w>
an ce
Neo Rec
ste ad
modi fying</w>
intern ally</w>
impl ant
ill in</w>
dur ability</w>
cann abis</w>
am ble</w>
UR AL</w>
2 O</w>
2 85</w>
1. 11.
navi g
il es</w>
commen ce</w>
at en</w>
Res piratory</w>
EC O</w>
th ick</w>
par ks</w>
out let</w>
in coming</w>
experi ments</w>
chec k
asi l</w>
Pat ent</w>
N om
10. 2012</w>
olog ous</w>
inval id</w>
glu cur
gen ic</w>
form erly</w>
boil er</w>
T aj
Pass enger</w>
A venue</w>
ver tically</w>
u k</w>
tin s</w>
d owns</w>
complain ants</w>
bl adder</w>
acqu ain
Prepar ations</w>
Che ap</w>
sor ting</w>
od a</w>
la sts</w>
exha ustion</w>
distinc tive</w>
ch airs</w>
br ush</w>
arre sted</w>
ad ata</w>
W ater
P ir
NO S</w>
ARE A</w>
sophis ticated</w>
omen tum</w>
justif ying</w>
is tical</w>
absor b</w>
Prin ting</w>
Al most</w>
str aw</w>
pheny toin</w>
man ually</w>
le ment</w>
fac ial</w>
competi tor</w>
col later
Sup porting</w>
Pl anning</w>
PC R</w>
D ro
Cre ate</w>
CER TI
B L
6 000</w>
3 45</w>
veri fier</w>
swit ches</w>
rig orous</w>
presum ption</w>
neg lec
lymph oma</w>
ic on</w>
collabor ative</w>
Y ar
C 3</w>
B ad
8. 4</w>
ul ent</w>
inst ability</w>
formul ae</w>
flex icurity</w>
doc k</w>
del ighted</w>
Wh e
trans formed</w>
Rom â
Fun ding</w>
Dan mark</w>
szá g</w>
im atinib</w>
diox in</w>
barg aining</w>
6. 8</w>
5 49</w>
yar ns</w>
th el
t ance</w>
regre ts</w>
mm Hg</w>
cru staceans</w>
contrad ic
ari ans</w>
aci ón</w>
SU R
Pub lication</w>
Ne u
Lo oking</w>
Ch ick
2 88</w>
w rought</w>
o ever</w>
min isterial</w>
consul tancy</w>
WHERE AS</w>
thal ene</w>
monopol y</w>
mil led</w>
im id
exclu des</w>
Supple mentary</w>
Su cc
PER S
L au
Fl ash</w>
B il
represent ations</w>
propag ating</w>
inter cultural</w>
coun cil</w>
con duci
compres sed</w>
ati ngs</w>
E asy</w>
0, 05</w>
stat ute</w>
ru ps</w>
pe el</w>
l au
clo ts</w>
Ri o</w>
3 36</w>
&apos; Article</w>
numb ered</w>
li ed</w>
cre atures</w>
In fl
3 62</w>
2 72</w>
wor rying</w>
st al
phys icians</w>
in ic</w>
fruc tose</w>
R ever
PE RI
NO K</w>
CER A</w>
trans pose</w>
sol es</w>
mil ling</w>
li tig
hem p</w>
g em
STE CF</w>
Inser t</w>
CI F</w>
Българ ия</w>
ul cer
sacrif ice</w>
pr an
g ifts</w>
e z</w>
S ay</w>
Multi annual</w>
MIR CERA</w>
19 24</w>
simil arly</w>
sear ching</w>
re valuation</w>
im poses</w>
REGAR DING</w>
en doc
el eration</w>
cir rhosis</w>
ac onazole</w>
RE X</w>
Pro file</w>
G y
CYP2C 9</w>
Applic able</w>
9. 2006</w>
13 80</w>
serv ic
mer ch
justi fies</w>
i one</w>
h l</w>
emplo ying</w>
conduci ve</w>
co ats</w>
Lo an</w>
In traven
seam less</w>
sanc tion</w>
h ides</w>
child bearing</w>
adi ene</w>
W at
Op portun
n ity</w>
min ced</w>
after wards</w>
Br and
plo t</w>
int ent</w>
corrid or</w>
P M
un avir</w>
se y</w>
ou tw
motiv ated</w>
fin gers</w>
down turn</w>
cor ner
cl otting</w>
Pi er
N ex
DEVELO P
C lo
3 90</w>
tr ine</w>
ph asing</w>
pen dic
man oeuv
ev ir
de ple
Symp toms</w>
STOR E</w>
Col umn</w>
BA S
B lis
4 15</w>
su stain</w>
slud ge</w>
idis m</w>
fair ness</w>
exten sions</w>
arin ux</w>
K G</w>
AD V
tac hycardia</w>
stabil ised</w>
s mar
ol ab
her self</w>
et o
cophen olate</w>
Reas ons</w>
Hon ey</w>
mut ations</w>
meth ane</w>
isol ates</w>
hy dri
harmon ising</w>
f loo
enth usi
ell ular</w>
TS E</w>
N y
G T</w>
mid st</w>
manag es</w>
con current</w>
cic losporin</w>
c ef
Mo z
Egy p
Comb ination</w>
Cas ino</w>
7 26</w>
25 00</w>
week end</w>
un certainties</w>
ol ol</w>
ati ne</w>
WOR K</w>
Rel ease</w>
4 79</w>
g um</w>
Evi dence</w>
ion ship</w>
bic ycle</w>
Th era</w>
R an
O P</w>
Nov o</w>
Mach ines</w>
J am
D addy</w>
Compu ter</w>
APPLIC ATION</w>
strugg le</w>
off spring</w>
li po
gr and</w>
for a</w>
em at
dissem inated</w>
an ted</w>
Ter r
S ah
y li
per pendic
liber ty</w>
high lighting</w>
expres ses</w>
compu ting</w>
O 2</w>
IS TA</w>
9 4
ne ar
k top</w>
horiz on</w>
h ran</w>
ec o
B ol
ter tiary</w>
le z</w>
Re g</w>
P rec
NR As</w>
M oun
E B
6. 2004</w>
uni form
fish ed</w>
appen dix</w>
16 98</w>
. 3</w>
vis ional</w>
savi valdy
m omentum</w>
less on</w>
dem arc
dap arinux</w>
carcin ogenicity</w>
advant ageous</w>
Rob ert</w>
Power ball</w>
Lit tle</w>
on ide</w>
hu a</w>
earth qu
d z
am ics</w>
Tr ac
Me ans</w>
1. 11</w>
tun nel</w>
or szág</w>
cat al
cab in
Lic ence</w>
L C</w>
Azo res</w>
7 8
tr ap</w>
small est</w>
en c
do z</w>
derm atitis</w>
TV 2</w>
T OR</w>
L eu
Intraven ous</w>
Incre asing</w>
Espa ña</w>
Arrang ement</w>
9. 3</w>
smu ggling</w>
retro spec
predic tability</w>
po is
ins omnia</w>
NeoRec ormon</w>
Jac ob</w>
Ha iti</w>
AC COUN
wit nesses</w>
strength ens</w>
sal v
len ses</w>
j et</w>
insu rers</w>
horm onal</w>
buty l
ar terial</w>
Sch edule</w>
v .</w>
th igh</w>
r ank</w>
end ogenous</w>
co generation</w>
as sh
as e
Govern ors</w>
6 A00
25 2</w>
un de
stic ks</w>
plen ty</w>
me tics</w>
ha i</w>
h ens</w>
cen trifu
TH ER
Pur ch
Pharmac otherapeutic</w>
4 29</w>
ι σ
ι κ
re agent</w>
pro hibitions</w>
manip ulation</w>
ma sters</w>
fo am</w>
cir cles</w>
arch ives</w>
Ad ults</w>
renov ation</w>
rati fy</w>
quot e</w>
gener ates</w>
decla res</w>
TE ST</w>
S. A.</w>
Me dian</w>
we g</w>
si gh
pro active</w>
positi oned</w>
omet ers</w>
moun tains</w>
here d
λ λ
s ad</w>
on er</w>
ome try</w>
mul tic
VE L</w>
Magne sium</w>
I gn
E mission</w>
Applic ant</w>
3. 0</w>
w ip
vibr ation</w>
sw abs</w>
r ays</w>
eshi p</w>
Mar ino</w>
Mag yar
Mab Thera</w>
M od
H earing</w>
ven ous</w>
sy rups</w>
on ds</w>
chang eable</w>
ba thing</w>
antim icro
E TI
Bo eh
5 12</w>
........ ....
whe eled</w>
vari ant</w>
cere mony</w>
Pack aging</w>
EN T</w>
C ou
yach t</w>
trem or</w>
terat ogenic</w>
recogn ize</w>
ob ia</w>
en edi
am une</w>
a ise</w>
Signific ant</w>
She et</w>
San doz</w>
I EC</w>
Furn iture</w>
ECONOM IC</w>
D id
vec tor</w>
stimul ates</w>
s aw
per sec
m s
in admissible</w>
cru shed</w>
atmosph eric</w>
am er</w>
NE D</w>
J i
D AS</w>
0. 25</w>
understand able</w>
cook ies</w>
Venez u
P regabalin</w>
K at
zo on
w aves</w>
tro l
tol u
revol ution</w>
corro sion</w>
Ri bavirin</w>
recover able</w>
y ch
rex ia</w>
propor tions</w>
k l
condi tion
ar bon
accumul ators</w>
N T</w>
Jur is
Do ha</w>
4 67</w>
4 36</w>
tic asone</w>
ta vis</w>
r il
dist ances</w>
cy ber</w>
Pl an
Arch itec
Ag ain</w>
vin egar</w>
train e
thre n</w>
tere phthalate</w>
opin ion
lun ch</w>
ic um</w>
ero idal</w>
e der</w>
bron ch
US ER</w>
U su
Sign s</w>
Es s
Cor rigendum</w>
Con servation</w>
withdraw ing</w>
wai ve</w>
n ar</w>
divor ce</w>
disc s</w>
biog e
XX I</w>
UL T
Th ai</w>
uniform ly</w>
supervis e</w>
is en</w>
glyco protein</w>
explo red</w>
b ival
D un
Boeh ringer</w>
A ward</w>
recover ing</w>
real ize</w>
p s
os ul
evir apine</w>
bit ol</w>
V y
REG I
E co</w>
ul ating</w>
pass ports</w>
pal m</w>
newsp apers</w>
medi ate</w>
it s
h es
go at</w>
ec t</w>
ear n</w>
S ver
Magyar ország</w>
Cust omer</w>
AN S</w>
00 1.
. The</w>
probl ematic</w>
ol ives</w>
non etheless</w>
lact ating</w>
experi ment</w>
er s
dres sed</w>
C reat
supervis ing</w>
ocarb ons</w>
fac ie</w>
du l</w>
child hood</w>
Wash ington</w>
Klaipe da</w>
D ol
Bor n</w>
6 -</w>
ass istant</w>
S erg
C iv
C ause</w>
C 6</w>
3 68</w>
o en
fluor ocarbons</w>
C EP
7 a</w>
w elling</w>
up wards</w>
under pin</w>
furn ished</w>
eg al
R ab
Organis ations</w>
INV ES
Diff erent</w>
Dam n</w>
C EN</w>
17 85</w>
mamm als</w>
gr az
egrad able</w>
P ending</w>
tourna ment</w>
spec ulation</w>
read iness</w>
ash ed</w>
Dis p
14 ,
0 9
. org</w>
x x
spre ads</w>
se aling</w>
expir ation</w>
We ap
Stat es
I TIES</w>
E s</w>
t arily</w>
sub type</w>
p ocket</w>
har der</w>
flo ods</w>
ex hibitions</w>
compr ised</w>
c ous</w>
ban ana</w>
SU RE</w>
Reci pe</w>
D L</w>
thromb in</w>
mal function</w>
gener ator</w>
es ome</w>
equili bri
d d</w>
Sp A</w>
RO N
F S</w>
we ird</w>
val pro
sen sation</w>
devi ations</w>
CHAR AC
Al low</w>
3 29</w>
2 94</w>
met eorological</w>
detec ting</w>
con fer
W ay</w>
Th i
San ofi</w>
Eth yl</w>
0 7.
wor ship</w>
str ö
res ol</w>
ration ale</w>
in effective</w>
co at</w>
ag linide</w>
G old</w>
F it
th y
po orly</w>
ph os
j a
insul ation</w>
elev ation</w>
band width</w>
D ED</w>
smo kers</w>
postpon ed</w>
inhal ed</w>
camp ing</w>
Tre asury</w>
Cardi ac</w>
COUR T</w>
COMM ON</w>
Ad option</w>
17 74</w>
trans amin
philosoph y</w>
frac ture</w>
carb amazepine</w>
at titudes</w>
accor ded</w>
RT D</w>
DR A
2 79</w>
wai ved</w>
transl ations</w>
stabil ising</w>
propi onate</w>
perform s</w>
method ological</w>
Bos ch</w>
Bar bie</w>
B orders</w>
perfor ated</w>
ling ual</w>
institu ted</w>
con dens
cit rus</w>
atro pin</w>
Carri age</w>
Air ways</w>
31. 5.
23. 12.
2 71</w>
propan e</w>
pip elines</w>
o e</w>
in yl</w>
in equality</w>
defec t</w>
cryst al</w>
SECURI TY</w>
31. 7.
win ners</w>
pr amipexole</w>
bl ame</w>
V es
UN DER
R R</w>
P NR</w>
G .</w>
there from</w>
second ment</w>
se ud
fl ame</w>
ell ose</w>
T R</w>
Solo Star</w>
Româ nia</w>
Mar ia</w>
B rig
31.12. 2002</w>
2 66</w>
ven tures</w>
swe ar</w>
s la
rep airs</w>
prev ail</w>
g astro
att esting</w>
annul led</w>
O .</w>
In land</w>
Curren cy</w>
3 73</w>
16 00</w>
th ick
ap er
W y
Sa har
R asi
C ancer</w>
6 15</w>
π ρο
s lot</w>
quanti fied</w>
n.e. s</w>
log istical</w>
inc ub
ign ore</w>
design ating</w>
boo ster</w>
Pl en
L ong
K K</w>
IP R</w>
F le
A de
A chi
ri vers</w>
r al
pen etr
ful ness</w>
da c</w>
PO B</w>
A mbass
tow er</w>
rel atives</w>
per pe
human ity</w>
Te hran</w>
SC I</w>
OS CE</w>
sper m</w>
silic a</w>
read ed</w>
cat alogue</w>
addi tions</w>
J ew
Ar med</w>
Aci d</w>
stain ed</w>
ro li
di hydrogen</w>
counter vailable</w>
bur den
bottlenec ks</w>
bl ast</w>
F .
7 000</w>
so y
sh aft</w>
n us</w>
b oss</w>
atin um</w>
L ake</w>
G PS</w>
Compati bility</w>
se wage</w>
port ers</w>
mag azine</w>
hyp oc
fle ets</w>
anti a</w>
T own</w>
T SIs</w>
Secon d
F is
3 24</w>
ob by</w>
merg ing</w>
legisl ator</w>
gradu ated</w>
fertilis er</w>
compar isons</w>
cent ur
artif icially</w>
Rh ine</w>
An dre
wor ms</w>
specif icity</w>
pu shing</w>
equival ents</w>
Ken ya</w>
o yl</w>
log book</w>
initi s</w>
g aining</w>
fo etus</w>
declar ing</w>
Pres entation</w>
P U
Ma ung</w>
H ear
CHARAC TER
C Z
sun light</w>
reper cus
prim a</w>
col lis
ce ases</w>
as i</w>
W O
Sul ph
Sh are</w>
O IE</w>
ENER GY</w>
C ore</w>
C om</w>
w er
ur ation</w>
rim on
recru ited</w>
neutro phil</w>
mitig ating</w>
h an</w>
UN F
Territ orial</w>
Down load</w>
oster one</w>
in sic</w>
W P</w>
T ests</w>
Rev ision</w>
Mi ke</w>
tri bunal</w>
reli es</w>
of s</w>
lin k
jour neys</w>
immun o
ak en</w>
ο υ</w>
st aff
ris es</w>
re alities</w>
pre dn
pop ulated</w>
g min
g es
Requ ests</w>
Op tional</w>
L ove</w>
B RE
A void</w>
19 63</w>
10 95</w>
secret ary</w>
ra j
im pressive</w>
cr acked</w>
boo ked</w>
Wor k
L akes</w>
Func tional</w>
Ar my</w>
se ized</w>
pres entations</w>
immun ities</w>
hal t</w>
commun icating</w>
classi c</w>
To ols</w>
Ham burg</w>
E state</w>
A. 1</w>
ve x</w>
up ward</w>
trac ted</w>
sm en</w>
over lap</w>
m ill</w>
j um
dial ogues</w>
RE CO
Cub a</w>
Ac tiv
5 th</w>
un declared</w>
sk ip
equilibri um</w>
aus kas</w>
MAN AG
K R
CO OPERATION</w>
lo v
emer gencies</w>
confisc ation</w>
bur nt</w>
bloc k
Saf e</w>
M ich
Jo ined</w>
H F</w>
G ROU
BO X</w>
3 32</w>
13 ,
secre ts</w>
precur sors</w>
modern ising</w>
con sume</w>
cat ering</w>
bid ding</w>
Wh olesale</w>
V lad
V ascular</w>
B EL
An ton
strö m</w>
st oring</w>
per tin
pend it
o gram</w>
ar isation</w>
Polic ies</w>
Petro leum</w>
C anc
particip atory</w>
oph thal
en burg</w>
T en</w>
Part ners</w>
Ab dul</w>
refrac tory</w>
r at
ly ophil
le ased</w>
estr adiol</w>
disman tling</w>
S and
F .</w>
2 37</w>
sty rene</w>
prom ellose</w>
oly tic</w>
me tre</w>
m as
Ver ord
Luxemb urg</w>
Le on
Al location</w>
tow ing</w>
prefer able</w>
l up
cru ise</w>
connec tive</w>
MF F</w>
Legisl ation</w>
L IM
Klai p
Fr aud</w>
wor m</w>
un wanted</w>
neg ligence</w>
near by</w>
homogen eous</w>
el y
dis charged</w>
col or
bur ned</w>
are l</w>
Pr ague</w>
ME R
IS TICS</w>
I FOR
0, 0
р а
un ilateral</w>
trim ester</w>
inqui ries</w>
exc essively</w>
8. 2.
19 65</w>
under mining</w>
pharmac ologically</w>
ow e</w>
n el
l l
cl oth</w>
bear ings</w>
b ent</w>
agon ists</w>
Wee k
V oc
Li br
Ex tension</w>
ometh ane</w>
deterg ents</w>
Re in
F lor
path way</w>
f en</w>
body weight</w>
bi ke</w>
affor ded</w>
SE E</w>
Plas ma</w>
p ins</w>
ed a</w>
deliber ate</w>
coun cils</w>
R he
R aw</w>
Pen sions</w>
J ul
2 A</w>
qu is
os ine</w>
grow ers</w>
cr y</w>
a it
B ay
Am ounts</w>
10 00
un bund
ren ia</w>
p it</w>
guil ty</w>
freez er</w>
Jo e</w>
tow ed</w>
securiti sations</w>
re organisation</w>
is omers</w>
bioge ographical</w>
Syn drome</w>
Qu estions</w>
Mus culoskeletal</w>
Lear n</w>
9 A
shel f</w>
p emetrexed</w>
equ ation</w>
appra isal</w>
Wh ole</w>
Sub si
Rom an</w>
ub icin</w>
tub ular</w>
ster re
sp inning</w>
selec tivity</w>
ro pes</w>
re pro
re conc
fi r</w>
assi mil
apost les</w>
To o</w>
F org
wit n
r aft</w>
eg o</w>
ann um</w>
ali en</w>
Parlia ments</w>
Hell enic</w>
Func tion</w>
1, 8</w>
toler ances</w>
mut ation</w>
hun gry</w>
de fl
correc ting</w>
ai da</w>
S on
2 78</w>
é t
repercus sions</w>
pyro technic</w>
pow i
orph an</w>
off er
in trac
fur on</w>
c m2</w>
ann y</w>
Hep atitis</w>
E M</w>
B uc
waf ers</w>
termin ology</w>
succ ession</w>
stu ck</w>
r amp</w>
nutri ents</w>
m ask</w>
k ler</w>
inhal er</w>
di agrams</w>
V s</w>
SAL W</w>
Intel ligence</w>
Amen ding</w>
10. 1993</w>
volun tarily</w>
nic o
g over
f lock</w>
Plac ebo</w>
5. 2.
4 42</w>
bre thren</w>
T all
S cal
K .</w>
IS L</w>
Enlarg ement</w>
Ca ref
sch ol
savivaldy bė</w>
ograp hic
imp air</w>
ick y</w>
assum es</w>
Tr ack</w>
Si e
Manufac turing</w>
H EX
Co sta</w>
2 89</w>
u ts</w>
hyper tro
funda mentally</w>
amino transferase</w>
Prof essor</w>
stipul ate</w>
sti ff
ren a</w>
n ig
distor ts</w>
ar y
VE HIC
Sver ige</w>
SI A</w>
Employ ers</w>
Co ast</w>
Air craft</w>
syn ergy</w>
connec tor</w>
confir matory</w>
Star ting</w>
ta vid</w>
ta g</w>
sk ir
oul s</w>
d.o. b</w>
at tracting</w>
Re ady</w>
Fer tavid</w>
AO C</w>
0, 01</w>
ro asted</w>
quan tification</w>
ep i
bul l
ans k</w>
Vis ual</w>
Inclu ding</w>
H B</w>
H B
Design ation</w>
28 47</w>
ul ous</w>
success or</w>
o estro
lo idal</w>
in the</w>
idi opathic</w>
counterfe it</w>
Princi pality</w>
N OR
El i</w>
Bo b</w>
4 12</w>
vir gin</w>
un fit</w>
py ri
finger prints</w>
connec tors</w>
care ers</w>
car tel</w>
am yl
N C</w>
Exc eeding</w>
Connec ting</w>
sor ghum</w>
ri l</w>
infring ed</w>
W ild</w>
OH IM</w>
E X</w>
nucle oside</w>
k nee</w>
dis pers
dig estion</w>
Second ary</w>
OR GAN
2 42</w>
wash ed</w>
var denafil</w>
s ap
re mark
ob struction</w>
ne es</w>
c i</w>
M 2</w>
š k
tu ce</w>
righte ousness</w>
op ted</w>
o ch
is co</w>
hypo the
foc us
Mis cellaneous</w>
IR ISL</w>
H F
CHARACTER ISTICS</w>
C ri
Bud apest</w>
Applic ants</w>
turb ines</w>
re a</w>
py r
our ly</w>
leg ible</w>
k Hz</w>
clar ifications</w>
c ements</w>
ac ic</w>
S ab
Me an
D al
tr ay</w>
ste e</w>
receiv able</w>
in dem
fol ded</w>
ch ic
Yugosla via</w>
Supervis ors</w>
SCO PE</w>
CY P</w>
Absol ute</w>
exc use</w>
consum ing</w>
TE M
Si rene</w>
R MP</w>
MA Y</w>
H and</w>
- 4</w>
ra w
prehen sive</w>
om i</w>
fir med</w>
cri pt</w>
col l
casu s</w>
M 3</w>
H D</w>
F uc
ES RB</w>
C ros
Br ing</w>
sedi ment</w>
op pon
est y</w>
ati de</w>
L U</w>
ro s</w>
pre -</w>
ord ning</w>
mass age</w>
invent ories</w>
deplo y</w>
de m</w>
Wh ere
al d</w>
advoc ates</w>
W ales</w>
Sim on</w>
Pati ent</w>
35 5</w>
str ing</w>
st ays</w>
j ail</w>
in fusions</w>
am ides</w>
Investig ation</w>
F i</w>
As set</w>
ore m</w>
membran es</w>
ex pendit
ci vic</w>
bl end</w>
as cer
AL L
A m</w>
sub contractors</w>
multi tude</w>
mo fe
ha ul
Rev .</w>
F IN</w>
unanim ity</w>
ti t
proportion ately</w>
hered itary</w>
employ ability</w>
em an
di hydro
de pressed</w>
de fe
contin ental</w>
Innov ative</w>
DI T</w>
6. 3.
19 0
under mined</w>
so ap</w>
phi de</w>
p our</w>
oper ability</w>
dynam ics</w>
S eeds</w>
4 40</w>
short ages</w>
pit ch</w>
ne o
atell ites</w>
al u</w>
West LB</w>
Some one</w>
Hum an
Bun des
ti tles</w>
ow l</w>
ogen esis</w>
mer it</w>
istr ies</w>
d é
N ap
D ry</w>
Cau casus</w>
24. 4.
u ated</w>
share holding</w>
litig ation</w>
liter acy</w>
kar nar</w>
in her
gover n</w>
er i</w>
anti de
St ation</w>
un lawfully</w>
trac ing</w>
pe sts</w>
intensi fy</w>
in ch</w>
hear ings</w>
ag ers</w>
Tel ephone</w>
Col or</w>
val orem</w>
pay ee</w>
e ums</w>
cont ag
asth enia</w>
Tit anium</w>
S aul</w>
IR D</w>
Gu ang
D EP
12. 2007</w>
11. 2006</w>
p ale</w>
nec rosis</w>
merg ed</w>
hal ogenated</w>
galac tose</w>
Per u</w>
G ad
ve c</w>
he parin</w>
er ia</w>
P UBLIC</w>
Moham ed</w>
Al ph
6. 2006</w>
pharmac ology</w>
ol ig
mofe til</w>
li a</w>
graph ite</w>
P IC</w>
D at
C ut</w>
str ands</w>
sl o</w>
s ach
perpendic ular</w>
h unger</w>
con jug
classi fications</w>
ac ter</w>
Mari e</w>
K ab
F ab
2 76</w>
wh el
propriet or</w>
multipl ying</w>
kin esia</w>
es h
em ics</w>
derog ate</w>
Un known</w>
R AN
PE X</w>
Fac ebook</w>
F al
4 10</w>
0, 6</w>
unde res
un favourable</w>
ol en</w>
ligh ters</w>
f ill
f ant
dis infec
G MO</w>
D GE
B y
10 83</w>
urg ed</w>
r ata</w>
O PA</w>
Juris diction</w>
senten ced</w>
pancre as</w>
i o
dra in</w>
comm and
ci v
bi op
si veness</w>
parti ality</w>
ovol ta
inf eri
e Call</w>
d ing
allevi ate</w>
Pro m
CS R</w>
7 15</w>
3. 3.
w ings</w>
volunte ering</w>
reciproc ity</w>
ak i</w>
Sah el</w>
IMP LEMEN
38 46</w>
top otecan</w>
serv ers</w>
re active</w>
p p</w>
over capacity</w>
numer ical</w>
cycl ical</w>
arr ay</w>
Maur iti
Ma c</w>
MSC .
Crim ea</w>
2 R</w>
0, 8</w>
represent ati
pre mixtures</w>
popul arity</w>
or ubicin</w>
light ning</w>
carb ide</w>
aun a</w>
ater ally</w>
GO I</w>
EG NOS</w>
per su
fraud ulent</w>
flu ores
do s</w>
brea the</w>
altern atively</w>
R ue</w>
R ather</w>
J SC</w>
ES I</w>
Cy pri
1 100</w>
0, 4</w>
ten ant</w>
moder ately</w>
h ill</w>
d s
ansopraz ole</w>
ad one</w>
Wh oa</w>
R ent</w>
R U</w>
P AC</w>
M as
DES CRI
D or
Con gress</w>
z al
y y</w>
weak ened</w>
wavel ength</w>
si x
ser ological</w>
pain ts</w>
ot es</w>
k iss</w>
eth ics</w>
C up</w>
10 05</w>
utili ties</w>
tr ag
thrombo embolic</w>
re taining</w>
par aff
co ils</w>
Tob acco</w>
Euro pa</w>
CAR IFOR
refriger ated</w>
ne a</w>
ib ly</w>
hon or</w>
em ble</w>
den y</w>
charg eable</w>
T ou
x 1</w>
under took</w>
stud ying</w>
qu et</w>
go l</w>
domes ticus</w>
ch op
bl urred</w>
bathro om</w>
St ocks</w>
Isra eli</w>
Cath olic</w>
CARIFOR UM</w>
Blis ter</w>
AV ING</w>
9 5
trans fusion</w>
min ds</w>
m asses</w>
conserv ative</w>
comm its</w>
cat astroph
L V
Ö sterre
ili ans</w>
g ates</w>
dark ness</w>
bo arding</w>
Pot ential</w>
K ICs</w>
Fac tor</w>
EC LI</w>
C 2</w>
vari ants</w>
up set</w>
sp ine</w>
re con
loc k
fil aments</w>
comm issions</w>
cl ad</w>
Pro visional</w>
Moham med</w>
MEDI A</w>
Impro vement</w>
Em ail</w>
so ils</w>
sk eletal</w>
poly mer
longit ude</w>
g sk
er ate</w>
d board</w>
alk yl</w>
ain ts</w>
a str
O f
NE W</w>
ING S</w>
Commit ments</w>
3 23</w>
s ongs</w>
fal si
S LO
R og
M om
ATE G
12 54</w>
pertin ent</w>
m it</w>
en es</w>
bedro om</w>
bar ometer</w>
accompl ished</w>
U m</w>
Quanti ties</w>
P estic
par ad
dang ers</w>
arbitr ary</w>
Yar n</w>
Infec tions</w>
Fore stry</w>
EN CE</w>
D re
B 2</w>
6 62</w>
13 06</w>
un processed</w>
tri pl
re ared</w>
k ick</w>
dro mes</w>
corticost eroid</w>
M SD</w>
Ch ro
un ification</w>
pro gen
p ref
oph obia</w>
ip i
ey el
V b</w>
Net works</w>
Mac ro
ur on</w>
swim ming</w>
stead ily</w>
pro long</w>
mus cular</w>
fi a</w>
entr ants</w>
dis rup
dis counted</w>
deal ers</w>
bureaucr atic</w>
He at</w>
Back ground</w>
A er
4 43</w>
sign atory</w>
retino pathy</w>
inter views</w>
inter nation
ep hon
commen ted</w>
Z oledronic</w>
Th ough</w>
K hal
ri b
re jo
ici ency</w>
UNF CCC</w>
Pier re</w>
N ik
Mon aco</w>
Klaip ė
with stand</w>
t t
re forming</w>
et ers</w>
bal lo
author ises</w>
absor bing</w>
Stat utes</w>
Shi p</w>
N I
A 4</w>
3 61</w>
0 4.
st ere
short ness</w>
sh ame</w>
rel ying</w>
propri etary</w>
pep sia</w>
op ec
ol in</w>
food stuff</w>
co ke</w>
ar ching</w>
W id
Ob vi
EL EC
wel ding</w>
out lets</w>
olog ist</w>
lo gs</w>
di agram</w>
Re f</w>
vic inity</w>
nit ros
es cent</w>
co ck
ach ments</w>
J ack
Hol dings</w>
Braz ilian</w>
2 46</w>
α ρ
s iness</w>
rhyth m</w>
pu shed</w>
pancre atitis</w>
p om
et or
St ev
Meth ods</w>
Com prehensive</w>
9 8
3 9.
insul ins</w>
in o
in ates</w>
V ent
T Y
S atellite</w>
S AS</w>
Particip ant</w>
It ems</w>
Com pensation</w>
é n
pec ted</w>
il is</w>
enjo ying</w>
counter parts</w>
con genital</w>
as m</w>
R AG</w>
F IL
Dur um</w>
DEVELOP MENT</w>
CD 4</w>
Belgi ë</w>
BU DGE
receiv er</w>
receiv ables</w>
e sian</w>
S pir
Pos itive</w>
P ure</w>
MP a</w>
ES T</w>
ris en</w>
on ec
l ou
im migrant</w>
f ü
adi er</w>
H i
ED PS</w>
00 9</w>
0. 0</w>
leg acy</w>
el t</w>
disci ples</w>
Week ly</w>
Tunis ian</w>
R ULES</w>
An dro
4 62</w>
si rolimus</w>
res cu
pa ste</w>
in si
fo oting</w>
car case</w>
ac ept</w>
Trad itional</w>
Mi k
HIC P</w>
G ATION</w>
Exci pients</w>
Discus sion</w>
s aquinavir</w>
furn aces</w>
flav oured</w>
encephal opathy</w>
Th rough
Sol id</w>
D ic
Bi odi
w ay
h CG</w>
Volun tary</w>
S imp
S at
PRE Z
In ter</w>
18. 8.
re actors</w>
mod ulation</w>
inno cent</w>
igno red</w>
dis charges</w>
Z h
Terr or
Spec ific
Dom in
D ual</w>
C IS</w>
2 65</w>
under stands</w>
un foreseen</w>
remun erated</w>
fe athers</w>
ar sen
access ed</w>
abol ic</w>
IT AL
F light</w>
Ac tually</w>
tr usted</w>
es ity</w>
construc t</w>
bru ising</w>
SE T</w>
Renew able</w>
Fil ter</w>
Di agn
Democr acy</w>
и т
z on
spe eches</w>
l on</w>
l is</w>
coun ty</w>
air ing</w>
ac oustic</w>
Neg oti
H AVING</w>
B our
veri fiable</w>
st ell
restrain ts</w>
reli ance</w>
opor osis</w>
n n
keto acidosis</w>
develop mental</w>
ambi tions</w>
S ter
H .</w>
st eroidal</w>
s porting</w>
port ation</w>
op y
l uminous</w>
intr insic</w>
helicop ters</w>
deal er</w>
R ash</w>
D ES</w>
00 0
wheel chair</w>
u i</w>
s lip
collec tions</w>
bo y
S cre
w ished</w>
resum ed</w>
re integration</w>
gen otoxicity</w>
bro ch
3. 10</w>
3 42</w>
x en
sil ence</w>
cont amin
abol ish</w>
Ur antia</w>
Mean while</w>
C K</w>
á n</w>
path ogens</w>
ho sts</w>
f ic
cong estive</w>
anonym ous</w>
ab le
Weap ons</w>
S ports</w>
PREZ ISTA</w>
A partment</w>
12 25</w>
y ear
radi olab
k on
dis agreement</w>
bureaucr acy</w>
ac t
Ver de</w>
Standardis ation</w>
Pur pose</w>
L oss</w>
Chan nel</w>
vi done</w>
un accompanied</w>
pr ayer</w>
phot ographic</w>
opa que</w>
d as
Qu es
P er</w>
4 09</w>
2 B</w>
1. 12</w>
1, 6</w>
ti sed</w>
neuro logical</w>
motiv ation</w>
exci ting</w>
el ly</w>
be fore
Trans actions</w>
Pro gram</w>
K and
E specially</w>
Di ab
B acillus</w>
ç ão</w>
x a</w>
vill ages</w>
presid ents</w>
mechan ically</w>
feeding stuff</w>
dor f</w>
an al</w>
Repe al</w>
Associ ated</w>
repos itories</w>
j am
id in</w>
fil lets</w>
du de</w>
defec tive</w>
brack ets</w>
Under tak
Techn i
Sp .</w>
Opportun ities</w>
M D
11. 2009</w>
motor cycles</w>
extre mis
esk á</w>
diam onds</w>
di hydro</w>
an ore
acc ord</w>
S l
Jud icial</w>
s atellites</w>
iz oph
inter connected</w>
gall ery</w>
centur ies</w>
acknowledg ement</w>
Pen sion</w>
Eth ics</w>
oc ity</w>
amm able</w>
T W
u pri
squ ee
so ya</w>
scre ens</w>
reimbur se</w>
pres ses</w>
perform ers</w>
p h</w>
lymph atic</w>
f ought</w>
ail ing</w>
Re b
AT 1</w>
AN CES</w>
2 77</w>
u sh
u plo
st ered</w>
lis tic</w>
e ur</w>
civ ilians</w>
ar om
acetyl salicylic</w>
S n
0. 75</w>
- 1</w>
out lines</w>
os ex
o tives</w>
bro k
ar ma
TA X
S ea
R é
OB JEC
N ON</w>
MARKE T</w>
I d
Addres sees</w>
2 74</w>
0 20</w>
tri be</w>
provin ces</w>
j er
consequ ent</w>
clu ster</w>
behavi or</w>
ari ous</w>
ab brevi
War saw</w>
U z
s can</w>
ro v
no des</w>
kilo gram</w>
in er</w>
end anger</w>
commission ed</w>
c ture</w>
as surances</w>
Tall inn</w>
Rev ol
Con s
AC TION</w>
ut ors</w>
sec tor
or ously</w>
mon oxide</w>
hydr ates</w>
hop s</w>
f et
dis ul
des loratadine</w>
convers ation</w>
comp elling</w>
accru ing</w>
Through out</w>
T OR
I. 1</w>
ulc ers</w>
st ery</w>
ost atic</w>
ol o</w>
l p</w>
instal ment</w>
comple ments</w>
Stri ke</w>
QT c</w>
Latvi ja</w>
IN ARY</w>
Euro barometer</w>
EE N</w>
11 th</w>
z ers</w>
wi res</w>
le av
induc ers</w>
conve y
Bas eline</w>
B T
the atre</w>
over whel
nigh t
inc ur</w>
dis regarded</w>
cu sh
Vac uum</w>
Up per</w>
Reser ve</w>
Por tal</w>
N. B.</w>
EU CAP</w>
rati tes</w>
peri od
dec eleration</w>
P SF</w>
s land</w>
od ine</w>
distil led</w>
dissem inating</w>
def ending</w>
carcin oma</w>
Por t
Cali for
. Article</w>
weigh s</w>
vir ine</w>
mel ting</w>
li ximab</w>
for fe
b old</w>
acquain ted</w>
Te ach
COMM UN
Bel i
31.12. 2007</w>
3 82</w>
1 20
sw allow</w>
on as</w>
int ers</w>
hydrogen ated</w>
compet encies</w>
am ol</w>
all er</w>
H Y
Co E</w>
4 07</w>
radi ological</w>
g est
duc ks</w>
atten ding</w>
Rec ord</w>
Elim ination</w>
COM PE
3 46</w>
emul sion</w>
chro mat
au to</w>
In flu
I b
15 01</w>
pur se</w>
par as
dg ed</w>
dec ree</w>
d ac
comb ines</w>
Pro tocols</w>
3 64</w>
s 2</w>
rab bit</w>
hypothe tical</w>
dipl omas</w>
descri p
With draw
C ell</w>
tic k</w>
phr ases</w>
o economic</w>
met adata</w>
le tin</w>
id ad</w>
es cap
D ul
AST M</w>
19. 10.
19 57</w>
14 0
prof ound</w>
ovolta ic</w>
op ia</w>
keep er</w>
god damn</w>
commen ced</w>
ch at</w>
br ands</w>
anis ed</w>
TH IRD</w>
Rasi lez</w>
J im</w>
w icked</w>
smo oth
re t</w>
pic ked</w>
deliber ately</w>
appro x</w>
S ee
Reg la
P B
Certif icates</w>
19 61</w>
oblig or</w>
in trad
fu elled</w>
cytotox ic</w>
cor k</w>
ag h
S ite</w>
M S
Compon ent</w>
5 52</w>
4. 3.
2 C
0, 25</w>
wal ked</w>
tes ti
l end</w>
hu b</w>
fav or</w>
contr av
cap tured</w>
St ep
RE COM
EN I
Chris tians</w>
re produced</w>
ex tru
continu ally</w>
borrow er</w>
trans atlantic</w>
sequ ent</w>
mo on</w>
lik es</w>
ephon y</w>
at ed
Z al
ter al</w>
spec tac
sen sible</w>
mobil ising</w>
mil lim
loo dy</w>
gol den</w>
eth oxy</w>
dist ant</w>
bu cks</w>
bri gh
bow el</w>
as ph
ar able</w>
an ed</w>
TRAN SP
NE T</w>
Mil an</w>
M AT
BA L
B le
6 80</w>
libr aries</w>
clou dy</w>
ch ur
ch ari
br ady
Mot or
G F
For mul
CYP 3A</w>
4 80</w>
re tro</w>
re formed</w>
p ha
ins ist</w>
erc ept</w>
agglomer ated</w>
Con tains</w>
AL DE</w>
4. 2.1</w>
27 71</w>
re mot
im partiality</w>
fa una</w>
d og
cre ature</w>
be sides</w>
anore xia</w>
Win dow</w>
Res ol
Mauriti us</w>
Dani el</w>
B ill</w>
5 74</w>
w agon</w>
ri pen
over compensation</w>
ov ed</w>
ij ing</w>
co st
al og
Inter fer
D 2</w>
8 47</w>
triglycer ides</w>
ol len</w>
myel oma</w>
envis ages</w>
ad ers</w>
Veget ables</w>
US B</w>
UN DER</w>
TM Z</w>
Lab elling</w>
L .
KO GEN
KOGEN ATE</w>
re producing</w>
k es
ju ices</w>
deduc t</w>
X VII</w>
UN DS</w>
Tw enty</w>
Requi red</w>
Person nel</w>
P ra
Oblig ations</w>
EC J</w>
6. 2009</w>
5 .</w>
vac ancies</w>
mut ag
lo vers</w>
her o</w>
diox ins</w>
ang el</w>
S AM
Ro om</w>
were n</w>
sp an</w>
pur ified</w>
or b
fortun ate</w>
cab bage</w>
DESCRI PTION</w>
Be ijing</w>
A bo
per ing</w>
ord er
ni ghts</w>
foun ding</w>
ex am</w>
cin ema</w>
ass ist
aren a</w>
Repe at</w>
OF FIC
Indic ate</w>
EM CD
D CA</w>
B M</w>
7. 7</w>
0 5.
m am
contro versi
ben ch</w>
ar c</w>
ang es</w>
ad hesion</w>
Res istance</w>
Rec e
P oul
IS T</w>
ES TAB
traw ls</w>
thor acic</w>
ten sions</w>
pro vo
mid azolam</w>
j ob
cop es</w>
ap l
Z enti
Undertak ings</w>
Sub sequent</w>
Lim it</w>
Bran ch</w>
13 07</w>
th ec
s pro
ra d</w>
cal ves</w>
agre eing</w>
MO D
H ard</w>
Cap sule</w>
univer ses</w>
un ambig
sau ce</w>
p regabalin</w>
expres sions</w>
dis appeared</w>
SP S</w>
P aren
L AG
Ø Ø
tr ust
sugg estion</w>
stimul us</w>
rep itant</w>
peg ylated</w>
on ions</w>
in er
dys pnoea</w>
cul p
ap repitant</w>
Zenti va</w>
TN F</w>
Reb if</w>
N 2</w>
9 000</w>
8 54</w>
p ali
mush rooms</w>
it rac
isc u
fron tiers</w>
epilep tic</w>
deser ves</w>
c af
asy mp
appro aching</w>
a erial</w>
L um
Contin u
Compar ison</w>
BLIS TERS</w>
Au th
sub jec
str aw
p one</w>
mil ls</w>
irrig ation</w>
gradu ate</w>
co atings</w>
SNC M</w>
P neum
Org an</w>
N ep
Mee tings</w>
G a
Exam ination</w>
D ried</w>
D B</w>
9. 30</w>
9 52</w>
p airs</w>
occurren ces</w>
im itation</w>
hab its</w>
gran ul
es si
dro g
breast feeding</w>
Her it
F arm
Em ir
Bo ok
wh oles
viro logical</w>
underp inning</w>
scr ap
mer ck
man dated</w>
k om
in age</w>
ic us</w>
fif ty</w>
dox orubicin</w>
distil late</w>
coordin ators</w>
Ter m</w>
B ou
z i</w>
ulc er</w>
sach et</w>
ref u
pl atinum</w>
optim isation</w>
om it</w>
o -</w>
locom otives</w>
li er</w>
flav our</w>
cab otage</w>
believ ers</w>
b ounded</w>
Th ou</w>
R U
MANAG EMENT</w>
H V
Dimen sions</w>
Conven tions</w>
ά δ
º C</w>
tin gling</w>
sen ds</w>
ow ski</w>
enh ances</w>
dy stro
drow siness</w>
allow able</w>
Cit rus</w>
8 34</w>
un ded</w>
presid ential</w>
it an</w>
insul ated</w>
haem ophilia</w>
h r
furn ace</w>
for t</w>
T ac
Sie mens</w>
produ k
electroly te</w>
d ene</w>
cultiv ated</w>
character isation</w>
ati sed</w>
UNI TED</w>
Pro vin
P ai</w>
Mob il
Hydro gen</w>
Horiz ontal</w>
E K</w>
C K
Arrang ements</w>
12. 2009</w>
slic ed</w>
o ats</w>
kn ives</w>
even ly</w>
Wor d</w>
Rel i
Ligh t
Indon esian</w>
Herit age</w>
with holding</w>
re mark</w>
prohib its</w>
o il
li de</w>
gradu ates</w>
evol ved</w>
eth an
dis charging</w>
dehydr ation</w>
carbon yl</w>
an ten
al together</w>
ag itation</w>
Therap y</w>
Sur face</w>
MAN Y</w>
EM FF</w>
Abo ve</w>
2 20
w ich</w>
sup pose</w>
se ab
it ch</w>
isch aemic</w>
h ome
claim ant</w>
ar b</w>
Tub es</w>
Sh rimp</w>
Rec re
RES UL
PC C</w>
Obvi ously</w>
Doc tor</w>
Der iv
3 34</w>
thr ust</w>
incorpor ates</w>
ge on</w>
Sh all</w>
Rep ub
Audi o</w>
Adap tation</w>
ANIM AL</w>
A round</w>
wh is
un satisfactory</w>
seaf ood</w>
re vi
is ten
deb ated</w>
amb ul
Un like</w>
P H</w>
H ost</w>
Ac coun
vis cos
und ice</w>
un avoidable</w>
re sh
omy ces</w>
old est</w>
no tional</w>
main stream</w>
elap sed</w>
distribu ting</w>
dis mis
S A.
Pro hibitions</w>
P I
Or din
M IL
Califor nia</w>
6. 2.
4 06</w>
immun oglob
extrap ol
dis infection</w>
Z i
H ap
H .
G SM</w>
ych elles</w>
st olen</w>
s ound
over arching</w>
fuc ker</w>
distr icts</w>
d well</w>
appren tic
app arel</w>
alcohol s</w>
ag ne</w>
V an
Pol y</w>
NR TIs</w>
EMCD DA</w>
Consider ation</w>
8. 6</w>
7 09</w>
sw allowing</w>
ren t
qu o</w>
pr one</w>
op tic</w>
ock ets</w>
li um</w>
fai thful</w>
f lip</w>
em ails</w>
electr ically</w>
eb er
ar dian</w>
R it
Me di
Cal cul
4. 10</w>
unanim ous</w>
umb ered</w>
tol it
co ol
anticip ate</w>
al an</w>
Se ychelles</w>
HD PE</w>
3 80</w>
ó w</w>
wor t</w>
un founded</w>
st eroid</w>
non -</w>
inev itably</w>
gu ides</w>
gi form</w>
SYSTE M</w>
S EPA</w>
R ac
Pro g
Ex hibition</w>
ESTAB LISH
Com pared</w>
re vir</w>
persec ution</w>
fuc kin</w>
comit ology</w>
bench marking</w>
activis ts</w>
SES AR</w>
Head ache</w>
Dum ping</w>
An aa</w>
your selves</w>
spr ings</w>
spec ul
out weigh</w>
opec ia</w>
avi er</w>
SO CI
L ength</w>
Ku en</w>
4 13</w>
2 H</w>
post pone</w>
n av
k u</w>
int entional</w>
ik i</w>
dimin ished</w>
br a</w>
bi le</w>
R elig
Mach ine</w>
Investig ations</w>
test osterone</w>
t osis</w>
o esoph
interpre ting</w>
in y</w>
im as</w>
disc overy</w>
cy ber
clos est</w>
Ser nam</w>
M and
EX PO
Österre ich</w>
the ft</w>
t elecommunication</w>
acce de</w>
St ars</w>
P ip
Heal thcare</w>
Bi ological</w>
AT S</w>
κ α
to oth</w>
sch aft</w>
cler osis</w>
cap ecitabine</w>
ast er
ad otro
absten tion</w>
REN CE</w>
In vol
E ither</w>
&apos; s
os in
discrepan cies</w>
deterior ated</w>
cust odi
commen sur
atten dance</w>
assess es</w>
ar box
Veget able</w>
TRAN SI
Sub sequently</w>
Shi ps</w>
Out put</w>
Jew ish</w>
D ang
CERTI FIC
C off
4 11</w>
sh am
read able</w>
oblig e</w>
n autical</w>
enrich ed</w>
ac il</w>
IN STITU
En erg
10 06</w>
soci oeconomic</w>
rememb ered</w>
redund ancies</w>
os ensi
im minent</w>
deple tion</w>
crimin als</w>
collis ion</w>
Direc tive
D T</w>
A w
19 60</w>
si ans</w>
grass land</w>
conver ters</w>
as ym
19. 8.
v entricular</w>
rock et</w>
respon ds</w>
ec tive</w>
associ ates</w>
X i
TI C</w>
Sal v
G RE
Fac tors</w>
Emir ates</w>
EFFEC TIVE</w>
CO P</w>
1. 2001</w>
ga stro</w>
an rix</w>
Pharmac ovigilance</w>
PE S</w>
P od
Hyp ogly
Cam bo
t adalafil</w>
stoc king</w>
hec tolit
deep ening</w>
condem n</w>
at y
SU PP
N il
oc eans</w>
flu ticasone</w>
eros ion</w>
discrim inate</w>
col o
al ers</w>
S ax
M UL
F arm</w>
4 3
y clic</w>
w ol
un conditional</w>
prob able</w>
lique fied</w>
hierarch y</w>
cr ash</w>
c et
att ered</w>
al c
Wo oden</w>
R w
N avi
F os
Ag ent</w>
6. 2008</w>
viscos ity</w>
tum or</w>
surroun ded</w>
relap se</w>
me try</w>
concer ts</w>
Sard inia</w>
PR O</w>
Neu pro</w>
Ma p</w>
4 26</w>
tri ple</w>
ten th</w>
rac ial</w>
phosph at
orig ins</w>
newsp aper</w>
im e
fluor inated</w>
cere bro
S it</w>
Po sted</w>
M U
M MF</w>
Jo b</w>
C ities</w>
Ar tif
no ting</w>
interpre t</w>
ef ruit</w>
dar unavir</w>
Trans f
L GD</w>
K ir
GER MANY</w>
Explan atory</w>
EP O</w>
B lo
B inding</w>
in ium</w>
consul tant</w>
compens ating</w>
Jo in</w>
Inclu sion</w>
D river</w>
Cypri ot</w>
4 96</w>
100 6
securiti sed</w>
prote in
privileg ed</w>
pig lets</w>
iz ations</w>
fluor ide</w>
eigh th</w>
dystro phy</w>
dipl om
alleg ations</w>
J as
Entrepreneur ship</w>
EL S</w>
C ATEG
3 85</w>
vas cul
upri ght</w>
speci alisation</w>
shel ter</w>
p to
on itrile</w>
nur sing</w>
dom inated</w>
ad here</w>
V ill
TR Y</w>
R ose</w>
P N</w>
HEX AL</w>
8 06</w>
pir a</w>
ni k</w>
ge ological</w>
col on
atic al</w>
a har</w>
Venezu ela</w>
Tu be</w>
Gen otype</w>
Ale x</w>
9 9,
200 7
suspen sions</w>
slaughter houses</w>
re ar
qu or
mortg ages</w>
in vi
exhib it</w>
cos metics</w>
ap olog
afen ib</w>
Ky r
K a
C ML</w>
st ems</w>
o is</w>
man ned</w>
f our
dis appointed</w>
detec tor</w>
boo sted</w>
Occup ational</w>
C ry
4 60</w>
2 86</w>
tri angle</w>
trans missible</w>
pen is</w>
m eg
i ary</w>
hi a</w>
deb tors</w>
X L</w>
W A</w>
Hel sin
Dri ve</w>
yy yy</w>
ur ring</w>
te enth</w>
pre amble</w>
mu cos
form ers</w>
enfor cing</w>
deterior ate</w>
confron ted</w>
bur ied</w>
b oring</w>
T in</w>
T ON
N ag
H L</w>
Foot wear</w>
- 2-</w>
te ar</w>
sli p</w>
shir ts</w>
per g
invo icing</w>
fur an</w>
dem anded</w>
conv ince</w>
conv iction</w>
canc ers</w>
TECHN ICAL</w>
As signed</w>
AC S</w>
- No</w>
withdraw als</w>
shif ting</w>
pr a</w>
per it
for ums</w>
et ta</w>
e j</w>
cap ped</w>
appell ant</w>
ad i</w>
RA PEX</w>
MEN D</w>
Langu ages</w>
C N
5. 3.
20 92</w>
sli de</w>
ro pe</w>
raj ono</w>
confl ic
advis ers</w>
Mon t
Herc ep
Clos ed</w>
B R</w>
ren in</w>
phot ometric</w>
pe a</w>
ore r</w>
leng thy</w>
k ets</w>
h t</w>
err al</w>
busin ess
bru shes</w>
bio fuel</w>
b og
al ize</w>
ac ies</w>
E A
B ee
6 03</w>
y east</w>
val ley</w>
transf ere
maxim al</w>
hosp it
evi čius</w>
doub led</w>
diure tic</w>
dil u
decor ative</w>
adoles cent</w>
Op tical</w>
EN D</w>
E mp
y k
nor ms</w>
hyp o</w>
eng ers</w>
al titude</w>
Hercep tin</w>
Americ ans</w>
2. 10</w>
revis ing</w>
pra ise</w>
pi ano</w>
iv a</w>
handic aps</w>
do dec
S ew
6 76</w>
10 60</w>
valpro ate</w>
v in</w>
sten osis</w>
sch izoph
ro tary</w>
res is</w>
outw ard</w>
od il
mang anese</w>
ferro us</w>
dr ical</w>
Syst emic</w>
Lif elong</w>
J an
Ger man
Ac ts</w>
A eri
5 15</w>
25 000</w>
pa sta</w>
p ou
ox icam</w>
on t
men tions</w>
h ind
equi voc
ent e</w>
discre tionary</w>
cont ex
amen ds</w>
Sub part</w>
S in
Refuge e</w>
PV DC</w>
L IN
J ans
Im prove</w>
IMP OR
F ast</w>
Addi tive</w>
weak er</w>
vic tory</w>
vel ocity</w>
s ins</w>
remark able</w>
re ts</w>
neutr alising</w>
mon ies</w>
int act</w>
ge ometric</w>
eco design</w>
controversi al</w>
Novo Mix</w>
IN N
zz les</w>
up pers</w>
ti trated</w>
ship yards</w>
preserv ative</w>
oste oporosis</w>
asymp tomatic</w>
arb ital</w>
Volun te
LT0000 12
Gro und</w>
EC G</w>
. LT</w>
t all</w>
pul led</w>
lear nt</w>
h en</w>
expl oring</w>
ent ac
dom ic
de part</w>
commen cing</w>
at om
Withdraw al</w>
Ves sel</w>
U g
SE B</w>
S AA</w>
Helsin ki</w>
F em
F IX</w>
200 000</w>
stat eless</w>
s tick
m ount</w>
m ess</w>
lo vely</w>
floo ding</w>
cop s</w>
calibr ated</w>
but tons</w>
alumin um</w>
Ser um</w>
S US
Provi ded</w>
Mu ch</w>
tu bing</w>
explos ion</w>
ang els</w>
Vlad im
Rati o</w>
GO ODS</w>
Fil grastim</w>
w ir
vertebr ates</w>
renew ing</w>
ov es</w>
interfer ons</w>
g od</w>
ev apor
endoc rine</w>
dis ru
deg en
commensur ate</w>
architec tural</w>
T MS</w>
Sh or
J .
F at</w>
Docu mentation</w>
C LO
Bo ards</w>
wil d
tou ched</w>
ome tre</w>
mom ents</w>
engine ers</w>
e tins</w>
Lo ad</w>
D IS</w>
u ci
te dness</w>
po ts</w>
no te
co ded</w>
back up</w>
as tigmine</w>
M az
IF P</w>
Go od
Gli vec</w>
CE F</w>
4. 0</w>
su ng</w>
str ained</w>
reiter ate</w>
imp utable</w>
hap p
fil tering</w>
expec tation</w>
bal listic</w>
PR IN
N ight</w>
Kand ahar</w>
C losing</w>
12 57</w>
v ested</w>
s u</w>
s at
s ar
reservo ir</w>
recon cile</w>
pr ag
invi ting</w>
f ears</w>
augh ters</w>
Consolid ated</w>
CV MP</w>
C art
Aqu aculture</w>
stream line</w>
so l</w>
salv ation</w>
refrig eration</w>
minim ising</w>
meth y
itrac onazole</w>
gu an
fon daparinux</w>
b are</w>
an hydri
ab normally</w>
Part ner</w>
Mich el</w>
Bru x
v ines</w>
la m</w>
l est</w>
g lim
e o</w>
cou ples</w>
confer ring</w>
bi os
Qu een</w>
Cent res</w>
Aar on</w>
registr ations</w>
os a</w>
naph th
log ging</w>
ev ich</w>
comprehen sible</w>
che eses</w>
centr ally</w>
an omal
an gry</w>
ai ded</w>
Riv astigmine</w>
Maurit ania</w>
Deleg ations</w>
о в
wel ded</w>
tor ney</w>
top s</w>
ph ased</w>
on ates</w>
mo tions</w>
mag n
ON LY</w>
IC A</w>
CON SI
AD A</w>
5 25</w>
0 8.
wi k
u ality</w>
tal e</w>
ser ot
over riding</w>
fl ur
bul k
bol us</w>
ann er</w>
O xy
Estim ated</w>
1. 8.
tion nai
gmin y</w>
form ulations</w>
appro ves</w>
al o</w>
Tem per
S ons</w>
O y</w>
DEFINI TIONS</w>
3 0000</w>
10 11</w>
un intended</w>
ten sile</w>
ster il
sleep iness</w>
r hin
out sourcing</w>
os tic</w>
is ate</w>
in forms</w>
develop ers</w>
commer ci
ast at</w>
VE TER
Uz be
Usu ally</w>
Sur vi
S ole</w>
Ordin ance</w>
OR IG
Liber ia</w>
E mil
su r</w>
st ayed</w>
r as
priv ately</w>
po on</w>
n aked</w>
figh ters</w>
f is
expec ting</w>
el ast
convul sions</w>
cit ric</w>
character ized</w>
Repres entation</w>
Kyr gy
IN TRO
EN T
Dar fur</w>
Am mon
Ac et
ATE S</w>
7. 6</w>
terror ists</w>
re locate</w>
hop ed</w>
adv enture</w>
ab an</w>
Saf egu
P ep
Acc es
A MEND
6. 2014</w>
Ε λλ
ys ed</w>
v s.</w>
un suitable</w>
un reasonable</w>
shir t</w>
ophy l
li m</w>
in accurate</w>
formul ate</w>
d are</w>
clari fies</w>
ch y</w>
S end</w>
IN CLU
Dang erous</w>
CIP AC</w>
A rena</w>
9. 4</w>
z ol
si les</w>
rec k
preci pit
p ads</w>
lev etiracetam</w>
inf il
distor ting</w>
as part
antipsycho tic</w>
Po ste</w>
Manu el</w>
Col our</w>
C EC
B ible</w>
An gi
righte ous</w>
investig ative</w>
helicop ter</w>
acr yl
Voc ational</w>
Th ematic</w>
Su omi</w>
Rol ling</w>
OLO GICAL</w>
E B</w>
Correc tion</w>
C NG</w>
6 60</w>
24.12. 1994</w>
tur tle</w>
termin ating</w>
par ath
i ae</w>
acqui rer</w>
Produc ers</w>
O L</w>
G ES</w>
CONTRO L</w>
Ab sorption</w>
rec tified</w>
r ye</w>
prot amine</w>
ong shan</w>
len alidomide</w>
gener ase</w>
N av
Disp ute</w>
Char lie</w>
Al ert</w>
A generase</w>
4 52</w>
17 ,
13 00</w>
è s</w>
weigh tings</w>
shar k</w>
os in</w>
lux ury</w>
insul a</w>
inser tion</w>
in deb
decis ion
cr ack
contain ment</w>
bri dges</w>
ari us</w>
Ess ential</w>
ER TMS</w>
Creat or</w>
Artif icial</w>
0. 01</w>
weak en</w>
or ds</w>
od al</w>
my algia</w>
low ered</w>
ing estion</w>
im partial</w>
h ept
fuc ked</w>
am ph
Lib yan</w>
E ther
Ce uta</w>
z y</w>
qu ad
prof iciency</w>
lis tened</w>
lifest yle</w>
li t</w>
her bs</w>
det ained</w>
br o</w>
Z on
S. A</w>
P ainting</w>
M ang
Ade qu
16 06</w>
&apos; am</w>
writ er</w>
hydro carbon</w>
dr unk</w>
cor ners</w>
comp ile</w>
c ute</w>
buty rate</w>
aut ologous</w>
Sloven ská</w>
Mix ed</w>
Interpre tation</w>
D eg
2, 0</w>
min istry</w>
kno ck</w>
fibro us</w>
end points</w>
edi c</w>
depu ty</w>
cop ying</w>
chi p</w>
IN F
E ight</w>
Ch alleng
Bang lad
Al ice</w>
uph eld</w>
tor ates</w>
spon giform</w>
purchas ers</w>
f lowing</w>
as p</w>
ar is</w>
Z YP
TAR Y</w>
PP Ps</w>
G od
AL E</w>
AD C</w>
1. 6.
w axes</w>
t ard</w>
sub group</w>
gri p</w>
col itis</w>
biog as</w>
Thro mb
Klaipė da</w>
Hur ry</w>
Expos ures</w>
C ept</w>
with drew</w>
wind screen</w>
wh iting</w>
post natal</w>
lit ter</w>
lis ed</w>
erad icate</w>
entac apone</w>
de position</w>
con currently</w>
attem pting</w>
ari o</w>
Cot ton</w>
A PE
10 a</w>
tung sten</w>
tr aphane</w>
th ence</w>
sulf ate</w>
si ves</w>
rimon ial</w>
power ment</w>
interpre tations</w>
halluc inations</w>
char coal</w>
b ell</w>
Mess age</w>
Intel ligent</w>
G 3</w>
Ac traphane</w>
A ero
6 a</w>
1 B</w>
trans verse</w>
l ansoprazole</w>
expec tancy</w>
der ma</w>
att aches</w>
art et</w>
SC A</w>
PR E</w>
P DF</w>
un regulated</w>
sor bitol</w>
oc yan
fo ol</w>
fir ing</w>
attrac ted</w>
ap ps</w>
Nor th
H N</w>
D uty</w>
A eg
5 05</w>
tion s
n els</w>
fin avir</w>
ess a</w>
diversi fied</w>
b iscu
all as</w>
Ver tical</w>
Reduc ing</w>
Mel illa</w>
Lac tose</w>
Cell Cept</w>
προ ς</w>
wrong ly</w>
u ximab</w>
oz ol
os i
n iv
legisl ators</w>
ke en</w>
ing s
gri ds</w>
et ables</w>
equ als</w>
earthqu ake</w>
commit ting</w>
carbo hydrate</w>
Sloven ija</w>
M IT
Hypogly caemia</w>
F D</w>
Edi tion</w>
10 3
train ers</w>
tradem arks</w>
ous ing</w>
htt ps</w>
har ness</w>
co bal
bun ch</w>
aer obic</w>
Y ears</w>
W E</w>
Prof itability</w>
Fig ures</w>
E SC</w>
sel ls</w>
receiv ers</w>
real ized</w>
firm ation</w>
bi otechnology</w>
ane di
all urg
ai tis</w>
addi tionally</w>
SO CIAL</w>
Res erv
Ph osph
Inter vention</w>
Gr and
5 33</w>
ph ine</w>
gr adi
gir l
en dr
avi a</w>
anti d
Ques tionnai
B ad</w>
AM A</w>
9. 2003</w>
ylox y</w>
q i</w>
pro state</w>
manif estly</w>
inev itable</w>
ev al</w>
K n
Inter operability</w>
F armac
F AR
5, 5</w>
2. 3.
tr il
le u
iz er</w>
in del
et sk</w>
cov enant</w>
con den
br icks</w>
ap o</w>
Supervis ion</w>
De signed</w>
Bal tic
Ah med</w>
3 93</w>
10. 2007</w>
y m</w>
sel lers</w>
rever sed</w>
k is
er mal</w>
enqui ries</w>
c ow
bin ds</w>
SP E</w>
Respon sibility</w>
P overty</w>
M ail</w>
IN DU
Cle arly</w>
CI P</w>
uni vers
ub bing</w>
pal p
en counter</w>
el ab
du es</w>
condi tioned</w>
benz odi
bad ly</w>
as leep</w>
War ning</w>
To k
Spec ify</w>
Mix tard</w>
L ater</w>
Ax is</w>
Any one</w>
6 16</w>
3 79</w>
con ceived</w>
burden some</w>
Ter minal</w>
P ain</w>
I de
G il
Derog ations</w>
wil derness</w>
thyro idism</w>
so oner</w>
min d
ir con
inten ding</w>
ic y</w>
i ency</w>
detec tors</w>
ar isen</w>
N AL</w>
t aneously</w>
rh initis</w>
ja undice</w>
inter connections</w>
Psy chiatric</w>
Di arrhoea</w>
Def ault</w>
Appe als</w>
volunte er</w>
tor so</w>
k V</w>
immunosup pressive</w>
celebr ate</w>
carbox ylate</w>
ai d
TI F</w>
SAF E</w>
P ens</w>
Lab el</w>
Is n</w>
G os
A us
A g</w>
expendit ures</w>
cycl ing</w>
ben ign</w>
V ial</w>
Recon struction</w>
P ush</w>
Nig er</w>
MB ERS</w>
FR A
Euro s</w>
Au to
3 26</w>
tail or</w>
li tis</w>
l j
j azz</w>
fores ee</w>
ca kes</w>
c g</w>
Y ou
STRU CT
R ay</w>
M IP</w>
K om
E cu
1. 2003</w>
ilit y
h is
graz ing</w>
dra g</w>
condem ned</w>
anaphy laxis</w>
anal ogy</w>
PL C</w>
Mus cle</w>
IS PA</w>
E Y</w>
Direc tory</w>
C alls</w>
C B
C AS
4 37</w>
st av
retro active</w>
rep airing</w>
log y</w>
l amb
in significant</w>
be e</w>
an ase</w>
ak ers</w>
W ING</w>
Ne uro
K wik
H us
Ex tra</w>
z ide</w>
phot ovoltaic</w>
p per</w>
o in</w>
mis siles</w>
conv ey</w>
TEN T</w>
L Y
Brux elles</w>
Ad ri
4. 2.2</w>
0. 05</w>
t ach
sh ine</w>
p ut
ox in</w>
n ail</w>
l ery</w>
e ment
ch ills</w>
bas ket</w>
auto immune</w>
ascer tained</w>
ang ular</w>
P S
Formul a</w>
D evelop</w>
Cy cle</w>
z n
flo ors</w>
evid enced</w>
differenti ate</w>
Tr ic
L aun
G au
Con tr
p act</w>
on ess</w>
ob esity</w>
lig ibility</w>
la kes</w>
hamp er</w>
gu ideline</w>
consisten cies</w>
cav ity</w>
Syn thetic</w>
S í
CI s</w>
AI R
up graded</w>
pers ists</w>
pedestri an</w>
n es</w>
mon o</w>
micro crystalline</w>
mat rimonial</w>
enjo ys</w>
a v</w>
15 ,
thiaz ide</w>
sh elled</w>
og g
incid ental</w>
gr ad</w>
fü r</w>
bival ve</w>
G ri
Ch ambers</w>
AF T</w>
24.12. 1987</w>
s enti
rel uc
pre condition</w>
ist ors</w>
ho ods</w>
haemorrh agic</w>
fai rer</w>
es z
e to</w>
am id</w>
am bo
Pro b
L em
Inclu des</w>
tr ate</w>
re aring</w>
pil ots</w>
on is</w>
mutag enic</w>
f asc
draf ts</w>
diam ond</w>
c amps</w>
att aching</w>
Nom inal</w>
GROU P</w>
Di pl
D M</w>
1. 2005</w>
we ed</w>
tel ephony</w>
ro t</w>
insu rer</w>
hi red</w>
for ty</w>
ar in</w>
amet ers</w>
Uni form</w>
Nu tri
Ne ed</w>
Man datory</w>
y b
t ch</w>
ozol omide</w>
colour ation</w>
S c
Du de</w>
AL SO</w>
4 27</w>
19 54</w>
vo ices</w>
spr aying</w>
pro xy</w>
plu g</w>
nutri ent</w>
l oud</w>
l ava</w>
glu co
g ang</w>
diver gent</w>
contamin ants</w>
chop ped</w>
anch orage</w>
Y MENT</w>
Land es
7. 9.
- Yeah</w>
yach ts</w>
tot y
ten nis</w>
sti g
sen sing</w>
oxid ase</w>
over coming</w>
kil ometre</w>
immun isation</w>
i ai</w>
hol istic</w>
encomp ass</w>
benz o</w>
REP OR
M ethyl
F entanyl</w>
Establish ing</w>
E dit</w>
De ath</w>
C M
Amen ded</w>
12 44</w>
.e u.int</w>
u a</w>
tom ato</w>
t less</w>
ri dic
repe als</w>
rac ism</w>
ra k
pep pers</w>
orig inated</w>
od ds</w>
illum ination</w>
TA IN
P av
ύ προς</w>
y ou
ro c
propag ation</w>
pi per
gl ands</w>
carbo hydrates</w>
al on
al ition</w>
Y S</w>
Techn ological</w>
PE R</w>
Gol den</w>
But ter</w>
5 17</w>
0.00 01</w>
u zumab</w>
tin ic</w>
preserv atives</w>
one al</w>
la sted</w>
counter part</w>
col loidal</w>
ano ate</w>
U sers</w>
Qu ick</w>
He ating</w>
G ases</w>
Audi ovisual</w>
8. 2008</w>
3 39</w>
stream lined</w>
sh ocks</w>
pregn ancies</w>
phot ography</w>
leth al</w>
le ak</w>
for cing</w>
aw a</w>
ab stained</w>
Z er
Tem odal</w>
TRI BU
SI C</w>
O DA</w>
Flo or</w>
CS DP</w>
Bra ke</w>
to ol
remin der</w>
rele asing</w>
p p
me ts</w>
im pres
dram atically</w>
Spec ifications</w>
Spec ification</w>
Set tings</w>
S eg
Poll ution</w>
N ord
Initi atives</w>
In ject</w>
IN DIC
Enh ancing</w>
EL ISA</w>
15 th</w>
trac he
stream lining</w>
pla que</w>
mol asses</w>
m ou
hom osex
fru str
fl ammable</w>
en closure</w>
con forms</w>
classi fy</w>
by the</w>
ar se</w>
Z inc</w>
VETER INARY</w>
Cambo dia</w>
Banglad esh</w>
5 35</w>
3 77</w>
xyl anase</w>
var n
spa ke</w>
sinc ere</w>
sep sis</w>
s ore</w>
ro es</w>
investig ator</w>
habit ual</w>
en yl</w>
Res cue</w>
Moder n
ME O</w>
G rain</w>
E x</w>
1. 13</w>
righ th
pollu ting</w>
liter ally</w>
imp ul
d aughters</w>
cap es</w>
bil iary</w>
K iv
E DP</w>
C AN
16. 9.2002</w>
zy me</w>
w a</w>
ves icular</w>
ul ates</w>
medic ated</w>
interven ing</w>
for got</w>
elab oration</w>
b ast
Sit uation</w>
Sco reboard</w>
Egyp tian</w>
synchron ous</w>
si ded</w>
shar ply</w>
ra ils</w>
l u</w>
domic iled</w>
bi polar</w>
The in</w>
TAI N</w>
Ex pir
ET CS</w>
Cer amic</w>
Ann a</w>
8 th</w>
un born</w>
re tinal</w>
mel an
hed ged</w>
R IS</w>
FR ANCE</w>
D eep</w>
Comb ating</w>
Ch ol
9 7
7. 8</w>
4 86</w>
10 5
tr agic</w>
stu ff
inf estations</w>
anth rac
addres see</w>
Up date</w>
Sh ang
Ex ac
EE G</w>
ARTIC LES</w>
ß e</w>
war ned</w>
spon dy
scru tin
preced ence</w>
om itted</w>
dev ast
coupl ings</w>
Val en
T L</w>
Pa ste
P SU
M a</w>
CS Ds</w>
3 81</w>
170 290
ultras ound</w>
shi el
sh ale</w>
res on
mi as</w>
k VA</w>
incredi ble</w>
harmon ized</w>
f eral</w>
S trip</w>
Pre mium</w>
Ph oto</w>
Mic ro</w>
Ag g
12. 1</w>
άδ α</w>
ur in
toler ability</w>
lac ks</w>
dat as
circul ated</w>
att achments</w>
TR ADE</w>
Com or
A min
1 18
stom atitis</w>
lymp h</w>
in let</w>
effici encies</w>
contag ious</w>
ch i</w>
bit uminous</w>
Tit les</w>
Moder n</w>
HE AL
EU PM</w>
5 60</w>
19 62</w>
s plen
registr ies</w>
r ag
qu asi</w>
pro be</w>
pos aconazole</w>
po ł
M. A.
Coff ee</w>
Appl y</w>
AN C</w>
4 39</w>
10. 2004</w>
ycl ine</w>
numer ic</w>
in efficient</w>
hydrol ysis</w>
dis cards</w>
bom b</w>
arma ment</w>
Y ach
X IN</w>
PROCEDU RES</w>
PRO CES
M on</w>
Har ry</w>
Cro p</w>
Analy tical</w>
Al g
3. 2007</w>
16 ,
ul arly</w>
physi ological</w>
nom ination</w>
lit axel</w>
in consistencies</w>
for ged</w>
estiv als</w>
cer amics</w>
cent ers</w>
biop sy</w>
ag onal</w>
adh erence</w>
acceler ating</w>
Pu h</w>
N itro
Mon thly</w>
L ub
Contro ls</w>
tan kers</w>
spar k</w>
opa usal</w>
ex terior</w>
corner stone</w>
conclu sive</w>
afer on</w>
Struc ture</w>
Educ ational</w>
B ic
Any thing</w>
12. 2004</w>
tran ches</w>
respon ders</w>
qu it</w>
n ung</w>
hop ing</w>
dra inage</w>
aw esome</w>
alc et</w>
ST AND
Ref er</w>
I G</w>
6 39</w>
4 33</w>
20. 12.2006</w>
wat ches</w>
sp p.</w>
sp ill</w>
quan tify</w>
instruc t</w>
comple menting</w>
anti trust</w>
TER MIN
T 5</w>
PP As</w>
Nig eria</w>
9 9.
trac es</w>
s v
le m</w>
fer tili
ea k</w>
ar do</w>
Specific ally</w>
Rub ber</w>
Re productive</w>
N ida</w>
E ligibility</w>
2. 30</w>
zh ou</w>
sur charge</w>
read ers</w>
oxid ation</w>
j ub
influ ences</w>
fro m
ed ul
econom ics</w>
br al</w>
at r
K id
INTERES T</w>
Hear t</w>
Head quarters</w>
D il
10. 2005</w>
ro unds</w>
re jecting</w>
pri de</w>
o cl
endang ered</w>
dig itisation</w>
col leg
bon uses</w>
before hand</w>
bec ue</w>
alk yl
Bar oness</w>
un available</w>
terr ace</w>
stiff ness</w>
s ati
remin ded</w>
opo i
new s
lip id</w>
lab s</w>
hypertro phy</w>
erythropoi esis</w>
ep iz
en o</w>
el iness</w>
diff usion</w>
adal imumab</w>
W EEE</w>
Pr ince</w>
Libr ary</w>
Im pl
G aul
E in
Deli very</w>
AB S</w>
8. 7</w>
6 61</w>
6 .</w>
25. 11.2005</w>
spe aks</w>
py raz
paren teral</w>
men ing
let tuce</w>
in tra
encour agement</w>
chro mos
ass ays</w>
ac alcet</w>
ab str
UR L</w>
IM A</w>
H ousing</w>
Euro control</w>
B EM
Ac tavis</w>
15 20</w>
1 106</w>
&apos; all</w>
tox ins</w>
stitu tion</w>
soy bean</w>
row ing</w>
p ad</w>
ox o
lib eral</w>
le x</w>
is ine</w>
inc ess</w>
in ator</w>
evol ve</w>
del icate</w>
carc ass</w>
P as
K ep
CE T1</w>
7. 2.
5 81</w>
som atropin</w>
in ers</w>
fol i
domes tically</w>
chlor inated</w>
autom ation</w>
Li ability</w>
I LI
Ether net</w>
Conc iliation</w>
Co ordin
CON FORM
APPLIC ABLE</w>
s ail</w>
pri zes</w>
pel agic</w>
indel ible</w>
es to</w>
WITH DRA
V F
TREAT MENT</w>
S V
Rev ised</w>
LI G
K DE</w>
H ide</w>
Gall ery</w>
t ogen
if erous</w>
ib and
ha ke</w>
dizz y</w>
br ut
Wel fare</w>
Vit amin</w>
Stud ents</w>
R ear</w>
O CT</w>
He avy</w>
Fac tory</w>
D ong</w>
7 69</w>
Í sland</w>
flu x</w>
eff lu
clar ithromycin</w>
ah n</w>
Ric hard</w>
CON TRAC
Be yond</w>
3. 2014</w>
3. 2.1</w>
viol ated</w>
tox in</w>
ten ding</w>
hn e</w>
g ang
fi de</w>
Pen alties</w>
L ind
Kwik Pen</w>
J ul</w>
Contribu tions</w>
Caref ul</w>
Acad emic</w>
uph old</w>
stat s</w>
is che</w>
ir reversible</w>
follic ular</w>
ec tin</w>
cr acking</w>
av i</w>
announ ce</w>
ag er
P SE</w>
Mat ters</w>
F AC
Dul oxetine</w>
Bet aferon</w>
vol can
ster ity</w>
ra f</w>
os amide</w>
ma ker</w>
ligh ter</w>
in ergic</w>
aspir ations</w>
P and
Influ enza</w>
w ives</w>
um -</w>
t ags</w>
symb olic</w>
las ers</w>
in us</w>
illustr ations</w>
fl ush</w>
dis colouration</w>
di version</w>
dec ou
au sterity</w>
Shar ing</w>
Provi ding</w>
Nil sson</w>
Ne utro
Mix tures</w>
IS OF
Ch arg
C 4</w>
tun ing</w>
ther mo
sym path
s lower</w>
re patri
ob arbital</w>
it er</w>
hur ry</w>
ho sted</w>
N it
Bu y</w>
3, 6</w>
th is
sol ub
pro toty
nit us</w>
lim b</w>
hang ing</w>
fluor o</w>
consci ence</w>
break through</w>
T B</w>
SUB JECT</w>
HS Y</w>
Con versely</w>
Are va</w>
Alex ander</w>
ü n
un successful</w>
un equivoc
pr ic
phosphat ase</w>
otro pic</w>
licen see</w>
est a</w>
er up
conflic ting</w>
b loody</w>
antimicro bial</w>
VI E
PROTE CTION</w>
PERI OD</w>
N em
Con tain
Brow n</w>
Bir th</w>
Bene FIX</w>
Anton io</w>
A 3</w>
18. 10.2003</w>
15 000</w>
seg regation</w>
rad ic
ov ulation</w>
instru mental</w>
in cl
identi fiers</w>
TRAN S</w>
So il</w>
Pro p
Im migration</w>
Bab ylon</w>
9 65</w>
с к
vertebr al</w>
trag edy</w>
suspec ts</w>
ser o
plur alism</w>
os us</w>
oper ation
ol et</w>
my cophenolate</w>
ir revoc
S ad
ENI AC</w>
4 28</w>
3 92</w>
z en
wh ee
under way</w>
t u</w>
perpe tr
par amount</w>
movi es</w>
mem ories</w>
mar ry</w>
gre di
form e</w>
dys pepsia</w>
co -</w>
M ild</w>
M ann
Dam asc
Cl au
12 50</w>
0 11</w>
re distribution</w>
predic t</w>
pan e</w>
good will</w>
eth oxy
dri ves</w>
bu g</w>
T emp
O X
N ickel</w>
In gredi
ISOF IX</w>
ET Y</w>
ER E</w>
EN G
set tling</w>
ron t</w>
j aw</w>
i k</w>
gl or
for give</w>
ch t</w>
av en
alk al
achiev able</w>
UNDER TA
Part nerships</w>
LD L</w>
COUN TRY</w>
CONFORM ITY</w>
C had</w>
л а
tex ture</w>
rent als</w>
psori atic</w>
pois oning</w>
per fum
inter changeable</w>
ad ays</w>
Ras p
MP ING</w>
Cir cular</w>
C oper
7 67</w>
7 2
ul ence</w>
ty ing</w>
t us
struc tive</w>
iv ing</w>
de an</w>
collec tor</w>
as tinal</w>
U P</w>
Scal e</w>
DU MPING</w>
Civ ilian</w>
CYP2C 19</w>
AM LR</w>
tribu te</w>
repl ication</w>
mus eums</w>
manif estations</w>
deb ating</w>
cy clic</w>
author ize</w>
acce ded</w>
EI OPA</w>
Dis count</w>
DG S</w>
BEL GI
200 8
20 22</w>
0 10
uc um
prescri ptions</w>
pharmac y</w>
mem o</w>
inspir ation</w>
iband ronic</w>
com m</w>
cocc al</w>
asi de
ambi que</w>
XX X</w>
Sh er
S ources</w>
S ap
P eter
Abra ham</w>
spe eding</w>
peti tive</w>
offer ings</w>
inst ant</w>
im eter</w>
h ull</w>
ex ert</w>
dy nia</w>
comp act</w>
T us
MAR K</w>
M ade</w>
D own</w>
Criter ion</w>
Cre ative</w>
CC AMLR</w>
uropa.e u.int</w>
s ab
metr ical</w>
ex a</w>
Stev ens</w>
Mun dus</w>
Dev ices</w>
Contin uous</w>
Al low
6 11</w>
z oledronic</w>
stu dio</w>
referen ced</w>
prison ment</w>
pec uli
micro wave</w>
gi ant</w>
bi ometric</w>
as eptic</w>
W ash</w>
R Y
Plen ary</w>
Land s
K ing
symp tom</w>
n evirapine</w>
l acti
has n</w>
depar ting</w>
Ty pes</w>
Pr o</w>
N T
J AN
Di zz
B olog
26. 10.2012</w>
р е
telec oms</w>
set tlements</w>
sem ination</w>
regret table</w>
pre rog
land fill</w>
impl ied</w>
hi ding</w>
her pes</w>
de d
chur ches</w>
Min eral</w>
Labor atories</w>
Hal f</w>
H P</w>
Be ans</w>
8 61</w>
ve ins</w>
opa edic</w>
lin ers</w>
in tim
ic illin</w>
head aches</w>
for ts</w>
epi ride</w>
de z</w>
aside .LT</w>
ag le</w>
W i</w>
Vi ew
Se aside.LT</w>
Ex press</w>
CH AN
C 0
Baltic Seaside.LT</w>
All ergic</w>
Aeg ean</w>
6. 0</w>
4 03</w>
ul lah</w>
re payable</w>
particip ates</w>
origin ates</w>
fu tures</w>
di ve</w>
bl ending</w>
Temper ature</w>
T elev
Rw anda</w>
Gaul le</w>
Fuc king</w>
Cl asses</w>
AN NU
80 2.
12 10</w>
.e u</w>
up side</w>
st amps</w>
re war
over head</w>
men opausal</w>
b arely</w>
Tra in</w>
PL ES</w>
K ey
EC A</w>
Ag ents</w>
u an</w>
om es</w>
in cur
frac tion
eu tenant</w>
c ord
bar rel</w>
advoc ate</w>
Z A</w>
T il
N ev
H V</w>
D ental</w>
5 80</w>
2. 2.1</w>
yn g
strong est</w>
sign atories</w>
s culp
r u</w>
parti te</w>
i to</w>
fl ask</w>
el is</w>
dis agree</w>
det er</w>
commun icable</w>
bl ade</w>
aus p
ac ea</w>
Trans portation</w>
Swit ch</w>
PA I</w>
Euro pass</w>
EG TC</w>
E 14</w>
A K</w>
10 43</w>
vac ation</w>
por tions</w>
j o</w>
i ka</w>
grap hic
go s</w>
gen otoxic</w>
discipl ines</w>
def aul
cylin drical</w>
convin cing</w>
advis or</w>
Sim ul
PF S</w>
Mix 25</w>
Lo oks</w>
Gu ys</w>
Don etsk</w>
5. 2003</w>
rec orders</w>
inspec t</w>
fo ref
ed ers</w>
biod egradable</w>
alph ab
Impro ved</w>
Hab it
Bet a</w>
14 84</w>
un specified</w>
to w</w>
pl ed</w>
phosph ates</w>
multi pack</w>
met allurg
kn ife</w>
g ay</w>
exc ited</w>
enqui ry</w>
dis courage</w>
clean ers</w>
b ery</w>
assh ole</w>
an um
V ati
S pl
Liber als</w>
L as
Identi fying</w>
Haz ard</w>
Damasc us</w>
5 42</w>
4 23</w>
pharmac euticals</w>
pe at</w>
off setting</w>
lap ping</w>
hi ring</w>
h ou
conf ec
aff inity</w>
O SE</w>
Moz ambique</w>
H I</w>
D KK</w>
C lear
B. V.</w>
10. 1</w>
r é
hi d</w>
gen ces</w>
coun sel</w>
arg y</w>
W inter</w>
SI FRO
R I</w>
P RES
EC AI</w>
6 79</w>
4 00
19 13</w>
some how</w>
scar city</w>
onec rosis</w>
of the
neph ro
it ters</w>
cros ses</w>
conven e</w>
ad ors</w>
Sch ul
SIFRO L</w>
S ame</w>
N ec
MR I</w>
Hol m</w>
E AN</w>
Dis play</w>
Ac commod
9 a</w>
um b</w>
tion ery</w>
sub set</w>
straigh t
ros es</w>
radi otherapy</w>
person alities</w>
necess itate</w>
k u
evac uation</w>
countr ies
cer v
av enue</w>
Y o</w>
Th ings</w>
Na usea</w>
Flav is</w>
6 75</w>
19 th</w>
18 00</w>
thro wn</w>
te as
reg istering</w>
in sight</w>
fore station</w>
compres sors</w>
ad el
N aph
IU PAC</w>
Hu h</w>
EM A</w>
ware houses</w>
rot ating</w>
res titu
gly cos
exclu sions</w>
T un</w>
NG O</w>
M ega</w>
INTER NATIONAL</w>
Gr ants</w>
7 96</w>
20 25</w>
12. 2008</w>
un restricted</w>
ple x</w>
ographic ally</w>
numb ness</w>
mar tial</w>
li d</w>
inter pol
di vest
country side</w>
consul tants</w>
a a
St one</w>
Prac tices</w>
MIR APE
MIRAPE XIN</w>
LAG s</w>
INTRO DUC
Dizz iness</w>
0, 7</w>
su itably</w>
ro x
re sts</w>
pollu ter</w>
nit ol</w>
man nitol</w>
el eg
az il
PA H</w>
NF L</w>
K re
J U</w>
Di versity</w>
Cir cus</w>
Biodi versity</w>
B us</w>
Ac cid
sw ab</w>
sur name</w>
schizoph renia</w>
ro oted</w>
re ticul
ni er</w>
n inth</w>
mark ers</w>
keep ers</w>
k ov
fat alities</w>
dismis sal</w>
cro wn</w>
cent red</w>
appreci ated</w>
altern ates</w>
aci di
Shi py
Hap py</w>
G dynia</w>
G T
Det ection</w>
B ID</w>
6, 5</w>
00 2.
v ed
tur ally</w>
ta i</w>
si es</w>
pe eled</w>
p. r.
meth anol</w>
in ted</w>
ill nesses</w>
i qu
gr ab</w>
abor tion</w>
TRI ES</w>
S. 13</w>
Pop .</w>
Ob servation</w>
ID ENTI
Ελλ άδα</w>
necess it
influ ential</w>
industri alised</w>
emb argo</w>
co decision</w>
ban ka</w>
Vent sp
K or
K it
Ho over</w>
Ex ports</w>
EU RO</w>
Coper nic
C AN</w>
1.7. 2006</w>
0, 9</w>
ty l</w>
to id</w>
t .
re sign
op posing</w>
l umin
fibr ill
di ast
S now</w>
O range</w>
O d
M ale</w>
80 s</w>
3. 2.2</w>
vot ers</w>
shar ks</w>
re tains</w>
prec arious</w>
finan ci
entr ust</w>
cros sed</w>
cogn itive</w>
bar k</w>
antide pressants</w>
U P
Rit onavir</w>
Par king</w>
P rit
Lot to
Issu es</w>
F Y
vag inal</w>
u c</w>
summar ies</w>
opportun istic</w>
mil iti
evol utionary</w>
adjuv ant</w>
Vati can</w>
Some body</w>
ANNU AL</w>
9 th</w>
10 10</w>
е р
un ci
train ees</w>
thr one</w>
pin ned</w>
forwar ding</w>
bid den</w>
ampou les</w>
amph et
S SR</w>
RI C</w>
R af
Pi oglitazone</w>
L aur
Com pul
BA M</w>
5, 6</w>
trau ma</w>
toxic ities</w>
ti m</w>
lor ries</w>
l op
dis cour
collec tors</w>
bio equivalent</w>
Sil ver</w>
SOL AS</w>
Rel ative</w>
Pal estine</w>
P ris
NR G</w>
Mov ing</w>
IC ATIONS</w>
0 90</w>
produc tions</w>
mor b
im prisonment</w>
fon t</w>
ef ul
ch a</w>
c ill
abund ance</w>
TE RI
SP A</w>
H em
AM O
viney ards</w>
ri bs</w>
resili ent</w>
ren eg
olog ists</w>
mat h</w>
intrad ay</w>
fe bri
febri le</w>
et res</w>
direc tional</w>
b erg
anc a</w>
ag a</w>
ac tic</w>
U CB</w>
Rel ation
RECO GN
IS E</w>
9 09</w>
w y
un sustainable</w>
sen sory</w>
ris ky</w>
pur ification</w>
os ity</w>
lob ster</w>
k istan</w>
ich t</w>
hor ri
f uro
condi tionality</w>
bromo butyl</w>
EURO PE</w>
Copernic us</w>
CF U</w>
Adequ ate</w>
AF C</w>
traw l</w>
pol itan</w>
o y
k its</w>
hol low</w>
fac tories</w>
em powerment</w>
b ou
b ore</w>
Sup er</w>
St and</w>
Squ are</w>
Hy po
F our
DO CU
Br on
4 05</w>
0 30
stav udine</w>
sol ids</w>
pain ted</w>
must ard</w>
medi astinal</w>
in tru
cross ings</w>
bil lions</w>
ap por
T .</w>
Op tim
No bel</w>
I sol
Human itarian</w>
FRE E</w>
Ex erc
At tention</w>
4 0000</w>
10 7
zi g</w>
qu een</w>
pre nor
it ement</w>
ide ation</w>
g ut
declar ant</w>
cath ode</w>
biscu its</w>
Sac char
SPEC IES</w>
May or</w>
C ass
Adverti sing</w>
5. 2006</w>
4 64</w>
vi tis</w>
ste al</w>
sec tional</w>
meth acrylate</w>
ju dic
den um</w>
cush ion</w>
car tons</w>
au t</w>
at t</w>
Pro fit</w>
Pe ti
P ent
K er
Bot sw
Ab dom
wor ded</w>
ta b</w>
sti tial</w>
radiolab elled</w>
ori entations</w>
oblig es</w>
naph thalene</w>
go tine</w>
fr iction</w>
cas e
bul let</w>
be have</w>
abat ement</w>
Tr ich
N iv
Dis odium</w>
CERTIFIC ATE</w>
Bolog na</w>
B iss
ru g
pow ering</w>
pan to
ov an</w>
opath ies</w>
mu cous</w>
intensi ties</w>
f ically</w>
den atured</w>
deep en</w>
circum vent</w>
chic ory</w>
car t</w>
ausp ices</w>
an ic</w>
UN SC</w>
Elec tion</w>
E v
C ann
4. 11</w>
10 93</w>
tem p
smooth ly</w>
sh ells</w>
ple dge</w>
p allet</w>
optim ised</w>
on ion</w>
morb idity</w>
let ting</w>
form aldehyde</w>
ens or</w>
comm em
Val ley</w>
Recre ation</w>
F M</w>
Di esel</w>
CE O</w>
4 78</w>
weak ening</w>
un il
ref uses</w>
prenor phine</w>
predomin ant</w>
molec ules</w>
entr ust
en grav
e pl
cr afts</w>
cas ein</w>
bal con
an aesthesia</w>
algorith m</w>
agend as</w>
Territ ories</w>
S ession</w>
J et</w>
In di
F iscal</w>
Ecu ador</w>
C 7</w>
Any way</w>
4 16</w>
proph et</w>
pos als</w>
pac litaxel</w>
out sourced</w>
fol ding</w>
ampl i
Ne ed
Mix 50</w>
E thi
Biss au</w>
Κ ύπρος</w>
transamin ases</w>
ch en
asu res</w>
Ventsp ils</w>
LT D</w>
Botsw ana</w>
A wards</w>
7. 2009</w>
19 50</w>
18.8. 1990</w>
ple en</w>
ple dged</w>
pe ar
harmon ious</w>
dos ed</w>
dom y
dis position</w>
di o
advoc ated</w>
Sam sung</w>
SI M</w>
S ADC</w>
Fil es</w>
DE SI
An tar
Ac tual</w>
3. 1.1</w>
1 13
ro pin</w>
parath yro
lev er
he m</w>
glob alised</w>
ess e</w>
educ ated</w>
cy clos
critic ised</w>
crip tase</w>
cerv ical</w>
ag el</w>
af t
Scho ols</w>
ST CW</w>
R ye</w>
R ange</w>
M emb
EP PO</w>
Cre ating</w>
8. 2005</w>
5. 2014</w>
turb ine</w>
tr aps</w>
negoti able</w>
multi lingual</w>
lit ropin</w>
i an
cryst als</w>
az ines</w>
Uzbe kistan</w>
PAC K</w>
In dication</w>
Hist or
Her t
H AN
C ol</w>
B ank
8 00
3, 2</w>
2. 2008</w>
sc and
proc uring</w>
hab domy
h us</w>
carbox ylic</w>
bor row</w>
at em
V IAL</w>
TI R</w>
STO CRI
STOCRI N</w>
E W
DEC LAR
Con serv
prop hets</w>
millim etres</w>
man ic</w>
m cg</w>
lo ver</w>
in ach</w>
f as
dis solve</w>
ch el
arrhyth mias</w>
all y
Vi ews</w>
P emetrexed</w>
M AC</w>
IN NRG</w>
Ery thro
Con grat
Commun ist</w>
Bir ds</w>
Ass istant</w>
Alph a</w>
9 98</w>
us a</w>
trim ethyl
scri pt</w>
scar ce</w>
requis ites</w>
open ly</w>
mal ian</w>
dic k</w>
construc ting</w>
Reduc ed</w>
R ica</w>
R ating</w>
Prote in</w>
P an</w>
Intr amuscular</w>
7. 2006</w>
14 00</w>
................................ ................
wid ening</w>
war n</w>
retail er</w>
ox ifene</w>
gu ardian</w>
conduc tor</w>
Simp le</w>
R ice</w>
Indic ator</w>
Hu EPO</w>
7 85</w>
3 67</w>
whee zing</w>
tu re
str aps</w>
short fall</w>
py rim
por no
or chestra</w>
ma il
le p
ho ok</w>
gam ma</w>
er ating</w>
ech st</w>
depar ted</w>
bul bs</w>
V ER</w>
Rest aur
Regla mento</w>
Prepar e</w>
Ho echst</w>
CR M</w>
CO PD</w>
CC I</w>
10 69</w>
wh ey</w>
tou ching</w>
str and</w>
sel f
scienti fically</w>
s lag</w>
retro actively</w>
rec al
pl y
mis cellaneous</w>
lymph ocytes</w>
legisl ature</w>
fl un
dic tionary</w>
cigaret te</w>
az ione</w>
ar f</w>
TR AIN
Smo king</w>
Serv ants</w>
STRI PS</w>
Pestic ide</w>
Depos its</w>
DR A</w>
Br un
won dering</w>
stri king</w>
pre dec
p ills</w>
om al</w>
illustr ate</w>
hypo kalaemia</w>
glu can
fron t
believ ing</w>
ab ide</w>
Q aida</w>
Pr amipexole</w>
NC As</w>
I PS</w>
Benef its</w>
ware housing</w>
re v</w>
ph ic</w>
grow s</w>
curricul a</w>
bic on
assimil ated</w>
ass ment</w>
V ec
Summ er</w>
Sol utions</w>
Separ ate</w>
Pro du
Hon dur
Enh anced</w>
Dis till
6 01</w>
11. 1996</w>
stres sing</w>
straight forward</w>
prof en</w>
od or
l augh
int estine</w>
disper sion</w>
demonstr ations</w>
bit ter</w>
Stal evo</w>
Prin ted</w>
O slo</w>
EI A</w>
Control led</w>
Cla use</w>
AUTHOR ITIES</w>
ū ni
t amp
prolif erative</w>
out reach</w>
k as
deter rent</w>
alg ae</w>
aband on</w>
Sahar an</w>
PP S</w>
N ab
C AT
Bre ast</w>
Al pine</w>
AC R</w>
yl osing</w>
un even</w>
pun ished</w>
phot ograph</w>
met ering</w>
mal formations</w>
illi ant</w>
glucan ase</w>
V ES</w>
S ale</w>
M erger</w>
F G</w>
Euro dac</w>
D 1</w>
Co operative</w>
3 98</w>
20 ,
wild life</w>
sp .</w>
qu ity</w>
par aesthesia</w>
orth opaedic</w>
manag erial</w>
er ron
cru ci
bacter ium</w>
assist ants</w>
age al</w>
V AR
Op Co</w>
ITAL Y</w>
He bre
Gre ens</w>
E ri
CT B</w>
B ON
2, 000</w>
- 3-</w>
sem ester</w>
prag matic</w>
eth ers</w>
bor tezomib</w>
bicon vex</w>
an il
ac rit</w>
T ony</w>
Ret acrit</w>
Program ming</w>
Pro posals</w>
PR CA</w>
G oth
Bi ocidal</w>
AR TEM
tr ichlor
ticul tural</w>
stamp ed</w>
s ely</w>
pro po
om ission</w>
lim bs</w>
inter mit
inher ited</w>
her oin</w>
destin y</w>
S EE
Deriv atives</w>
Ar m
voy age</w>
organ ize</w>
ircon ium</w>
ion ine</w>
group ings</w>
girl friend</w>
dis infected</w>
co il</w>
c ous
bas al</w>
Lo g</w>
L ack</w>
G am
Dev ice</w>
7 94</w>
0, 00
valid ate</w>
safegu arded</w>
pot ency</w>
obstruc tive</w>
impe di
h amm
fe atured</w>
elabor ated</w>
au coma</w>
W T</w>
There after</w>
SOL ID
Produc er</w>
Liber ties</w>
E MEND</w>
Compon ents</w>
An aemia</w>
6 38</w>
pr inter</w>
particip ations</w>
parti tion</w>
dr ums</w>
concentr ating</w>
c lot</w>
Nor d</w>
GR AN
Fif th</w>
EI R</w>
7. 2007</w>
witn essed</w>
tur n
of il
od d</w>
minim isation</w>
func tion
em ir</w>
em e
dir ty</w>
def ense</w>
correc tness</w>
CONCER NED</w>
4 53</w>
0 40
spac ing</w>
prioriti se</w>
lo ving</w>
for ge</w>
emat ographic</w>
direc ting</w>
cou mar
ch o</w>
anticoagul ants</w>
ann ers</w>
Wy eth</w>
UN D</w>
RT GS</w>
PO W
N EE
M eg
Employ ees</w>
CU STO
Ac knowledg
6 92</w>
12 ,5</w>
yli dene</w>
prioriti sation</w>
h op</w>
f used</w>
cross border</w>
co g</w>
body work</w>
agg ression</w>
TI N</w>
S z
Prom ote</w>
Num bers</w>
L D</w>
Id entity</w>
Compul sory</w>
C at</w>
3 69</w>
1. 2009</w>
valu ations</w>
u sia</w>
st air
sco reboard</w>
s late</w>
ro dents</w>
pl uses</w>
per me
ge ometry</w>
ec al</w>
b ach</w>
Sem in
SOL V
H b</w>
8 10</w>
7.9. 1987</w>
3 89</w>
warr ants</w>
su preme</w>
pl ating</w>
medi ately</w>
dr a</w>
demonstr ators</w>
co p</w>
bull shit</w>
ator vastatin</w>
Spi ro
Shang hai</w>
S ir
Peri odic</w>
Ki ev</w>
Ef forts</w>
Chick en</w>
Champ ionship</w>
Abdom inal</w>
AT P</w>
4. 1.2</w>
was her</w>
t rou
pul ling</w>
inf lows</w>
incre ments</w>
head line</w>
g lobe</w>
fe eds</w>
at i</w>
answ ering</w>
advis ing</w>
We igh
Hondur as</w>
Acc ept
&apos; Cause</w>
subscri be</w>
psycho active</w>
pas sion</w>
meth adone</w>
mel ons</w>
ith erto</w>
fif teen</w>
exacerb ation</w>
electr o</w>
deleg ates</w>
d ening</w>
b log</w>
UN E</w>
Simpl ification</w>
S pon
Intro duc
Ex pected</w>
Dis card</w>
COUN TRIES</w>
AC TI
9 11</w>
2 O
1 150</w>
ty l
pres ently</w>
jo ke</w>
int ment</w>
in vertebrates</w>
h ourly</w>
f ör
e ine</w>
c age</w>
b ap
U C</w>
P ec
Le ip
Greitai. lt</w>
Fac ulty</w>
Clau de</w>
Al cohol</w>
30.6. 2001</w>
underes tim
toler ate</w>
str ang
sor ted</w>
re agents</w>
nitros ated</w>
nit rated</w>
nel finavir</w>
iti es
hos es</w>
disbur sed</w>
det on
collater alised</w>
co ok</w>
co c
acc eding</w>
No ise</w>
Mech anical</w>
Fu sion</w>
30 8
ub s</w>
trans criptase</w>
stand by</w>
sl ope</w>
rol ysis</w>
resign ation</w>
fron tal</w>
dis playing</w>
br assica</w>
Ver sion</w>
Tw itter</w>
L G</w>
House hold</w>
Hos pira</w>
EC I</w>
un laden</w>
ti es
sear ches</w>
li gn
configur ations</w>
aw aiting</w>
Rap amune</w>
Hand book</w>
Dat ab
y o
ox one</w>
op ic</w>
i ah</w>
hand les</w>
fr an
di pped</w>
bl ank
appoint ments</w>
VE GA</w>
SC S</w>
RF ID</w>
J acqu
I v
11 a</w>
proportion ally</w>
m as</w>
law n</w>
incid ences</w>
in visible</w>
gon adotro
down wards</w>
cub ic</w>
ai c</w>
Po or</w>
D ear</w>
Ac quis
10. 2008</w>
work places</w>
vi gn
tri um</w>
tolu ene</w>
stand still</w>
sim vastatin</w>
ro ti
reli ably</w>
po p</w>
multi forme</w>
heart beat</w>
deb ossed</w>
brief ed</w>
T .
Stat ements</w>
P K</w>
N ick</w>
Mon th</w>
Mar tin
Ingredi ents</w>
Indic ators</w>
HEAL TH</w>
H ahn</w>
Farm ers</w>
Cor ps</w>
3 87</w>
3 74</w>
representati veness</w>
perit oneal</w>
extingu ishing</w>
exam ines</w>
dri p</w>
col ored</w>
at ran</w>
Un ion
L ew
L amps</w>
H ij
H ING</w>
CONCER NING</w>
B IC</w>
7 16</w>
x ious</w>
trans boundary</w>
tif ying</w>
sw ollen</w>
rec urring</w>
port ability</w>
ph on
cr ying</w>
chlor ine</w>
brady cardia</w>
al ian</w>
Un able</w>
Trans l
Kaun o</w>
GF CM</w>
EC HR</w>
D a</w>
Congrat ulations</w>
C ells</w>
BR D</w>
6 09</w>
s prin
pres tig
o ak</w>
implant ation</w>
epiz ootic</w>
d B
cu red</w>
buck le</w>
Z ero</w>
W ant</w>
T on
St r</w>
S ic
Proc essed</w>
O I</w>
M ak
L av
In hal
DO WN</w>
CR S</w>
Ar bitr
AB ILITY</w>
8 21</w>
13 11</w>
ν ο
tou gh
te c</w>
t ul
re bel
prud ence</w>
po orer</w>
over lapping</w>
i P
fant astic</w>
el even</w>
d is</w>
a stric
Out look</w>
L ady</w>
IN VEGA</w>
BI OLOGICAL</w>
12. 2005</w>
0 12</w>
sulphon ated</w>
serot onin</w>
pre defined</w>
ophyl line</w>
ocy tosis</w>
milest one</w>
materi ally</w>
harmon y</w>
envis age</w>
di g</w>
ano ic</w>
an abolic</w>
Wash ing</w>
Telev ision</w>
TF E</w>
R ole</w>
R hin
Log istics</w>
INI TI
7 25</w>
13 70</w>
uni or</w>
un cooked</w>
tr ast
shoul ders</w>
quin ol
program med</w>
ol ders</w>
en tailed</w>
des ktop</w>
compl ain</w>
ar ith
F el
1. 14</w>
tr ail</w>
surviv ors</w>
propag anda</w>
pe as</w>
of ing</w>
nit rates</w>
foot print</w>
emp ha
aff lic
Pro bl
I DE</w>
B av
4. 2006</w>
1 B
po le</w>
oc ation</w>
im mer
con junc
cir cl
ar one</w>
Re action</w>
Moun tain</w>
Min ing</w>
Ma x
Interfer on</w>
In din
Gard asil</w>
Distill ates</w>
DS B</w>
Cru de</w>
B illy</w>
3 99</w>
vil eg
sh aking</w>
s aus
rec ord
pr av
pali peridone</w>
opoi etic</w>
on ics</w>
k k
it ude</w>
foref ront</w>
elabor ate</w>
d rought</w>
d az
back bone</w>
Tran sit</w>
S ig
S ach
Ma astric
Im mediately</w>
G AL
Co des</w>
Bi os
5 65</w>
tur ition</w>
stret ch</w>
sp in</w>
sit u</w>
s now
s mile</w>
rel s</w>
lat ex</w>
anticip ation</w>
ab a</w>
San itary</w>
P ill
F a
Break down</w>
us eful
stro bin</w>
ro c</w>
rit es</w>
min istries</w>
m itted</w>
l agging</w>
exer ted</w>
ex tradition</w>
dr al</w>
ar ter
Terror ism</w>
Pro long
Pri vileg
G as
7. 2002</w>
gos pel</w>
fo ren
er ical</w>
Leip zig</w>
E k
Did n</w>
CC CTB</w>
B ed
5 09</w>
4 65</w>
2 S</w>
zh ongshan</w>
u al
tigh tness</w>
t egravir</w>
sed ation</w>
li x</w>
epid emic</w>
co aches</w>
SOLV IT</w>
PR S</w>
NE AFC</w>
INN CN</w>
H E</w>
Cris is</w>
Comm od
BUDGE T</w>
5. 2002</w>
1, 2,
0 15</w>
ut as</w>
s clerosis</w>
rit e</w>
prosper ous</w>
p av
out going</w>
dy es</w>
an thro
Indin avir</w>
F T
Ch ris</w>
B NFL</w>
18 ,
ul tra</w>
ti tre</w>
ta z
special ized</w>
spec tro
out weighs</w>
or able</w>
lo yalty</w>
fa res</w>
erec tile</w>
ere ction</w>
ecu le</w>
discrepan cy</w>
crow d</w>
ch equ
audi ble</w>
Rem ote</w>
Per fec
N D</w>
J A</w>
HF SF</w>
Ex pan
DE TAI
C 5</w>
1, 3,5</w>
. 10</w>
τ α
relax ation</w>
k t</w>
in soluble</w>
el o
concep tion</w>
c es
avi roc</w>
ab ra
TREAT Y</w>
Gh ana</w>
GOVER NING</w>
D é
Cau ca
Ban kno
5 77</w>
ur i</w>
n arr
man uals</w>
key board</w>
ex chang
P om
L az
D M
Con version</w>
C ad
ARTEM IS</w>
5 01</w>
3. 11</w>
un explained</w>
trast uzumab</w>
institu tion
g ain
diast olic</w>
ab rad
F L</w>
Exc essive</w>
Con sor
4 51</w>
2, 7</w>
viney ard</w>
tu bers</w>
tri ght</w>
tempor al</w>
surpr ising</w>
sti r
ir is</w>
fru it
employ s</w>
distur bed</w>
bas ins</w>
Tr ue</w>
Som ali</w>
R od
N 3</w>
K GB</w>
D yn
yng itis</w>
umb rella</w>
th en
str anded</w>
re jects</w>
ra in
out flows</w>
l ever</w>
benzodi azep
Sil apo</w>
R ock</w>
P ag
Issu ed</w>
In jury</w>
Far oe</w>
CO X</w>
7. 2008</w>
var .</w>
sh ots</w>
press ant</w>
phen obarbital</w>
pers istence</w>
n in
mon d</w>
k ation</w>
ick le</w>
V in
Tr inity</w>
S cand
H air</w>
Chec ks</w>
B earing</w>
AG EN
z z</w>
wat ering</w>
ure th
um p
quali fies</w>
p is
l on
iz za</w>
harmon ization</w>
fav ours</w>
etan us</w>
contex ts</w>
autom ob
Tan z
Pro hibition</w>
M DGs</w>
L ines</w>
L ever
Fi re
AGR IC
5. 0</w>
115 4</w>
tre mend
schol ar
rep aglinide</w>
prop an</w>
no de</w>
mon key</w>
mo x
adv ancing</w>
Sem i</w>
Re ding</w>
PR T</w>
O D
J unc
H ard
En able</w>
sur geon</w>
subscri bers</w>
ro man
ph an</w>
mark edly</w>
g ad
ell ery</w>
dr on
de priv
b ans</w>
ass ists</w>
ad renal</w>
a S
Streng then</w>
Phil is
Novo Rapid</w>
Maastric ht</w>
GOVER N
DE L</w>
C over</w>
8 22</w>
6 35</w>
28.11. 2003</w>
18 82</w>
0 6.
wir ing</w>
sweet eners</w>
preced ent</w>
pas m</w>
no tary</w>
ly n</w>
low n</w>
ic oxib</w>
Y e</w>
T ap</w>
Ser bian</w>
PE G</w>
E vol
DA Y</w>
Co ach</w>
B ar</w>
AC CES
5 08</w>
24 00</w>
under water</w>
se ated</w>
r DNA</w>
og a</w>
mam malian</w>
laun dry</w>
is able</w>
id o</w>
et y
entr e</w>
dis posing</w>
dev ote</w>
T elec
T AN
Sub mission</w>
SE AR
Rog er</w>
Li eutenant</w>
L jub
EM P
Accommod ation</w>
AGRE ED</w>
3, 0</w>
3 H</w>
uph ol
t z</w>
t at
pension ers</w>
main land</w>
li o</w>
ing o</w>
fo vir</w>
enforce ability</w>
em power</w>
dispers ed</w>
d welling</w>
chair person</w>
aggrav ated</w>
Survi val</w>
Form at</w>
Dra wing</w>
st unning</w>
spondy litis</w>
reti red</w>
manufactu res</w>
inval id
confec tionery</w>
cerebro vascular</w>
arg ine</w>
Negoti ations</w>
Individu als</w>
Gu atem
G r</w>
G B
F at
B SCA</w>
AI IR
6. 9</w>
ut ter</w>
s p</w>
ps r</w>
install ing</w>
ici le</w>
g et
f ills</w>
escal ation</w>
dur um</w>
c ant</w>
VIE W</w>
Pa ul
Mal m
Kh in</w>
G on
Ar th
A gro
27 99</w>
wan ting</w>
under pinned</w>
u cle
traine eships</w>
ter ry</w>
syst olic</w>
satur ation</w>
s burg</w>
res ist</w>
remov als</w>
encry ption</w>
design er</w>
cl onal</w>
ax ial</w>
aty pical</w>
al do
P ed
9 31</w>
2. 2.2</w>
vac ancy</w>
ter ror</w>
take over</w>
reaf firms</w>
lun omide</w>
fl ed</w>
fibrill ation</w>
be ast</w>
ag ia</w>
Vi k
TRANSP ORT</w>
T ree</w>
SP AIN</w>
Princi ple</w>
In duc
For ms</w>
F lag</w>
Con sign
Adjust ments</w>
6 04</w>
trav elled</w>
trans porter</w>
tis m</w>
ph ar
ov aries</w>
op har
it ė</w>
id le</w>
habdomy olysis</w>
h its</w>
exhib its</w>
emb ro
ar teries</w>
an n</w>
ac resol</w>
WOR DS</w>
R ates</w>
Pr int</w>
J al
Hot els</w>
G O</w>
FIL LED</w>
Eg gs</w>
AS S</w>
6. 2007</w>
1, 7</w>
н а
unil aterally</w>
re versal</w>
good ness</w>
az in</w>
atur ing</w>
REV EN
Privileg es</w>
N as
N ami
Merc os
K L
IF T</w>
Fem ale</w>
F low</w>
Cor s
C argo</w>
Andro id</w>
AGRIC ULT
A X</w>
5 14</w>
tom y</w>
tigh tly</w>
swit ch
specul ative</w>
ro yalty</w>
men stru
if f</w>
catal ogues</w>
av ail</w>
and ro
Wh arf</w>
J ere
H ou
Bee f</w>
AMO UN
8. 8</w>
4 b</w>
4 22</w>
un equal</w>
tot alling</w>
t ours</w>
t ami
oc rati
nar co
k os</w>
influ encing</w>
illustr ates</w>
fluores cent</w>
engine er</w>
ed ness</w>
e aten</w>
cor related</w>
adverti sement</w>
RO M</w>
D ak
Cle an
9 94</w>
7. 2003</w>
4 08</w>
sur ge</w>
reciproc ally</w>
p he
on itis</w>
mol ecule</w>
intestin es</w>
happ iness</w>
bur st</w>
broad ening</w>
Gen u
G etting</w>
Effici ent</w>
D istance</w>
Co ast
B 6</w>
Al u</w>
8 49</w>
6, 6</w>
2 100</w>
under cut</w>
tre asury</w>
reneg oti
read er</w>
re port
r ho
leth argy</w>
for d
alleg ing</w>
ab stain</w>
V eg
Transf ers</w>
S CI
R ay
R ING</w>
P un
OU R</w>
O EF</w>
N RT
Min i</w>
F ID</w>
E ven
phot osensi
over weight</w>
om bud
og ical</w>
in hab
gl argine</w>
emb les</w>
e uropa.eu.int</w>
cho oses</w>
atri al</w>
ast y</w>
am ation</w>
Tak fir</w>
St an
S ING</w>
Mercos ur</w>
In tra</w>
COMMUN ICATION</w>
B obby</w>
7. 2000</w>
19 47</w>
to the</w>
se ize</w>
pen ic</w>
op enia</w>
ment s.
m ä
glim epiride</w>
fast est</w>
col ony</w>
ch a
Repub lic
Relation ship</w>
Purch ase</w>
L CD</w>
Junc ker</w>
Con firmation</w>
y le
susp icious</w>
mort als</w>
interpre ters</w>
i as</w>
friend ship</w>
chol est
b en</w>
Tom orrow</w>
Ky aw</w>
K ol
Import ers</w>
4. 2008</w>
1 14
ven s</w>
reb ates</w>
hop efully</w>
f estivals</w>
demarc ated</w>
ay ers</w>
at able</w>
M IS
H ill</w>
F TT</w>
Di agram</w>
DI ES</w>
5 96</w>
. lt</w>
sur fac
sal monella</w>
revol ving</w>
rescu ing</w>
no ble</w>
k ol
infring e</w>
f t
ell i</w>
des per
amb ia</w>
am el</w>
ac ious</w>
Z u
Z AN
Resul t</w>
N I</w>
Bu ff
tan ker</w>
simil arity</w>
pun ishable</w>
ph in</w>
glaz ing</w>
emb arr
cru el</w>
com positions</w>
b read
The atre</w>
TI GATION</w>
Stake holders</w>
Mil lions</w>
Inter governmental</w>
In direct</w>
In corpor
IS SU
I O</w>
Cle aning</w>
CC C
AP A</w>
AIF s</w>
4 74</w>
28.2. 2006</w>
transfere e</w>
seni ūni
s pleen</w>
s -</w>
re petition</w>
random ly</w>
ov al
optim istic</w>
ne sia</w>
l ace</w>
jeopardis ed</w>
in finite</w>
hum ane</w>
ensu ing</w>
coll agen</w>
bri dging</w>
arsen ic</w>
aldo ster
al li
N T2</w>
C over
Bas ketball</w>
Author ised</w>
4 69</w>
10 50</w>
10 0,000</w>
uni formity</w>
un fortunate</w>
tiv a</w>
sur pluses</w>
sle y</w>
po vidone</w>
laz o</w>
inter change</w>
dynam ometer</w>
depriv ation</w>
cred it
cont ests</w>
X ol
Sha ke</w>
M ig
ES DP</w>
Dimen sion</w>
Austr alian</w>
21 11</w>
th ri
so red</w>
sc attered</w>
ridic ulous</w>
myel oid</w>
mus icians</w>
mus culoskeletal</w>
impl icit</w>
imag ination</w>
gol f</w>
f airs</w>
e keeping</w>
cri ed</w>
coun selling</w>
bever age</w>
b order
Writ e</w>
Ug anda</w>
Res pec
Reg istered</w>
Ref lec
For ward</w>
Fi ji</w>
F U</w>
CE POL</w>
Am bi
um a</w>
stad t</w>
s es
mem antine</w>
gl aucoma</w>
fast eners</w>
dev il</w>
c is</w>
bot t</w>
appro ached</w>
Xol air</w>
Vilni aus</w>
P. O.</w>
N H
Guang Dong</w>
EU CI</w>
Dro p</w>
war s</w>
ven dor</w>
re tractor</w>
on omic</w>
mis match</w>
micro phone</w>
men tioning</w>
in clin
expos e</w>
er ic
as par
all ot
V essels</w>
TI ME</w>
Secret aries</w>
Prac tical</w>
I TE
Haem oglobin</w>
GA AP</w>
D ave</w>
D assis</w>
Ar ri
4 85</w>
wr ath</w>
ta ils</w>
shor tened</w>
s ouls</w>
r algia</w>
om ing</w>
inter cep
infra red</w>
gl os
f owls</w>
em e</w>
dis closures</w>
bon ded</w>
bl essed</w>
b ay</w>
arth ralgia</w>
PAR T
ON G</w>
G ren
ES CO</w>
10 90</w>
tow ers</w>
ti ously</w>
tel es
t at</w>
sur rec
st agn
scre ws</w>
recover ies</w>
omy cin</w>
o ath</w>
le af
j as</w>
in vert</w>
fertilis ation</w>
ex agg
eg er</w>
azil and</w>
aes thetic</w>
Sw aziland</w>
Sec toral</w>
Restric tions</w>
REVEN UE</w>
Is le</w>
E AS
B inoc
Aeri us</w>
8, 5</w>
28.11. 2012</w>
survi ving</w>
rou ting</w>
pursu es</w>
immunoglob ulin</w>
fo p</w>
emo tions</w>
denom inator</w>
chann elled</w>
bu l</w>
boy friend</w>
I ce</w>
G AS</w>
Fac ilit
Ben j
7 53</w>
3 D</w>
wast ed</w>
ur us</w>
selec tor</w>
protection ism</w>
dys kinesia</w>
deduc tible</w>
c ass
bre ath
b ps</w>
auc tioning</w>
Tur n
P on
K O</w>
Excell ent</w>
D airy</w>
CUSTO MS</w>
6. 2005</w>
useful ness</w>
thir st</w>
th ic</w>
ship owners</w>
no where</w>
ist at</w>
in ulin</w>
in eligible</w>
fe eder</w>
er ra</w>
enn ial</w>
diversi fy</w>
den ed</w>
bid ders</w>
West ferry</w>
S au
Revol utionary</w>
Probl ems</w>
Gr ad
Collec tive</w>
An sw
wid est</w>
survi ved</w>
st r</w>
dr ill</w>
co arse</w>
car to
bat ches</w>
Qu artet</w>
G reg
ACTI VI
4 HB</w>
20 23</w>
ul um</w>
sh ifts</w>
ref urb
modern ised</w>
invo ke</w>
i fies</w>
fa ke</w>
co existence</w>
c zy
c ac
bet ting</w>
aw a
ator ium</w>
ar ic</w>
anti hist
Selec ted</w>
Sacchar omyces</w>
Ro y
P it
P ick</w>
IMPLEMEN TATION</w>
F IF
Depos it</w>
De ity</w>
19. 7.2005</w>
10. 2009</w>
yl actic</w>
tri fluor
cy top
contin ence</w>
al pha
a ar</w>
Tab lets</w>
P is
Lou is</w>
Identi fy</w>
14.12. 2012</w>
12. 2001</w>
0, 15</w>
. 4</w>
w p
thr in</w>
lup us</w>
k us</w>
justi fiable</w>
inf liximab</w>
indeb tedness</w>
in stan
dar ling</w>
concep tual</w>
cap itals</w>
camp ings</w>
bl ends</w>
belong ed</w>
analys er</w>
ER C</w>
CONCLU SION</w>
vul c
s awn</w>
ph atic</w>
os se</w>
hus ked</w>
ex its</w>
engrav ed</w>
dere g
be side</w>
a -</w>
Th ess
Tel misartan</w>
TIV ES</w>
Se as</w>
SS M</w>
S ti
Proc edural</w>
N ur
Lux OpCo</w>
League. 8.
F D
Exerc ise</w>
CON TI
11. 2008</w>
- l</w>
yel low
privileg e</w>
per pet
it ative</w>
h ing
fol litropin</w>
encomp assing</w>
di dan
didan osine</w>
defici ent</w>
Tanz ania</w>
Out side</w>
Of ten</w>
Ljub lj
IP MENT</w>
Brig adier</w>
vel i
unbund ling</w>
to e</w>
replac eable</w>
pyr roli
peti tions</w>
om ed</w>
hy dra
fi ber</w>
con ut</w>
certif ic
car ing</w>
an iline</w>
S ão</w>
S ample</w>
Rec ently</w>
REN T</w>
P le
Over seas</w>
IN TO</w>
Econom ics</w>
Con fl
5 85</w>
work load</w>
wash ers</w>
ung inned</w>
tami vir</w>
r um
past es</w>
o intment</w>
ma k
lacti n</w>
h itherto</w>
democr atisation</w>
c ence</w>
ad diction</w>
Uni que</w>
SUBST ANCES</w>
RE SEAR
L ed</w>
Karve zide</w>
Arti st</w>
Ab bott</w>
AD Rs</w>
wo od
t anning</w>
s labs</w>
pyrid ine</w>
mathem atical</w>
in sufficiently</w>
for bidden</w>
depl eted</w>
chew able</w>
blo od
adverti sements</w>
W ere</w>
Taj ik
R B
P urity</w>
L AN</w>
Bi H</w>
3 600</w>
19 ,
1 12
- di
surroun dings</w>
shor test</w>
ri er</w>
idi ot</w>
fol k</w>
colleg es</w>
cer ti
af fixing</w>
Tex as</w>
Suppl iers</w>
Pro t
Peti tions</w>
Mu ham
L os</w>
Foc us</w>
AUTHOR ITY</w>
7. 9</w>
е л
s ad
p ill</w>
l aps</w>
dy eing</w>
att acked</w>
af fix</w>
SI DEN
Mom my</w>
H G
8 91</w>
30. 9.
ú n</w>
wholes alers</w>
uli ai</w>
sub ordinate</w>
scrap ie</w>
rec tify</w>
pow dered</w>
inter section</w>
h l
g ren
dipl oma</w>
ad ium</w>
WA Y</w>
Tajik istan</w>
Tai wan
Sh an</w>
Rec ords</w>
O PE
Hy draulic</w>
Domin ican</w>
Contr ary</w>
B it
substanti ate</w>
ro ts</w>
pro tests</w>
complain ed</w>
bo ot</w>
ate way</w>
acet yl</w>
ac les</w>
V all
M AL
Lic en
Ear lier</w>
Candi date</w>
As perg
AB C</w>
tif ications</w>
th io</w>
sinc erely</w>
se ag
po ons</w>
pe ars</w>
p t
p seud
immun ological</w>
id ical</w>
hor n</w>
gener ous</w>
equi p</w>
envel opes</w>
en g</w>
ch en</w>
Th un
T G</w>
ME P</w>
LAN DS</w>
Ac cred
ACTIVI TIES</w>
9 36</w>
21 31</w>
ü s
tow els</w>
sho e</w>
reg ression</w>
pl aster</w>
moul ds</w>
maxim ising</w>
li des</w>
k oz
ing en</w>
hyper plasia</w>
ge ographically</w>
erythro mycin</w>
dic ate</w>
di ary</w>
beli efs</w>
M PA</w>
ETI AS</w>
Con f
Ab dul
5 55</w>
10. 2</w>
z ai</w>
v ague</w>
tram way</w>
sh afts</w>
righth olders</w>
pro test</w>
past ure</w>
mat t
k sand
i ent</w>
bon eless</w>
bol one</w>
ab ig
T ap
S UL
R ING
M ust
AIIR As</w>
4. 3.1</w>
27. 3.
2. 1.
115 9</w>
veget ation</w>
rec tal</w>
ol es</w>
n. o</w>
mol yb
ma x
ini quity</w>
dis regard</w>
dis cer
comp iling</w>
Vinc ent</w>
Taiwan ese</w>
EU TM</w>
10 24</w>
1, 200</w>
0 3.
zoon oses</w>
sub section</w>
oppon ents</w>
manoeuv re</w>
ma ke
la b</w>
id ase</w>
h alls</w>
enedi amine</w>
end less</w>
ec raft</w>
capit alisation</w>
bur y</w>
TI VA</w>
Qu ar
Pat r
PL AN
P ets</w>
O t
Navi gate</w>
Nami bia</w>
N AS
IN ATION</w>
Co dex</w>
C en
AS EAN</w>
и н
w ovens</w>
the art</w>
rin se</w>
rest lessness</w>
rel aun
no table</w>
hydroxy benzoate</w>
ho oks</w>
ent ora</w>
di agonal</w>
determin ations</w>
dem ol
contrad iction</w>
allot ment</w>
abrad ine</w>
TIC E</w>
R EC</w>
Preven ar</w>
Ou ter</w>
Mar co</w>
L om
H SH</w>
Ce iling</w>
BA D</w>
Au j
2. 11</w>
ta utas</w>
road worthiness</w>
par as</w>
o coccal</w>
n ylon</w>
my stery</w>
ir o</w>
fung i</w>
extingu ish
etr on</w>
dig estive</w>
dem ocrati
col on</w>
argu ing</w>
abig atran</w>
TH EIR</w>
T asks</w>
Mun ich</w>
LO T</w>
Eff entora</w>
CRE DIT</w>
An d
AS SOCI
A V</w>
yan a</w>
vi a
to cog</w>
th in
quick er</w>
pro lactin</w>
new born</w>
micro bial</w>
merch ant</w>
ji ang</w>
gas oline</w>
follic le</w>
etan ercept</w>
encomp asses</w>
aeros ol</w>
abu sive</w>
P DE
P CE</w>
Nep al</w>
M ount</w>
Ljublj ana</w>
L R
G es
G UE</w>
E sti
6 10</w>
31.12. 2008</w>
well being</w>
secu ted</w>
n our
liber alised</w>
lam b</w>
h f</w>
compl ication</w>
circum stance</w>
bank rupt</w>
as les</w>
appreci able</w>
an cho
UF 6</w>
TE X</w>
Intere sts</w>
ER M</w>
15 0
π ο
super se
spro uts</w>
s por
radi ated</w>
pl au
mal absorption</w>
lac osamide</w>
ion ising</w>
i que</w>
epid ermal</w>
devi ate</w>
cere vis
Qual ifications</w>
M ust</w>
IT AL</w>
H it
Con temporary</w>
5 00000</w>
3. 1.2</w>
www .e
wrap ping</w>
wat ched</w>
prin ces</w>
pain tings</w>
is one</w>
id opa</w>
bec k</w>
as much</w>
D osing</w>
23. 11.
1. 2006</w>
1, 2,4</w>
tw ine</w>
trigg ering</w>
re ign</w>
itch y</w>
hydr ation</w>
gu es</w>
b ite</w>
azep am</w>
Spiro max</w>
O WN</w>
N ou
J US
INTRODUC TION</w>
H I
CEC AF</w>
Accred itation</w>
7, 8</w>
4 72</w>
31. 3.2006</w>
η ς</w>
we aned</w>
sh am</w>
question able</w>
overwhel ming</w>
mis lead</w>
minim ised</w>
l ent</w>
curricul um</w>
convic ted</w>
bel ly</w>
ac idity</w>
V HS</w>
To ol</w>
PE F</w>
Coast al</w>
AC COR
7 30</w>
mal aise</w>
incl ination</w>
deriv es</w>
collabor ate</w>
c il
W AS</w>
R y
Presid ential</w>
Indic ative</w>
H ass
H T</w>
F ees</w>
Euro med</w>
Co Aprovel</w>
CR F</w>
Br atis
B GB</w>
é ri
unambig uous</w>
tre ad</w>
tetra hydro
straw berries</w>
spon taneously</w>
ser otypes</w>
seag oing</w>
s ows</w>
re ign
pol es</w>
ome tr
mat uration</w>
man i
k š
hat red</w>
fresh water</w>
en al</w>
Qual ification</w>
M U</w>
Ch art</w>
seas ons</w>
pan ic</w>
milest ones</w>
less ly</w>
incenti vis
hex yl</w>
even tual</w>
eren tly</w>
enjo y
creati ne</w>
carb idopa</w>
bon ed</w>
benz o
air borne</w>
add ers</w>
P ass</w>
K le
Auj esz
7 10</w>
5 20</w>
2, 1</w>
13 th</w>
13 05</w>
. uk</w>
ét é</w>
unci ation</w>
te en
s inging</w>
progres sing</w>
nom in
man kind</w>
in compatibility</w>
g aming</w>
eti dine</w>
de structive</w>
bu st
anten na</w>
Lev etiracetam</w>
G Y
C ob
Asperg illus</w>
4 35</w>
13 34</w>
y r</w>
viro logic</w>
trans forming</w>
tr ick</w>
sulfon ate</w>
squee ze</w>
promot ers</w>
mor tem</w>
le flun
leflun omide</w>
lab or</w>
insul ating</w>
gen tle</w>
fl ue</w>
e er</w>
denom inations</w>
d d
contradic tory</w>
com promising</w>
com promises</w>
broad en</w>
X A</w>
WH ERE</w>
Po ker
Mal osse</w>
Har v
Ar ms</w>
6 69</w>
4. 4.1</w>
trans missions</w>
sub contracting</w>
star ches</w>
re vit
quin idine</w>
omy r</w>
objec tivity</w>
no c
multi lingu
ket one</w>
diver gences</w>
dec oration</w>
clim b</w>
av en</w>
Th an</w>
Techni ques</w>
Neg ative</w>
I K
BLIS TER</w>
19 80s</w>
μ ο
whol e
sor ts</w>
reaf firmed</w>
re g</w>
mell ose</w>
interru pt</w>
car mellose</w>
blin ds</w>
bin ary</w>
ag ro
WITH OUT</w>
U AN
Ten ders</w>
O T
Lam ivudine</w>
EQ F</w>
Cro hn</w>
BELGI UM</w>
B ovine</w>
AM P
5. 1.
4 92</w>
rup ture</w>
practition er</w>
g ov
flu oxetine</w>
ex istent</w>
embar kation</w>
das atinib</w>
b ag
antid ote</w>
aflu oro
O k
Lic ences</w>
En tries</w>
Bar ley</w>
6 25</w>
14 22</w>
s qui
recre ation</w>
occup ants</w>
it al
is k</w>
intermit tent</w>
in security</w>
econom ical</w>
di odes</w>
bi ology</w>
ad os</w>
Tr im
Ser ver</w>
SUS TIVA</w>
K au
vulc anised</w>
un affected</w>
trou t</w>
ste er</w>
pi e</w>
p ants</w>
mur dered</w>
m ates</w>
la st
inferi or</w>
ere t</w>
cabin ets</w>
anhydri de</w>
alph anum
Win d</w>
Sí mi</w>
So e</w>
FR F</w>
Exac tly</w>
Cri tical</w>
Az omyr</w>
A vas
3 S</w>
16 th</w>
12 73</w>
10 00000</w>
u itary</w>
to dex
sel en
pe aches</w>
ou tright</w>
or ate</w>
medic ally</w>
li veli
intermedi ation</w>
in capacity</w>
haemat opoietic</w>
gluco cortic
fun eral</w>
ed itor</w>
del ta</w>
car dboard</w>
S ING
Re pl
G ent
F SC</w>
Aujesz ky</w>
Al ready</w>
1 180</w>
ti dine</w>
resear cher</w>
remedi ed</w>
re assessment</w>
observ ing</w>
mag azines</w>
ist a</w>
dil ute</w>
des ert</w>
dehydr ated</w>
def er
cr ack</w>
atro phy</w>
aper ture</w>
V EL
S tain
S ets</w>
Om ar</w>
M m</w>
Lithuan ians</w>
Issu e</w>
H 2O</w>
Guatem ala</w>
Consul tations</w>
5 3
4 31</w>
á s</w>
un itary</w>
tic ulture</w>
sk o</w>
n os
it é</w>
in trav
i res</w>
ho kes</w>
exhib ited</w>
ath let
ad dic
Shipy ard</w>
Moroc can</w>
Des cri
C l</w>
19.10. 1992</w>
vascul itis</w>
omy el
multipl y</w>
emb race</w>
defe at</w>
cyan ide</w>
cel ain</w>
V MS</w>
Tric ho
Resi dues</w>
Publish ed</w>
Pl ug
L F</w>
K un
J av
CE E</w>
A H</w>
6 56</w>
wor sen</w>
si fication</w>
ro z
re unification</w>
re ap</w>
pro s
plo ts</w>
mis conduct</w>
induc er</w>
equi ties</w>
electro des</w>
degr ading</w>
de c</w>
cul t</w>
cor ne
be ams</w>
back drop</w>
atten uated</w>
a ł
V omiting</w>
Min or</w>
M ama</w>
In stan
Hep at
FOLLO WING</w>
Equ ally</w>
D ap
Car l</w>
Avas tin</w>
Acces sibility</w>
25 35</w>
0 13</w>
tot al
subscri ptions</w>
ro cks</w>
re .
ran ked</w>
oct adec
law fulness</w>
i er
ec z
de forestation</w>
b arium</w>
atin g
Y ES</w>
Pan ev
PC I</w>
Mar se
HC R</w>
F MC</w>
Cour ts</w>
C ran
Av entis</w>
0 16</w>
sco red</w>
pi one
person alised</w>
orig ami</w>
nee ding</w>
impl ant</w>
destro ying</w>
day time</w>
Li a
J PG</w>
DECLAR ATION</w>
D P
CEL F</w>
5 30</w>
14 C</w>
О О
vig orously</w>
ur t</w>
tur bo
tru stee</w>
s add
refriger ating</w>
per ce
pen s
long est</w>
kill er</w>
buil ders</w>
at taining</w>
are th</w>
PERS ONS</w>
Karve a</w>
Hos p
Gro up
E O</w>
Bar becue</w>
AL Y
12 th</w>
varn ishes</w>
ret ard
reflec tor</w>
myel osup
mbass y</w>
licen ses</w>
lear ners</w>
inter stitial</w>
imp actor</w>
dres ses</w>
di ol</w>
compu ted</w>
ben d</w>
an no
adren ergic</w>
ac tion
Veg as</w>
Teach er</w>
E mbassy</w>
Dis tribu
Cr ime</w>
Comor os</w>
Ch at</w>
An der
Ambass ador</w>
AP S</w>
4. 2005</w>
tri bes</w>
transi tions</w>
ner ves</w>
n.e. c.</w>
elap se</w>
d well
cr amps</w>
break downs</w>
W it
PP C</w>
P reservation</w>
H aw
DE TERMIN
Clear ance</w>
CS Os</w>
B eth
B ars</w>
B ET
AD ING</w>
11. 2003</w>
us sy</w>
th ouse</w>
succ esses</w>
sto ols</w>
pran ational</w>
pl ain
phot o
li bid
i ana</w>
e osin
de pic
c im
Thun nus</w>
ST AR</w>
R CA</w>
Med DRA</w>
K ft</w>
GR AP
Dis per
C AR</w>
v ar</w>
tro users</w>
st ore
spl itting</w>
recru it</w>
or anges</w>
mal e
hyper stimulation</w>
est ors</w>
cit abine</w>
anti gens</w>
al arming</w>
af tor</w>
aero dromes</w>
V enti
SY RING
Norm ally</w>
J un
H im</w>
Cl ash</w>
ОО Д</w>
ö l
warm ly</w>
te ars</w>
str um</w>
rec tification</w>
ra k</w>
p p.</w>
p ounds</w>
multipl ication</w>
multilingu alism</w>
lamb s</w>
ili p</w>
i ų</w>
gl ass
ed .</w>
dis solution</w>
chos pasm</w>
bed ding</w>
b led</w>
Thess alon
Inter face</w>
H Be
Gr ant</w>
EN VI
Cop y
5 95</w>
4 75</w>
11. 1</w>
10. 3</w>
tal ents</w>
poss esses</w>
p itation</w>
ic les</w>
frag ments</w>
clar ity
ch am
bi as</w>
ati ve
WITHDRA WAL</w>
Reas on</w>
R im
Q D</w>
Ob ama</w>
Mem antine</w>
Medic ine</w>
LI TH
I AN</w>
EXPO SURE</w>
EQU IPMENT</w>
D av
9. 6</w>
1. 2010</w>
yl amine</w>
tim eliness</w>
regul ates</w>
pic king</w>
offen ders</w>
ins isted</w>
initi alled</w>
in en</w>
cerevis iae</w>
care rs</w>
ai res</w>
advis er</w>
VA X
Pe as</w>
Habit ats</w>
radic alisation</w>
protein uria</w>
jur idical</w>
iner tia</w>
el ders</w>
don ations</w>
dilu ent</w>
bu prenorphine</w>
aphy lo
anal ge
W P.
VEHIC LE</w>
Scot t</w>
S MB
O UR
Natur ally</w>
Ira qi</w>
Exclu sion</w>
Cy cl
CH P</w>
C im
B ox
B Y
19.8. 1991</w>
wrap ped</w>
w ares</w>
under mines</w>
ulcer ation</w>
r t</w>
l ings</w>
ing u
inf er
feed stock</w>
ethan ol
es cor
en rol
c ages</w>
Schul z</w>
Pill ar</w>
P eak</w>
Ex plo
Edi ble</w>
3. 8.
3 83</w>
10 80</w>
trans pon
repro duci
re structure</w>
re consider</w>
oz ide</w>
ot to</w>
et z</w>
est one</w>
end ants</w>
X ML</w>
Tem plate</w>
Scand in
S EP
S AR</w>
RESEAR CH</w>
REL ATING</w>
N IC</w>
MUL TI
M in</w>
M ass
Kep pra</w>
F TA</w>
Elev ated</w>
EU FOR</w>
B arri
Antar ctic</w>
4 82</w>
v ain</w>
u tin</w>
pit uitary</w>
man ia</w>
libid o</w>
lap sed</w>
exem pl
e on</w>
cur ves</w>
contribu tors</w>
boo ts</w>
ag in
We ak
Stain less</w>
PROGRAM ME</w>
O live</w>
In fusion</w>
IP v
Bul k</w>
Bratis lava</w>
7. 2010</w>
3. 2008</w>
16 0
е л</w>
trans fusions</w>
tab les
sul phide</w>
remot ely</w>
minim ize</w>
lyophil isate</w>
iv ed</w>
dou bling</w>
do c</w>
chan dis
Sar ah</w>
Over view</w>
EL D</w>
ü c
san itation</w>
ple as</w>
neighb our</w>
m us</w>
il ate</w>
h ills</w>
gradi ent</w>
glucur on
caus ation</w>
au er</w>
advis ors</w>
Th yro
O MC</w>
Ex it</w>
Do c</w>
Binoc rit</w>
B AR
u pl
u ate</w>
reg ain</w>
or ative</w>
ophosph ate</w>
o ther
f m</w>
distur b</w>
dis armament</w>
def erral</w>
cere bral</w>
avi olet</w>
Tricho derma</w>
Phar a
O PC
NE R</w>
Ma h
F ant
Diff erence</w>
C il
An dr
AL IS</w>
separ ating</w>
sec urely</w>
qu est</w>
pre vail
p g</w>
oxy gen
ox idis
mono clonal</w>
k le</w>
inter rup
ic ited</w>
embro id
ell schaft</w>
categor ised</w>
but ter
am ous</w>
V illa</w>
T art
S um</w>
M agn
K ill</w>
Impl ement</w>
G ord
Fl ash
D an</w>
B US
0 50</w>
µ l</w>
tim escal
s ax
py rexia</w>
fe ast</w>
Wor l
Vis it</w>
Pl ates</w>
Mon tre
Mix ture</w>
ID A</w>
H as
Benj amin</w>
xen ophobia</w>
stand ardi
s cor
re wards</w>
prop ell
li vers</w>
lact ate</w>
la c</w>
estim ating</w>
emphas ising</w>
cong regation</w>
Institu tional</w>
H ere
Fin dings</w>
F aero
ECO FIN</w>
4 30</w>
10. 2010</w>
1. 9.2006</w>
sub groups</w>
sty les</w>
sound ness</w>
ref unded</w>
radi on
p es
ol ia</w>
lo os
la ze</w>
k en
hy promellose</w>
graphic s</w>
figu red</w>
endr onate</w>
clos es</w>
but adiene</w>
audi ences</w>
Vir gin</w>
Un employment</w>
SMB V</w>
K now</w>
F DI</w>
Dis c</w>
AM RO</w>
AB N</w>
6 28</w>
w ed</w>
trans formers</w>
the ast</w>
ser otype</w>
s lowing</w>
refin ery</w>
r ush</w>
ont ally</w>
iv er</w>
ic ade</w>
har assment</w>
en atide</w>
dos ages</w>
clarity n</w>
al opecia</w>
VAX PRO</w>
R ated</w>
Psy ch
Prob ably</w>
Pol ysorbate</w>
Neo clarityn</w>
L ip
J UST</w>
H ack</w>
Excep tional</w>
EU LEX</w>
E TSI</w>
B U</w>
35 00</w>
0 40</w>
z ia</w>
un resolved</w>
tw in</w>
th ed</w>
t res
stamp ing</w>
ren ting</w>
re v
re payments</w>
re m</w>
ra emia</w>
jew ellery</w>
j ah</w>
fr agr
degr aded</w>
counter ing</w>
adjuv anted</w>
Z ak
Met al
J azz</w>
J ar
HBe Ag</w>
Gen eration</w>
E EC
At tribu
tu ber</w>
syn cope</w>
se amed</w>
resid es</w>
ral tegravir</w>
ph arm</w>
o ked</w>
kin ase</w>
hyper kalaemia</w>
gr asp</w>
foun der</w>
bel oved</w>
S CE</w>
M mm</w>
LITH UAN
IRE LAND</w>
Fac ilities</w>
Expl os
Commod ity</w>
CONSI DER
C ed
8 89</w>
8 42</w>
5 93</w>
19 56</w>
sli ding</w>
lock wise</w>
irrit ability</w>
infring ing</w>
indem nity</w>
en tions</w>
del icious</w>
dec o
bur gh</w>
achiev es</w>
Sof t</w>
Qu in
Pal m</w>
Har b
Franc isco</w>
Cl ass
CONTI NU
CEP T</w>
C RO
Bure aux</w>
B eg
B 12</w>
5 11</w>
10. 6</w>
è g
vou cher</w>
tur key</w>
p im
nit ting</w>
lob b
it ers</w>
h ul
dir t</w>
diagnos tics</w>
deterior ating</w>
convic tions</w>
circul ate</w>
c locks</w>
as part</w>
anu ts</w>
Ur inary</w>
Su itable</w>
Spec trum</w>
SO s</w>
S B</w>
Promo tional</w>
P UB
Jo h
J UL
Fis cher</w>
EC H</w>
Can not</w>
8 51</w>
7 23</w>
www. ema.europa.eu</w>
ref lux</w>
prosec utors</w>
porno graphy</w>
perfec tion</w>
inclin ed</w>
fruit ful</w>
for t
fil tered</w>
efflu ent</w>
doub ted</w>
condens ation</w>
accompl ish</w>
Valen cia</w>
Sar koz
Publish ing</w>
Pro of</w>
Philis tines</w>
M organ</w>
J im
I OR
HU MAN</w>
Absol utely</w>
A 6</w>
9 10</w>
6 89</w>
5. 2009</w>
under writing</w>
tic ides</w>
sn ack</w>
sc anning</w>
pur ple</w>
pol ys
ophosph amide</w>
oci de</w>
len der</w>
in grad</w>
ic ia</w>
gr af
function alities</w>
fol ia</w>
dro pping</w>
cin ematographic</w>
cin acalcet</w>
all otted</w>
E RENCE</w>
Dis continuation</w>
D ed
Cat aly
CR D</w>
5 82</w>
12 68</w>
tun nels</w>
s &apos;</w>
omyel itis</w>
le er</w>
insec ts</w>
in do
in continence</w>
hi er</w>
e b</w>
and y</w>
align ing</w>
Wi en</w>
Lim its</w>
J ones</w>
II A</w>
H au
H ang</w>
Discus sions</w>
CONCLU SIONS</w>
BEM P</w>
Addi tives</w>
9 71</w>
3 00000</w>
than king</w>
reson ance</w>
res our
quanti fiable</w>
duc ts</w>
dis gu
complain ing</w>
bl ended</w>
Z ar
Str ong</w>
RECOM MEND
K ap
Jans sen</w>
Ed itor</w>
ENVI RON
Consor tium</w>
B lan
AD DI
. j
- 5</w>
w et
ta ire</w>
suff ice</w>
sequ ences</w>
s ocket</w>
ration alisation</w>
in ella</w>
hamp ered</w>
celebr ation</w>
bor on</w>
Val ues</w>
Se x</w>
RF MO</w>
OPER ATIONS</w>
Labor ato
Jacqu es</w>
IT E</w>
D ichlor
Br assica</w>
Bah rain</w>
Ab seamed</w>
70 s</w>
7 20</w>
6, 4</w>
10. 2006</w>
о д
y g
w ick
un commonly</w>
su pranational</w>
squ ares</w>
record ings</w>
oc tocog</w>
not aries</w>
formul ating</w>
enti ne</w>
conver tible</w>
constrain t</w>
champ ion</w>
bene ath</w>
an ian</w>
V EN</w>
Regul amento</w>
RESUL TS</w>
M im
LO C
Flex Pen</w>
E BRD</w>
Arti sts</w>
6 30</w>
11. 2004</w>
ė ž
t -</w>
sugg estive</w>
multipl ier</w>
ground handling</w>
for wards</w>
extru ded</w>
enta iling</w>
cau tious</w>
bra ve</w>
be aches</w>
bast ard</w>
ac uity</w>
T in
Pro lif
N ine</w>
GRO UNDS</w>
Datab ase</w>
DR AFT</w>
6 40</w>
13 42</w>
ucum bers</w>
u th</w>
tob acillus</w>
staff ing</w>
retrospec tive</w>
phys ics</w>
palp itations</w>
p ure
optim ising</w>
op ent
mic ron
iso propyl</w>
in correctly</w>
fl ute</w>
c asing</w>
amor tisation</w>
Y ep</w>
Tim es</w>
Te tr
Scot tish</w>
Sarkoz y</w>
S ak
Rem ov
R ain
NO TE</w>
N m3</w>
K A
Jos hua</w>
Hy bri
G s</w>
FUN D</w>
F ru
D H</w>
B ren
3 10
viol ate</w>
si de
ri fab
relig ions</w>
q .</w>
p ick
moul ding</w>
lo op
il ia</w>
bis phosph
alleg ation</w>
agen icity</w>
X VIII</w>
Trac leer</w>
Ti bet</w>
TI P</w>
Sk ager
S pot</w>
Pop ular</w>
O OD</w>
HC l</w>
H EI
ET F</w>
Cre ation</w>
Bud gets</w>
9 74</w>
3 97</w>
19 51</w>
un safe</w>
st ab
reflec tive</w>
prerog atives</w>
ou l</w>
or ic</w>
ne ur</w>
he a</w>
favour ably</w>
est e</w>
bul b</w>
bio ethanol</w>
ambo o</w>
Thro mbo
Prepar ing</w>
Meth od
M N</w>
IC Ts</w>
Enter tainment</w>
CON F
C EE
5 04</w>
4 58</w>
sk ull</w>
re allocation</w>
publish ers</w>
ophil us</w>
ob o
gar dens</w>
ess ors</w>
ec urity</w>
ball ast</w>
arrhyth mia</w>
accoun tancy</w>
a the
T im</w>
S ven
Mari o</w>
K il
Gl uc
F AB
Bo at</w>
AL U
sp ic
sh oc
ser a</w>
rou tin
robo t</w>
pot ash</w>
pix words</w>
govern or</w>
f ainting</w>
encephal opathies</w>
em an</w>
do or
d ell</w>
d ancing</w>
cr anes</w>
conduc ts</w>
c ally</w>
V TE</w>
Tow er</w>
REPOR TING</w>
Par tial</w>
Mor ning</w>
J UR
ID EL
H ans
Fac to</w>
Dy namic</w>
C UR
19 49</w>
1. 2008</w>
y ne</w>
trol ley</w>
s our</w>
quin oline</w>
promp ted</w>
om im
molyb denum</w>
lin ings</w>
glu con
f an
co asts</w>
civil ization</w>
ble ed</w>
and the</w>
al caemia</w>
Vladim ir</w>
V assi
S hal
No tified</w>
Fish ery</w>
C BS</w>
4 77</w>
10 73</w>
w ounds</w>
solub ility</w>
rifab utin</w>
poly esters</w>
oper a</w>
ish op</w>
index .
in capable</w>
fore ign
erythem at
ef ly</w>
dro pper</w>
V oting</w>
U K
T arc
Se imas</w>
Re Facto</w>
Off ices</w>
Lu g
Lan tus</w>
L G
FF T</w>
Arch ives</w>
9. 2009</w>
4 61</w>
3. 3.1</w>
y lo
th ered</w>
str ati
routin ely</w>
pol ishing</w>
oestro gen</w>
ob acter</w>
met acresol</w>
head gear</w>
h es</w>
flo at</w>
fertilis ing</w>
disbur sement</w>
di az
def ended</w>
construc tions</w>
bu m
ad ul
accumul ate</w>
T win
SC O</w>
Qu ot
Mar ks</w>
K IC</w>
IN A</w>
Co ol</w>
Clean er</w>
B us
9 80</w>
7. 7.
7 97</w>
4 17</w>
31. 10.2003</w>
17 02</w>
14 51</w>
èg lement</w>
ung s
un lock</w>
t ant
t angle</w>
ste aming</w>
st ati
s wor
pre clinical</w>
porte dly</w>
mol ar</w>
ip er</w>
dep ths</w>
at ar</w>
ai ah</w>
adren aline</w>
Viet nam
Ti bet
Th or
TI PS</w>
Spir its</w>
S AR
R M</w>
Or chestra</w>
Montre al</w>
K itch
IR IS</w>
EX IS
De al</w>
Adri atic</w>
un well</w>
tus sis</w>
sh aken</w>
merck .</w>
jack et</w>
in definite</w>
hair cut</w>
bin der</w>
ass ed</w>
adap tability</w>
acad emia</w>
YE AR</w>
VAL UE</w>
Skager rak</w>
Sax ony</w>
S imply</w>
Mul lah</w>
IN TEN
CER TAIN</w>
Bot tle</w>
8 20</w>
5 70</w>
sol em
min i
lau gh</w>
is ms</w>
invest ee</w>
exacerb ated</w>
congrat ulations</w>
be en
b b</w>
ab l
S erial</w>
S eb
R H
POR TU
Lac tobacillus</w>
J en
Hydro xy
D ERS</w>
Consi der</w>
C LE
B each</w>
Att achment</w>
Ass ad</w>
AT OM</w>
6 74</w>
w all
t estic
remin ds</w>
quor um</w>
nit ric</w>
l ag
cr ush</w>
anomal ies</w>
adv ancement</w>
Tem ozolomide</w>
TH ERE
Sm ith</w>
Res ear
POS ED</w>
O edema</w>
N ames</w>
INVES TIGATION</w>
Hen ry</w>
E igh
Du f
Cat tle</w>
6 13</w>
5 57</w>
ό ς</w>
v as</w>
tax is</w>
pro pen
over heads</w>
or o</w>
motor way</w>
e ed
def er</w>
cl icking</w>
ank ylosing</w>
al ous</w>
VI A</w>
Tarc eva</w>
S id
S ear
PAC T</w>
L da</w>
J our
H PAI</w>
Del ta</w>
A IS</w>
6 34</w>
6 08</w>
sup press</w>
sequ el
rot ated</w>
road side</w>
ris t</w>
perpetr ators</w>
occup ations</w>
motor ways</w>
mollus c</w>
k is</w>
in ches</w>
imp at</w>
ha uli
ex otic</w>
el et</w>
cy stic</w>
conduc tors</w>
cher ries</w>
ax a</w>
M ut
Li z</w>
L ess
De ad</w>
5 A</w>
5 ,000</w>
sequel ae</w>
recal cul
pro ven
powi at</w>
pe dal</w>
pa ve</w>
over load</w>
k ov</w>
illum inated</w>
ge ese</w>
cycl ophosphamide</w>
c ed
addres sees</w>
V impat</w>
Sa ar
Re placement</w>
P AN
Im atinib</w>
Harmon isation</w>
Bas ket
4 44</w>
0. 000</w>
sub divisions</w>
stri kes</w>
s. r.
per oxide</w>
gre ening</w>
g ig
dis appearance</w>
ac aftor</w>
S leep</w>
In no
IV a</w>
Hol land</w>
Ex elon</w>
Copy right</w>
5. 2.1</w>
w ax
u gen</w>
t etanus</w>
s inks</w>
ol amento</w>
mother fucker</w>
lin ess</w>
le ware</w>
igh bor
hon estly</w>
glut en</w>
e ks</w>
coun sel
arch ive</w>
a than</w>
Vietnam ese</w>
Ste ady</w>
S urg
OH SS</w>
NG L</w>
Lu kas
ID ES</w>
G AR</w>
11. 2.
üc ken</w>
uni tions</w>
tur bul
tremend ous</w>
soldi er</w>
si vity</w>
s cour
respon dent</w>
minim a</w>
k N</w>
gr ubbing</w>
ge opol
d est</w>
consor tia</w>
bro ker</w>
Stake holder</w>
Pro posed</w>
M id</w>
Leu k
D ates</w>
Arch ive</w>
4 73</w>
4 0,000</w>
ū nas</w>
plan etary</w>
norm alisation</w>
li qu
leng ths</w>
ha vens</w>
g ard</w>
egal y</w>
cos mic</w>
cobal t</w>
Tok yo</w>
Str a
Si erra</w>
Produc tivity</w>
NC A</w>
N an
L ym
IS M</w>
Fe eling</w>
An gl
Al right</w>
9 A00
suff ers</w>
plas tic
ox amine</w>
ki ah</w>
im peri
id aemia</w>
i z</w>
gar age</w>
fir o</w>
escap ed</w>
en acted</w>
dis proportionately</w>
dimin ish</w>
coumar in</w>
contrac tion</w>
Resol utions</w>
R il
Protec ted</w>
Po ker</w>
N eb
C ap</w>
B ILITY</w>
6, 7</w>
3A 001.
3. 2.3</w>
20 37</w>
17 01</w>
par alysis</w>
o h
it alia</w>
ip es</w>
high way</w>
fl or
ess ences</w>
che apest</w>
bu vir</w>
am ia</w>
aldoster one</w>
Re funds</w>
Peri pheral</w>
N FE</w>
3 2.
tax i</w>
roti gotine</w>
phot oc
on tia</w>
metro politan</w>
inhib itory</w>
hind ered</w>
col oration</w>
ab ul
Reserv ation</w>
Kid ney</w>
K ris
Ex istence</w>
Diagn ostic</w>
4. 2.3</w>
stra at</w>
sal ad</w>
r ashes</w>
ply wood</w>
om y</w>
ol u
no zzle</w>
multic entre</w>
fix tures</w>
dict ator
co bic
br ation</w>
arti kel</w>
ad sor
T est
She ep</w>
SW ED
S pot
S ant
Re duce</w>
Provin cial</w>
Or th
MON IT
G ot
FIS HING</w>
E is
Bri dge</w>
BO UR
A y
8. 2006</w>
4 59</w>
119 8</w>
yan g</w>
tw isted</w>
stimul ated</w>
reinfor ces</w>
ran ial</w>
program me
melan oma</w>
fix ation</w>
endeav ours</w>
dere cogn
contribu tor</w>
ay e</w>
Tox ic</w>
P B</w>
Leon ardo</w>
Jon athan</w>
G ear</w>
FD LR</w>
Da firo</w>
12 35</w>
wo ods</w>
vou chers</w>
re surrec
p ains</w>
out lining</w>
ori ent
nan omat
mod ality</w>
k nees</w>
k it
har dness</w>
cal c
bul letin</w>
bal lot</w>
V ä
Sust ained</w>
S ACE</w>
Muham mad</w>
Malm ström</w>
L H</w>
Inter actions</w>
II b</w>
G el
For d</w>
AI M</w>
ADV ATE</w>
0 60</w>
tel em
tach ograph</w>
str anger</w>
pr inters</w>
pi virine</w>
out dated</w>
nur ses</w>
new est</w>
mel amine</w>
inter rog
histor ically</w>
gen es</w>
classi fying</w>
c r</w>
amor tised</w>
am ate
Tur ning</w>
Tox icity</w>
T OL
Suppl ier</w>
P SA</w>
Inhal ation</w>
EUR ATOM</w>
Dub ai</w>
Diff erences</w>
D N</w>
B ond</w>
Ap point
An drew</w>
5 89</w>
12. 2003</w>
1 1,
е н</w>
tr as</w>
pu y</w>
pre neur</w>
os buvir</w>
mal administration</w>
in adver
im men
extern ally</w>
erc o</w>
eber ries</w>
diver gence</w>
decor ated</w>
d oms</w>
char ts</w>
Ver ts</w>
R est</w>
Lukas hen
I PCC</w>
H ow
FRO N
Erythro poi
Di am
Derog ation</w>
Decre ased</w>
9 63</w>
6 12</w>
4 88</w>
3. 2009</w>
л и
tum ors</w>
trav eling</w>
the ir
tap ping</w>
roman tic</w>
log 10</w>
leng th
for the</w>
b laz
aspir ation</w>
ar thro
ang el
Y ING</w>
WP. 29</w>
Transi ent</w>
Thessalon iki</w>
Te ams</w>
Rep ay
R AS</w>
Pro met
Nor disk</w>
NE THER
Munici pal</w>
Mer cury</w>
Marse ille</w>
Jon as</w>
Instruc ts</w>
Euro group</w>
EN ISA</w>
Diff icul
Ben el
AM L</w>
thromb ocytop
stad ium</w>
rear ward</w>
pr anavir</w>
p ity</w>
orth ostatic</w>
mono amine</w>
la in</w>
isol one</w>
internation alisation</w>
graph s</w>
fir st
el or</w>
cre ws</w>
chromat ography</w>
bund le</w>
broch ure</w>
bow l</w>
benz oic</w>
b illing</w>
ash amed</w>
asc ending</w>
appen ded</w>
Verord nung</w>
UN HCR</w>
TRANSI TIONAL</w>
Sho ot</w>
Inter mediate</w>
In dependence</w>
IS K</w>
F P</w>
8 04</w>
5. 2004</w>
12 23</w>
uni qu
to f
sustain ably</w>
st om</w>
se ines</w>
ren ted</w>
progres sed</w>
pre determined</w>
per centi
mph ony</w>
ik in</w>
emb ossed</w>
ee k</w>
dur ance</w>
diver ging</w>
descrip tive</w>
custom ary</w>
alk ali</w>
al arms</w>
ad he
accept ability</w>
ZAN U</w>
Vari able</w>
Standardis ed</w>
Schem es</w>
Princi pal</w>
P c
Or ders</w>
Op .</w>
L ap
IN R</w>
II I.
F igh
Di visions</w>
D AC</w>
Cop alia</w>
Con fig
Ch ap
Benel ux</w>
8 67</w>
6 65</w>
6 22</w>
w ins</w>
tol ls</w>
spec ts</w>
on ment</w>
man ship</w>
gluc os
g ear
distil l
con glomer
c f</w>
bre ached</w>
assemb ling</w>
a or
Wid th</w>
T um
Prolif eration</w>
N m</w>
Indic ations</w>
Hor n</w>
EM SA</w>
DI N</w>
D 3</w>
CR A</w>
Ber n
8 44</w>
8 07</w>
6 20</w>
20 31</w>
10 01</w>
1 16
tin i</w>
teas poon</w>
sou p</w>
remov able</w>
re acted</w>
pro min
path ological</w>
met a</w>
lubric ating</w>
im od</w>
h mm</w>
ex cur
enter itis</w>
compl i
cobic istat</w>
cand les</w>
Trans position</w>
Sh we</w>
Rem icade</w>
R 0
M AG
LE O</w>
Ke eping</w>
H PLC</w>
FR U
EO US</w>
EM I</w>
Co coa</w>
CATEG ORY</w>
B is</w>
B ag
Adjust er</w>
5 90</w>
о р
z ir</w>
w rap</w>
view point</w>
u ously</w>
summar ized</w>
ro y
ris ed</w>
oxid ative</w>
no s</w>
har sh</w>
falsi fied</w>
down loaded</w>
dispen sing</w>
de pressive</w>
bre eders</w>
bin ders</w>
al s
Venti lation</w>
S NE</w>
Requi re
Re place</w>
Paste ur</w>
N P</w>
IR E</w>
H 2</w>
Flash lights</w>
E 1</w>
8 08</w>
5. 2007</w>
3, 7</w>
10. 10.
1. 15</w>
. 5</w>
ί α</w>
ti vitis</w>
thi er</w>
ther ine</w>
sur rendered</w>
rejo ice</w>
re deemed</w>
au ght</w>
W ire</w>
S 1</w>
IN S</w>
Georg ian</w>
Ex tracts</w>
Dis pose</w>
Co op
C XL</w>
7 47</w>
7 00
2 160</w>
12 51</w>
up stairs</w>
un reported</w>
str ings</w>
pun cture</w>
proph ylactic</w>
oste onecrosis</w>
ori fic</w>
monopol ies</w>
mis matches</w>
m ating</w>
j ute</w>
hol inergic</w>
fos amprenavir</w>
dev ise</w>
coinci de</w>
ch in
but ane</w>
TE STS</w>
Refuge es</w>
P in
Ori on</w>
OPC W</w>
Mor t
M IC</w>
Hand ling</w>
Ge o
F A
EE T</w>
B erg
5 31</w>
3 1
á r
utilis e</w>
uter ine</w>
resum ption</w>
publish es</w>
phenyl alanine</w>
me asles</w>
journ als</w>
intoler ant</w>
inf used</w>
harb our</w>
follic les</w>
f ted</w>
el ite</w>
deal ings</w>
c ans</w>
borrow ed</w>
b ic</w>
aver aged</w>
ar ipi
all ergies</w>
SW F</w>
P ear
M ong
L IS</w>
I ne
Go ing</w>
G N</w>
F IC</w>
Duf erco</w>
Dem onstr
Cors ica</w>
Arbitr ation</w>
A ro
A lis
6 14</w>
19 55</w>
worth while</w>
ur ry</w>
tr is
sustain ing</w>
refu ge</w>
re y</w>
per imeter</w>
oter ol</w>
diplom acy</w>
br illiant</w>
ati vity</w>
aripi prazole</w>
amb ass
Wh eat</w>
Tel zir</w>
S Z
Respec t</w>
Rem oval</w>
Re actions</w>
Lo to</w>
In sufficient</w>
CLAS S</w>
C Bs</w>
A cl
w adding</w>
uter us</w>
under goes</w>
un necessarily</w>
tripl a</w>
the ophylline</w>
sun flower</w>
spo on</w>
paras ites</w>
ot te</w>
n if
ments. net</w>
h il
ford shire</w>
for tune</w>
democrati cally</w>
contin ents</w>
bron chospasm</w>
ben ding</w>
at orial</w>
adver ts</w>
W D</w>
V ig
Strateg ies</w>
Require ments.net</w>
Phara oh</w>
Pc Requirements.net</w>
L P</w>
H all
B one</w>
B AL</w>
AC C</w>
A tripla</w>
5. 10</w>
w ells</w>
ureth ane</w>
trap ped</w>
tar ines</w>
st ole</w>
sor ship</w>
p us</w>
notic eable</w>
neglec ted</w>
inter nal
ide ally</w>
icul ture</w>
g out</w>
di arr
ballo on</w>
ab sur
Restaur ant</w>
R VR</w>
Partic ularly</w>
No tifications</w>
F ully</w>
E ar</w>
DO C</w>
D oses</w>
4 2
wat ch
un manned</w>
tim etables</w>
res et
rel las</w>
reaf firm</w>
progen itor</w>
pep ti
n ul
k el
ind exed</w>
emb er
cru shing</w>
bread th</w>
artic hokes</w>
anticoagul ant</w>
anc ers</w>
UN ESCO</w>
MF s</w>
Kitch en</w>
9 34</w>
z ab
tap es</w>
sur f
stru ggling</w>
rob bery</w>
r ys
par turition</w>
mil l
it z</w>
fin s</w>
eb all</w>
e dit</w>
d abigatran</w>
cher ry</w>
at omic</w>
as tically</w>
amphet amine</w>
ad mi
V IIIa</w>
TI N
Sub jects</w>
St rep
Pen fill</w>
N MS</w>
ME IP</w>
L os
D aughter</w>
Confi dentiality</w>
Con crete</w>
Bor tezomib</w>
Bo y</w>
5 73</w>
12 21</w>
- 0.
wi g</w>
ris peridone</w>
mor atorium</w>
journ alist</w>
innov ate</w>
horiz ontally</w>
fol ks</w>
elec oxib</w>
deplo ying</w>
char ity</w>
Z E</w>
Pro v
Pi x
Architec ture</w>
7 07</w>
6 3
5 51</w>
11. 10.1993</w>
stop pers</w>
phy to
p ies</w>
l ysis</w>
j u</w>
f aint</w>
er sel</w>
cop enia</w>
al istic</w>
Vor iconazole</w>
OF I</w>
O T</w>
LI KE</w>
I AS
H 1
Diab etes</w>
AIF Ms</w>
8 05</w>
2. 1.1</w>
u z
tw ist</w>
rul ers</w>
over ly</w>
on the</w>
mir acle</w>
foreg round</w>
er ce</w>
balcon y</w>
L 1</w>
INSTRU MENTS</w>
CE L</w>
BA N</w>
Al bu
Ad ded</w>
10 13</w>
ul ins</w>
sli des</w>
shif ted</w>
ro p
rhin o
grass roots</w>
fl int</w>
en ius</w>
broadca ster</w>
bas s</w>
anal og
ab ling</w>
Zh ong
Star bucks</w>
Soci alists</w>
SYSTE MS</w>
Or d
OPER ATIONAL</w>
H ell</w>
un secured</w>
selec tively</w>
s ink</w>
res sed</w>
read ings</w>
predn isone</w>
pr ince</w>
pr amine</w>
pig ments</w>
pati ence</w>
organis ers</w>
ne on
identi ties</w>
fin alise</w>
el ong
develop er</w>
S MP</w>
Ris ks</w>
Promet ax</w>
Magne tic</w>
Kal in
Gad us</w>
Cust omers</w>
CI ALIS</w>
B oli
B OR
y ol
wi pe</w>
sup porters</w>
smar t
ro tor</w>
plac ements</w>
om onas</w>
menstru al</w>
jeopardis ing</w>
immun ogenicity</w>
forec asting</w>
f lies</w>
be i</w>
al izing</w>
U ARY</w>
Sam ples</w>
S ever
S BA</w>
R if
MO DEL</w>
Lev ites</w>
G ros
Ele k
Ch am
Alex and
5 62</w>
19. 5.2005</w>
ycl o</w>
ur ination</w>
tis one</w>
th umb</w>
testi mony</w>
stret ched</w>
so da</w>
se a
ro und
repl icate</w>
over laps</w>
over haul</w>
net ted</w>
inter regional</w>
dial og</w>
broadca sts</w>
ble aching</w>
b ris
Vir g
So on</w>
Perfec t</w>
Opin ions</w>
M ü
LE VEL</w>
L AM
Hyper tension</w>
Cat ch</w>
C 12</w>
An gol
Acc ess
4 63</w>
vir ase</w>
vail ability</w>
til la</w>
sul furon</w>
sho ots</w>
sequ ential</w>
seg mentation</w>
pro m</w>
p ockets</w>
over run</w>
or n</w>
lique ur</w>
k ie</w>
ill o</w>
hydr ated</w>
ge al</w>
endor sements</w>
disru ptions</w>
ca ff
br ass</w>
b ail</w>
av as</w>
artic ulated</w>
aband onment</w>
ab sc
Vill age</w>
SU N</w>
P 2</w>
NETHER LANDS</w>
Lo ading</w>
Exem ptions</w>
Comp act</w>
Classi c</w>
Bon n</w>
BT WC</w>
6. 1.
4 66</w>
4 46</w>
2. 2006</w>
- one</w>
tab ern
st ag
set up</w>
se ised</w>
rol lers</w>
real ising</w>
re processing</w>
oc rit</w>
multi modal</w>
lia m</w>
in hibiting</w>
ic ides</w>
fu elling</w>
ere rs</w>
den i
d t</w>
buff alo</w>
bios ecurity</w>
at torney</w>
Z aw</w>
V IS
S hap
PSU R</w>
O US</w>
M es
H mm</w>
D raw</w>
Cli k</w>
An dy</w>
AT ORY</w>
AD I</w>
30.6. 1995</w>
1 17
án dez</w>
www. ec
se ine</w>
region alisation</w>
qu art
par a
ov ich</w>
oen ological</w>
nor m</w>
margin alised</w>
k ills</w>
dri ft</w>
cabin et</w>
asser tion</w>
all er
ag raf</w>
Vy tautas</w>
V a
SE K</w>
Raf ah</w>
LT L</w>
I ersel</w>
Flo rence</w>
F ar</w>
En cour
Ad vice</w>
5 44</w>
23 42</w>
thro wing</w>
str on
sol o</w>
schedul ing</w>
proven ance</w>
pro p</w>
ox ins</w>
ol i</w>
mon t</w>
flu conazole</w>
di one</w>
dev ised</w>
dec on
avo ids</w>
arith metic</w>
anti diabetic</w>
Z O
SW IFT</w>
REL ATED</w>
Pr ad
Phil ip
Opti Clik</w>
Min ister
Jus tification</w>
H ans</w>
Gly cer
GH TS</w>
F ight</w>
CAP ITAL</w>
Bankno tes</w>
B less
5, 0</w>
28 26</w>
y d</w>
vis itor</w>
view ers</w>
vers ati
ta m</w>
t ages</w>
rot ate</w>
prev ent
pi re</w>
ob tains</w>
man ikin</w>
le sion</w>
le ases</w>
instan taneous</w>
h ello</w>
enz ootic</w>
en do
clou ds</w>
che z</w>
anch or</w>
all i</w>
ali phatic</w>
Ter restrial</w>
Se ed</w>
R ach
M MFs</w>
Lux SCS</w>
IT T</w>
H id
Foot ball</w>
E a
De struction</w>
D ir
Ch ron
Cer tain
Car cin
CON SOLID
3 94</w>
2 A.
tw o
to k
s ounding</w>
rec ept
nico tinic</w>
n is
lipo dystrophy</w>
kin dness</w>
if lu</w>
grap efruit</w>
funda ment
enthusi asm</w>
de em
d ella</w>
back grounds</w>
aw ait</w>
air way</w>
ab o
T ay
T W</w>
SAF ETY</w>
R al
Pot ato</w>
Oblig ation</w>
L ag
ISI N</w>
E sch
Dyn astat</w>
Cho ice</w>
CON TRIBU
C red
Bat aller</w>
8 84</w>
7 48</w>
17 60</w>
summar ises</w>
repatri ation</w>
pen insula</w>
over looked</w>
occ er</w>
n il</w>
mal todex
ix ate</w>
gel atine</w>
en der</w>
em pir
ed ic
duc k</w>
car til
aver ages</w>
assign ments</w>
ab rupt</w>
Z omet
WITH IN</w>
VF END</w>
Semin ar</w>
SE L</w>
Regul ation
Mus lim</w>
In virase</w>
Hel ixate</w>
G P
Ethi opia</w>
C oc
5 13</w>
sp un</w>
polys ac
oun der</w>
lign ite</w>
li pi
j ournal</w>
illustr ation</w>
hun t</w>
gre ener</w>
exc eed
ester ase</w>
ep ith
divest ment</w>
depos itors</w>
d un
d ential</w>
correspon dent</w>
contrac tually</w>
ac a</w>
Zomet a</w>
SU GAR</w>
Direc tion</w>
CER s</w>
C 8</w>
Bu ch
APPROV ED</w>
6 86</w>
0 14</w>
Š ia
transl ating</w>
spac ecraft</w>
re produce</w>
re assessed</w>
program m
prof essor</w>
impro per</w>
eri fied</w>
ep age</w>
d L</w>
co res</w>
cap tivity</w>
brut al</w>
Tr in
Sil icon</w>
Rom puy</w>
Respon ses</w>
Rec ipes</w>
Nex Gen</w>
Mig uel</w>
Mat the
Do ing</w>
D ress</w>
C MR</w>
tre asure</w>
sp as
ski p</w>
simpl icity</w>
share holdings</w>
sh asa</w>
rec order</w>
quot ation</w>
p reg
ket a</w>
j el
is ions</w>
har dened</w>
gh ost</w>
fl are</w>
f ledg
capac itors</w>
Tam iflu</w>
N SA</w>
M erg
L es</w>
H a</w>
Gener alised</w>
C ut
BO TT
Ammon ium</w>
7 -</w>
25 71</w>
yn geal</w>
trans itory</w>
sin us</w>
she ep
re no
prim itive</w>
ofil ament</w>
o i
ile ad</w>
glucur onide</w>
fr aming</w>
flat ulence</w>
del aying</w>
c ensus</w>
b lown</w>
St om
REF ERENCE</w>
PL US</w>
L as</w>
Hosp ital</w>
DA Q</w>
D anny</w>
B road</w>
Adv agraf</w>
AN A</w>
9. 3.2005</w>
25 80</w>
. G
tec avir</w>
te e
swe at</w>
sw im</w>
see ker</w>
re vel
ran ks</w>
pro gn
per tussis</w>
n n</w>
multi media</w>
k ern
illum inating</w>
hed ges</w>
fe ared</w>
euro zone</w>
detail ing</w>
de formation</w>
c lockwise</w>
anti -</w>
ancho red</w>
ad is</w>
acet one</w>
Kin shasa</w>
Dis closure</w>
CRI TERI
BL UE</w>
6. 2003</w>
4 91</w>
4 90</w>
3. 12</w>
17. 7.1999</w>
12 58</w>
10 04</w>
vig orous</w>
remov es</w>
rec oxib</w>
predn isolone</w>
ome prazole</w>
ob iliary</w>
heter ogen
ear ity</w>
di asis</w>
del eting</w>
borrow ers</w>
b anning</w>
appe aled</w>
ad ings</w>
a mentary</w>
Zer it</w>
Y a
Un cle</w>
Prog ressive</w>
Ph ilip</w>
NAS DAQ</w>
Leg o</w>
FRA ME
Dim itri
De ad
Au x
An dean</w>
Acknowledg es</w>
Ab normal</w>
AC TIONS</w>
7 88</w>
vi x</w>
un interrupted</w>
ultr aviolet</w>
si eve</w>
pun ish</w>
paraff in</w>
oci des</w>
k ok</w>
en um
el ty</w>
draw bar</w>
dB m</w>
bor g</w>
b less</w>
b ak
arr ays</w>
VO C</w>
T ariffs</w>
Poker Stars</w>
P SI</w>
F lem
F atigue</w>
Excell ence</w>
Ex ha
Erythropoi etin</w>
C utting</w>
8 09</w>
14 th</w>
var ic
um en</w>
rep o</w>
predec essor</w>
mil it
macro gol</w>
le b
lad der</w>
is y</w>
imp s</w>
im printed</w>
f icial</w>
em powering</w>
elec tive</w>
el oda</w>
cumul ated</w>
ch ip
bos entan</w>
at ted</w>
ap am
Z y
W W
U se
SP s</w>
Radi o
R ud
Pri orities</w>
G H</w>
En joy</w>
Cauca sian</w>
C ov
8 65</w>
6 06</w>
10 51</w>
z stan</w>
writ ers</w>
vo or</w>
ster ols</w>
occup y</w>
n y
l ane</w>
ick ers</w>
i p</w>
haul age</w>
edi pine</w>
coc ci
authentic ated</w>
ast on
ar rows</w>
T akes</w>
Sign alling</w>
P Is</w>
N au
LEG AL</w>
IC S</w>
F uk
7 74</w>
5, 7</w>
4 57</w>
. net</w>
&apos; clock</w>
viol in</w>
tra jec
tr i</w>
st ur
reciproc ating</w>
poly amide</w>
percep tions</w>
p cs</w>
o vi
numer ically</w>
im pressed</w>
heav ens</w>
equip ments</w>
em bo
con tends</w>
ari x</w>
acad emics</w>
X eloda</w>
Th ought</w>
Sub stan
St eph
OR ING</w>
O .
K ev
Cur ie</w>
4. 2007</w>
............ ....</w>
v et
tigh tening</w>
st asy</w>
shr ink</w>
recommen ding</w>
p assi
os cill
oph os</w>
op ing</w>
obenz ene</w>
hydroxy ethyl</w>
din ium</w>
defen ders</w>
brok ering</w>
ben ec
acknowledg ing</w>
R emer
R F</w>
PROV IDED</w>
P LI
Lac tation</w>
G MT</w>
F lower</w>
Connec t</w>
Basket ball
Al stom</w>
Addres sing</w>
yl amino</w>
surviv or</w>
shor ts</w>
scre ened</w>
ro yal</w>
reticul ocyte</w>
pr un
por tr
om b</w>
mis used</w>
lob by
lipi ds</w>
in fin
in ert</w>
i odi
et on</w>
emb ark</w>
back wards</w>
aw s</w>
amen ities</w>
V M</w>
V EI
T oler
St ark</w>
SH IP</w>
O pr
Novo Seven</w>
Novo Let</w>
Measu rements</w>
J in
DEN MARK</w>
C ELL
Bat tery</w>
Bang kok</w>
B ak
A ub
0, 00</w>
reg ated</w>
r pm</w>
provin cial</w>
practi se</w>
milli grams</w>
m ica</w>
fri gh
em placement</w>
el u
el in</w>
disc over
cul arly</w>
cor tisone</w>
con spic
comb us
aw ful</w>
ZYP RE
ZYPRE XA</w>
VI a</w>
To ys</w>
Ri b
Qu ite</w>
Hebre w</w>
F ul
Basketball Zone</w>
6 83</w>
wh oever</w>
pen ta
op ol</w>
iss ance</w>
isol ate</w>
g org
furn ish</w>
er min</w>
dru g
bid der</w>
algorith ms</w>
Verord ening</w>
UL E</w>
Remer on</w>
R un
Poul try</w>
N ow
Ly on</w>
For t</w>
BE NE
5 58</w>
200 9
vin yl
pun ch</w>
perce ive</w>
ox aban</w>
op al
objec ted</w>
navig ational</w>
hex ane</w>
con e</w>
aff iliation</w>
U R</w>
Shi eld</w>
Sam uel</w>
Qual ifying</w>
OL S</w>
Conver ter</w>
Car ton</w>
C amp</w>
Brand t</w>
Adv ance</w>
AO E</w>
5 41</w>
ń sk</w>
yl ates</w>
t art
repe ating</w>
reb ounds</w>
re considered</w>
os el
opi oids</w>
f ting</w>
erron eous</w>
epith el
cut lery</w>
cath eter</w>
anim ation</w>
RES OUR
Pig s</w>
Pan ama</w>
NO TI
L ock</w>
Cour se</w>
Cor rid
Coordin ator</w>
Busin esses</w>
B RI
7 57</w>
17. 12.
11. 2</w>
0 1
- Yes</w>
transport ers</w>
supple mentation</w>
supple mental</w>
spo il</w>
ru b</w>
ren ders</w>
ra x</w>
n ails</w>
la ur
induc ing</w>
g ul
fl our
er ci
er able</w>
e le</w>
dynam ism</w>
comm ands</w>
aspir in</w>
an us</w>
al tering</w>
a ther
X IX</w>
Sap ard</w>
Relig ious</w>
L yn
IC C</w>
G SC</w>
D EL
6. 8.
5 8.
- N</w>
utilis ing</w>
subscri ber</w>
strateg ically</w>
retrospec tively</w>
ren umbered</w>
re par
re f</w>
pur a</w>
on board</w>
nam ics</w>
lo yal</w>
les see</w>
had dock</w>
cri ptions</w>
a at</w>
TI S
Previ ously</w>
Port fol
OB LIG
N EU
K et
G L</w>
G FR</w>
E ve</w>
Dis ability</w>
AC T</w>
19 46</w>
11. 3</w>
suc kler</w>
sh allow</w>
scal ing</w>
ol eptic</w>
lu tide</w>
laun ches</w>
k g
i odine</w>
design ers</w>
b other</w>
an za</w>
Tru ck</w>
T rit
S B
M Wh</w>
Lev emir</w>
IN O
GAL I
Fi b
Er n
Ad diction</w>
7 93</w>
än der</w>
yiel ded</w>
the sia</w>
oper able</w>
obe y</w>
hal f
g ums</w>
dra ined</w>
ass ent</w>
VEI LL
VEILL ANCE</w>
Shi p
Rec ycl
NU MBERS</w>
Infec tion</w>
Ib erian</w>
INTERES TED</w>
Ham as</w>
Attribu tes</w>
won ders</w>
un cle</w>
symb ol
repres sive</w>
pip ette</w>
ost at</w>
mon ster</w>
it orial</w>
inter modal</w>
in adequately</w>
hon ey
ge usia</w>
focus sed</w>
fo et
est u
cur tain</w>
cur b</w>
conduc tive</w>
celebr ated</w>
car pet</w>
bro kers</w>
av ery</w>
Ré union</w>
J ak
AD ER</w>
6 49</w>
5 56</w>
4 48</w>
20 26</w>
. 90</w>
ut terly</w>
rec ur</w>
re start</w>
re bound</w>
pa stry</w>
noti fies</w>
mac ular</w>
fas hi
ess ness</w>
es co
dis crete</w>
cri tically</w>
b if
acc us
V AS</w>
Ul timately</w>
Trans atlantic</w>
T asm
Sec ure</w>
SUR VEILLANCE</w>
ST A</w>
Prolong ed</w>
Poly ethylene</w>
Institu t</w>
IG H</w>
Fit ness</w>
F IT
F CH</w>
Exclu sive</w>
7 29</w>
19 48</w>
z g
www. ef
than ked</w>
ques tioning</w>
pell et</w>
pa res</w>
over time</w>
open ings</w>
od our</w>
narr ative</w>
mor ontia</w>
los es</w>
inhab ited</w>
hor ns</w>
h ubs</w>
enti n</w>
di meth
compos er</w>
c rap</w>
ak is</w>
SYRING E</w>
Multi lateral</w>
MEAS URE</w>
Kyrgy zstan</w>
Inv ent
Gu yana</w>
Genu air</w>
GRAP H
EMP LO
Connec tion</w>
Cl oud</w>
C od</w>
9. 2007</w>
- It</w>
ц ия</w>
wel coming</w>
us en</w>
tra its</w>
th readed</w>
t sch
struc turally</w>
s port
rever sing</w>
po x</w>
po ison</w>
len ders</w>
it ated</w>
in ver
in et</w>
ic ation
hal i
gu it
eren cing</w>
d led</w>
corne al</w>
char itable</w>
best ow
b x</w>
auc tioned</w>
Wil liam</w>
Re fin
P ret
MONIT ORING</w>
I bra
H UN
ES E</w>
Cons isten
Chang ing</w>
Buil dings</w>
sw ing</w>
sn ake</w>
re structured</w>
r one</w>
lum ps</w>
if ers</w>
gel atin</w>
fun gin</w>
fin alisation</w>
en ne</w>
conc ise</w>
ch im
amp ing</w>
activ ating</w>
Un specified</w>
Tom atoes</w>
R WA</w>
N EC</w>
GALI LEO</w>
Fol der</w>
Col lateral</w>
B OR</w>
Associ ations</w>
Al italia</w>
6 70</w>
5. 11</w>
11. 2010</w>
1, 9</w>
under went</w>
un ite</w>
um umab</w>
ta via</w>
s icum</w>
res et</w>
r habdomyolysis</w>
pix els</w>
pip ettes</w>
organiz ing</w>
ne ighbor
it t
invo iced</w>
ex pulsion</w>
d les</w>
bo om</w>
ad sorption</w>
X en
MT X</w>
MA O</w>
K im</w>
IN ST
IN SPEC
H G</w>
FRAME WORK</w>
Ex tra
E pi
Accoun tancy</w>
AR DS</w>
7 37</w>
22 20</w>
2 30
ê u
z irconium</w>
x x</w>
venti l
spar ing</w>
ore station</w>
leth yl</w>
inform ation
in human</w>
ign or
en i
dy ed</w>
do zen</w>
crim ination</w>
credit worthiness</w>
con stell
arrang ing</w>
architec t</w>
ag ine</w>
Z av
Speci ally</w>
So fia</w>
Shi re</w>
John ny</w>
H ann
F ern
Cer tified</w>
CE TA</w>
8 77</w>
4. 12</w>
w asting</w>
vi o</w>
un conscious</w>
tor ial</w>
over see</w>
osel tamivir</w>
mo il</w>
il er</w>
ha b</w>
gly col
fl ours</w>
en ly</w>
cur se</w>
ati o</w>
asser t</w>
X IV
V ision</w>
U M
Resid ence</w>
Kin eret</w>
EC S</w>
Dep ression</w>
Ce dex</w>
Bri an</w>
50 th</w>
28 ,
underestim ated</w>
un altered</w>
spe edy</w>
inter dependence</w>
int ered</w>
ha il</w>
eric hia</w>
coun ters</w>
conve yed</w>
W ATE
Succ ess
O EM</w>
N LB</w>
M ug
In put</w>
Estab lish</w>
Esch erichia</w>
Cop olymer</w>
CR As</w>
Bri x</w>
Bar nier</w>
B ris
B MD</w>
Achi eving</w>
7 56</w>
3. 3.2</w>
α ς</w>
tr unk</w>
so m</w>
sand wich</w>
proc ured</w>
nerv ousness</w>
inf requ
hectolit res</w>
ham ster</w>
fl ashing</w>
distribu tions</w>
devast ating</w>
acidi fication</w>
VE GE
Rus sians</w>
In formal</w>
CYP2C 8</w>
Bal tics</w>
.... ..</w>
sweet ened</w>
se in</w>
n il
geopol itical</w>
g az
exacer bate</w>
emul si
decision making</w>
car av
antic ancer</w>
adhe sives</w>
Tax i</w>
Sew ing</w>
N GA</w>
HV DC</w>
G ently</w>
FRON TEX</w>
E ver</w>
CONTRAC TING</w>
BON US</w>
8. 2003</w>
25 ,
z ens</w>
spon sored</w>
r als</w>
pass ages</w>
p oured</w>
og o</w>
n ium</w>
may or</w>
m asks</w>
lif ec
incredi bly</w>
fraction ation</w>
fire works</w>
collec ts</w>
be ats</w>
ba ths</w>
b att
ap revir</w>
an ate</w>
acqui res</w>
Sk y
Rhin eland</w>
Reli ef</w>
PC B</w>
PAR AGR
ME T
I HN</w>
G un
Du o
Ban que</w>
6 19</w>
4 38</w>
3 pts</w>
nec rolysis</w>
motor cycle</w>
kern els</w>
j us</w>
ing the</w>
hi r</w>
exc av
coun ties</w>
bit ches</w>
ab used</w>
Wh it
W er
Vacc ines</w>
T TIP</w>
Sil gard</w>
Rel ax</w>
Patr ick</w>
O TH
Maj esty</w>
Incorpor ating</w>
IS ING</w>
Haem at
E ur</w>
DEP BS</w>
CO LL
24 ,
19 27</w>
verti go</w>
univers ally</w>
ten acity</w>
simul ated</w>
restric ts</w>
rec tangle</w>
prototy pe</w>
pr z
on idine</w>
m our
lo tinib</w>
l amin
ili aries</w>
evel amer</w>
dum b</w>
dis coloration</w>
cr an
categor isation</w>
cal orific</w>
bub ble</w>
ateg linide</w>
af ety</w>
S cann
PARAGR AP
P ain
Op position</w>
Mon te</w>
L ov
Kalin ingrad</w>
CI TES</w>
Barro t</w>
BA SF</w>
6 90</w>
6 27</w>
4. 2001</w>
13 0
y i</w>
ven ting</w>
trim med</w>
tor ia</w>
th ia</w>
sac hets</w>
recru iting</w>
re training</w>
pal lets</w>
oc tan
meth ionine</w>
inspi re</w>
he al</w>
ger m</w>
func tionally</w>
fl ash
ele mentary</w>
eg al</w>
ec te
dis miss</w>
bur ns</w>
brea sts</w>
bloc ker</w>
al liance</w>
V AN
Sil denafil</w>
S peak</w>
PRE PAR
P ad
Lis ted</w>
Liqui d
K im
Hy promellose</w>
H ü
Flex ible</w>
F ill</w>
Dou g</w>
Clin ically</w>
Certain ly</w>
CAL C
C ADE</w>
A mb
7 90</w>
7 80</w>
7 14</w>
19 59</w>
19 00</w>
119 1</w>
. 6</w>
í n</w>
um es</w>
trav els</w>
syn erg
resid ency</w>
post menopausal</w>
p izza</w>
militi a</w>
metro logy</w>
in asmuch</w>
hi l</w>
flow ering</w>
entrust ment</w>
ens embles</w>
dis appears</w>
defl ection</w>
by pass</w>
block ade</w>
be ating</w>
analog ous</w>
an xious</w>
amyl ase</w>
ae us</w>
ack er</w>
abol ishing</w>
ST ATI
S U</w>
Proce edings</w>
NRT I</w>
Mov ed</w>
I ON
H ope</w>
Freed oms</w>
Fer re
Cat ering</w>
B 3</w>
Angel es</w>
Al y
10. 1.2004</w>
0000 000</w>
swee theart</w>
reconc iling</w>
protection ist</w>
pol ished</w>
pi perid
op yr
oct ane</w>
o F</w>
metast ases</w>
ink ai</w>
ero on</w>
ca ve</w>
ca res</w>
a rel
Turk men
Sha res</w>
S J
Protec tive</w>
Protec t</w>
Nor vir</w>
Memb ership</w>
Lith ium</w>
Exc ess</w>
En ough</w>
Do esn</w>
Con figure</w>
Cast le</w>
Bo ston</w>
Bel ize</w>
AMOUN T</w>
AF F</w>
8 55</w>
7 32</w>
4. 3.2</w>
vis u
un reliable</w>
tiz ed</w>
ter ol</w>
su ite</w>
sof osbuvir</w>
re used</w>
in one</w>
impul se</w>
chron ological</w>
agu a</w>
St ef
P h</w>
Hybri d</w>
F V
Contain er</w>
Ambass adors</w>
Al bert</w>
9. 7</w>
6 05</w>
2 pts</w>
11. 2002</w>
αρ ι
re. in</w>
re activation</w>
radion uc
rad ically</w>
practi sed</w>
pos ology</w>
ped ag
k h
heal th
dr yer</w>
cy tes</w>
cou gh
c ra
athlet es</w>
afford ability</w>
Wi reless</w>
Su rely</w>
Stre am</w>
Str aw
Reg ard
Mab Camp
MabCamp ath</w>
Iso fix</w>
Gab ri
Comm itment</w>
6 45</w>
17 02
ν ισ
wid en</w>
sulph ur
stri ving</w>
real ization</w>
r r
policy makers</w>
po fungin</w>
pa ste
oli qui
o estradiol</w>
n ad
m at</w>
lim it
he ights</w>
gu inea</w>
ger minal</w>
e de
d an</w>
T ack
Sustain ability</w>
Phot o
Mobil Com</w>
M IN</w>
J ab
F lowers</w>
Char l
Car ry</w>
Bless ed</w>
AU STRI
6 33</w>
v od
transport able</w>
teach ings</w>
resul tant</w>
reli eved</w>
re bate</w>
r age</w>
profession alism</w>
pr ze
ph os</w>
lit as</w>
g laze</w>
ex ped
egrad ability</w>
com eth</w>
candi diasis</w>
bas t</w>
W ell
VEL CADE</w>
Proper ties</w>
PC T</w>
CON SU
C00 10</w>
B EN
4 94</w>
2, 8</w>
zi one</w>
volcan ic</w>
ud a</w>
trav eller</w>
plau sible</w>
om ab</w>
mathem atics</w>
liber ties</w>
inv ented</w>
index ation</w>
in sti
hydrox ides</w>
hali but</w>
fer rets</w>
esco re.in</w>
ely x</w>
dec arbon
cur ious</w>
b yl</w>
au re
advis es</w>
abul ary</w>
Z ea</w>
Y ang
W IN
Val uation</w>
V iv
Qu e
P Z
OR I</w>
O AT
Liv escore.in</w>
L es
H il
Flu or
Farmac êu
F red</w>
F CL
Character isation</w>
Ca elyx</w>
Appl ying</w>
12 5
ver ing</w>
venti on
vas odil
simpl ifications</w>
o grams</w>
k ing
is i</w>
ir responsible</w>
investig ational</w>
infring es</w>
i 2010</w>
fo ol
etor icoxib</w>
electro cardi
cy sts</w>
br ace</w>
Z en
Z ambia</w>
Where ver</w>
R ech
Oxy gen</w>
Neutro penia</w>
Greg or</w>
Exha ust</w>
E I</w>
Cil ag</w>
Cam eroon</w>
9 13</w>
6 96</w>
25 th</w>
st es</w>
pre conditions</w>
p aving</w>
ob ese</w>
lec ith
gro ats</w>
fo aming</w>
f ö
correspon ded</w>
bulk head</w>
b ows</w>
an aemic</w>
abo ard</w>
Turkmen istan</w>
Tasm ar</w>
T ag</w>
RESOUR CES</w>
R ace</w>
P ML</w>
Man n</w>
In finite</w>
Forg et</w>
E rit
C et
AM UNE</w>
AG L</w>
3 G</w>
vec tors</w>
toxic ology</w>
slow ed</w>
sh ov
prim eo</w>
pre requisites</w>
pancre atic</w>
over fishing</w>
market place</w>
justif ications</w>
hus band
hes itate</w>
gsk .</w>
g estation</w>
fledg ed</w>
entre preneur</w>
en am
ell fish</w>
e tra
dem er
ch ina</w>
ca reg
arbon ate</w>
St amp</w>
S primeo</w>
Liber ation</w>
Ex tended</w>
Electro lux</w>
7 55</w>
7 13</w>
wi red</w>
us eless</w>
sub divided</w>
servic es
panto graph</w>
p ine
neon atal</w>
light weight</w>
en tecavir</w>
dig iti
colo strum</w>
believ able</w>
az a</w>
ag glu
Th iaz
T our</w>
T ech</w>
S patial</w>
Questionnai re</w>
Qu ick
PROGRAM MES</w>
PC s</w>
P acks</w>
Mil ano</w>
H op
H ad
F ima</w>
F IT</w>
ES Cs</w>
Dy ne
Chris top
Amen d</w>
Ale ksand
5 76</w>
100 190
withdraw s</w>
wh ist
un saturated</w>
po d
over alls</w>
out flow</w>
occup ant</w>
min ded</w>
isch aemia</w>
in secure</w>
heart burn</w>
fr anch
finger print</w>
em powers</w>
egr an</w>
doc trine</w>
de a</w>
cartil age</w>
abnorm ality</w>
Zon egran</w>
Zi agen</w>
S ounds</w>
O li
Jam a
Issu ing</w>
Impro vements</w>
INSTITU TIONS</w>
I X
Faero e</w>
Exc ise</w>
EU JUST</w>
E ric</w>
D j
Chro me</w>
Che ese</w>
2. 2004</w>
ush ima</w>
tal ented</w>
spon sorship</w>
roun ding</w>
rein su
re z</w>
re build</w>
projec tors</w>
pre pares</w>
pr é
plan ets</w>
pen t
me l</w>
had n</w>
el nuts</w>
dwell ings</w>
dig it
ac z
ac ne</w>
a an</w>
Ter mination</w>
Sep i</w>
SW R</w>
Pul monary</w>
P assive</w>
Modi fied</w>
In ci
IF R
GO D</w>
DU TIES</w>
CRITERI A</w>
Boli via</w>
5. 1.1</w>
10 59</w>
trigg ers</w>
refer rals</w>
m sec</w>
lev ying</w>
impl ying</w>
ill i</w>
hosp italisation</w>
g il
dom icile</w>
command ments</w>
c al</w>
ast es</w>
antipsycho tics</w>
T ot
Resi dual</w>
RE PLY</w>
Pol o</w>
PRO JEC
OBJEC TIVE</w>
Nic ar
LE TS</w>
L ec
Hel ic
HE RE
F ever</w>
B ilateral</w>
7 79</w>
18 th</w>
1 R</w>
-------------------------------- ----------------
wa ited</w>
un bleached</w>
thrombo embolism</w>
tetra hydro</w>
t 1</w>
st ack</w>
scr atch</w>
ro asting</w>
pursu ance</w>
poly urethane</w>
p i</w>
or ch
onn y</w>
irrevoc able</w>
i tin
here in</w>
em as</w>
be tr
ba it</w>
aud it
ac e
a ults</w>
S NCB</w>
LIS A</w>
L änder</w>
INTER POL</w>
Good bye</w>
Fuk ushima</w>
Explan ation</w>
15 0000</w>
ung in</w>
trache itis</w>
to oth
ten derness</w>
plac ental</w>
organ oleptic</w>
o o
moul ded</w>
in digestion</w>
fle a</w>
f es
conc es
c coli</w>
bil li
Weigh ing</w>
Vo ice</w>
Tren bolone</w>
Step s</w>
R ing</w>
Pres ent</w>
PRE SIDEN
PER FORM
Kev in</w>
Hert fordshire</w>
H O</w>
Gr ace</w>
G ilead</w>
Form al</w>
Explan ations</w>
CCC ME</w>
As sum
AGRE EMENT</w>
6 36</w>
19 29</w>
Т ел</w>
seni ority</w>
reluc tant</w>
program mes
pr azo</w>
per oxides</w>
isot opes</w>
injec table</w>
i et</w>
dis connected</w>
dex tro
behavi ours</w>
atin ate</w>
acet amide</w>
ac eous</w>
Vacc ination</w>
T UR
Reci proc
LITHUAN IA</w>
Invest bx</w>
IR GC</w>
IN ED</w>
IC M</w>
Hav ona</w>
Consisten cy</w>
BUS IN
Ah mad</w>
Acc el
14. 1</w>
t ment</w>
pris ons</w>
pla ice</w>
o virus</w>
lands capes</w>
interf ering</w>
ic le</w>
fil amentary</w>
attribu tion</w>
amin ergic</w>
ai a</w>
ad ex</w>
V P</w>
Transi tion</w>
T ul
T ir
SE TS</w>
Portfol io</w>
Ob ject</w>
NE SS</w>
Inf anrix</w>
IR R</w>
Histor ical</w>
Ha ji</w>
F ee</w>
En d
AN TI</w>
we al
transl ators</w>
the dral</w>
s auna</w>
roy alties</w>
ration ality</w>
ol is</w>
obstruc t</w>
moun tings</w>
lifec ycle</w>
is amide</w>
for age</w>
eter nity</w>
ed in</w>
distingu ishes</w>
cre denti
actu arial</w>
Z he
S car
Rever se</w>
Plug in</w>
P ears</w>
P ASI</w>
Mann itol</w>
Lef lunomide</w>
L ud
Gr av
F ag
F RES
EM BER</w>
CON TAIN
Broad band</w>
Be er</w>
19 70s</w>
10. 4</w>
00 0000</w>
yl line</w>
voy ages</w>
un ch</w>
tw er
tiv es
stuff ed</w>
sero conversion</w>
reign ed</w>
r ation</w>
pon at
pa recoxib</w>
hand book</w>
ex pon
dis astro
des ic
comm on
cim etidine</w>
ch ap
ann e</w>
al er</w>
Sur ve
Matthe w</w>
Kh an</w>
Ig G</w>
Hepat obiliary</w>
Bal i</w>
BAS ED</w>
7 70</w>
24. 6.
19 53</w>
simil arities</w>
seab ed</w>
poss essed</w>
plac e
ph ther
our less</w>
ot ene</w>
orb rit
now adays</w>
narrow ing</w>
mean ings</w>
it as</w>
ins ane</w>
engine ered</w>
dimin ishing</w>
develop ment
den ial</w>
counter act</w>
cos ting</w>
b as</w>
ant as</w>
announ cements</w>
XX IV</w>
W ake</w>
St orbrit
Pol ym
P seud
Le ad
Jim my</w>
J ake</w>
F M
Dis til
Challeng es</w>
CT C</w>
Bour get</w>
Beau ty</w>
Ann e</w>
3 7.5</w>
1.11. 1975</w>
yr inth</w>
to ken</w>
ter rain</w>
ten si
swe ets</w>
r as</w>
ph agia</w>
p r</w>
oc ellular</w>
i bu
haemat ocrit</w>
eri e</w>
e ant</w>
di ves</w>
demer sal</w>
credenti als</w>
can al</w>
br ick</w>
b ordering</w>
aspart ate</w>
agr o</w>
Un wrought</w>
TH AN</w>
REP RES
Mon itor</w>
H SC</w>
De c</w>
Compet ence</w>
Can al</w>
Beau tiful</w>
9 45</w>
6 07</w>
Е ООД</w>
v y
tril lion</w>
sun set</w>
sub ur
stand point</w>
ph ils</w>
min t</w>
m is</w>
inhib ited</w>
geo thermal</w>
fen cing</w>
benz ene
ass y</w>
abstr act</w>
TER E</w>
T DI</w>
Su ffici
ST AT
R ow</w>
QUAL ITY</w>
Peter sburg</w>
O o</w>
L evel
Gab on</w>
Frequ ent</w>
Condi tion</w>
CV S</w>
CT P</w>
But adiene</w>
AM s</w>
5 54</w>
2. 12</w>
zoon otic</w>
wh oa</w>
wal ks</w>
vulner abilities</w>
view er</w>
tot als</w>
togen etic</w>
sym metrical</w>
st i</w>
sc ar</w>
re now
pro claimed</w>
poly vinyl</w>
ov y</w>
om idine</w>
ol one</w>
nai ve</w>
l af
ha ve
fr amed</w>
f ence</w>
en ox
ed es</w>
e House</w>
di m
connec ts</w>
at ter</w>
W on
Uni verse</w>
TAX O
TAXO TERE</w>
Simpl ified</w>
Sha red</w>
Ri prazo</w>
Regard less</w>
Pal atinate</w>
N am
Lot tery</w>
Imp aired</w>
Her n
GU IDEL
G da
Expir y</w>
Europe Aid</w>
Bon ds</w>
Bay ern
6. 5.
3. 1.3</w>
27. 1.
10 08</w>
ст в
un wrought</w>
treat s</w>
tal es</w>
tabern acle</w>
spir al</w>
si ghts</w>
rel ay</w>
particul ates</w>
p ound</w>
p id
ow ers</w>
ow er</w>
ob o</w>
lum bar</w>
ime tric</w>
ic al
ab om
V FR</w>
Rach el</w>
Prot aphane</w>
PAR TI
MS Y</w>
Lia ison</w>
K ent</w>
IF B</w>
D ANCE</w>
Col um
Chil d
Al lo
8 4.
5 72</w>
4 45</w>
wh it
v ans</w>
prestig ious</w>
on os
omy opathy</w>
observ able</w>
multi dose</w>
m ise</w>
in tox
go at
furo ate</w>
empir ical</w>
co oled</w>
catastroph e</w>
bol ts</w>
ax ine</w>
Sub stance</w>
Pic ture</w>
My co
M SC</w>
DE V
Ch ocolate</w>
Bi o</w>
v ais</w>
un detectable</w>
trap id</w>
tr um
stere otypes</w>
stan bul</w>
respon siveness</w>
res pir
rep ai
p ically</w>
ow o</w>
nom inate</w>
metal lised</w>
link ages</w>
leg end</w>
l ately</w>
glass ware</w>
enrol ment</w>
embry onic</w>
de w</w>
ch al
c el</w>
bu tox
as ero</w>
abr icated</w>
Sign atory</w>
SWED EN</w>
S SP</w>
Lea ther</w>
L L</w>
Jer sey</w>
In side</w>
I o
Fer ro
But ter
Bav aria</w>
BET W
B UL
Arab ic</w>
Ac trapid</w>
ACCOUN T</w>
7 30
5 36</w>
tre asures</w>
s own</w>
reflec tors</w>
re started</w>
paste ur
ow a</w>
n ano
iz ard</w>
instru mentation</w>
gr ay</w>
dr astic</w>
dispen sed</w>
automob ile</w>
ap ro
alphab e
al right</w>
W aters</w>
Tax es</w>
Si x
Per spec
IPv 6</w>
H ad</w>
Gro und
D ist
Ca therine</w>
Appoint ment</w>
A EL</w>
5 16</w>
12. 1.2001</w>
- Oh</w>
z ą
ver b</w>
ust er</w>
un loaded</w>
ro gation</w>
li v
lem on</w>
k ir
heal ed</w>
fri dge</w>
ec stasy</w>
e ast
chol ine</w>
brigh tness</w>
attrac tion</w>
apprentic eships</w>
Zhong Shan</w>
Twin rix</w>
S ex
Rev .2</w>
Mem ory</w>
M M
LU X
IS ED</w>
Dyne po</w>
Ch est</w>
Cap able</w>
BETW EEN</w>
ADDI TIONAL</w>
αρι θ</w>
renow ned</w>
rem n
redund ancy</w>
pig ment</w>
mob il</w>
mo s</w>
gro s
epo etins</w>
end ome
condi tionally</w>
combus tible</w>
ag ar</w>
UNDERTA KING</w>
T ick
S ign</w>
RE T</w>
R AD
Os se
ME R</w>
Kno wn</w>
Heal thy</w>
Gh or</w>
G M
F as
En tac
EN TSO</w>
COM P</w>
C ant
Blu efin</w>
Al k
AR AN
7 95</w>
v entional</w>
ulcer ative</w>
u tion
tre x
til les</w>
tec h
st ation
smar ter</w>
slud ges</w>
multi disciplinary</w>
monu ments</w>
mel oxicam</w>
l ang
iodi de</w>
en durance</w>
e print</w>
distor tive</w>
co s</w>
co incidence</w>
ci ón</w>
b ner</w>
at oms</w>
U m
TAB LES</w>
S. p.
Por table</w>
N er
Jer ry</w>
Inter pol</w>
I stanbul</w>
H PC</w>
GRAN TED</w>
Ex tavia</w>
E ternal</w>
D T
C ef
An th
Access ories</w>
AB ILI
8 90
7 60</w>
6 57</w>
4. 2011</w>
30 72</w>
27. 4.2004</w>
2. 1.2</w>
x i</w>
trim m
sp ell</w>
sac red</w>
s isters</w>
o cial</w>
my steri
in der</w>
dom inate</w>
dis ks</w>
den se</w>
bra ins</w>
bi oliqui
adh ered</w>
UR I</w>
O ber
K roes</w>
IM POSED</w>
IC TY</w>
Fo od
FUN DS</w>
Entac apone</w>
EI s</w>
Des ktop</w>
CZ ECH</w>
Ak h
Adverti sement</w>
5 27</w>
un foreseeable</w>
ul isine</w>
transpon der</w>
thre w</w>
tap ped</w>
sle pt</w>
persu ade</w>
per e</w>
oth i
oesoph ageal</w>
intrac ranial</w>
hypo thyroidism</w>
gl ulisine</w>
fr ank
en closures</w>
eg g
disastro us</w>
cytop enia</w>
caff eine</w>
asti a</w>
arom atised</w>
allo on</w>
af ungin</w>
Vassi li
Tun a</w>
Sulph ur</w>
SERV ICE</w>
R AL</w>
NA V</w>
N Y
Inv esting</w>
Incre ases</w>
Hy potension</w>
Comple x</w>
CO P
Ar gu
20 ,000</w>
17 th</w>
yiel ding</w>
where in</w>
sanc tioning</w>
s ocks</w>
rou ter</w>
rep aired</w>
r c.
ol ip
nanomat erials</w>
nan otechnology</w>
mis taken</w>
mer cap
le ys</w>
insi der</w>
gr af</w>
depri ve</w>
clo ths</w>
VEHIC LES</w>
Saf er</w>
P MI</w>
Modi fication</w>
IT L</w>
IF s</w>
Gda ńsk</w>
G IS</w>
Fin ishing</w>
Excep tions</w>
Amin o</w>
4, 7</w>
24 46</w>
17 25</w>
techn icians</w>
skir ts</w>
resurrec tion</w>
r ay
proc ure</w>
pre tend</w>
om issions</w>
mo is
milli on
ki er
ion ale</w>
ici aries</w>
gr ill</w>
ger icht</w>
extinguish ers</w>
en coding</w>
eff usion</w>
ea ther</w>
diarr hea</w>
c any</w>
be g</w>
architec ts</w>
an aerobic</w>
Val idity</w>
R ig
Pret ty</w>
NR A</w>
ES DC</w>
Co ok</w>
Cell ul
Canc ún</w>
Ar rest</w>
Am ber</w>
7 99</w>
7 92</w>
5 61</w>
31.12. 2003</w>
3. 4.
28 th</w>
tran shipped</w>
shor ten</w>
ship yard</w>
scho ol
re introduction</w>
r av
pal ace</w>
ol umab</w>
ocyan ate</w>
o thing</w>
n ing
kitch en
id ol</w>
graph ical</w>
gar ment</w>
exem pting</w>
doc toral</w>
conden sing</w>
al endronate</w>
af lat
ac lop
abr afenib</w>
St aphylo
Reg isters</w>
Parlia ment
O ste
M ou
IFR Ss</w>
F IMA</w>
Ce de
Cat al
BO DIES</w>
AUSTRI A</w>
6 55</w>
5 02</w>
3 4.1.1</w>
wp 29
sym pathy</w>
relap sed</w>
opro st</w>
metallurg y</w>
ma ster
hypoc alcaemia</w>
gran ular</w>
fo stered</w>
emerg es</w>
di phenyl
cub its</w>
ce forth</w>
carri ages</w>
c elecoxib</w>
ab in
TI D</w>
Spar e</w>
Salv ador</w>
STR Y</w>
SAN CO</w>
S 2R</w>
Ro ot</w>
Or phan</w>
Lic ense</w>
Gaz ette</w>
D Y</w>
Continu ed</w>
Chan cell
B ret
9 78</w>
- 1-</w>
wom b</w>
web s</w>
tr on</w>
stabil isers</w>
ril pivirine</w>
ri pe</w>
preci pitation</w>
mitig ated</w>
migr aine</w>
mar aviroc</w>
insec t</w>
immuno deficiency</w>
fam ine</w>
dron at</w>
deduc ting</w>
curren ts</w>
apprentic eship</w>
an terior</w>
a j</w>
a be</w>
Wel comes</w>
Vacc ine</w>
S ensi
PERFORM ANCE</w>
P ay</w>
LL C</w>
Fe ed
F av
F EV
EP As</w>
Counter party</w>
Contin ental</w>
Con gol
BOTT LE</w>
B ell
2 c</w>
vertebr ate</w>
ub a</w>
rul er</w>
pure bred</w>
phos ate</w>
par ish</w>
k nitting</w>
j ets</w>
favor able</w>
alphanum eric</w>
VIR AMUNE</w>
V as
Rasp berry</w>
Play mobil</w>
IT P</w>
Grap h
For tun
D MA</w>
Concentr ation</w>
Cede fop</w>
CR P</w>
Bar r</w>
AD H
3. 2002</w>
23. 2.
20. 12.
11. 2012</w>
- beta</w>
troub led</w>
ru in</w>
poly amides</w>
pneum onitis</w>
od arone</w>
mid night</w>
meth rin</w>
materi alise</w>
log istic</w>
log in</w>
is a</w>
instruc tor</w>
in ine</w>
il ers</w>
gr is</w>
di hydrochloride</w>
co conut</w>
bacter i
ac ional</w>
Y esterday</w>
X ES</w>
Vinc i</w>
Veter in
V ul
S aid</w>
Repay ment</w>
P ink</w>
Nutri tion</w>
Me et</w>
Man agers</w>
K el
JUR Y</w>
J ou
Haz ardous</w>
F 1</w>
Chair s</w>
Bon dronat</w>
B all</w>
ACCOR DANCE</w>
10. 5</w>
1 162</w>
tit res</w>
tim eline</w>
sp ot
sp inach</w>
sh ellfish</w>
sep tic</w>
se q</w>
pri da</w>
plug ins</w>
lan es</w>
influ x</w>
im mobil
ic ol
hydrol ysed</w>
horri ble</w>
e ity</w>
drog ę</w>
diff use</w>
det omidine</w>
cr ank
confi gu
con strained</w>
con ceiv
compres sor</w>
chromos ome</w>
ballo ons</w>
arbitr ators</w>
analy sts</w>
Whe el</w>
TS H</w>
OF F</w>
M EE
L iter
L ate</w>
Im prida</w>
Identi fier</w>
IN JURY</w>
H s</w>
G AL</w>
F TP</w>
D in
D ark</w>
Congol ese</w>
Buch arest</w>
Beli eved</w>
B IS</w>
A in</w>
6 40
2, 4,6</w>
sto ol</w>
ser y</w>
repl en
par am
ocar cin
m unitions</w>
lobby ists</w>
lic ensor</w>
lact ase</w>
in semination</w>
h erence</w>
gly cine</w>
g ure</w>
g ateway</w>
favour ite</w>
fac t
extrapol ation</w>
extern alities</w>
en ie</w>
aci dic</w>
W is
V id
V al</w>
Str ing</w>
Par ameter</w>
Jas on</w>
INDU STRY</w>
Dimitri adis</w>
Dar bepoetin</w>
D HL</w>
Ab sence</w>
6 66</w>
5 97</w>
19 35</w>
transm itter</w>
tam pering</w>
su ch
out ta</w>
oty pic</w>
ob s
n em
imp acted</w>
g y</w>
f ist
e el</w>
d fish</w>
cous in</w>
contrad ict</w>
ass ass
anti bacterial</w>
an id</w>
Tack ling</w>
Spl it</w>
Pal ace</w>
LUX EM
JUS TICE</w>
Hern ández</w>
H AL
EX TEN
EM S</w>
Cy an
Aw areness</w>
An k
An aphy
1. 1.1</w>
ž i
tel ithromycin</w>
spa w
separ ati
sc anners</w>
sacrif ices</w>
ros ine</w>
reduc tase</w>
re opening</w>
pep tide</w>
iz a</w>
isot ope</w>
inf low</w>
heal thier</w>
ex tr
eth n
dis appointment</w>
den za</w>
cre ators</w>
certi fies</w>
aclop rid</w>
VER Y</w>
Sach sen</w>
S ailing</w>
O VER
Nitro gen</w>
Ku wait</w>
K ate</w>
H ed
Guaran tees</w>
Dis crimination</w>
Co alition</w>
Broad casting</w>
Ap id
5. 2.2</w>
wel t</w>
wat ts</w>
tal c</w>
swim wear</w>
pre text</w>
post marketing</w>
p addy</w>
opo e
n. p.r.
m ing
en ligh
eigh teen</w>
d rou
carb am
an ib</w>
absur d</w>
a ção</w>
W FD</w>
Seri ously</w>
POL AND</w>
P TA</w>
Om nitro
Joh ann
EXP ORT</w>
E TA</w>
Docu mentary</w>
Beau vais</w>
A 7</w>
5 84</w>
3 d</w>
27 ,
1 1000</w>
z u</w>
vi er</w>
ul us</w>
ty ping</w>
tr icks</w>
su nam
sp y</w>
sk ie</w>
sal ine</w>
s intered</w>
relax ed</w>
pur pura</w>
prison er</w>
phi a</w>
perfor ation</w>
percenti le</w>
mean while</w>
inter branch</w>
il legality</w>
fluor ophenyl</w>
d ice</w>
conf using</w>
comprehen sively</w>
command ment</w>
co ck</w>
circl ed</w>
Protec ting</w>
PC DD</w>
P ure
Omnitro pe</w>
K att
K I</w>
H1 N1</w>
Dim ethyl</w>
Def ense</w>
COMP LI
B MW</w>
AR RAN
A vailability</w>
A AS</w>
9 70</w>
7 31</w>
29 ,
1702 30
slow down</w>
registr ant</w>
prze z</w>
por k</w>
lat ent</w>
is tically</w>
inspec ting</w>
in stantly</w>
im o</w>
har n
gen ius</w>
f owl</w>
celebr ating</w>
budg et
PROCES SING</w>
Nicar agua</w>
Mid d
G edi
F old</w>
EP P</w>
Do g</w>
Coun t</w>
C WC</w>
Al ong</w>
Abdul lah</w>
5 0,000</w>
36 0
27 10
2 C</w>
x es</w>
un realistic</w>
to ji</w>
ter med</w>
super ficial</w>
subjec tive</w>
s ary</w>
r um</w>
phen ols</w>
period ical</w>
perfor atum</w>
mu til
le y
imp unity</w>
immunosup pression</w>
ic i</w>
flo x
ec k
din itro
author izations</w>
Sear ching</w>
R arely</w>
R 00
P ine</w>
Mel ch
LUXEM BOUR
Fis cal
FIN LAND</w>
Esti mate</w>
E sp
Co di
Co ated</w>
B is
Apid ra</w>
Angol a</w>
6. 2.1</w>
26 ,
24. 9.
ä ä
vigil ant</w>
ves ti
trex one</w>
ti pranavir</w>
sulph uric</w>
s 1</w>
postpon ement</w>
omer ic</w>
medi um-</w>
lin s</w>
hy poten
g .
extremis m</w>
du re
distur bing</w>
desc ending</w>
d ining</w>
cry pto
commun au
brack et</w>
ab err
W ik
Val idation</w>
S qui
Pl aying</w>
PL AN</w>
OB SERV
Nik ol
Lin k
Le one</w>
Fin ances</w>
F AI
Du chy</w>
Declar ations</w>
Coun ter</w>
Comple mentary</w>
Com bus</w>
ARRAN GE
AF TER</w>
A my</w>
35 ,
3. 13</w>
tart aric</w>
sn ap</w>
replac ements</w>
op her
merch ants</w>
lac toid</w>
k shire</w>
her b
gener ational</w>
gain ful</w>
et ti</w>
dap agliflozin</w>
cyto k
cord age</w>
cor ps</w>
comp ares</w>
as vir</w>
Z ur
THERE OF</w>
Spe aking</w>
ST AFF</w>
SO 2</w>
S ites</w>
Mon net</w>
L AT
Ital ian
FF HG</w>
Europe an
Eg g</w>
Cur onian</w>
CO PPS</w>
CF C</w>
C ig
At l
Al f
6 84</w>
vi es</w>
v ax</w>
te ther</w>
potenti ate</w>
oph armac
ol im
me a</w>
malign ancy</w>
main s</w>
laf axine</w>
intern alisation</w>
ins ists</w>
h ed</w>
eti ology</w>
ero i</w>
ere r</w>
ep hal
draf t
do zens</w>
cle av
ci us</w>
chari de</w>
c ation</w>
blaz ers</w>
bi eg
ath ion</w>
abat acept</w>
You Tube</w>
YE I</w>
T rail
P yr
MIT TED</w>
IF RIC</w>
Hyper icum</w>
Hass an</w>
Ded icated</w>
Cor relation</w>
Clos ure</w>
Canc el</w>
Arth ur</w>
A d</w>
8. 9</w>
20 24</w>
0. 45</w>
к о
τ ο
traine eship</w>
t ones</w>
swee tie</w>
real m</w>
op rene</w>
olym ers</w>
no zzles</w>
mal le
leaf lets</w>
fish es</w>
f r</w>
ecz ema</w>
den ying</w>
commerci alisation</w>
ak in
Tus cany</w>
St eve</w>
S ay
P are
K an
G LO
Four thly</w>
EU MM</w>
D educ
CO L
C G
Bo eing</w>
Appl ied</w>
Ad venture</w>
6 68</w>
16 23</w>
04 06</w>
sk is</w>
por celain</w>
off line</w>
link age</w>
ing e</w>
individu alised</w>
govern s</w>
fl asks</w>
fix ture</w>
carb amate</w>
Vir us</w>
Ter min
T wel
SP V</w>
Norm an</w>
Nap les</w>
Mac ao</w>
Hor se</w>
Helic obacter</w>
H IGH</w>
Gedi min
G MP</w>
Flem ish</w>
Euro stars</w>
EXP OR
EX AM
E d</w>
D i</w>
Cust om</w>
Author isations</w>
AS SETS</w>
7 33</w>
6 54</w>
2. 3.1</w>
16 01</w>
0 22</w>
ö t
w rec
ul if
trac ed</w>
sax agliptin</w>
pos edly</w>
pa thetic</w>
our acil</w>
neighbor hood</w>
met er
m op
legisl ations</w>
injec tor</w>
gsk .com</w>
ex position</w>
configu red</w>
ap ort</w>
SE AFO</w>
S can</w>
Moder ate</w>
Gu est</w>
Fat ty</w>
Euro pharm</w>
CYP 450</w>
30 th</w>
2. 7.
14. 3</w>
12 36</w>
μ l</w>
ń ski</w>
yl ation</w>
win ds</w>
uplo ad</w>
trig ine</w>
ti az
ti an
s ch</w>
projec t
part ner
ov á</w>
okin ase</w>
o trigine</w>
ma ils</w>
intensi fication</w>
ill umin
hon oured</w>
he el</w>
h itting</w>
ful l
exempl ary</w>
ethanol amine</w>
es .</w>
emet ery</w>
do t</w>
cont acting</w>
claim ants</w>
bureau x</w>
antihist amines</w>
TS Es</w>
Reas oned</w>
He in
ES M</w>
Charl eroi</w>
Car los</w>
Author ising</w>
Att ach</w>
AL LY</w>
A men</w>
7 66</w>
4 95</w>
30.12. 1989</w>
18 39</w>
10 02</w>
1. 16</w>
н о
yellow ish</w>
whole hear
un covered</w>
tu ary</w>
ther mia</w>
sympath omim
s ard
precur sor</w>
pl c</w>
or us</w>
lep tic</w>
la v</w>
incub ation</w>
igh s</w>
hor se
gorg eous</w>
dro ve</w>
cough ing</w>
bi kes</w>
ba king</w>
ans a</w>
ach elor</w>
Wol f</w>
Th y
Stal le</w>
R ah
Pap a</w>
N D
Licen sing</w>
Kab ul</w>
IM PACT</w>
Hü bner</w>
Flu id</w>
Ex forge</w>
Estim ates</w>
Elec toral</w>
9. 2004</w>
31. 3.2004</w>
3. 2010</w>
s worn</w>
rhino tracheitis</w>
res emb
quot es</w>
perform er</w>
over seeing</w>
o. o</w>
merg e</w>
manif ested</w>
lo e</w>
legiti mately</w>
endor sing</w>
e tically</w>
czy k</w>
con stric
clin ic</w>
c er</w>
ali ens</w>
Use ful</w>
Rep aglinide</w>
REG UL
Plat forms</w>
Lum ia</w>
IN F</w>
IF R</w>
H 5</w>
FRES H</w>
Du ties</w>
DETAI LED</w>
Cre am</w>
Comp ounds</w>
Brand enburg</w>
Al ongside</w>
AP P</w>
6 72</w>
24. 11.2009</w>
with the</w>
utili zation</w>
tri partite</w>
substitu tions</w>
siz ing</w>
sen sations</w>
rub ella</w>
phther ia</w>
me detomidine</w>
loc alised</w>
j ar</w>
inc eption</w>
govern ors</w>
class room</w>
cholester ol
Z om
Tru stee</w>
R yan</w>
Par ameters</w>
PARAGRAP H</w>
P references</w>
OR IES</w>
O ro
I A
EP S</w>
CRI XIV
CO SME</w>
A partments</w>
9 04</w>
6 94</w>
ó ł
vis c
transm itters</w>
sl urry</w>
pl os
per missions</w>
offen sive</w>
nic he</w>
hex a
ep s</w>
electroly tes</w>
du od
disrup ting</w>
decon tam
coh ort</w>
br ac
ami pril</w>
Ven ice</w>
Uni ver
U T
TAB LETS</w>
Son ata</w>
SLO VEN
PRIN CI
I TION</w>
Hij ra</w>
Gluc ose</w>
G old
Frequ encies</w>
Electr onics</w>
Dim ethyl
Com ing</w>
Cart ons</w>
Bud d
Bro ther</w>
AM M</w>
A VI
7 .</w>
5. 1.2</w>
27 77</w>
19 52</w>
1 126</w>
0. 15</w>
. ind
v est</w>
there with</w>
saw s</w>
res istors</w>
psych osis</w>
mal functioning</w>
iv abradine</w>
husband ry</w>
hn ess</w>
deb its</w>
d addy</w>
cur tains</w>
bestow al</w>
are mar</w>
an emia</w>
ait os</w>
Tri al</w>
Th is
TR LIS</w>
Repe ated</w>
Prof .</w>
Pol it
Ph oen
Multi pack</w>
LT00008 30
K ids</w>
German s</w>
Extra ordinary</w>
Exci pient</w>
EC DIS</w>
EAS O</w>
Con sen
CRIXIV AN</w>
Bel grade</w>
AUC 0</w>
AN ALY
7 61</w>
3. 4.1</w>
work able</w>
tu ition</w>
suc k</w>
ste ep</w>
sham po
sex ually</w>
rumin ant</w>
rock ets</w>
respon sibly</w>
reservo irs</w>
rel ine</w>
ne d
nan cial</w>
my th</w>
mil ky</w>
lin e
il ee</w>
goat meat</w>
firm ative</w>
e try</w>
dop aminergic</w>
cumul atively</w>
cor rupt</w>
com ber</w>
brom o</w>
Vir amune</w>
Sen ate</w>
STATI S
SH IPS</w>
S ED</w>
N in
MAR POL</w>
IT U</w>
IN ES</w>
F owls</w>
E phr
DEC ISIONS</w>
D res
D AR
Cli ent</w>
Bar bad
As th
7 03</w>
15 92</w>
v ý
tur moil</w>
trajec tory</w>
sel dorf</w>
precau tion</w>
mil k
methoxy phenyl</w>
ma ys</w>
key words</w>
is taxis</w>
inc l</w>
harmon ic</w>
g ab
fis sile</w>
eb al
contrav ention</w>
carbox y
bust ness</w>
anis ation</w>
alphabe tical</w>
adverti sed</w>
Zhe jiang</w>
Thir ty</w>
Ten ofovir</w>
Sw allow</w>
Radi ation</w>
Phil adel
Oc ca
OF Is</w>
O H</w>
H it</w>
Gent lemen</w>
D CI</w>
Ch arge</w>
As surance</w>
Acquis ition</w>
7 21</w>
19 45</w>
10 35</w>
tr is</w>
system ically</w>
spe ed
se em
ro mi
po s</w>
phosphor ic</w>
op ting</w>
oil seed</w>
n í</w>
loc ating</w>
leu copenia</w>
ir regularly</w>
gem citabine</w>
fur yl</w>
follow ers</w>
extrem ities</w>
el eph
compet ency</w>
ax y</w>
aux iliaries</w>
ar ch</w>
antic holinergic</w>
ampli fiers</w>
a eg
Sy mphony</w>
S ov
Resear chers</w>
Mis sing</w>
L ü
Jere mi
J ane</w>
Flex ibility</w>
Figh ting</w>
Di vi
Bayern LB</w>
Bad en</w>
Alban ian</w>
7 b</w>
15.12. 2010</w>
13 a</w>
vo iced</w>
trans g
stor ms</w>
st ad</w>
silic one</w>
sh op
refin eries</w>
ref resh
rec asting</w>
predic tive</w>
ot or</w>
nur series</w>
lob by</w>
lem an</w>
hyper cal
foreg one</w>
f eline</w>
erad icating</w>
encry pted</w>
ef f</w>
cot tage</w>
contribu tory</w>
broch ures</w>
ann u
SC LC</w>
S cr
Re strain
Ow ner</w>
N DI
M K
L umin
L app</w>
G W</w>
Config uration</w>
